Patient with advanced or metastatic solid tumor and has disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment that meets the following requirements for the part of the study they will participate in:Xx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXMust have achieved an objective response (CR/PR) or stable disease (SD) upon completion of scheduled treatmentXx_NEWLINE_xXParticipants may not have had prior use of PARP inhibitors; patients may not have received prior treatment affecting the VEGF pathway including but not limited to thalidomide, bevacizumab, sunitinib, or sorafenibXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, cannabis, S. John’s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto or ginseng)\r\n* Raloxifene is allowed for patients taking it for bone healthXx_NEWLINE_xXNote: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.Xx_NEWLINE_xXPrior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangementsXx_NEWLINE_xXNote: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.Xx_NEWLINE_xXFor patients with CNS tumors, any baseline neurologic deficit, including seizures, must be stable for at least one week prior to initiating study treatmentXx_NEWLINE_xXMust have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin with or without bevacizumab for metastatic disease. All patients must have received a minimum of 6 weeks of the first-line regimen that included bevacizumab (if applicable), oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or < 6 months after the last dose of first-line therapy.Xx_NEWLINE_xXPatients must be accessible for treatment and follow-up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.Xx_NEWLINE_xXProtocol treatment is to begin within 2 calendar days of patient randomization.Xx_NEWLINE_xXWomen who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.Xx_NEWLINE_xXPrior treatment with napabucasin.Xx_NEWLINE_xXPatients who plan to receive yellow fever vaccine during the course of the study treatment.Xx_NEWLINE_xXAny active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.Xx_NEWLINE_xXThe patient must have experienced disease progression or intolerance as outlined above after treatment with 1 or more prior chemotherapiesXx_NEWLINE_xXThe patient must be willing to undergo a biopsy prior to treatmentXx_NEWLINE_xXPrior treatment with TRC105Xx_NEWLINE_xXPatients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor sizeXx_NEWLINE_xXPrior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).Xx_NEWLINE_xXPRIOR TREATMENTXx_NEWLINE_xXAny prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease\r\n* NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist\r\n* NOTE: Patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment\r\n* NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocolXx_NEWLINE_xXSTEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have documented disease progression while on CETIRI (Arm 2) on this protocol; the Follow-up Tumor Assessment Form documenting disease progression must be submitted to Southwest Oncology Group (SWOG) prior to step 3 crossover registration; registration to step 3 crossover must be within 28 days of discontinuation of CETIRI protocol treatment; patients going off treatment for any other reason are not eligibleXx_NEWLINE_xXPatients may be treated with bone modifying agents such as bisphosphonates or RANK-ligand agents (e.g. denosumab) per American Society of Clinical Oncology (ASCO) guidelines; whenever possible, patients requiring bone modifying agents should start treatment >= 7 days prior to study therapy and should continue the same agent throughout study unless clinically compelled to changeXx_NEWLINE_xXPatients must not have a history of immune-mediated pneumonitis or colitis that required interruption of therapy or treatment of steroidsXx_NEWLINE_xXNo currently active other malignancies which require systemic treatmentXx_NEWLINE_xXThere is no limit to the number of prior lines of treatment a patient has receivedXx_NEWLINE_xXAll patients must be receiving standard of care androgen deprivation treatment (surgical castration versus LHRH agonist or antagonist treatment); subjects receiving LHRH agonist or antagonist must continue treatment throughout the time on this studyXx_NEWLINE_xXPatients with prior treatment with PLDXx_NEWLINE_xXPatients requiring treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumabXx_NEWLINE_xXPrior or concurrent therapy with SSA is permitted; a stable dose at least 2 months prior to study start and must continue on the stable dose while receiving study treatment; SSA is not considered as systemic treatmentXx_NEWLINE_xXNO hepatic artery embolization or cryoablation/radiofrequency ablation of hepatic metastasis within 2 months of study treatment startXx_NEWLINE_xXNo more than 3 prior systemic treatment regimens for advanced PNETXx_NEWLINE_xXThere is no limit to the number of prior lines of treatment a patient has receivedXx_NEWLINE_xXTreatment with systemic immunostimulatory medications (including, but not limited to interferon [IFN]-alpha or interleukin [IL]-2 within 42 days prior to randomizationXx_NEWLINE_xXPatients requiring treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g., denosumab) who cannot discontinue it before treatment with atezolizumabXx_NEWLINE_xXPatient has not had prior treatment with blinatumomabXx_NEWLINE_xXPrior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permittedXx_NEWLINE_xXPatients must not have received prior systemic treatment for this melanomaXx_NEWLINE_xXPatients with recurrent carcinoma of the vulva regardless of previous treatmentXx_NEWLINE_xXPrevious steroid treatment and/or radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass; emergent steroid treatment and/or radiation treatment should stop once protocol therapy is initiatedXx_NEWLINE_xXPatients with undetectable pre-treatment plasma EBV DNAXx_NEWLINE_xXNo prior treatment with high-dose chemotherapy (defined as treatment utilizing stem cell rescue)Xx_NEWLINE_xXNo prior treatment with TIP with the exception when given as a bridge to treatment on protocol for patients with rapidly progressive disease who cannot wait to complete the eligibility screening process; only one cycle is allowedXx_NEWLINE_xXNo concurrent treatment with other cytotoxic drugs or targeted therapiesXx_NEWLINE_xXPrior treatment with brentuximab in the last 6 months or had refractory or progressive disease to prior BV treatmentXx_NEWLINE_xXPrior treatment with PM01183, topotecan or anthracyclines.Xx_NEWLINE_xXHistory of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatmentXx_NEWLINE_xXHistory of peptic ulcer disease within 3 months of treatment.Xx_NEWLINE_xXPrior treatment with alisertibXx_NEWLINE_xXPrior exposure to abiraterone acetate or other specific cytochrome P450 (CYP)-17 inhibitors; abiraterone acetate given in the castration-sensitive setting is permissible if stopped at least 6 months prior to initial protocol treatmentXx_NEWLINE_xXPrior treatment. Patients must have received:Xx_NEWLINE_xXPrior treatment with PM01183 or trabectedinXx_NEWLINE_xXPatients who need to continue treatment with any prohibited medicationsXx_NEWLINE_xXSubject must be referred for treatment with ibrutinib.\r\n* Since ibrutinib will not be supplied as part of the study, the subject’s ability to obtain ibrutinib from a commercial supplier must be confirmed prior to enrollmentXx_NEWLINE_xXFor Cohort E only: prior treatment with fulvestrant is prohibitedXx_NEWLINE_xXClinical indication for treatment with azacitidine for MDS or AML.Xx_NEWLINE_xXProgressive disease during or after treatment with at least one of the agents listed aboveXx_NEWLINE_xXWithin 21 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXPatient received prior treatment with a CD33 antibody.Xx_NEWLINE_xXprior treatment failure with at least two cycles of hypomethylating agent.Xx_NEWLINE_xXPrior treatment with an anti-CD123-directed agentXx_NEWLINE_xXPrior treatment with immunotherapyXx_NEWLINE_xXMust have previously received first line treatment regimenXx_NEWLINE_xXPatients must not have received prior treatment with inotuzumab ozogamicin; previous treatment with other anti-CD22 antibodies must have been completed at least 90 days prior to registrationXx_NEWLINE_xXPreceding line of treatment included response to anti-androgen, progression documented after withdrawal of the anti-androgen.Xx_NEWLINE_xXTreatment before study withXx_NEWLINE_xXTreatment before study withXx_NEWLINE_xXParticipant must have received at least one prior line of treatment of multiple myeloma; for pomalidomide-containing arm(s), patients must have received at least one prior line of treatment and must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of proteasome inhibitor (either in separate regimens or within the same regimen) unless not a candidateXx_NEWLINE_xXPrior pomalidomide treatment (for patients on the pomalidomide arm)Xx_NEWLINE_xXPrior treatment with systemic chemotherapy for bladder cancer. (Prior intravesical treatment is allowed.)Xx_NEWLINE_xXOther prior malignancy active within the previous 2 years except for local or organ-confined early stage cancer that has been definitively treated with curative intent or does not require treatment, does not require ongoing treatment, has no evidence of active disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the endpoints of the study.Xx_NEWLINE_xXPrior treatment with idelalisib;Xx_NEWLINE_xXPast, current or planned treatment with tumor treatment fields; oncolytic viral treatment; or prior exposure to an investigational agent or device within 28 days of receiving the first dose of treatment;Xx_NEWLINE_xXDiagnosis of immunodeficiency or treatment with systemic immunosuppressive therapy within 28 days prior to the first dose of trial treatment, other than dexamethasone for the underlying disease under investigation, as noted in the inclusion criteria;Xx_NEWLINE_xXTreatment with any of the following for prostate cancer within 4 weeks prior to day 1 of treatment:Xx_NEWLINE_xXSubjects with soft tissue sarcoma must have radiographic evidence of progression within the previous 3-4 months and must have received, or been intolerant to, prior treatment with an anthracycline +/- olaratumab or ifosfamide;Xx_NEWLINE_xXSystemic treatment with interferon (IFN)-? within the previous 6 months.Xx_NEWLINE_xXPrior severe reaction to treatment with a human antibody that cannot be managed with standard supportive measures.Xx_NEWLINE_xXPrior treatment with a BCMA-targeted agentXx_NEWLINE_xXNeutrophils >= 1.5 x 10^9/L (for treatment phase)Xx_NEWLINE_xXAny prior ALK inhibition (for screening and treatment phases)Xx_NEWLINE_xXPrior RT or clinically relevant major surgery (e.g. craniotomy, metastasectomy) within 2 weeks prior to first day of study treatment (for treatment phase)Xx_NEWLINE_xXClinically significant cardiovascular disease, including:\r\n* Corrected QT (QTc) interval by Bazett’s formula > 480 ms (for treatment phase)\r\n* Symptomatic bradycardia < 45 beats per minute (for treatment phase)\r\n* Other clinically significant electrocardiogram (ECG) abnormalities (e.g. bundle branch block) may be eligible after discussion with the principal investigator (for treatment phase)\r\n* Clinically uncontrolled hypertension in the investigator’s opinion (for treatment phase)\r\n* The following within 6 months prior to cycle 1 day 1:\r\n** Congestive heart failure (New York Heart class III or IV) (for treatment phase)\r\n** Cardiomyopathy (for treatment phase)\r\n** Arrhythmia or conduction abnormality requiring medication; note: patients with atrial fibrillation/flutter adequately controlled by medication in the opinion of the treating physician and arrhythmias controlled by pacemakers are eligible (for treatment phase)\r\n** Severe / unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction (for treatment phase)\r\n** Cerebrovascular accident or transient ischemia (for treatment phase)Xx_NEWLINE_xXAny serious, active infection at the time of treatment such as bacteremia (for treatment phase)Xx_NEWLINE_xXHas received treatment with any proscribed treatments within specified time frames prior to study drug administrationXx_NEWLINE_xXTreatment failure of rituximab monotherapy (Cohort A) or rituximab plus any concurrent or sequentially administered chemotherapy regimen (Cohort B) for treatment of PTLD. Note: Subjects with CD20 negative disease are eligible to enroll without prior anti-CD20 therapy after failure of first-line treatment (reduction of immunosuppression is not considered first-line therapy) and discussion with the sponsor's medical monitor.Xx_NEWLINE_xXAre not using steroids for at least 7 days prior to trial treatmentXx_NEWLINE_xXSubjects who experienced immune related pneumonitis, pituitary or thyroid dysfunction, or pancreatitis while on treatment with immuno-oncology agentsXx_NEWLINE_xXLive vaccination is not allowed for at least 4 weeks prior to the start of AMG 757 treatment, during treatment, and until end of last study doseXx_NEWLINE_xXPrior treatment with venetoclaxXx_NEWLINE_xXConcurrent treatment with a prohibited medication.Xx_NEWLINE_xXCohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Prior CDK4/6 inhibition is allowed; participants who have had prior ribociclib must have received treatment at full-dose without any dose-reductions; the last dose is required to be >= 21 days prior to first study treatmentXx_NEWLINE_xXCohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Treatment with prior PD1/PDL1/CTLA4 inhibitors is prohibitedXx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Treatment with prior CDK4/6 inhibitors is prohibitedXx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Treatment with prior PD1/PDL1/CTLA4 is prohibitedXx_NEWLINE_xXExpansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Treatment with prior CDK4/6 inhibitors are prohibitedXx_NEWLINE_xXExpansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Treatment with prior PD1/PDL1/CTLA4 inhibitors are prohibitedXx_NEWLINE_xXInclusion criteria:\n\n        Parts A, B, C and D:\n\n          -  Patients must be postmenopausal women\n\n          -  Histological diagnosis of breast adenocarcinoma\n\n          -  Locally advanced or metastatic disease\n\n          -  Measurable disease\n\n          -  Previously treated for advanced disease\n\n          -  Either primary tumor or any metastatic site to be positive for Estrogen Receptors\n             (ER+) and negative for human epidermal growth factor receptor 2 (HER2-) by\n             immunohistochemistry (IHC)\n\n        Exclusion criteria:\n\n          -  Medical history or ongoing gastrointestinal disorders that could affect absorption of\n             SAR439859 and/or palbociclib (including difficulties with swallowing capsules)\n\n          -  Patient with any other cancer (except for adequately treated basal cell or squamous\n             cell skin cancer, in situ cervical cancer or any other cancer from which the patient\n             has been disease free for >3 years)\n\n          -  Patients with known brain metastases and endometrial disorders\n\n          -  Treatment with anticancer agents (including investigational drugs) less than 2 weeks\n             before first study treatment starts (less than 4 weeks if the anticancer agents were\n             antibodies)\n\n          -  Prior treatment with another selective ER down-regulator (SERD) (except fulvestrant)\n\n          -  Inadequate hematological and biochemical lab tests\n\n          -  Patients with Gilbert disease\n\n          -  Treatment with human immunodeficiency virus (HIV)-antiviral, antifungal and\n             antioxidant agents less than 2 weeks before study treatment starts\n\n          -  Treatment with strong and moderate CYP3A inducers/inhibitors within 2 weeks before\n             first study treatment\n\n        Part A only:\n\n        Patients with liver metastases only\n\n        Parts C and D only:\n\n          -  Prior therapy with any selective cyclin-dependent kinase (CDK) 4/6 inhibitor\n\n          -  Treatment with strong and moderate CYP3A inducers or strong CYP3A inhibitors within 2\n             weeks before first study treatment starts\n\n          -  Medical conditions requiring concomitant medications with that are metabolized by\n             CYP3A\n\n        The above information is not intended to contain all considerations relevant to a patient's\n        potential participation in a clinical trial.Xx_NEWLINE_xXTreatment-related, immune-mediated adverse events associated with prior immunotherapeutic agentsXx_NEWLINE_xXReceived prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).Xx_NEWLINE_xXHistory within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic eventXx_NEWLINE_xXTreatment with any investigational products within 14 days before the first dose of protocol-indicated treatmentXx_NEWLINE_xXAllogeneic HSCT within three months prior to start of AMG 673 treatment.Xx_NEWLINE_xXPrior treatment with a monoclonal antibody or chimeric antigen receptor T cell (CAR-T) infusion for the treatment of AML (CD33 or other target).Xx_NEWLINE_xXInclusion Criteria:\n\n        Specific criteria for patients who continue treatment as well as safety and survival\n        follow-up in the extension study:\n\n          -  Eligible for continuing or crossing over to atezolizumab-based therapy at the time of\n             the parent-study closure as per the parent study or eligible for continuing the\n             comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the\n             parent-study closure as per the parent study\n\n          -  First dose of study treatment in the extension study will be received within the\n             treatment interruption period allowed by the parent study\n\n          -  Continue to benefit from atezolizumab-based study treatment or from the comparator at\n             the time of parent-study closure as assessed by the investigator\n\n          -  Negative serum pregnancy test within 7 days prior to start of study treatment in women\n             of childbearing potential\n\n        Specific criteria for patients who do not continue treatment in the extension study and/or\n        receive commercially available atezolizumab (Tecentriq) outside this extension study and\n        continue safety and survival follow-up only in the extension study:\n\n        - Discontinuation of atezolizumab-based therapy in parent study and in survival follow up\n        at the time of parent study closure, or eligible for continuing or crossing over to\n        atezolizumab-based therapy as per the parent protocol and have access to commercially\n        available atezolizumab (Tecentriq) outside this extension study at the time of the\n        parent-study closure\n\n        Exclusion Criteria:\n\n        Specific criteria for patients who continue treatment as well as safety and survival\n        follow-up in the extension study:\n\n          -  Meet of any of the study treatment discontinuation criteria specified in the parent\n             study at the time of enrollment in the extension study\n\n          -  Study treatment is commercially marketed in the patient's country for the patient\n             specific disease and is accessible to the patient\n\n          -  Time between the last dose of treatment received in parent study and first dose in\n             extension study is longer than the interruption period allowed in the parent study\n\n          -  Treatment with any anti-cancer treatment (other than treatment permitted in the parent\n             study) during the time between last treatment in the parent study and the first dose\n             of study treatment in the extension study\n\n          -  Permanent discontinuation of atezolizumab for any reason during the parent study or\n             during the time between last treatment in the parent study and the first dose of study\n             treatment in the extension study (if applicable)\n\n          -  Any unresolved or irreversible toxicities during the parent study that required\n             permanent discontinuation of study treatment, in accordance to the parent study or\n             local prescribing information\n\n          -  Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to\n             (<=) 1 from the parent study or during the time between last treatment in the parent\n             study and the first dose of study treatment in the extension study\n\n          -  Any serious uncontrolled concomitant disease that would contraindicate the use of\n             study treatment at the time of the extension study or that would place the participant\n             at high risk for treatment-related complications\n\n          -  Concurrent participation in any therapeutic clinical trial (other than the parent\n             study)\n\n        Specific criteria for patients who do not continue treatment in the extension study and/or\n        receive commercially available atezolizumab (Tecentriq) outside this extension study and\n        continue safety and survival follow-up only in the extension study:\n\n        - Discontinuation of comparator in parent study and in survival follow-up at the time of\n        parent study closureXx_NEWLINE_xXClinical conditions requiring treatment with oral or parenteral anticoagulants or antiplatelet agents unless treatment can be discontinued 7 days (or 5 half-lives) prior to initiation of study treatment (except used as flushes for indwelling catheters)Xx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment line.Xx_NEWLINE_xXPrior treatment with MM-310Xx_NEWLINE_xXDisease progression within 6 months after the last treatment.Xx_NEWLINE_xXPatients who had therapeutic paracentesis of ascites (> 1L) within the 3 months prior to starting study treatment or who, in the opinion of the investigator, will likely need therapeutic paracentesis of ascites (> 1L) within 3 months of starting study treatment.Xx_NEWLINE_xXPrevious treatment with Apatinib.Xx_NEWLINE_xXPatients must be willing to donate a small amount of whole blood prior to treatment and during treatment for laboratory analysisXx_NEWLINE_xXPhase 2 only: Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsyXx_NEWLINE_xXPrior treatment with CD47 or signal regulatory protein alpha (SIRP?) targeting agents.Xx_NEWLINE_xXPrevious treatment with investigational agents that inhibit MDM2 or MDMX activity (some MDM2-treated patients may be eligible)Xx_NEWLINE_xXResolution of treatment-related toxicitiesXx_NEWLINE_xXPrior anti-PD-1 treatment for combination dose expansion cohorts 3a - 3dXx_NEWLINE_xXConditions that could interfere with treatment or protocol-related proceduresXx_NEWLINE_xXPatient have received anti-cancer therapies within defined time frames prior to the first dose of study treatmentXx_NEWLINE_xXMen are eligible, as long as on a GnRH agonist for at least 6 weeks prior to study entry; men MUST remain on the GnRH agonist for the duration of protocol treatmentXx_NEWLINE_xXCOHORT 1: Not be appropriate candidate for intensive salvage chemotherapy due to co-morbidities or other disease- or treatment-related factors\r\n* NOTE: Subjects who received prior treatment with hypomethylating agents either for myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or AML will be eligible\r\n* NOTE: Subjects who had prior allogeneic stem cell transplant (alloHSCT) will be eligible as long as they have been at least 3 months after allogeneic HSCT and are off of all immune suppression for at least 3 weeks (>21 days) and have no evidence of active graft versus host disease (GVHD); subjects with prior alloHSCT will NOT be eligible for enrollment during the safety run in phaseXx_NEWLINE_xXCOHORT 2: Have received NO prior treatment for AML with the exception of hydroxyurea / leukapheresis\r\n* NOTE: Subjects may have been treated for pre-existent myeloid disorder such as myelodysplastic syndrome or myeloproliferative neoplasm including hypomethylating agentsXx_NEWLINE_xXCOHORT 1: Has a white blood cell count > 30 x 10^9/L\r\n* NOTE: Leukapheresis and hydroxyurea is permitted to meet this criterion and should be stopped >= 12 hours before starting treatment on the studyXx_NEWLINE_xXCOHORT 2: Has a white blood cell count > 30 x 10^9/L\r\n* NOTE: Leukapheresis and hydroxyurea is permitted to meet this criterion and should be stopped >= 12 hours before starting treatment on the studyXx_NEWLINE_xXPrior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways.Xx_NEWLINE_xXPatients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs (e.g. cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to start of the study treatment (day 1 [D1] of cycle 1)Xx_NEWLINE_xXSubjects have no known curative treatment.Xx_NEWLINE_xXMore than two prior systemic treatments for MDS. Prior systemic therapies are those that have been received at standard doses for at least one full treatment cycle.Xx_NEWLINE_xXPrevious treatment with palbociclibXx_NEWLINE_xXPatients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of the treatment and/or for at least 5 days before starting treatmentXx_NEWLINE_xXPatients who have had previous treatment with bevacizumabXx_NEWLINE_xXAre eligible for a curative treatment option.Xx_NEWLINE_xXPrevious progression (radiographic or PSA progression) while on treatment with abiraterone, enzalutamide, or a combination.Xx_NEWLINE_xXHas received previous treatment with another agent targeting the lymphocyte-activation gene 3 (LAG-3) receptor.Xx_NEWLINE_xXPrevious treatment with any anti-CD30 directed therapyXx_NEWLINE_xXRecovery from prior treatment-related toxicitiesXx_NEWLINE_xXPrior treatment with regorafenibXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXCohort A:\r\n* Prior treatment with at least one regimen containing trastuzumab and taxane\r\n* No prior treatment with T-DM1 that was discontinued due to disease progression or toxicity\r\n* No more than 4 prior lines of therapy in the metastatic settingXx_NEWLINE_xXPatients have had no previous treatment except corticosteroid useXx_NEWLINE_xXFor men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least for at least 2 months after the last dose of study treatmentXx_NEWLINE_xXFor obinutuzumab in combination with polatuzumab vedotin and lenalidomide (G + Pola + Len) treatment group: R/R FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigatorXx_NEWLINE_xXMust be capable of treatment without general anesthesiaXx_NEWLINE_xXNo previous treatment with the specific assigned study drug or any other drug sharing the same target; prior treatment in monotherapy when treated in one of the combination arms in the study is allowedXx_NEWLINE_xXPrior treatment with the same agent or combination as the study drug; prior treatment in monotherapy when treated in one of the combination arms in the study is allowedXx_NEWLINE_xXFor the phase I cohort, subjects with one prior systemic treatment are eligibleXx_NEWLINE_xXSubjects who have a history of brain metastasis are eligible for the study provided all the following criteria are met:\r\n* Must have completed their treatment for brain metastasis\r\n* Must be asymptomatic\r\n* Must not have evidence of disease progression for >= 3 months or hemorrhage after treatment\r\n* Must be off-treatment from dexamethasone for 4 weeks prior to study registration and\r\n* Must not have an ongoing requirement for dexamethasone or anti-epileptic drugsXx_NEWLINE_xXNo prior systemic treatment is allowed, except for subjects in the phase I cohort who are permitted one prior systemic treatmentXx_NEWLINE_xXMust not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatmentXx_NEWLINE_xXMust not have known allergic reaction against any of the components of the study treatmentXx_NEWLINE_xXAny prior treatment with taxotere or carboplatinXx_NEWLINE_xXTreatment with clarithromycin, anti-myeloma therapy including investigational agents or plasmapheresis within 15 days prior to treatment in this studyXx_NEWLINE_xXPrevious treatment with ixazomib or pomalidomideXx_NEWLINE_xXPrior treatment with radiopharmaceutical including radium-223, strontium-89, or samarium-153Xx_NEWLINE_xXPatients with recurrent disease may have received multiple prior chemotherapies for treatment of their uterine cancerXx_NEWLINE_xXPrior treatment with 3rd generation TKIXx_NEWLINE_xXPhaseII : Prior treatment with any of the following agents:Xx_NEWLINE_xXReceived prior treatment with AZD9291 (osimertinib) or CO1686 (rociletinib) and experienced disease progression.Xx_NEWLINE_xXSuitable for treatment with nivolumab per package insertXx_NEWLINE_xXPrior treatment with a cancer vaccine for this indicationXx_NEWLINE_xXPrior treatment with any methotrexate containing systemic regimen within 1 year (excluding intrathecal methotrexate)Xx_NEWLINE_xXNo prior therapy with inhibitors affecting the mitogen-activated protein kinase (MAPK) pathways at any level (BRAF, mitogen-activated protein [MAP]/extracellular signal-related kinase [ERK] kinase [MEK], neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], ERK inhibitors) for unresectable stage IIIC or stage IV (metastatic) melanoma; no limit to other therapies (immunotherapy or chemotherapy); prior systemic treatment in the adjuvant setting is allowed; (note: ipilimumab treatment must end at least 8 weeks prior to study day 1)Xx_NEWLINE_xXNo prior lapatinib within 7 days prior to initiation of protocol treatmentXx_NEWLINE_xXHave previously received at least 2 but no more than 5 previous systemic regimens for the treatment of DLBCLXx_NEWLINE_xXPatients must be geographically accessible and willing to participate in all stages of treatmentXx_NEWLINE_xXTreatment with any of the following prior therapies:Xx_NEWLINE_xXLesion must be sonographically visible at the time of treatment.Xx_NEWLINE_xXConcomitant use of drugs that may cause significant QT prolongation and/or torsades de pointes that cannot be discontinued or switched to a different medication prior to treatmentXx_NEWLINE_xXConditions which can result in impaired absorption, distribution, metabolism or excretion of the study treatment.Xx_NEWLINE_xXParts H, and I: Must be able and willing to undergo mandatory tumor biopsies prior to study treatment and at the time of discontinuation from study treatment.Xx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* Concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\r\n* Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirinXx_NEWLINE_xXAny previous autologous EBV specific T cell treatment.Xx_NEWLINE_xXPrevious treatment for ALL, except for prior steroids and/or hydroxyureaXx_NEWLINE_xXPrevious androgen suppression therapy is allowed if it was completed at least 3 months prior to initiation of study treatmentXx_NEWLINE_xXPatients who have had previous treatment with tivozanib are excludedXx_NEWLINE_xXParticipants who have received treatment with a TKI within 7 days of the first dose of study treatment; (an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by principal investigator and the investigatorXx_NEWLINE_xXPrior treatment with ziv-aflibercept is not allowedXx_NEWLINE_xXPrior eligibility for and on study treatment from an antecedent vemurafenib protocolXx_NEWLINE_xXAbility to begin treatment in the extension (rollover) protocol within 15 days following the last day of the study in the antecedent protocolXx_NEWLINE_xXPatient after progression with to imatinib at the dose of 400 mg as first line treatment. Resistance Progression is defined as a RECIST 1.1 and/or CHOI disease progression while receiving imatinib treatmentXx_NEWLINE_xXPrevious imatinib treatment should be permanently discontinued within 4 days prior randomisation and patient should have recovered from potential toxicity related to imatinibXx_NEWLINE_xXPatients must be considered bevacizumab-resistant, i.e.; have a treatment-free interval following a response to bevacizumab (complete response [CR], partial response [PR], or stable disease [SD]) of less than 6 months, or have progressed during treatment with a bevacizumab-containing therapyXx_NEWLINE_xXPatients who have had previous treatment with nintedanibXx_NEWLINE_xXPatients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinideXx_NEWLINE_xXPatients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinideXx_NEWLINE_xXPts who have received prior treatment with carfilzomib (Phase II only)Xx_NEWLINE_xXPts who have received prior treatment with pomalidomide (Phase II only)Xx_NEWLINE_xXPts who have received prior treatment with both carfilzomib & pomalidomide (Phase I only)Xx_NEWLINE_xXPatients must be able to start treatment within 56 days of randomization.Xx_NEWLINE_xXEvidence of an active lesion including: plexiform neurofibroma, malignant peripheral nerve sheath tumor, or other cancer requiring concurrent treatment with chemotherapy or radiation therapy; patients not requiring treatment for these lesions are eligible for this protocolXx_NEWLINE_xXPrior treatment with 89-Strontium or 153-Samarium containing compounds (e.g. Metastron®, Quadramet®)Xx_NEWLINE_xXExpectation by the investigator that the participant may continue to benefit from additional single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment or Expectation of the investigator that the participant may continue to benefit from control arm treatment as given in study BO21976/TDM4450g and at the time of disease progression may benefit from single-agent trastuzumab emtansine treatmentXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal (GI) bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPatient must not have had prior treatment with paclitaxel or nab-paclitaxelXx_NEWLINE_xXNo prior treatment with ONC201.Xx_NEWLINE_xXParticipants must not have more than 5 new or progressive lesions in the brain requiring SRS treatment (greater than 5 total brain lesions are allowed as long as no more than 5 lesions require SRS treatment)Xx_NEWLINE_xXHas evidence of active, noninfectious pneumonitis that requires treatment with steroidsXx_NEWLINE_xXHave received treatment with a therapeutic antibody less than 4 weeks before the first dose of AG-270. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of AG-270 may be permitted in subjects with rapidly progressive or aggressive subtypes of lymphoma following discussion with the medical monitor.Xx_NEWLINE_xXRequire continued treatment with medications that are known to carry a risk of torsades de pointes.Xx_NEWLINE_xXIf female, may participate if not pregnant, not breastfeeding, and at least one of the following conditions apply: 1) not a woman of childbearing potential (WOCBP); or 2) a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 180 days after the last dose of study treatment.Xx_NEWLINE_xXCohorts 1 to 3: Have platinum-resistant disease and have documented test results assessing alterations in the BRCA1 and BRCA2 genes prior to receiving study treatment.Xx_NEWLINE_xXPatients that have had prior treatment must show disease progression during or following the last treatment according to RECIST 1.1 criteria.Xx_NEWLINE_xXThe subject is a candidate for surgery or loco-regional treatment with curative intent.Xx_NEWLINE_xXLesion amenable to treatment with both PLA and HIGRT; for PLA treatment this requires the lesion be visible via ultrasound and/or non-contrast CT or feasible per treating physicianXx_NEWLINE_xXConfirmed radiologic disease progression during or following recent treatmentXx_NEWLINE_xXPrior treatment with immune checkpoint inhibitors and MEK inhibitorsXx_NEWLINE_xXParticipants with prostate cancer who are unable to interrupt treatment with ketoconazole; ketoconazole treatment must be discontinued 2 weeks prior to first dose of study medication and is not allowed during Cycle 1, but may be used in the optional extension phase.Xx_NEWLINE_xXCurrent treatment with oral or parenteral anti-coagulants/antiplatelet agentsXx_NEWLINE_xXThe disease should be progressing/relapsed during or after the previous treatment.Xx_NEWLINE_xXHas documented disease-free interval (DFI) > 8 weeks after completion of initial therapy; DFI is from the time of completion of initial treatment (from date last known disease-free at end of initial treatment) to the diagnosis of local or loco-regional recurrenceXx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXPrior investigational drugs or interventions for invasive breast cancer treatment within 6 months before registration are not allowed; prior participation in window-of-opportunity trials without therapeutic intent is allowed if intervention is no more than 3 weeks in durationXx_NEWLINE_xXNo prior treatment for CAH/EIN/ECXx_NEWLINE_xXHas been on any hormonal treatment (including progestin-containing intrauterine device [IUD]) for CAH/EIN or grade 1 endometrial carcinoma in last 3 monthsXx_NEWLINE_xXReceived any previous treatment for AMLXx_NEWLINE_xXSubject must appropriately be able to complete Screening assessments before beginning treatment for DLBCL, in the judgement of the Investigator. For subjects with bulky disease, B-symptoms, compressive disease, elevated bilirubin due to lymphoma, rapidly progressing adenopathies, or worsening performance status, pre-phase treatment with up to 100 mg/day prednisone, or equivalent, for a maximum of 10 days is permitted prior to beginning the treatment period, at the discretion of the Investigator. A washout period is not required, however, the Screening positron emission tomography (PET), CT, tumor biopsy (if needed), and bone marrow biopsy (if needed) should be completed before initiating corticosteroids.Xx_NEWLINE_xXPrior treatment with any immunotherapyXx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to first day of study treatment:Xx_NEWLINE_xXEvidence of tumor progression on or after the last treatment regimen received and within 6 months prior to study enrollmentXx_NEWLINE_xXTreatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXAgrees to undergo a pretreatment and a post-treatment biopsy.Xx_NEWLINE_xXWomen who have received treatment with Selective Estrogen Receptor Modulators (SERMs) (e.g. tamoxifen, raloxifen) or aromatase inhibitorsXx_NEWLINE_xXAny patient receiving treatment with short-acting octreotide, which cannot be interrupted for 48 hours before and 24 hours after the administration of yttrium Y 90-edotreotide (90Y-DOTA-TOC), or any patient receiving treatment with octreotide LAR or lanreotide, which cannot be interrupted for at least 4 weeks before the administration of 90Y-DOTA-TOC\r\n* Concurrent somatostatin receptor analog (SSA) allowed if progression has been documented and the SSA dose has been stable for at least two months; long-acting SSA cannot be given within four weeks of treatment and short-acting SSA cannot be given with 48 hours of treatment; SSA therapy can restart one day after treatmentXx_NEWLINE_xXAt least one previous treatment for WM with either documented disease progression or no response (stable disease) to the most recent treatment regimenXx_NEWLINE_xXOne prior disease progression episode on or after vascular endothelial growth factor (VEGF)-targeted treatment (for example, but not limited to, sunitinib, sorafenib, pazopanib, cabozantinib, bevacizumab, axitinib, vatalanib, AV951/tivozanib) administered for the treatment of RCC. Prior programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) treatment in addition to 1 prior VEGF-targeted treatment is allowed.Xx_NEWLINE_xXMore than 1 prior VEGF-targeted treatment for advanced RCCXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients planning to embark on a new strenuous exercise regimen after the first dose of study treatmentXx_NEWLINE_xXSignificant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroidsXx_NEWLINE_xXIf participant was treated with bevacizumab, at least 4 weeks must elapse before treatment with either agent (cyclophosphamide or rQNestin34.5v.2)Xx_NEWLINE_xXSubjects with active HSV-1 infection on current valacyclovir, acyclovir or ganciclovir therapy must be off treatment with any of these agents at least 7 days prior to surgeryXx_NEWLINE_xXActive hepatitis C (HCV) infection without treatment is permitted; concomitant treatment of HCV is not permitted on this studyXx_NEWLINE_xXPrevious treatment with CDK4/6 inhibitors or mTOR inhibitorsXx_NEWLINE_xXMalignancies other than head and neck cancer within 5 years prior to Day 1 of treatment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcomeXx_NEWLINE_xXIs willing to undergo a mandatory pre-treatment research biopsyXx_NEWLINE_xXTreatment with abiraterone acetate for castration-resistant prostate cancer (CRPC) in the past is required; it does not need to be the last treatment prior to enrollmentXx_NEWLINE_xXPrior treatment with enzalutamide for CPRC; non-CRPC use is allowed (e.g., neoadjuvant, combined with radiation for localized disease and didn’t progress while on it in those settings)Xx_NEWLINE_xXNon-escalating steroid requirement at the time of consent and study drug initiation for the treatment of CNS symptomsXx_NEWLINE_xXINCLUSION - TREATMENT: Pulse oximetry of > 90% on room airXx_NEWLINE_xXSubjects with known symptomatic or impending spinal cord compression, except if subject has received definitive treatment for this and demonstrates evidence of clinically stable diseaseXx_NEWLINE_xXPrior treatment against NSCLC with an EGFR monoclonal antibodyXx_NEWLINE_xXPatient is pregnant or breastfeeding, or plans to become pregnant or father children from time of signing consent and lasting until 6 months after the last dose of trial treatmentXx_NEWLINE_xXNo prior systemic NSCLC treatment.Xx_NEWLINE_xXPrior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.Xx_NEWLINE_xXPrior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)Xx_NEWLINE_xXHistologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatmentXx_NEWLINE_xXConfirmation that the patient’s health insurance will pay for the treatment in this study (patients may still be responsible for some costs, such as co-pays and deductibles); if the patient’s insurance will not cover a specific treatment in this study and the patient still wants to participate, confirmation that the patient would be responsible for paying for any treatment receivedXx_NEWLINE_xXNo previous treatment with the specific assigned study drug or any other drug sharing the same targetXx_NEWLINE_xXPrevious treatment with any HER2-targeted therapy ErlotinibXx_NEWLINE_xXTreatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXPrior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapiesXx_NEWLINE_xXPrior treatment with cabozantinib (XL184)Xx_NEWLINE_xXThe participant has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe participant has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXAgreement to biopsies before and during treatment, depending on study partXx_NEWLINE_xXPrior treatment with SGN-LIV1A or prior treatment with an MMAE-containing therapyXx_NEWLINE_xXPatients must be accessible for treatment and follow up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.Xx_NEWLINE_xXProtocol treatment is to begin within 2 calendar days of patient randomization for patients randomized to Arm 1. Patients randomized to Arm 2 must begin protocol treatment within 7 calendar days of randomization.Xx_NEWLINE_xXWomen who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with nab-paclitaxel and gemcitabine and for 180 days after the last dose of nab-paclitaxel and gemcitabine.Xx_NEWLINE_xXAny active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.Xx_NEWLINE_xXAny number of prior treatment regimensXx_NEWLINE_xXNo prior treatment with enzalutamide, ARN-509, ODM-201, galeterone or other investigational androgen receptor (AR) targeted treatment is allowedXx_NEWLINE_xXPatients on either treatment arm will considered for crossover if they demonstrate evidence of radiographic disease progression from the initial treatmentXx_NEWLINE_xXPrior treatment with enzalutamide is prohibitedXx_NEWLINE_xXPrior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:Xx_NEWLINE_xXTreatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ?100 mg per day, within the last 2 weeksXx_NEWLINE_xXProgressive disease before initiating study treatmentXx_NEWLINE_xXPrior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis. Previous treatment with itraconazole and fluconazole is permitted.Xx_NEWLINE_xXPrior treatment with enzalutamide or other potent androgen-receptor blockers, approved or experimental (e.g., ARN-509, ODM-201, or galeterone)Xx_NEWLINE_xXPrior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of Cycle 1, Day 1Xx_NEWLINE_xXPrior treatment with approved or experimental therapeutic agents with known inhibition of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitorsXx_NEWLINE_xXPrevious treatment with gemcitabineXx_NEWLINE_xXPrior treatment with FR-targeting investigational agents is not allowedXx_NEWLINE_xXHistory or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatmentXx_NEWLINE_xXPatient must be accessible for treatment and follow-up.Xx_NEWLINE_xXRadiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, e.g., gefitinib or erlotinib. In addition, other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered, prior to enrolling in the study.Xx_NEWLINE_xXPresence of at least 1 non-target lesion suitable for multiple biopsies while on treatment.Xx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXConcurrent treatment with other experimental treatments for NSCLC while on the studyXx_NEWLINE_xXNo prior treatment with an EGFR TKI for the advanced NSCLCXx_NEWLINE_xXPrevious hysterectomy and/or prior treatment for cervical precancer conditionXx_NEWLINE_xXTreatment with cytotoxic or targeted antineoplastics within 3 weeks of initiation of study treatment. For cytotoxic agents that have major delayed toxicity a washout period of one cycle is indicated (examples are nitrosoureas and mitomycin C which typically require a 6 week washout). Prior antibodies or immunotherapies require a 6 week washout.Xx_NEWLINE_xXSubjects must have received at least 1 and not more than 3 previous lines of treatment and have had a response to at least 1 prior Treatment in the past (i.e., achieved a minimal response [MR] or better) according to the IMWG uniform response criteria.Xx_NEWLINE_xXPrior treatment with radium-223 dichloride or any experimental radiopharmaceutical.Xx_NEWLINE_xXOngoing treatment with immunosuppressive drugs or dexamethasone > 4 mgXx_NEWLINE_xXParticipant has received or will receive some form of treatment for their cancer prior to completing a minimum of 14 days of study agent dosing; (a biopsy is not considered a form of treatment)Xx_NEWLINE_xXTREATMENT INCLUSION: Pulse oximetry of > 90% on room airXx_NEWLINE_xXTREATMENT INCLUSION: Electrocardiography (EKG) shows no significant arrhythmiasXx_NEWLINE_xXTREATMENT INCLUSION: Available autologous T cells with ? 15% expression of CD30CAR determined by flow-cytometryXx_NEWLINE_xXPrevious treatment with ixazomib, or participation in a study with ixazomib whether treated with ixazomib or notXx_NEWLINE_xXFemales of child bearing potential and males with female partners must and use of contraceptive methods with a failure rate of less than or equal to (</=)1% per year is required during treatment and for 6 months post treatment. Males should not expose pregnant partners to sperm and refrain from donating sperm for 6 months post treatmentXx_NEWLINE_xXPrior treatment with clofarabine within 6 months or history of clofarabine-induced liver dysfunctionXx_NEWLINE_xXHas demonstrated clinical benefit from treatment with tazemetostat.Xx_NEWLINE_xXHas been permanently discontinued from tazemetostat therapy due to adverse event, intolerance or treatment failureXx_NEWLINE_xXPatients may have had previous systemic treatment regimens (no limit to number of prior therapies); patients with prior treatment with bevacizumab are eligible for enrollment into the study; NOTE: except for bevacizumab, a 28 day wash-out period prior to registration is mandatory for all systemic treatmentsXx_NEWLINE_xXNo more than 3 prior lines of treatment for cGVHD.Xx_NEWLINE_xXNote: (supportive transfusions will be allowed during treatment as deemed necessary by the treating physician)Xx_NEWLINE_xXEligible for otherwise curative treatment or undergoing concurrent therapyXx_NEWLINE_xXPrior treatment as follows:Xx_NEWLINE_xXCytoreduction allowed with hydroxyurea and/or leukapheresis for up to 14 days prior to day (D)1 of treatment under LCCC1522; patients must be off hydroxyurea for >= 12 hours prior to D1 of treatment under LCCC1522Xx_NEWLINE_xXFor patients that relapse following a response to prior treatment with bortezomib or carfilzomib, six months must have elapsed since the last dose of treatmentXx_NEWLINE_xXPeripheral blood lymphoblasts =< 50,000 mcL; hydroxyurea and/or leukapheresis is permitted to reduce the peripheral blast count prior to enrollment and treatmentXx_NEWLINE_xXPrevious treatment with nelarabine for relapsed or refractory diseaseXx_NEWLINE_xXRelapse or progression following previous autologous EBV specific T cell treatment.Xx_NEWLINE_xXParticipation in another concurrent treatment protocolXx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXOngoing treatment with Coumadin.Xx_NEWLINE_xXPsoriasis or eczema not requiring systemic treatment.Xx_NEWLINE_xXHave received vaccination against Neisseria meningitidis at least 2 weeks prior to beginning study protocol (only for cohorts where patients receive eculizumab treatment) in accordance with the most current Advisory Committee on Immunization Practices (ACIP) recommendationsXx_NEWLINE_xXPrior treatment with ERK inhibitors.Xx_NEWLINE_xXConsent for on-treatment paired biopsiesXx_NEWLINE_xXParticipants with ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known to be strong CYP3A4/5 inhibitors, or has taken any disallowed therapies as noted in Section 8.2, Prohibited Medications, before the planned first dose of study drugXx_NEWLINE_xXAble to tolerate CPI treatment regimen {if already starteXx_NEWLINE_xXrequiring treatment for relapsed or relapsed/refractory diseaseXx_NEWLINE_xXprior treatment with DAC inhibitorsXx_NEWLINE_xXThe patient has undergone at least one prior, but no more than 2 prior standard, therapies for pancreatic cancer.If the patient has had prior gemcitabine treatment, the last date of gemcitabine administration-should be > 3 months prior to screening for the study. All patients who have previously received gemcitabine should be discussed with the medical monitor during screeningXx_NEWLINE_xXWillingness to have pre treatment and on treatment tumor biopsies.Xx_NEWLINE_xXPatients must be eligible for treatment with decitabineXx_NEWLINE_xXActive chronic graft versus host disease requiring immunosuppressive treatment.Xx_NEWLINE_xXPhase I extension and Phase II only: Prior treatment with a hypomethylating agent, such as prior treatment for MDS.Xx_NEWLINE_xXHistologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option existsXx_NEWLINE_xXSymptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.Xx_NEWLINE_xXPrior treatment with PM01183, trabectedin (Yondelis®) or topoisomerase I inhibitors (irinotecan, topotecan, etc.).Xx_NEWLINE_xXPrior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled in group 1 and 2 in the dose expansion part. Exceptions may be made after documented agreement between Novartis and Investigator.Xx_NEWLINE_xXInclusion criteria for all parts of the study\n\n          -  Confirmation of locally advanced/metastatic cancer. Refractory or resistant to\n             standard therapy, or have no effective standard\n\n          -  Aged at least 18 yrs\n\n          -  Reasonable health (performance status 0 or 1), stable over the previous 2 weeks\n\n          -  Females who can have children must use contraception; have a negative pregnancy test,\n             & not be breast feeding\n\n          -  Sexually active male patients must use contraception for duration of study and for 3\n             months afterwards Inclusion criteria for Part B only\n\n          -  Tumour(s) that can be measured by CT or MRI, at least 1cm in size Inclusion Part B\n\n          -  Confirmation of metastatic/locally advanced cancer of specific tumour type which\n             failed to respond to standard treatments Exclusion criteria for all parts of the study\n\n          -  Prior treatment with an ATM inhibitor\n\n          -  Past medical history of an inflammatory type(interstitial) lung disease or current\n             inflammatory lung disease\n\n          -  Radiotherapy within the last 4 weeks, except palliative radiotherapy for bone pain\n             relief\n\n          -  Prior treatment with drugs that may cause lung damage\n\n          -  Poor of lung function\n\n          -  History/presence of muscle weakness or abnormal blood tests relating to muscle\n             function\n\n          -  Cancer affecting the spinal cord and/or brain unless asymptomatic and stable\n\n          -  Any evidence of severe or uncontrolled diseases, active bleeding,kidney transplant, or\n             active infection including liver infections (hepatitis B, hepatitis C) and human\n             immunodeficiency virus (HIV).\n\n          -  Evidence of severe lung infections\n\n          -  Receiving, or having received during the four weeks prior to starting study treatment\n             other chemotherapy treatment for your cancer\n\n          -  Treatment with certain doses of steroids during the two weeks prior to starting study\n             treatment\n\n          -  A known sensitivity to AZD0156 or any of its components\n\n          -  Treatment with any unapproved medicine within 28 days prior to starting study\n             treatment\n\n          -  Receiving, or having received medications, herbal supplements and/or foods that\n             significantly affect how your liver works\n\n          -  Low numbers of certain blood cells\n\n          -  If your liver and kidney aren't working normally\n\n          -  If your heart isn't working normally or you have a strong family history of certain\n             heart diseases\n\n          -  Other cancers within the past 3 years, except for certain types of cervical and skin\n             cancers\n\n          -  Sickness and vomiting, digestive diseases or previous significant bowel removal\n\n          -  Patients with uncontrolled fitting\n\n          -  Infections requiring treatment\n\n          -  Other severe and/or uncontrolled medical conditions in addition to your cancer\n\n          -  A blockage in your digestive system or severe bleeding from the stomach within 4 weeks\n             before your take medication on the stuy\n\n          -  Patients with acute leukaemia or certain bone marrow diseases\n\n          -  Patients with a known sensitivity to olaparib or its components (Module 1), or\n             components of FOLFIRI (Module 2)\n\n          -  Any previous treatment with drugs that work like olaparib. (Module 1 Only)Xx_NEWLINE_xXTreatment with colchicine is excluded.Xx_NEWLINE_xXOngoing treatment with immunosuppressive drugsXx_NEWLINE_xXPrior EGFR inhibitorsXx_NEWLINE_xXThe patient should have received all established therapies where there is a clear, superior available regimen available for the patient and the patient should have demonstrated progressive disease on or since completion of the last treatment regimenXx_NEWLINE_xXPatients with hospitalization within 4 weeks of treatment initiation date for co-morbid conditions or any complication of disease or therapy that is deemed by the principal investigator as unstable or incompletely treatedXx_NEWLINE_xXPatients with LCH must require systemic therapy according to the Histiocyte Society LCH Evaluation and Treatment Guidelines OR patients with HS requiring systemic treatment as defined by disease that cannot be surgically resected and/or encompassed in a single radiation fieldXx_NEWLINE_xXAllogeneic HSCT within three months prior to start of AMG 330 treatmentXx_NEWLINE_xXPrior treatment with a monoclonal antibody or chimeric antigen receptor T cell infusion for the treatment of AMLXx_NEWLINE_xXInflammatory eye disease requiring steroid treatmentXx_NEWLINE_xXTreatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.Xx_NEWLINE_xXPrevious assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.Xx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXPHASE I: Prior treatment with erlotinib, gefitinib or EGFR-blocking monoclonal antibodies (cetuximab and panitumumab) is allowedXx_NEWLINE_xXPHASE IB: No prior treatment with erlotinib is allowed for pancreatic cancer patientsXx_NEWLINE_xXPrior treatment with afatinibXx_NEWLINE_xXSubjects are willing to undergo a biopsy to confirm lower GI aGVHD. Biopsy results are not needed to initiate treatment. However, if aGVHD is not confirmed histologically, treatment with F-652 will be discontinued.Xx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXPatients undergoing primary medical treatment (hormone or chemotherapy) as initial treatment with neoadjuvant intent of reducing tumor sizeXx_NEWLINE_xXReceived anti-cancer therapies within the following time frames prior to the first dose of study treatment:Xx_NEWLINE_xXrelevant toxicity from previous treatmentXx_NEWLINE_xXOngoing treatment with chronic, therapeutic dosing of anti-coagulants.Xx_NEWLINE_xXPatients can continue to receive other immunosuppressive drugs for treatment of GVHD as determined by their primary teamXx_NEWLINE_xXActive other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment and would interfere with follow-up assessments through year 5Xx_NEWLINE_xXPrior treatment with any anti-angiogenic agent (including bevacizumab)Xx_NEWLINE_xXTreatment with the modified Atkins diet (MAD) for any cause within the 9 months prior to study enrollmentXx_NEWLINE_xXChronically taking an oral medication known to be a P-gp substrate within 7 days of starting treatment with Oratecan.Xx_NEWLINE_xXUnresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatmentXx_NEWLINE_xXDisease progression (AD worse) in non-risk organs at any time during continuation treatmentXx_NEWLINE_xXActive disease at the end of Stratum I treatmentXx_NEWLINE_xXDisease reactivation in non-risk organs at any time after completion of Stratum I treatmentXx_NEWLINE_xXPatients may have received treatment of completely resected early stage melanoma, comprising interferon, radiation treatment, or experimental vaccine therapy, and in the metastatic setting patient can have had treatment such as chemotherapy, immunotherapy (except prior treatment with ipilimumab and IL-2), and other experimental agent which was completed 4 weeks prior to enrollmentXx_NEWLINE_xXPatients who have had prior treatment with LY2606368 or other Chk inhibitorsXx_NEWLINE_xXPatients may be treatment-naive or have failed previous regimen of intravesical therapyXx_NEWLINE_xXPrevious or concurrent treatment with selective estrogen receptor modulator (SERM) and/or hormonal replacement therapy within 3 months of the studyXx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXConcomitant systemic treatment with chronic use (based on the investigator’s judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agentsXx_NEWLINE_xXReceived prior treatment targeting the signaling pathway of TGF-?.Xx_NEWLINE_xXPrior treatment with compounds with the same mode of actionXx_NEWLINE_xXPatients must agree not to donate blood, sperm/ova during the course of taking protocol therapy and for at least 4 weeks after stopping treatmentXx_NEWLINE_xXPatient’s physician has already recommended enzalutamide for treatment of progressionXx_NEWLINE_xXPrevious treatment with enzalutamide (MDV3100)Xx_NEWLINE_xXPatients cannot have received any other immunomodulatory therapies (including vaccines) as treatment for this or any other cancer.Xx_NEWLINE_xXHave taken any chemotherapeutic agent within 5 weeks of treatment with the NanoKnife irreversible electroporation (IRE) systemXx_NEWLINE_xXTreatment with proton pump inhibitors within 3 days prior to study entry; if continued use of gastrointestinal (GI) prophylaxis is required, the patient will be switched to an appropriate histamine (H2) antagonist with appropriate counsel and cautionXx_NEWLINE_xXFor phase 2, prior intravesical treatment with nab-rapamycin or gemcitabine is not allowedXx_NEWLINE_xXConcurrent treatment with any chemotherapeutic agentXx_NEWLINE_xXPrevious treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors or FGFR-specific antibodies)Xx_NEWLINE_xXPrior treatment with mTOR or TORC1/2 inhibitors (eg, rapamycin, temsirolimus, everolimus, deferolimus) is NOT allowedXx_NEWLINE_xXINCLUSION - TREATMENT: Diagnosis of refractory or metastatic GD2-positive sarcoma not responsive to standard treatment; (patients with osteosarcoma do not require GD2 testing of their tumors)Xx_NEWLINE_xXINCLUSION - TREATMENT: Pulse oximetry of ? 90% on room airXx_NEWLINE_xXPatients with prior treatment of histone deacetylase (HDAC) inhibitors or doxorubicin liposome or doxil are eligibleXx_NEWLINE_xXHypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causesXx_NEWLINE_xXPatients taking drugs leading to significant QT prolongation and unable to stop drugs prior to treatmentXx_NEWLINE_xXPatients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of treatment and/or for at least 5 days before starting treatmentXx_NEWLINE_xXPatients who have had previous treatment with bevacizumab and/ or NovoTTF 100A systemXx_NEWLINE_xXPatients enrolling in the expansion cohorts must have disease amenable to biopsy and be willing to undergo pre-and post-treatment biopsiesXx_NEWLINE_xXConcomitant treatment with other anti-neoplastic agents, with the exception, when clinically indicated, of prophylaxis in the post-transplantation setting with intrathecal chemotherapyXx_NEWLINE_xXPatients that have been prescribed sipuleucel-T and have not started treatmentXx_NEWLINE_xXUse of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for the duration of the study.Xx_NEWLINE_xXHistory of changes in baseline LVEF that occurred during prior treatment with anti-HER2 treatmentXx_NEWLINE_xXFor Cohorts 1, 3 and 4 only: Has received treatment with rituximab, alemtuzumab, ofatumumab or any other chemotherapeutic agent for CLL. Cohort 8: Received prior treatment with bendamustine and did not respond during treatment or relapsed less than sex months after completing treatment.Xx_NEWLINE_xXConcurrent systemic treatment or prior therapy within 4 weeks for SMM; NOTE: Treatment with corticosteroids for other indications is permittedXx_NEWLINE_xXPatients who have not fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). The required minimum time elapsed from prior treatments are:Xx_NEWLINE_xXtreatment with molecular targeted agents within 2 weeks prior to treatment with APS001F.Xx_NEWLINE_xXPresence of any condition or concurrent requirement for treatment with agents known to result in immune deficiency.Xx_NEWLINE_xXNo prior therapies are allowed for the treatment of the newly diagnosed breast cancer; patients with a prior diagnosis of malignancy treated >= 5 years ago are eligible, provided that they have not received prior taxanes or carboplatin as part of their prior treatment regimen, and that they meet all eligibility criteriaXx_NEWLINE_xXPatients with previous treatment with abraxaneXx_NEWLINE_xXPatients must be able to start treatment within 56 days of randomization.Xx_NEWLINE_xXPatients should be > 24 hours from radiation therapy (RT) treatment to areas of the neuro-axis and all effects of treatment should have resolvedXx_NEWLINE_xXPatients who are in the estimation of the principal investigator (PI), deemed unable or unlikely to adhere to protocol treatmentXx_NEWLINE_xXTREATMENT WITH SJCAR19: Detectable diseaseXx_NEWLINE_xXTREATMENT WITH SJCAR19: Agreement to participate in long-term follow-up on protocol NCT00695279Xx_NEWLINE_xXTREATMENT WITH SJCAR19: Evidence of active, uncontrolled neurologic diseaseXx_NEWLINE_xXPrior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohortXx_NEWLINE_xXHistory of neurological conditions that would confound assessment of treatment-emergent neuropathyXx_NEWLINE_xXHistory or evidence of thrombotic disorders within 6 months before first study treatment unless stable on anticoagulation for > 3 monthsXx_NEWLINE_xXParticipant must be willing to undergo a pre-treatment screening biopsy for enrollment and subsequent biomarker analyses.Xx_NEWLINE_xXPatients must not have received previous treatment with PARP inhibitorsXx_NEWLINE_xXConcurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).Xx_NEWLINE_xXPatients must have received treatment with prior enzalutamide for greater than three 28-day cycles and must have had evidence of disease progression while on enzalutamide.Xx_NEWLINE_xXPatients with microscopic hematuria (defined as > 100 red blood cells [RBCs] on urinalysis) or worsening urinary symptoms within 7 days prior to the initiation of study treatment.Xx_NEWLINE_xXPrior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.Xx_NEWLINE_xXDiagnosis and Prior Treatment:Xx_NEWLINE_xXPrior history of treatment with blinatumomabXx_NEWLINE_xXTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigatorXx_NEWLINE_xXPrior treatment with a therapeutic agent targeting CD33 and/or CD3 (e.g. gemtuzumab ozogamicin, SGN-CD33A or AMG 330).Xx_NEWLINE_xXConcomitant receipt of the breast cancer resistance protein (BCRP) transporter-sensitive substrate rosuvastatin (unless the participant can be transferred to another medication at least 5 half-lives prior to the start of study treatment)Xx_NEWLINE_xXPrior treatment with CD137 agonists or immune checkpoint blockade therapies;Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents;Xx_NEWLINE_xXMajor surgery within prior 4 weeks of treatment initiation (the surgical incision should be fully healed prior to all neoadjuvant treatment initiation)Xx_NEWLINE_xXFor patients that have refused treatment with sorafenib, the benefits of sorafenib have been discussed in detail with the patient.Xx_NEWLINE_xXSubjects who have received prior PSA, MUC1, and/or brachyury-targeted immunotherapy (e.g. vaccine) are eligible for this trial if this treatment was discontinued at least 3 months prior to enrollmentXx_NEWLINE_xXPrior enzalutamide and/or abiraterone treatment is allowedXx_NEWLINE_xXPrior treatment with adenovirus-based vectors immunotherapyXx_NEWLINE_xXNo prior treatment with temozolomideXx_NEWLINE_xXInclusion criteria:\n\n          -  Existence of archival or fresh tumor biopsy specimen for FGFR1/3 mRNA expression\n             testing\n\n          -  High FGFR1 or 3 mRNA expression levels (RNAscope score of 3+ or 4+) in archival or\n             fresh tumor biopsy specimen\n\n          -  Documented locally advanced (T4, any N; or any T, N2-3) or metastatic urothelial\n             carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis,\n             ureters, urethra, meeting all of the following criteria:\n\n          -  No prior systemic treatment for locally advanced or metastatic urothelial carcinoma.\n             For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation\n             for urothelial carcinoma, a treatment-free interval > 12 months between the last\n             treatment administration and the date of recurrence is required in order to be\n             considered treatment-naïve in the metastatic setting. Prior local intra-vesical\n             chemotherapy or prior local immunotherapy is allowed.\n\n          -  Ineligibility for cisplatin-based chemotherapy as defined by any one of the following\n             criteria:\n\n               -  Impaired renal function (GFR > 30 but < 60 mL/min/1.73 m2) according to the\n                  modification of diet in renal disease (MDRD) abbreviated formula\n\n               -  Hearing loss (measured by audiometry) of 25 dB at two contiguous frequencies\n\n               -  Grade ? 2 peripheral neuropathy (i.e. sensory alteration or paresthesia including\n                  tingling)\n\n          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.\n\n        Exlusion criteria:\n\n          -  Active symptomatic or untreated brain metastases as determined by CT or MRI evaluation\n             during screening and prior radiographic assessment.\n\n          -  History of autoimmune disease, including but not limited to myasthenia gravis,\n             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,\n             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid\n             syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré\n             syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n          -  History or current condition of an uncontrolled cardiovascular disease including any\n             of the following conditions:\n\n               -  Congestive heart failure (CHF) NYHA Class 2 or greater, unstable angina (symptoms\n                  of angina at rest) or\n\n               -  New-onset angina (within last 3 months before the first study drug\n                  administration)\n\n               -  Myocardial infarction (MI) within past 6 months before the first study drug\n                  administration\n\n               -  Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.\n\n          -  Patients with known coronary artery disease, congestive heart failure not meeting the\n             above criteria, or known left ventricular ejection fraction < 50% must be on a stable\n             medical regimen that is optimized in the opinion of the treating physician, in\n             consultation with a cardiologist if appropriate.\n\n          -  Current diagnosis of any retinal disorders including retinal detachment, retinal\n             pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.\n\n          -  Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g.\n             parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis,\n             paraneoplastic hypercalcemia).\n\n          -  Concomitant therapies that are known to increase serum calcium or phosphate levels\n             (i.e. antacids, phosphate-containing laxatives oral/rectal, potassium phosphate) and\n             that cannot be discontinued or switched to a different medication before the first\n             study drug administration\n\n          -  Treatment with systemic corticosteroids or other systemic immunosuppressant\n             medications within 2 weeks before the first study drug administration, or anticipated\n             requirement for systemic immunosuppressive medications during the trial.Xx_NEWLINE_xXPatients who are eligible for and willing to receive treatment with blinatumomab, inotuzumab ozogamizin, or tisagenlecleucelXx_NEWLINE_xXIn the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents.Xx_NEWLINE_xXPatient must have relapsed/refractory disease with an indication for treatmentXx_NEWLINE_xXSubject must have received no prior treatment for AML; hydroxyurea is not considered a treatment and is allowedXx_NEWLINE_xXPatients who received imatinib and 1 or 2 other TKIs as prior treatment regimens. Patients who experienced intolerance to prior therapies must have objective disease progression prior to enrollment onto BLU-285-1303 study.Xx_NEWLINE_xXPatients who have received prior treatment with avapritinib or regorafenib.Xx_NEWLINE_xXPatients who have received more than 3 different prior TKI treatment regimens.Xx_NEWLINE_xXPrior treatment with ixazomibXx_NEWLINE_xXWOCBP must use appropriate method(s) of contraception from the time of enrollment for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post treatment completion for subjects enrolled to treatment arm A (nivolumab). Subjects enrolled to treatment arm B (nivolumab + bevacizumab) must use appropriate method(s) of contraception for 6 months post treatment completion.Xx_NEWLINE_xXPrevious treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization.Xx_NEWLINE_xXDose Expansion cohorts: Prior treatment with osimertinib (Tagrisso®). Prior treatment with osimertinib (Tagrisso®) is allowed for subjects participating in the dose escalation portion of the studyXx_NEWLINE_xXCohort #1: received only frontline CD20-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy for patients with DLBCL; monotherapy rituximab or other CD20-directed immunotherapy prior to frontline chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the frontline treatment plan are permitted; last treatment dose should be 3 weeks before start of study treatmentXx_NEWLINE_xXCohort #2: prior treatment with ibrutinib is allowed; patients should not have received any anti-lymphoma therapy within 3 weeks from start of study treatment, with the exception of ibrutinibXx_NEWLINE_xXIf a patient engages in sexual intercourse with a woman of childbearing potential, a condom and another form of birth control must be used during and for 100 days after completing treatment with CORT125281 or enzalutamide. A condom is required during and for 100 days after completing treatment with enzalutamide if a patient is engaged in sexual activity with a pregnant woman. Patients must also agree to avoid sperm donation during the study and for at least 100 days after the final treatment administration.Xx_NEWLINE_xXCohort A: Patients must have progressed during treatment with abirateroneXx_NEWLINE_xXReceived chemotherapy, radiotherapy, immunotherapy, or any investigational cancer therapies within 28 days prior to the first dose of enzalutamide and/or CORT125281, or treatment with such therapies is planned during protocol treatmentXx_NEWLINE_xXReceived prior treatment with enzalutamide, orXx_NEWLINE_xXReceived herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC- HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation or plans to initiate treatment with these products/alternative therapies during the entire duration of the studyXx_NEWLINE_xXUse of any prohibited concomitant medications within 14 days prior to treatment start, or use of prohibited concomitant medications within the outlined windows\r\n* Note: Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to treatment startXx_NEWLINE_xXConcurrent treatment with non-permitted drugs and other interventions.Xx_NEWLINE_xXPrevious treatment with dual PI3K/mTOR inhibitors, TORC1/2 inhibitors or TORC1 inhibitors.Xx_NEWLINE_xXPatients must have had at least prior treatment with a fluoropyrimidine and either oxaliplatin or irinotecan.Xx_NEWLINE_xXHad prior treatment with GliadelXx_NEWLINE_xXAbility to comply with treatment, PK and test schedulesXx_NEWLINE_xXPrior treatment with CD74 targeting therapyXx_NEWLINE_xXWilling to undergo mandatory biopsy at screening and on treatment. Part A only: the first 3 subjects in each cohort are exempt from this requirement.Xx_NEWLINE_xXA medically appropriate candidate for ibrutinib treatment (based on the judgement of the clinical investigator).Xx_NEWLINE_xXRadiologically documented disease progression on previous osimertinib treatment.Xx_NEWLINE_xXConcomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within 2 weeks prior to starting treatment. Concurrent dexamethasone is allowed.Xx_NEWLINE_xXTreatment with any of the drugs listed in Section 8.4.5 at the time of study treatment initiation.Xx_NEWLINE_xXConcurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXPatients with active infection or with a fever > 38.5 degrees (^0) Celsius (C) within three days prior to the first treatmentXx_NEWLINE_xXPrevious treatment with osimertinib, or a 3rd generation EGFR TKI. NOTE: Patients who are receiving initial osimertinib (6-12 weeks) outside this study are not excludedXx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatmentXx_NEWLINE_xXSubjects taking prohibited medications with the exception of systemic corticosteroids. A washout period of at least 5 elimination half-lives (or as clinically indicated) should occur for prohibited medications prior to the start of treatmentXx_NEWLINE_xXHas an adequate treatment washout period prior to enrollmentXx_NEWLINE_xXRelapse/refractory is defined as at least 1 course of treatment for AML excluding any patients treated with azacitidine or decitabineXx_NEWLINE_xXAny prior treatment with azacitidine or decitabineXx_NEWLINE_xXADDITIONAL EXCLUSION CRITERIA for subjects on the arm of combination treatment of pembrolizumab and ramucirumab.\r\n* The subject has a known allergy or hypersensitivity to ramucirumab.\r\n* The subject is receiving chronic therapy with any of the following within 7 days prior to the first dose of trial treatment:\r\n** Nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents), or \r\n** Other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide). Aspirin use at doses up to 325 mg/day is permitted.\r\n* The subject received previous systemic chemotherapy with a cumulative dose of > 900 mg/m^2 of epirubicin or > 400 mg/m^2 of doxorubicin. \r\n* The subject has a significant bleeding disorder or vasculitis or had a grade >= 3 bleeding episode within 12 weeks prior to the first dose of study drug.\r\n* The subject experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to the first dose of trial treatment.\r\n* The subject experienced any grade 3 or 4 venous thromboembolic event (VTE) that is considered by the investigator to be life-threatening or that is symptomatic and not adequately treated by anticoagulation therapy, within 6 months prior to the first dose of study drug.\r\n* The subject has symptomatic congestive heart failure (CHF; New York Heart Association IIIV) or symptomatic or poorly controlled cardiac arrhythmia.\r\n* The subject has uncontrolled hypertension, as defined in Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, prior to initiating study treatment, despite antihypertensive intervention. CTCAE version 4.0 defines uncontrolled hypertension as grade > 2 hypertension; clinically, the patient continues to experience elevated blood pressure [systolic > 160 mmHg and/or diastolic > 100 mmHg] despite medications).\r\n* The subject has a history of gastrointestinal (GI) perforation or fistula within 6 months prior to the 1st dose of treatment.\r\n* The subject has an acute or subacute bowel obstruction or history of chronic diarrhea that is considered clinically significant in the opinion of the investigator.\r\n* The subject has a serious non healing: (a) wound, (b) peptic ulcer, or (c) bone fracture, within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXSTUDY TREATMENT: Lymphocyte count >= 300/uL within 14 days prior to the first study treatment.Xx_NEWLINE_xXRx with an investigational drug w/in 1 month of infusion, other than for treatment of their underlying diseaseXx_NEWLINE_xXPatients excluded with any prior treatment of pneumonitis requiring corticosteroids.Xx_NEWLINE_xXDocumented progression of disease, defined as any progression that requires a change in treatment, prior to randomizationXx_NEWLINE_xXActive malignancies (that is, requiring treatment change in the last 24 months) other than urothelial cancer (except skin cancers within the last 24 months that is considered completely cured)Xx_NEWLINE_xXResearch participants does NOT have any known history of congestive heart failure (CHF) or cardiac symptoms consistent with NYHA classification III-IV within 6 months prior to Day 1 of protocol treatment, cardiomyopathy, myocarditis, myocardial infarction (MI), exposure to cardiotoxic medications or with clinical history suggestive of the above must have an EKG and echocardiogram (ECHO) performed within 42 days prior to registration and as\r\nclinical indicated while on treatmentXx_NEWLINE_xXSubjects may have previously progressed on treatment with one of the 3 agents being used in this trial or treatment with other checkpoint inhibitors, as long as they have recovered from previous toxicity; subjects that previously progressed on treatment with a combination of any 2 of the 3 agents being used in this trial are eligible for the triplet cohort onlyXx_NEWLINE_xXOn treatment with ruxolitinib for at least 3 months and have been on a stable dose for at least 8 weeks and have not achieved a complete response (CR) by International Working Group (IWG) criteriaXx_NEWLINE_xXMust be agreeable to the mandatory research tumor biopsies (pre-treatment and on-treatment); tumor biopsies are mandatory at pre-treatment and at on-treatment; there is an optional biopsy at post-progressionXx_NEWLINE_xXPatient received BCG treatment for UC during the 6 months prior to Visit 1.Xx_NEWLINE_xXFor the CPI-Treated Expansion Cohort: Subject must have received prior treatment with a CPI in the metastatic setting.Xx_NEWLINE_xXDiagnosis: Patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.Xx_NEWLINE_xXTreatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresisXx_NEWLINE_xXImmunotherapy-naive and have either progressed on, are intolerant to, or refused treatment with sorafenib. Subjects who receive treatment with systemic therapies other than sorafenib are not eligible.Xx_NEWLINE_xXIn stratum A, patients must have failed one prior systemic chemotherapy regimen; in stratum B, patients must have failed one prior systemic chemotherapy regimen, which must include cladribine/cytarabine or are not considered to be eligible for such treatment; in stratum C, Rosai Dorfman disease (RDD) patients must have failed treatment with corticosteroid; Erdheim Chester disease (ECD) patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatmentXx_NEWLINE_xXPatients demonstrating disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment,Xx_NEWLINE_xXParticipant has received treatment with the following:Xx_NEWLINE_xXNo previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP])Xx_NEWLINE_xXReceived any previous systemic treatment for cGVHD with the exception of corticosteroids administered for cGVHD within the 72 hours prior to signing the informed consent form.Xx_NEWLINE_xXReceived prior treatment for cancer with a camptothecin-derived agent.Xx_NEWLINE_xXPrior treatment with NKTR-102.Xx_NEWLINE_xXPrevious treatment with a pyrrolobenzodiazepine (PBD)-based drug Additional exclusion criteria for the SC-003 and ABBV-181 combination treatment regimen:Xx_NEWLINE_xXNo prior therapy with mTOR inhibitors except for rapalog treatment as part of graft-versus-host (GVH) prophylaxis or treatmentXx_NEWLINE_xXPrior intra-anal use of topical 5-fluorouracil 5% or imiquimod 2.5%, 3.75% or 5% for treatment of HSIL at any point, use of intra-anal or topical 5-fluorouracil 5% or imiquimod 2.5%, 3.75% or 5% for treatment of condyloma within 6 months prior to randomization or perianal imiquimod 2.5%, 3.75% or 5% or topical 5-fluorouracil 5% within 6 months prior to randomizationXx_NEWLINE_xXExtensive concurrent perianal or lower vulvar HSIL or condyloma requiring a different treatment modality than the study treatment, or treatment that cannot be deferred in observation arm, per examining providerXx_NEWLINE_xXTreatment for anal or perianal HSIL, low-grade squamous intraepithelial lesion (LSIL) or condyloma within 4 months of randomization; please note that infrared coagulation (IRC) or electrocautery of a biopsy site to stop bleeding does not constitute treatmentXx_NEWLINE_xXPatients must have received treatment on PBTC-029 or PBTC-029B for a minimum of 12 courses with at least stable disease, or had a sustained response (partial response [PR]/ complete response [CR]) but remained on treatment < 12 coursesXx_NEWLINE_xXFor phase II trial portion, patients will be enrolled as two parallel cohorts:\r\n* Arm A (treatment naive): patients who are newly diagnosed and treatment naive; patient who underwent curative intent chemotherapy and/radiation in the neoadjuvant or adjuvant setting are allowed to enroll if tumor recurrence occurred greater than 6 months from completion of therapy; patients with NSCLC tumor known to harbor a genomic aberration for which FDA approved treatment is available (i.e, non-resistant EGFR mutations, EGFR T790M mutation, ALK rearrangement, ROS rearrangement, BRAF V600E mutation) are allowed to enroll if they have received prior treatment with the FDA approved targeted therapy\r\n* Arm B (pre-treated group): patients who have received prior immunotherapy; patients who are primary refractory to immunotherapy (i.e., patients who were previously treated with immunotherapy and did not at least achieve stable disease on first imaging assessment on immunotherapy) or have relapsed disease (i.e., patients that were treated with immunotherapy, achieved at least stable disease on first imaging assessment and subsequently developed disease progression or relapse); patients with NSCLC tumor known to harbor a genomic aberration for which FDA approved treatment is available (i.e, non-resistant EGFR mutations, EGFR T790M mutation, ALK rearrangement, ROS rearrangement, BRAF V600E mutation) are allowed to enroll if they have received prior treatment with the FDA approved targeted therapyXx_NEWLINE_xXPrior treatment with nintedanib (BIBF1120)Xx_NEWLINE_xXTreatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)Xx_NEWLINE_xXDocumented disease progression occurring within 12 months from the last treatment with curative intentXx_NEWLINE_xXNo prior treatment with an anthracycline and taxaneXx_NEWLINE_xXPrior treatment with cabozantinib or other cMET inhibitors.Xx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment.Xx_NEWLINE_xXThe subject has experienced any of the following: a. clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment; b. hemoptysis >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment; c. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment. Tumor invading any major blood vessel at the time of study enrollment.Xx_NEWLINE_xXAny prior treatment for NSCLCXx_NEWLINE_xXRelapsed or refractory after at least one prior treatment regimenXx_NEWLINE_xXHigh-risk neuroblastoma with either primary refractory or secondary refractory osteomedullary disease (persistent neuroblastoma at osteomedullary sites after prior treatment)Xx_NEWLINE_xXSubjects may not be enrolled concurrently on other treatment studiesXx_NEWLINE_xXTreatment with rituximab monotherapy within 3 months or rituximab combination therapies (example, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollmentXx_NEWLINE_xXOther malignancies requiring active treatment in the last 6 monthsXx_NEWLINE_xXCurrently under alcohol or drug abuse rehabilitation or treatment programXx_NEWLINE_xXAny prior treatment for SCCHNXx_NEWLINE_xXPatient has been previously permanently discontinued from study treatment in the parent protocol.Xx_NEWLINE_xXPrincipal Investigator adjudicated efficacy response defined as either transfusion independence\, \stable disease\, \minor HI-E response\ or \major HI-E response\ and in the opinion of the Principal Investigator the patient may benefit from continued treatment with OPN-305 monotherapy or combination treatment with azacitidine.Xx_NEWLINE_xXPatients must have exhausted all available therapies known to provide clinical benefit and has progressed, relapsed or is refractory to last line of treatmentXx_NEWLINE_xXA WOCBP who agrees to follow the contraceptive guidance in protocol during the treatment period and for at least 120 days after the last dose of trial treatment.Xx_NEWLINE_xXPatients with persistent disease and local recurrence must not be amenable to local treatment.Xx_NEWLINE_xXPatients who have relapsed or have MRD after HCT may receive other agents for treatment of disease and remain eligible for the protocolXx_NEWLINE_xXPresence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by irRECISTXx_NEWLINE_xXBaseline pulmonary function tests (PFTs) available or will be obtained prior to treatment startXx_NEWLINE_xXUnwillingness to accept the treatment;Xx_NEWLINE_xXResolution of treatment-related toxicities.Xx_NEWLINE_xXPrior treatment with immune checkpoint inhibitorsXx_NEWLINE_xXInclusion Criteria:\n\n        For inclusion in this study, patients must fulfil the following criteria:\n\n          -  Has read and understands the informed consent form (ICF) and has given written\n             informed consent prior to any study procedures.\n\n          -  Female or male aged ?18 years.\n\n          -  Has completed 1 of the parent AZD1775 clinical pharmacology studies (ie, D6014C00002,\n             D6014C00003, D6014C00004, D6014C00005, or D6014C00006) and in the Investigator's\n             opinion will continue to benefit from treatment with AZD1775. Patients who discontinue\n             early from the parent study will be considered by the Sponsor and treating physician\n             on a case-by-case basis.\n\n          -  Any prior radiation must have been completed at least 7 days prior to the start of\n             study treatment, and patients must have recovered from any acute effects prior to the\n             start of study treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1.\n\n          -  Baseline laboratory values within 7 days of study treatment initiation in the CA\n             study:\n\n               -  Absolute neutrophil count (ANC) ?1500/?L.\n\n               -  Haemoglobin ?9 g/dL.\n\n               -  Platelets ?100,000/?L.\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 x upper\n                  limit of normal (ULN) or ?5 x ULN if known hepatic metastases.\n\n               -  Serum bilirubin within normal limits or ?1.5 x ULN in patients with liver\n                  metastases; or total bilirubin ?3.0 x ULN with direct bilirubin within normal\n                  limits in patients with well documented Gilbert's Syndrome.\n\n               -  Serum creatinine ?1.5 x ULN, or measured creatinine clearance (CrCl) calculated\n                  by Cockcroft-Gault method ?45 mL/min (confirmation of creatinine clearance is\n                  only required when creatinine is >1.5 x ULN) CrCl (glomerular filtration rate) =\n                  (140-age) x (weight/kg) x Fa (72 x serum creatinine mg/dL) where F = 0.85 for\n                  females and F = 1 for males.\n\n          -  Female patients who are of non-childbearing potential and fertile women of\n             childbearing potential (WoCBP) who agree to use adequate contraceptive measures that\n             are in place during screening (or consent), for the duration of the study, and for 1\n             month after treatment stops; who are not breastfeeding; and who have a negative serum\n             or urine pregnancy test prior to the start of study treatment.\n\n          -  Male patients must be willing to use barrier contraception (ie, condoms) for the\n             duration of the study and for 3 months after study treatment discontinuation.\n\n          -  Willingness and ability to comply with the study and the follow-up procedures.\n\n        Exclusion Criteria:\n\n        Patients must not enrol in this study if any of the following exclusion criteria are\n        fulfilled:\n\n          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca\n             personnel and/or personnel at the study centre).\n\n          -  Previous enrolment and received study treatment in the present study. Patients can,\n             however, be re-screened if the reason for the screen failure no longer exists.\n\n          -  Concurrent enrolment in another clinical study, unless it is an observational\n             (non-interventional) clinical study or the follow-up period of an interventional\n             study.\n\n          -  Must not have received another systemic anti-cancer therapy in the interval following\n             participation in the AZD1775 clinical pharmacology study and the start of treatment on\n             the CA protocol.\n\n          -  Not developed any clinical findings suggestive of brain metastasis. Patients continue\n             to be neurological stable and remain off systemic corticosteroids following treatment\n             of known brain metastases.\n\n          -  Did not tolerate AZD1775 in the parent study in the opinion of the Investigator.\n\n          -  Where a course of palliative radiotherapy was indicated, the last fraction must have\n             been delivered before the start of study treatment on the CA study.\n\n          -  Major surgical procedures ?28 days of beginning study treatment, or minor surgical\n             procedures ?7 days. No waiting period required following port-a-cath placement or\n             other central venous access placement.\n\n          -  Grade >1 toxicities from prior therapy, according to the Common Terminology Criteria\n             for Adverse Events (CTCAE), excluding alopecia or anorexia.\n\n          -  Continue to be able to swallow oral medication, did not undergo placement of a\n             percutaneous endoscopic gastrostomy tube and did not require total parenteral\n             nutrition.\n\n          -  Has had prescription or non-prescription drugs or other products known to be sensitive\n             to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be\n             moderate to strong inhibitors/inducers of CYP3A4 between the parent study and entry\n             into this CA study. Co administration of aprepitant or fosaprepitant during this study\n             is prohibited.\n\n          -  Has consumed herbal preparations between the parent study and entry into this CA\n             study.\n\n          -  Has consumed grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges between the parent study\n             and entry into the CA study.\n\n          -  Any known hypersensitivity or contraindication to AZD1775 or to the components\n             thereof.\n\n          -  Any of the following cardiac diseases currently or within the last 6 months as defined\n             by the New York Heart Association ?Class 2:\n\n               -  Unstable angina pectoris.\n\n               -  Congestive heart failure.\n\n               -  Acute myocardial infarction.\n\n               -  Conduction abnormality not controlled with pacemaker or medication.\n\n               -  Significant ventricular or supraventricular arrhythmias (patients with chronic\n                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities\n                  are eligible).\n\n          -  AZD1775 should not be given to patients who have a history of Torsades de pointes\n             unless all risk factors that contributed to Torsades have been corrected. AZD1775 has\n             not been studied in patients with ventricular arrhythmias or recent myocardial\n             infarction.\n\n          -  Patient with mean resting QTc interval (specifically QTc calculated using the\n             Fridericia formula [QTcF]) >450 ms for males and >470 ms for females from 3\n             electrocardiograms (ECGs) performed within 2 to 5 minutes apart during screening, or\n             congenital long QT syndrome.\n\n          -  Pregnant or lactating female patients.\n\n          -  Serious, symptomatic active infection at the time of study entry, or another serious\n             underlying medical condition that would impair the ability of the patient to receive\n             study treatment.\n\n          -  Active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).Xx_NEWLINE_xXInclusion Criteria\n\n        Subjects must fulfil all of the following requirements:\n\n          1. A histologically or cytologically confirmed cancer that is metastatic and is approved\n             to be treated with Nivolumab or Atezolizumab with the following origins: melanoma,\n             NSCLC, HNSCC, RCC, and urothelial cancer, as well as the following:\n\n               1. Subjects must not be considered eligible for a potentially curative resection.\n\n               2. Subjects who are eligible for PD-1/PD-L1 therapy or who have exhausted all\n                  standard therapies for their disease except for immunotherapy.\n\n                  either c) or d)\n\n               3. Subjects progressed on their prior treatment before initiating treatment on\n                  current study.\n\n                  Or\n\n               4. Subjects, who are currently being treated with PD-1 or PD-L1 inhibitors Nivolumab\n                  or Atezolizumab and have achieved at least stable disease (SD), and who, in the\n                  judgment of their treating physicians, could benefit from the addition of\n                  DSP-7888 vaccine to improve or maintain their response.\n\n             In expansion part only: All subjects who are candidates for immunotherapy including\n             PD-1/PD-L1 inhibitors are eligible to enroll in the study. Subjects must have at least\n             1 target lesion based on RECIST criteria and other supporting disease specific\n             evaluation criteria.\n\n          2. Subjects must be positive for at least 1 of the following human leukocyte antigens\n             (HLA):\n\n               1. HLA-A*02:01\n\n               2. HLA-A*02:06\n\n               3. HLA-A*24:02\n\n          3. ? 18 years of age.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          5. Either archival tumor tissue must be available or subject must consent to undergo a\n             tumor biopsy before administration of first dose.\n\n          6. Females of childbearing potential must have a negative serum pregnancy test.\n\n          7. Male or female subjects of child-producing potential must agree to use contraception\n             or use prevention of pregnancy measures (true abstinence) during the study and for 150\n             days after the last dose.\n\n          8. Total bilirubin of ? 2.0 mg/dL (? 3.0 mg/dL for subjects with known Gilbert's\n             syndrome)\n\n          9. Aspartate aminotransferase (AST) ? 3.0 × the upper limit of normal (ULN) or < 5 × ULN\n             if considered to be due to liver metastases.\n\n         10. Alanine transaminase (ALT) ? 3.0 × the upper limit of normal (ULN) or < 5 × ULN if\n             considered to be due to liver metastases.\n\n         11. Glomerular Filtration Rate > 40 mL/min.\n\n         12. Multigated acquisition (MUGA) scan or echocardiogram with left ventricular ejection\n             fraction (LVEF) > 40%.\n\n         13. Life expectancy ? 3 months.\n\n         14. Subjects must be willing to provide a personally signed and dated informed consent\n             document.\n\n        Exclusion Criteria\n\n        Subjects with any of the following will be excluded from the study:\n\n          1. Anticancer chemotherapy (including molecular targeted drugs), immunotherapy, or\n             investigational agents within 7 days of the first dose of DSP-7888; radiotherapy\n             within 4 weeks of the first dose of DSP-7888. Subjects may begin DSP-7888 on a date\n             determined by the Investigator and medical monitor for the Sponsor provided that all\n             treatment related adverse events (AEs) have resolved or have been deemed irreversible.\n             This exclusion is not applied to subjects who meet the inclusion criterion 1d.\n\n          2. In expansion part only: Subjects progressed on their prior checkpoint inhibitors\n             (PD-1/PD-L1) treatment before initiating treatment on current study.\n\n          3. Major surgery within 4 weeks prior to study treatment.\n\n          4. Subject has received a live vaccine within 30 days prior to the first dose.\n\n          5. Any known, untreated brain metastases. Subjects with treated brain metastases must be\n             clinically stable for 4 weeks after completion of treatment for brain metastases and\n             have radiographic image documentation of stability. Subjects must have no clinical\n             symptoms from brain metastases and not have required systemic corticosteroids > 10\n             mg/day prednisone or equivalent for at least 2 weeks prior to the first dose of study\n             drug.\n\n          6. Subject has multifocal glioblastoma.\n\n          7. Pregnant or breastfeeding.\n\n          8. Subject has an active autoimmune disease requiring immunosuppression with the\n             exception of subjects with isolated vitiligo, resolved childhood asthma or atopic\n             dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid subjects with\n             a history of Grave's disease.\n\n             a. Subjects with controlled hyperthyroidism must be negative for thyroglobulin and\n             thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to study\n             drug administration.\n\n          9. Subject has interstitial lung disease or active, non-infectious pneumonitis.\n\n         10. Known hypersensitivity to a component of protocol therapy.\n\n               1. Subjects with known hypersensitivity to any of the components of DSP-7888 Dosing\n                  Emulsion.\n\n               2. Subjects with known hypersensitivity to Nivolumab or Atezolizumab are excluded\n                  from receiving combination therapy that includes the agent to which they are\n                  hypersensitive.\n\n         11. Uncontrolled concurrent illness including, but not limited to, ongoing or active\n             infection, clinically significant non-healing or healing wounds, symptomatic\n             congestive heart failure, unstable angina pectoris, severe and/or uncontrolled cardiac\n             arrhythmia, significant pulmonary disease, uncontrolled infection or psychiatric\n             illness/social situations that would limit compliance with study requirements.\n\n         12. Subjects with a history of another primary cancer with the exception of: a) curatively\n             resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ;\n             c) localized prostate cancer not requiring systemic therapy; and d) any another cancer\n             from which the subject has been disease free for ? 2 years that, in the opinion of the\n             Investigator and medical monitor for the Sponsor, will not affect subject outcome in\n             the setting of the current diagnosis.\n\n         13. Patient has a QTcF (QT corrected based on Fridericia's equation) interval > 480 msec\n             (CTCAE = Grade 2) or other factors that increase the risk of QT prolongation or\n             arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT\n             interval syndrome) at screening. (Patients with bundle branch block and a prolonged\n             QTc interval should be reviewed by the Medical Monitor for potential inclusion.)\n\n         14. Subject has a medical history of frequent or sustained ventricular ectopy.\n\n         15. Subject has, in the opinion of the treating Investigator, any concurrent conditions\n             that could pose an undue medical hazard or interfere with the interpretation of the\n             study results.\n\n         16. Known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or\n             untreated hepatitis C; patients who have completed a course of anti-viral treatment\n             for hepatitis C are eligible.\n\n         17. Subject has baseline signs and symptoms consistent with clinically significant,\n             decreased pulmonary function: (1) blood saturation oxygen level (SpO2) < 90% at rest\n             on room air; (2) dyspnea at rest or required supplemental oxygen within 2 weeks of\n             study enrollment.Xx_NEWLINE_xXInclusion Criteria:\n\n          -  Patient has histologically or cytologically proven advanced (unresectable) or\n             metastatic cancer as outlined below according to study part and disease type:\n\n          -  Part A: Patients with previously treated advanced or metastatic cancer. Patient may\n             have received no more than 4 lines of treatment for advanced or metastatic cancer.\n             Hormonal treatment will not be considered a prior line of treatment.\n\n          -  Part B: Patients with advanced or metastatic cancer for which treatment with\n             carboplatin-paclitaxel is considered appropriate therapy. Patient may have received no\n             more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment\n             will not be considered a prior line of treatment.\n\n          -  Part C: Patients with previously treated advanced or metastatic cancer. Patient may\n             have received no more than 4 lines of treatment for advanced or metastatic cancer.\n             Hormonal treatment will not be considered a prior line of treatment.\n\n          -  Part D: Patients in whom carboplatin-paclitaxel and bevacizumab is considered\n             appropriate therapy. Patient may have received no more than 1 prior line of\n             chemotherapy in the metastatic setting. Hormonal treatment will not be considered a\n             prior line of treatment.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          -  Patient has adequate organ function\n\n          -  Female patient has a negative serum pregnancy test within 72 hours prior to taking\n             study treatment if of childbearing potential and agrees to abstain from activities\n             that could result in pregnancy from screening through 180 days after the last dose of\n             study treatment, or is of non-childbearing potential.\n\n          -  Male patient agrees to use an adequate method of contraception and not donate sperm\n             starting with the first dose of study treatment through 90 days after the last dose of\n             study treatment. Note: Abstinence is acceptable if this is the established and\n             preferred contraception for the patient.\n\n          -  Patient has measurable lesions by RECIST v1.1.\n\n        For Part A and C, in addition to the general inclusion criteria, patients must also meet\n        the following additional criterion to be considered eligible to participate in this study:\n\n          -  Patient is able to take oral medications.\n\n          -  For patients to be eligible for any parts of the study using niraparib 300 mg as a\n             starting dose, a screening actual body weight ? 77 kg and screening platelet count ?\n             150,000 u/L is necessary.\n\n        Exclusion Criteria:\n\n        (Patients will not be eligible for the study entry if any of the following criteria are\n        met)\n\n          -  Patient has known active central nervous system metastases, carcinomatous meningitis,\n             or both.\n\n          -  Patient has a known additional malignancy that progressed or required active treatment\n             within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous\n             cell carcinoma of the skin that has undergone potentially curative therapy, or in situ\n             cervical cancer.\n\n          -  Patient is considered a poor medical risk due to a serious, uncontrolled medical\n             disorder, nonmalignant systemic disease, or active infection that requires systemic\n             therapy.\n\n          -  Patient has a condition (such as transfusion-dependent anemia or thrombocytopenia),\n             therapy, or laboratory abnormality that might confound the study results or interfere\n             with the patient's participation\n\n          -  Patient is pregnant or expecting to conceive children within the projected duration of\n             the study, starting with the screening visit through 180 days after the last dose of\n             study treatment.\n\n        Note: No data are available regarding the presence of niraparib or its metabolites in human\n        milk, or on its effects on the breastfed infant or milk production. Because of the\n        potential for serious adverse reactions in breastfed infants from niraparib, female\n        patients should not breastfeed during treatment with niraparib and for 1 month after\n        receiving the final dose.\n\n          -  Patient has a known history of human immunodeficiency virus (type 1 or 2 antibodies).\n\n          -  Patient has known active hepatitis B or hepatitis C.\n\n          -  Patient has an active autoimmune disease that has required systemic treatment in the\n             past 2 years.\n\n          -  Patient has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2,\n             anti-CTLA-4 including ipilimumab), or any other antibody or drug specifically\n             targeting T-cell co-stimulation or checkpoint pathways.\n\n          -  Patient has undergone prior treatment with a known PARP inhibitor.\n\n          -  Known history or current diagnosis of MDS or AML.\n\n        For Parts C and D only, patients will not be eligible for study entry if the following\n        additional exclusion criterion is met:\n\n          -  Patient has clinically significant cardiovascular disease (e.g., significant cardiac\n             conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac\n             arrhythmia or unstable angina, New York Heart Association Grade 2 or greater\n             congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or\n             greater peripheral vascular disease, and history of cerebrovascular accident [CVA])\n             within 6 months of enrollment.\n\n          -  Patient has a history of bowel obstruction, including subocclusive disease, related to\n             the underlying disease and history of abdominal fistula, gastrointestinal perforation,\n             or intra abdominal abscesses. Evidence of recto-sigmoid involvement by pelvic\n             examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.\n\n          -  Patient has proteinuria as demonstrated by urine protein: creatinine ratio ?1.0 at\n             screening or urine dipstick for proteinuria ?2 (patients discovered to have ?2\n             proteinuria on dipstick at baseline should undergo 24-hour urine collection and must\n             demonstrate <2 g of protein in 24 hours to be eligible).\n\n          -  Patient is at increased bleeding risk due to concurrent conditions (e.g., major\n             injuries or surgery within the past 28 days prior to start of study treatment, history\n             of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or\n             clinically significant hemorrhage within the past 3 months).\n\n          -  Patient has a known hypersensitivity to bevacizumab components or excipientsXx_NEWLINE_xXPrior treatment with TAS-102Xx_NEWLINE_xXConcomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs), during the treatment phase of the study and within 2 weeks prior to starting treatmentXx_NEWLINE_xXPrior treatment with cisplatin and/or gemcitabineXx_NEWLINE_xXConcurrent treatment with bisphosphonates or denosumab is requiredXx_NEWLINE_xXActive gout or inflammatory arthritis requiring treatmentXx_NEWLINE_xXInclusion Criteria:-\n\n          -  Participants with histologically confirmed advanced ovarian cancer or triple negative\n             breast cancer who in the opinion of the Investigator are appropriate for this study\n\n          -  Measurable disease by RECIST criteria version 1.1 prior to study drug administration\n\n          -  Performance status of 0 or 1 on the eastern Cooperative Oncology Group (ECOG) scale\n\n          -  Life expectancy, in the opinion of the Investigator, of at least 3 months\n\n          -  Disease-free of active second/secondary or prior malignancies for => 2 years with the\n             exception of squamous cell carcinoma of the skin, or carcinoma in situ of the cervix\n             or breast\n\n          -  Willing to provide the protocol specified tumor biopsies\n\n          -  Acceptable hematologic status, liver and renal function\n\n          -  Participants who have received prior treatment with CD137 agonists or immune\n             checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1\n             therapeutic antibodies, may be enrolled, provided the following requirements are met:\n\n               -  Minimum of 5 months from the last dose of anti-PD-1, anti-CTLA-4, anti-PD- L1 or\n                  CD137 agonist treatment\n\n               -  No history of severe immune-related adverse effects from CD137 agonist,\n                  anti?CTLA-4, anti-PD-1 or anti-PD-L1 (NCI CTCAE Grade 3 and 4). Any toxicity\n                  related to the therapy must have resolved completely, no residual toxicity as\n                  assessed by NCI CTCAE (v4.03)\n\n          -  Agree to use protocol defined methods of contraception\n\n        Exclusion Criteria:\n\n          -  Participants with history of prior malignancy except solid tumor treated curatively\n             more than 3 years ago without evidence of recurrence\n\n          -  Asymptomatic or symptomatic, untreated, or actively progressing central nervous system\n             (CNS) metastases\n\n          -  History of leptomeningeal disease\n\n          -  Uncontrolled tumor-related pain\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures. Participants with indwelling catheters are allowed.\n\n          -  Uncontrolled or symptomatic hypercalcemia\n\n          -  New York Heart Association Class III or IV cardiac disease, pericarditis, myocardial\n             infarction within the past 6 months, unstable arrhythmia\n\n          -  Fredericia-corrected QT interval (QTcF) > 470 milli seconds (msec) (female) or > 450\n             msec (male), or history of congenital long QT syndrome. Any electrocardiogram (ECG)\n             abnormality, including pericarditis, which in the opinion of the Investigator would\n             preclude safe participation in the study.\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections within 7 days of study\n             entry requiring systemic therapy\n\n          -  Known clinically important respiratory impairment\n\n          -  History of major organ transplant\n\n          -  History of an autologous or allogeneic bone marrow transplant\n\n          -  Serious non-malignant disease that could compromise protocol objectives in the opinion\n             of the Investigator and/or the Sponsor\n\n          -  Pregnant or nursing women\n\n          -  Any systemic anticancer therapy within 3 weeks prior to Cycle 1 Day 1\n\n          -  Any radiation treatment to metastatic site within <= 14 days of Cycle 1 Day 1\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days\n             prior to Cycle 1 Day 1 or anticipation of need for major surgical procedure during the\n             course of the study\n\n          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to\n             chimeric or humanized antibodies or fusion proteins\n\n          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster\n             ovary cells or any component of the atezolizumab formulation\n\n          -  Active or history of autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced\n             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic\n             organizing pneumonia), or evidence of active pneumonitis on screening chest computed\n             tomography (CT) scan. History of radiation pneumonitis in the radiation field\n             (fibrosis) is permitted\n\n          -  Positive test for Human immunodeficiency virus (HIV)\n\n          -  Active hepatitis B or hepatitis C\n\n          -  Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or\n             anticipation that such a live, attenuated vaccine will be required during the study\n\n          -  Treatment with investigational therapy within 28 days prior to initiation of study\n             treatment\n\n          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation\n             of study treatment\n\n          -  Consumption of agents which strongly inhibit CYP3A4 enzyme, within 7 days prior to the\n             first dose of study treatment and during the study\n\n          -  Consumption of agents which strongly induce CYP3A4 enzyme, within 14 days prior to the\n             first dose of study treatment and during the study\n\n          -  Treatment with systemic immuno-stimulatory agents within 4 weeks or five half-lives of\n             the drug (whichever is shorter) prior to the first dose of study treatment\n\n          -  Treatment with systemic corticosteroids or other systemic immunosuppressive\n             medications within 2 weeks prior to the first dose of study treatment, or, anticipated\n             requirement for systemic immunosuppressive medications during the trial\n\n          -  History of allergic reactions attributed to components of the formulated product(s)\n\n          -  Unwillingness or inability to comply with procedures required in this protocolXx_NEWLINE_xXPreviously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;Xx_NEWLINE_xXHistory of treatment with known kinase inhibiting agentsXx_NEWLINE_xXMust have an absolute blast count (ABC) of < 15 K/ul in the peripheral blood prior to initiating study treatment, performed within 10 days of treatment initiation; use of hydroxyurea to control blast counts prior to initiating study treatment is acceptableXx_NEWLINE_xXHave received prior treatment with olaratumab, doxorubicin, or ifosfamide, or have participated in other trials investigating olaratumab.Xx_NEWLINE_xXDisease status defined as refractory to or relapsed after >=1 prior treatment lines.Xx_NEWLINE_xXPrevious treatment with CD19-targeted CAR T cellsXx_NEWLINE_xXAt least one cutaneous lesion that is amenable to treatment with topical imiquimodXx_NEWLINE_xXPrior treatment as follows:Xx_NEWLINE_xXTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.Xx_NEWLINE_xXIn dose expansion, patients must be willing to undergo a pre-treatment biopsy, and four research PET imaging techniques (11C-Glutamine and 18F-FSPG), two pre-treatment and two after one cycle of treatmentXx_NEWLINE_xXPatients must be off sorafenib for at least four days prior to TACE treatmentXx_NEWLINE_xXPatients receiving anti-herpes medication (i.e., acyclovir, famciclovir, or valacyclovir) within 1 week prior to initiating HF10 treatment; patients may not require intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug other than intermittent topical useXx_NEWLINE_xXThe investigator must document that he/she believes the subject would not benefit from additional BCG treatment at the time of study entryXx_NEWLINE_xXSubjects can be treatment naive or may have had two prior regimens for recurrent cancer. They must be naive to treatment with PD-1/L1 or CTLA-4 inhibitors.Xx_NEWLINE_xXTaking medications with risk of prolonging the QT interval or inducing torsade de pointes, if such treatment cannot be discontinued or switched to a safe alternative medication prior to starting treatmentXx_NEWLINE_xXHas radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, or afatinib.Xx_NEWLINE_xXHas received treatment with any of the following:Xx_NEWLINE_xXPatients must have no prior history of treatment for HCC (treatment naive).Xx_NEWLINE_xXKnown active infection requiring parenteral anti-infective treatment at the time of initiation of treatmentXx_NEWLINE_xXTreatment with Somatostatin analogs injections (octreotide or lanreotide) for at least 6 months with a stable dose for at least the last three months of therapyXx_NEWLINE_xXInclusion Criteria:\n\n          -  Signed a written informed consent form(s).\n\n          -  ECOG performance status 0-1.\n\n          -  Women of childbearing potential must use adequate contraception (hormonal or barrier\n             method of birth control; abstinence).\n\n        HLA INCLUSION\n\n        • Pathologically confirmed advanced/metastatic solid tumors such as one of the following\n        indications:\n\n          -  Pathologically confirmed diagnosis of stage IIIB/IV recurrent NSCLC\n\n          -  Pathologically confirmed diagnosis of stage III/IV recurrent or metastatic HNSCC (oral\n             cavity, pharynx, larynx)\n\n        MAIN SCREENING & LEUKAPHERESIS INCLUSION\n\n          -  Pathologically confirmed advanced/metastatic solid tumors such as one of the following\n             indications:\n\n               -  Pathologically confirmed diagnosis of stage IIIB/IV recurrent NSCLC\n\n               -  Pathologically confirmed diagnosis of stage III/IV recurrent or metastatic HNSCC\n                  (oral cavity, pharynx, larynx)\n\n          -  HLA phenotype positive NOTE: Patients who were previously HLA-typed for participation\n             in other Immatics' sponsored clinical trials and were HLA phenotype positive may enter\n             IMA201-101 main screening\n\n          -  Patient's tumor must express specified biomarkers. NOTE: Patients who were previously\n             screened for participation in other Immatics' sponsored clinical trials and whose\n             biomarkers are positive for IMA201-101 based on IMA_Detect may enter IMA201-101\n             screening\n\n          -  Recommended acceptable organ and marrow function, defined per protocol\n\n          -  Measurable disease\n\n          -  At least one lesion (metastasis or primary tumor) being considered accessible for a\n             biopsy.\n\n          -  Adequate hepatic function, as defined per protocol\n\n          -  Serum creatinine within 1.5 x normal range for age OR creatinine clearance with a\n             recommended GFR ? 50 mL/min/1.73m2.\n\n          -  Adequate pulmonary function, defined per protocol and oxygen saturation >92% on room\n             air.\n\n          -  Acceptable coagulation status: INR ?2.0 x ULN and PTT ?2.0 x ULN.\n\n          -  Confirmed availability of production capacities for the patient's ACTengine IMA201\n             product prior to the leukapheresis.\n\n        TREATMENT INCLUSION:\n\n        Patients may enter the treatment phase if:\n\n          -  Disease recurs/progresses\n\n          -  Disease becomes refractory or previous anti-cancer treatment is no longer warranted\n\n               -  Available IMA201 T-cell product that was produced for the patient and passed all\n                  release tests.\n\n               -  Adequate hepatic function per protocol.\n\n               -  Serum creatinine within 1.5 x normal range for age or creatinine clearance with a\n                  recommended GFR ? 50 mL/min/1.73m2.\n\n               -  Measurable disease\n\n               -  Male patients must agree to use effective contraception or be abstinent while on\n                  study and for 90 days after the infusion of IMA201.\n\n        Exclusion Criteria:\n\n        • Pregnant or is breastfeeding.\n\n        HLA EXCLUSION:\n\n          -  History of other malignancies (except for adequately treated basal or squamous cell\n             carcinoma or carcinoma in situ) within the last 3 years.\n\n          -  Serious autoimmune disease\n\n        MAIN SCREENING EXCLUSION:\n\n          -  Any condition contraindicating leukapheresis.\n\n          -  Brain metastases.\n\n          -  HIV infection, active Hepatitis B or C infection\n\n          -  Concomitant therapy indicated with any of the following: interferons or other\n             non-study immunotherapy regimens; immunosuppressive agents; other investigational\n             therapies; or chronic use of systemic corticosteroids.\n\n          -  Severe immune-related toxicities related to checkpoint inhibitors defined per\n             protocol.\n\n          -  Cardiac conditions per protocol\n\n          -  Prior stem cell transplantation or solid organ transplantation.\n\n          -  Concurrent severe and/or uncontrolled medical disease that could compromise\n             participation in the study\n\n          -  Active diverticulitis, intra-abdominal abscess or gastrointestinal (GI) obstruction.\n\n          -  History of other malignancies (except for adequately treated basal or squamous cell\n             carcinoma or carcinoma in situ) within the last 3 years.\n\n          -  Serious autoimmune disease\n\n          -  History of hypersensitivity to cyclophosphamide, fludarabine or IL-2.\n\n          -  History of or current immunodeficiency disease or prior treatment compromising immune\n             function\n\n          -  Patients with active pneumonitis.\n\n          -  Investigator's judgment\n\n        TREATMENT EXCLUSION\n\n          -  Received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3\n             weeks (4 weeks for monoclonal antibodies or investigational drugs, 1 week for tyrosine\n             kinase inhibitor (TKI) (e.g. erlotinib, gefitinib) or the patient has not recovered\n             (from grade ?2 side effects of the previous therapy) prior to lymphodepletion regimen.\n\n          -  Active pneumonitis.\n\n          -  Patient unable to tolerate lymphodepletion, low-dose IL-2 and/or ACTengine IMA201\n             treatment.\n\n          -  Severe immune-related toxicities related to checkpoint inhibitors defined per\n             protocol.\n\n          -  Investigator's judgmentXx_NEWLINE_xXAny number of prior treatments allowed for patients under 65 years (y), over 65y must have at least one prior line of TKI treatment (excluding anaplastic patients).Xx_NEWLINE_xXInvestigator determined assessment of disease progression after treatment with pembrolizumab monotherapy, ORXx_NEWLINE_xXHave peripheral blood levels of IgG anti-?-glucan antibody (ABA) of ? 20 mcg/mL as determined by an ELISA test within 90 days prior to start of study treatmentXx_NEWLINE_xXHas a known prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatmentXx_NEWLINE_xXSubject and subject's parent(s) or legal guardian agree that the subject will not participate in another interventional study while on treatment.Xx_NEWLINE_xXDocumented failure to achieve at least PR with, or documented disease progression after, the most recent treatment regimen.Xx_NEWLINE_xXPatients who have received no prior systemic treatmentXx_NEWLINE_xXPatients with a known activating mutation in EGFR (exon 19 deletion, G719A, S768I, V769L, T790M, L833F, L858R, L861Q), must have progressed or been intolerant to treatment with a first-line EGFR TKI (erlotinib, afatinib, gefitinib, or osimertinib); patients whose tumors were found to have an EGFR T790M mutation must also have progressed or been intolerable to treatment with osimertinibXx_NEWLINE_xXPatients with a known ROS-1-rearrangement must have progressed or been intolerant to treatment with crizotinib or entrectinibXx_NEWLINE_xXDocumented disease progression or intolerance to treatment either during or after treatment with most recent therapyXx_NEWLINE_xXA new diagnosis of de novo, secondary or treatment-related AMLXx_NEWLINE_xXPatients must consent to pre and on treatment research biopsiesXx_NEWLINE_xXPresence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by RECIST 1.1Xx_NEWLINE_xXPrior treatment with PI3K/AKT inhibitorsXx_NEWLINE_xXSubjects with prior anti-PD-1, anti-PD-L1 treatment. For Arms A and D, subjects may not have had prior 4-1BB treatment. For Arms B and E, subjects may not have had prior OX40 treatment. For Arms C and F, subjects may not have had prior 4-1BB or OX40 treatment.Xx_NEWLINE_xXREP ELIGIBILITY: Has not had a partial or complete response to nivolumab treatmentXx_NEWLINE_xXPrior treatment with cabozantinib or erlotinibXx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal (GI) bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment; and\r\n* Clinically confirmed history of interstitial lung disease (ILD)Xx_NEWLINE_xXPrior treatment with histone deacetylase (HDAC) inhibitors (e.g. valproic acid, Zolinza (SAHA), romidepsin (Istodax)Xx_NEWLINE_xXPatients who require or are likely to require corticosteroid or other immunosuppressive drugs for intercurrent disease (any other significant medical problem related to or independent from the neuroblastoma or its treatment) while tentatively scheduled to receive treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product transfusion in order to avoid allergic transfusion reactionsXx_NEWLINE_xXTreatment with rituximab or other anti-B cell specific antibodies within previous 3 monthsXx_NEWLINE_xXPrior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignmentXx_NEWLINE_xXHistory of severe eczema (as determined by the investigator) requiring medical treatmentXx_NEWLINE_xXPrevious treatment with investigational gene or chimeric antigen receptor therapy;Xx_NEWLINE_xXPrior yttrium-90 radioembolization treatmentXx_NEWLINE_xXPatient willingness and disease accessible to pre-treatment, on-treatment tumor, and progression biopsies (core biopsies); a cell block from a pleural effusion may be substituted for a core biopsy; in select cases, patients may be allowed to enroll without a pre-treatment biopsy and/or continue treatment without an on-treatment biopsy (even if a pre-treatment biopsy is obtained) after speaking with the sponsor if performing the biopsy is technically challenging, poses significant risk to the patient, or may result in significant discomfortXx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasm; NOTE: Bisphosphonates are considered to be supportive care rather than therapy and are allowed while on protocol treatmentXx_NEWLINE_xXPrior treatment with pazopanibXx_NEWLINE_xXSubjects taking prohibited medications; a washout period of prohibited medications for a period of at least two weeks or as clinically indicated should occur prior to the start of treatmentXx_NEWLINE_xXPatient must be willing to undergo two biopsies- before and on-treatment, provided the procedure is not deemed high-risk and is clinically feasibleXx_NEWLINE_xXHistologically documented progressive squamous cell head and neck cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatmentXx_NEWLINE_xXAvailability of curative treatment option for the patient’s cancer, whether surgery, chemotherapy, radiation, or combination thereof, unless the patient has documented refusal of curative treatmentXx_NEWLINE_xXPatients who have received previous treatment with T-DM1 and had systemic progression of disease while on it, are ineligible; patients receiving treatment with TDM1 whose only site of disease progression was brain are allowed to enroll in this trialXx_NEWLINE_xXPrevious treatment with investigational gene or chimeric antigen receptor therapy.Xx_NEWLINE_xXLast dose of any antineoplastic therapy >= 2 weeks (including chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents); patients receiving hormone manipulation (e.g. selective estrogen receptor modulators [SERMs], aromatase inhibitors, luteinizing hormone releasing hormone [LHRH] agonist, etc.) for reasons other than treatment of metastatic breast cancer may continue this treatment at the discretion of the investigatorXx_NEWLINE_xXprior treatment as follows:Xx_NEWLINE_xXPrior treatment with murine and hu3F8 is allowedXx_NEWLINE_xXPrior treatment with irinotecan or temozolomide is permittedXx_NEWLINE_xXTreatment with any of the following: histamine receptor 2 inhibitors, proton pump inhibitors or antacids within 7 days of start of study treatment.Xx_NEWLINE_xXTreatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.Xx_NEWLINE_xXPrior treatment with carotuximab (TRC105)Xx_NEWLINE_xXHistory of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatmentXx_NEWLINE_xXHistory of peptic ulcer within the past 3 months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days prior to study treatmentXx_NEWLINE_xXThe diagnosis of relapsed FL must have been made within the last 6 months of screening if no other treatment is given for the FL in the interim; if an interim treatment is given within the last 6 month, re-biopsy will be required even if there is already a biopsy proven relapsed FL within the last 6 monthsXx_NEWLINE_xXSTUDY TREATMENT: Neutrophils >= 1500/ulXx_NEWLINE_xXSTUDY TREATMENT: Able to start study treatment in less than or equal to 90 days after completion of chemoradiationXx_NEWLINE_xXAchieved at least a partial response (PR) and did not have PD during treatment with or within 60 days after the last dose of bortezomib or carfilzomib, ORXx_NEWLINE_xXPrior treatment with nab-paclitaxel (abraxane)Xx_NEWLINE_xXInclusion Criteria\n\n          1. Histologic confirmation of metastatic NSCLC. For subjects with EGFR mutations, prior\n             therapy must have included an EGFR tyrosine kinase inhibitor. Subjects must not have\n             ALK rearrangement.\n\n          2. Availability of archival (diagnostic) specimens or willing to undergo a pre-treatment\n             biopsy.\n\n          3. Subjects with treated brain metastases must have been treated with surgery and/or\n             radiation therapy ? 21 days pre-study and must be clinically stable with no\n             requirement for steroids.\n\n          4. Laboratory parameters for vital functions should be in the normal range.\n\n          5. ECOG Performance Status ? 2.\n\n        Exclusion Criteria\n\n        Subjects may not enter the study if they fulfill any of the following criteria:\n\n          1. Treatment with an investigational agent within 4 weeks of starting treatment or prior\n             treatment with a checkpoint inhibitor (CTLA-4, PD-1 or PD-L1 antibodies).\n\n          2. Active, suspected or prior documented autoimmune disease, clinically significant\n             cardiovascular disease, or clinically uncontrolled hypertension.\n\n          3. History of pneumonitis or interstitial lung disease, or any unresolved immune-related\n             adverse events following prior therapy.\n\n          4. Major surgery within 4 weeks of starting treatment (or scheduled for surgery during\n             the projected course of the study) or prior cancer vaccine treatment or allogeneic\n             bone marrow transplantation.\n\n          5. Subjects who are immunosuppressed, including those with known immunodeficiency or have\n             active infection including tuberculosis or other serious illnesses.\n\n          6. Skin disease (e.g., psoriasis) that may prevent intradermal administration of the\n             vaccine into the target areas.Xx_NEWLINE_xXAdditional criteria for expansion cohorts: A) patients must have histologically-confirmed advanced or recurrent ovarian cancer with RPA or that had progression during prior PARP inhibitor treatment, endometrial cancer with RPA, or other solid tumor types with RPA; B) measurable and biopsy-accessible disease; C) patient must be willing to undergo biopsy procedure; D) prior treatment with PARP inhibitors is allowedXx_NEWLINE_xXPatients with an active infection requiring treatment or having an unexplained febrile illnessXx_NEWLINE_xXP-glycoprotein/ABCB1 inhibitors such as amiodarone, atorvastatin, azithromycin, clarithromycin; if previously on such agents, the patient must be off of it for at least two weeks prior to study treatmentXx_NEWLINE_xXHas had prior treatment with pembrolizumabXx_NEWLINE_xXHas had prior treatment with cabozantinibXx_NEWLINE_xXDocumented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC.Xx_NEWLINE_xXTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.Xx_NEWLINE_xXAdult subjects with advanced MDS requiring treatment with HMA and either refractory to at least 4 cycles or progressing after previously documented response\r\n* Patient must be treated within 6 months of the last HMA treatment and must be willing to be treated with the same agent they last received on this study\r\n* Prior treatment with novel HMA analog of decitabine on clinical trial is allowed; in such cases, decitabine will be used as the standard of care agentXx_NEWLINE_xXFOCBP and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment periodXx_NEWLINE_xXNo implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator’s opinionXx_NEWLINE_xXSubjects must not have history of scleroderma or lupus erythematosus with either cutaneous manifestation or requiring active treatmentXx_NEWLINE_xXSubjects must not have implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator’s opinionXx_NEWLINE_xXNo endoluminal stent in place at the time of treatmentXx_NEWLINE_xXPrior treatment with palbociclibXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Concurrent treatment with postmenopausal hormone replacement therapy; prior treatment must be stopped for at least 28 days prior to first baseline biopsyXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Blood or platelet transfusion within 7 days prior to treatment startXx_NEWLINE_xXNo restrictions on prior treatment to be eligibleXx_NEWLINE_xXAgreement to use adequate contraception from 2 weeks before the start of treatment with Minnelide and until 90 days after completion of treatment.Xx_NEWLINE_xXAbility to cooperate with study treatment and follow-up.Xx_NEWLINE_xXPrevious treatment with immune checkpoint inhibitorsXx_NEWLINE_xXAppropriate for treatment with sunitinib in the opinion of the treating physicianXx_NEWLINE_xXSubjects must have received intravesical treatment with at least two doses of BCG within six months of nivolumab treatment initiationXx_NEWLINE_xXHistory of neurological conditions that would confound assessment of treatment-emergent neuropathyXx_NEWLINE_xXHistory or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatmentXx_NEWLINE_xXCRITERIA FOR LYMPHODEPLETING CHEMOTHERAPY AND huJCAR014 TREATMENT: Presence of active acute or chronic GVHDXx_NEWLINE_xXWilling to refrain from using other lotions, creams, etc. during the treatment period;Xx_NEWLINE_xXAbstinence from all manner of physical contact near the treatment area during and up to 2 weeks after the treatment phase.Xx_NEWLINE_xXOpen or ulcerated wound(s) extending through the dermis within the treatment area;Xx_NEWLINE_xXElective surgery for treatment of the cutaneous metastases during the study and up to 4 weeks after the treatment period. Cutaneous metastases are required to remain in-situ and measurable for up to 2 weeks after last treatment to achieve study objectives;Xx_NEWLINE_xXNo prior treatment with ONC201Xx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXHistologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatmentXx_NEWLINE_xXPatients with options for treatment that are known to be curative are not eligible.Xx_NEWLINE_xXPrior treatment with axitinibXx_NEWLINE_xXPatients with prior invasive malignancies are allowed, provided they have been treated with definitive intent and have no evidence of active disease requiring treatment in the past 2 yearsXx_NEWLINE_xXPrevious treatment with talimogene laherparepvec or any other oncolytic virusXx_NEWLINE_xXSexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXReceived prior treatment with nab-paclitaxel.Xx_NEWLINE_xXAt time of day 1 of protocol treatment, subjects with central nervous system metastases must have been treated and must be asymptomatic and meet the following:\r\n* No concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids\r\n* Neurologic stability (lack of signs and symptoms greater than baseline prior to x-ray therapy [XRT]) until the time of dosing\r\n* For radiation treatment, patients must not receive stereotactic radiosurgery or gamma knife treatment within 7 days of day 1 of protocol treatment; for whole brain radiotherapy (WBRT), there should be at least 28 days between last day of WBRT and day 1 of protocol treatment\r\n* Note: patients with leptomeningeal disease or cord compression are excluded from the studyXx_NEWLINE_xXAny previous treatment with a hypomethylating agent, including decitabine, azacitidine, or SGI-110Xx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXConcurrent treatment with any chemotherapeutic agent.Xx_NEWLINE_xXProlonged antibiotic treatment (>= 10 days, within 3 weeks of enrollment) as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing anti anaerobic antibioticsXx_NEWLINE_xXConcurrent treatment with a non-permitted drugXx_NEWLINE_xXTreated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantationXx_NEWLINE_xXPrior treatment with trabectedinXx_NEWLINE_xXPatients with previous history of vandetanib or cabozantinib treatment for more than 28 days of treatment (patients have discontinued treatment for 28 days before enrolling)Xx_NEWLINE_xXPrior treatment with gene modified T cellsXx_NEWLINE_xXSexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXParticipant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for Myelodysplastic Syndrome is allowed except for use of cytarabine.Xx_NEWLINE_xXPrevious treatment with venetoclax and/or current participation in any other research study with investigational products.Xx_NEWLINE_xXAcute or chronic GVHD with ongoing active systemic treatmentXx_NEWLINE_xXNot suitable for SBRT treatmentXx_NEWLINE_xXPrior treatment with either decitabine or azacitidineXx_NEWLINE_xXPatient who has had prior treatment with mistletoeXx_NEWLINE_xXConcurrent treatment for cancer except agents specified within the treatment protocolXx_NEWLINE_xXPrior treatment with either venetoclax or ibrutinibXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter the studyXx_NEWLINE_xXPrior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:Xx_NEWLINE_xXCOHORT 1 (WITH SORFENIB): No previous systemic therapy including sorafenib or chemotherapy treatment; previous TACE and local treatments are permittedXx_NEWLINE_xXPatients who are simultaneously enrolled in any other treatment studyXx_NEWLINE_xXHave relapsed, refractory, or progressive disease following last line of treatmentXx_NEWLINE_xXPRE-SCREENING: No prior treatment with anetumab ravtansine (or any other mesothelin-based therapy)Xx_NEWLINE_xXPrevious assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the studyXx_NEWLINE_xXPatients must not have received prior treatment with bevacizumab.Xx_NEWLINE_xXPatients must not have had prior treatment of glioblastoma with stereotactic radiosurgery, brachytherapy, or carmustine-impregnated wafers (Gliadel).Xx_NEWLINE_xXPatients may not have undergone previous treatment with lomustine.Xx_NEWLINE_xXHas significant toxicities from prior treatment that have not resolved or stabilizedXx_NEWLINE_xXPatient is concurrently receiving chemotherapy, biologics, immunotherapy for cancer treatment; systemic anti-cancer treatment or investigational treatmentXx_NEWLINE_xXPrior treatment with cytotoxic drugs within 5 years of screening for any condition (example [e.g.], cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibodyXx_NEWLINE_xXRituximab within 12 months prior to study registration; only exception will be if rituximab was given for indications other than the treatment of aggressive lymphoma, or for one prior cycle of treatmentXx_NEWLINE_xXPer investigator's judgment, be eligible for treatment with valganciclovir.Xx_NEWLINE_xXBe on treatment with anti-CMV agents (ganciclovir, valganciclovir, foscarnet or cidofovir) for the current CMV infection for longer than 72 hours. Note: A subject who is receiving these anti-CMV agents must discontinue their use before the first dose of study treatment. A subjects who may be receiving cidofovir must discontinue this antiviral at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Note: Subjects who were administered these anti-CMV agents for prophylaxis, should have these treatments completed at least 2 weeks prior to the study entry or start of the treatment for current infection, whichever comes first and have undetectable CMV DNA (based on local laboratory) for at least two weeks between the completion of this treatment and onset of the current infection.Xx_NEWLINE_xXHave severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of study treatment that would preclude administration of oral medication.Xx_NEWLINE_xXPrior treatment with all-trans retinoic acid (ATRA) or systemic retinoid for the treatment of hematologic malignancy.Xx_NEWLINE_xXFor the treatment phase: Patients with any histological subtype are eligibleXx_NEWLINE_xXPatient must agree to the required research biopsies at baseline and after the two-week treatment with endocrine therapy in the initial part of the study (“window phase”); or at baseline and after two-week treated with endocrine therapy plus or minus palbociclib for those patients enrolled directly into the treatment phase of the studyXx_NEWLINE_xXPatients may concurrently receive bisphosphonates or rank ligand inhibitors while on this study if necessary for treatment or prevention of osteopenia or osteoporosis; prior treatment with LHRH agonists is allowed for premenopausal women; topical vaginal estrogen therapy is allowableXx_NEWLINE_xXTumor recurrence after previous treatment, which must have included at least radiation therapy and one cytotoxic chemotherapy; there is no limit on number of previous recurrences or lines of treatmentXx_NEWLINE_xXHas previously received treatment with bevacizumabXx_NEWLINE_xXTreatment with alemtuzumab within 6 months of leukapheresis or fludarabine or cladribine within 3 months of leukapheresisXx_NEWLINE_xXTreatment plan that includes post-transplant maintenance therapyXx_NEWLINE_xXEvidence of an active optic glioma or other low-grade glioma, requiring treatment with chemotherapy or radiation therapy; patients not requiring treatment are eligible for this protocolXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\r\n* The subject has radiographic evidence of cavitating pulmonary lesion(s); chest x-ray will not be required as part of this trial, unless cavitating pulmonary lesion is clinically suspectedXx_NEWLINE_xXPrior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib, neratinib).Xx_NEWLINE_xXUnwilling or unable to discontinue disallowed disease-modifying antirheumatic drugs (DMARDs) for treatment of SSc prior to mobilizationXx_NEWLINE_xXUnwilling to use contraceptive methods for at least 15 months after starting treatmentXx_NEWLINE_xXPatients must have radiological evidence of disease progression following the most recent treatmentXx_NEWLINE_xXPatients should be excluded if they have had prior treatment with cabozantinib; previous use of other antiangiogenic agents other than cabozantinib is allowedXx_NEWLINE_xXThe subject has experienced any of the following: \r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment; \r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment; \r\n* Any other signs indicative of hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXSubject with extensive pelvic mass at risk of fistulization, or history of bowel obstruction within 3 months prior to the proposed first dose of study treatmentXx_NEWLINE_xXPrior treatment with DCC-2618Xx_NEWLINE_xXEligible to receive treatment with a CPI.Xx_NEWLINE_xXReceived any prior treatment with a CPI.Xx_NEWLINE_xXReceived any prior treatment with CD137 agonists or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors.Xx_NEWLINE_xXPrior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).Xx_NEWLINE_xXPatients may continue on a daily multi-vitamin, calcium and vitamin D, but all other herbal, alternative and food supplements (i.e. prostate cancer [PC]- hope [spes (Latin)], saw palmetto, St John’s wort, etc.) must be discontinued before starting protocol treatment; hormonal-acting agents such as diethylstilbestrol (DES) are forbidden during the trial and must be stopped starting protocol treatment; no washout period will be required; patients on megestrol acetate for hot flashes are allowed to continue therapyXx_NEWLINE_xXPrior treatment with any LAG-3 targeting biologic or small moleculeXx_NEWLINE_xXPrior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)Xx_NEWLINE_xXPrior treatment with idelalisibXx_NEWLINE_xXPrevious treatment with any weekly taxane regimen.Xx_NEWLINE_xXNo prior treatment with carmustine wafersXx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXThere must be evidence of progression on or after last treatment regimen received and within 6 months of enrollmentXx_NEWLINE_xXPrior treatment with fosbretabulin is allowed, if not given in combination with everolimusXx_NEWLINE_xXPrior treatment with lenvatinibXx_NEWLINE_xXActive treatment for VTEXx_NEWLINE_xXPatients should agree to serial liver metastases biopsy pre-treatment, post-radioembolization, and post-combination immunotherapyXx_NEWLINE_xXPrior treatment or preventative use of any hormonal agent such as aromatase inhibitors (AI), fulvestrant, raloxifene, tamoxifen or other SERM, or with any other hormonal agent used for the treatment or prevention of BC or for any other indication (e.g. osteoporosis).Xx_NEWLINE_xXConcurrent treatment with a non-permitted drugXx_NEWLINE_xXHistory of treatment with ibrutinib or blinatumomabXx_NEWLINE_xXPatients who have received sorafenib or other systemic therapies for treatment of HCC in the pastXx_NEWLINE_xXPrior systemic treatment must be completed at least 14 calendar days prior to registration and the subject must have recovered from the toxicities of treatment to grade 1 or betterXx_NEWLINE_xXPrevious treatment information (name of agent, treatment starting date, and date of progression) must be available for reviewXx_NEWLINE_xXUnavailable for follow-up visits after treatmentXx_NEWLINE_xXHas history of not tolerating interferon treatmentXx_NEWLINE_xXDose expansion - KRAS mutant patients groups: Prior treatment with a RAFi (including any BRAFi and pan-RAFi), MEKi and/or ERKi. BRAF mutant patients group: Prior treatment with an ERKi and/or a pan-RAFi.Xx_NEWLINE_xXBe willing to undergo normal skin biopsy prior to initiation of treatment and after treatmentXx_NEWLINE_xXCardiac testing with either exercise stress test or thallium stress test, within 3 months of start of the first treatment day; atrial fibrillation that is rate controlled is allowed; note – the first treatment day is about 9 weeks before the first IL-2 treatment day; if a cardiologist’s evaluation determines that this is superfluous based on other assessments, then this may be omittedXx_NEWLINE_xXPrior decitabine for the treatment of this cancer; patients with previous exposure to therapy with gemcitabine are allowed in the studyXx_NEWLINE_xXPatients who have the following risk factors are considered to be at increased risk for cardiac toxicities and may be enrolled only with increased monitoring: i) prior treatment with anthracyclines; ii) prior treatment with trastuzumab; iii) a New York Heart Association classification of II controlled with treatment; iv) prior central thoracic radiation therapy (RT), including RT to the heartXx_NEWLINE_xXPhase II mandatory pre-treatment and post-treatment fresh biopsies to determine PD-L1 and EGFR expression and other biomarkersXx_NEWLINE_xXPatients with prior bevacizumab use for tumor treatment; patients who received bevacizumab for symptom management, including but not limited to cerebral edema, pseudoprogression can be included in the studyXx_NEWLINE_xXHave documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib; intolerance to sorafenib is defined as: Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 drug-related adverse event(s) which both a) persisted in spite of comprehensive supportive therapy according to institutional standards and b) persisted or recurred after sorafenib treatment interruption of at least 7 days and dose reduction by one dose level; patients treated on sorafenib as the last treatment may start pembrolizumab at least 14 days after the last dose of sorafenibXx_NEWLINE_xXHas had esophageal or gastric variceal bleeding within the last 6 months; all subjects will be screened for esophageal varices, unless such screening has been performed in the past 12 months before first dose of treatment; if varices are present, they should be treated according to institutional standards before starting study treatmentXx_NEWLINE_xXPatient must have disease progression with abiraterone treatmentXx_NEWLINE_xXSubjects must have failed hypomethylating treatment where \failure\ is defined as: Progression (according to 2006 International Working Group [IWG] criteria) at any time after initiation of the hypomethylating treatment OR Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least 4 cycles treatment OR Relapse after initial complete or partial response or HI (according to 2006 IWG criteria).Xx_NEWLINE_xXPrior treatment with temozolomide, dacarbazine or procarbazineXx_NEWLINE_xXCurrent use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drugXx_NEWLINE_xXSubjects with active infection or with a fever > 38.50 degrees Celsius (C) within t3 days prior to the first scheduled treatmentXx_NEWLINE_xXTreatment with prohibited medicationsXx_NEWLINE_xXConcomitant treatment with other hormonal therapy or 5alpha-reductase inhibitorsXx_NEWLINE_xXPrevious history of grade 3 or worse drug-induced QTc prolongation requiring treatment withdrawalXx_NEWLINE_xXTreatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic indexXx_NEWLINE_xXHas received more than one systemic treatment for steroid refractory aGvHD.Xx_NEWLINE_xXConcurrent disease - patients under treatment for concurrent medical conditions will be eligible for protocol treatment if, in the opinion of the physician responsible for hyperthermia treatment that the concurrent medical condition will neither interfere with the process of the treatment or patient assessments nor add significantly to the risks or complications of the treatmentXx_NEWLINE_xXFOCBP and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment periodXx_NEWLINE_xXHas prior treatment using an anthracyclineXx_NEWLINE_xXThis study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (i.e., subject has not been randomized / has not been treated); if re-enrolled, the subject must be re-consentedXx_NEWLINE_xXPrior DNA methyl transferase inhibitor administration (azacitidine, decitabine or guadecitabine) for AML or for antecedent MDS is allowed if this clinical trial is considered the best treatment option, but azacitidine, decitabine or guadecitabine must have been stopped at least 3 weeks prior to day 1 of treatment on the studyXx_NEWLINE_xXHyperleukocytosis with > 50,000 blasts/ul; hydroxyurea for blast count control is permitted before starting treatment, but must be stopped prior to starting treatment on the study; patients will be withdrawn from the study if > 50,000 blasts/ul occur or recur > 14 days after starting treatment on the studyXx_NEWLINE_xXPrevious treatment with talazoparibXx_NEWLINE_xXFailure to one induction course of chemotherapy (these patients will be analyzed separately); patients who require steroids, ara-c or hydrea to manage disease symptoms prior to finalization of diagnosis and treatment plan are allowed and eligibleXx_NEWLINE_xXHistory of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.Xx_NEWLINE_xXTreatment with any of the following within the specified time frame prior to the study drug administration:Xx_NEWLINE_xXHistory of peptic ulcer disease requiring treatment within the last 5-yearsXx_NEWLINE_xXPatients may be treatment naive or have received any number of prior therapies\r\n* NOTE: Prior immunotherapy is contraindicated and not permittedXx_NEWLINE_xXPatients must not have had prior treatment with nivolumab or any other PDL1 or PD-1 antagonistsXx_NEWLINE_xXPatients must not have elevated lung shunting precluding treatment with Y-90Xx_NEWLINE_xXPatients having received prior radiotherapy, treatment with cytotoxic agents, treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the 4 weeks prior to treatment with selinexor, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)Xx_NEWLINE_xXNo treatment with paclitaxel or nab-paclitaxel within 4 months prior to initiation of study therapyXx_NEWLINE_xXPatients not previously treated for their FL, including any previous treatment for FL under clinical trials except localized radiation therapy for previous limited stage disease.Xx_NEWLINE_xXFemales who are pregnant, breastfeeding, or planning a pregnancy during the treatment period or within 12 months after the last infusion of study drug.Xx_NEWLINE_xXPatients must have received one course of induction treatment with BCG (4-6 weekly doses), irrespective of the interval since last treatment; patients are allowed to have received any number of prior chemotherapy instillations\r\n* NOTE: Patients may have received prior intravesical interferonXx_NEWLINE_xXPrior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted; prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is > 3 yearsXx_NEWLINE_xXEvidence of severe concurrent disease requiring treatmentXx_NEWLINE_xXTreatment with radiation therapy within 12 weeks prior to the first dose of study treatment, unless there is tissue confirmation of tumor recurrence or there is progression outside the treatment fieldXx_NEWLINE_xXPrior treatment with intracystic P-32 or intracystic bleomycinXx_NEWLINE_xXPatients must have newly diagnosed AML or ALL without previous treatment; hydroxyurea will be allowed to control peripheral blast count as clinically indicated but would need to be stopped prior to initiation of tyrosine kinase inhibitor [TKI]); all-trans retinoic acid (ATRA) is permitted during the period prior to ruling out a diagnosis of APL; previous radiation treatment is allowable; patients must be deemed eligible for treatment with cytotoxic induction chemotherapy with cytarabine and idarubicin for AML or hyper-cyclophosphamide, dexamethasone, doxorubicin, vincristine sulfate (CVAD) for ALL; patients newly diagnosed with ALL must have received no prior treatment for their ALL with the exception of steroids (i.e. prednisone, dexamethasone); intrathecal methotrexate or cytarabine, allowed prior to and throughout the enrollment period for AML and ALLXx_NEWLINE_xXReceived systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocolXx_NEWLINE_xXReceived 3 or more prior myelotoxic treatment regimensXx_NEWLINE_xXConcurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXELIGIBILITY FOR TREATMENT WITH TCRC4-TRANSDUCED CD8+ CELLSXx_NEWLINE_xXEXCLUSION FOR TREATMENT WITH TCRC4-TRANSDUCED CD8+ CELLSXx_NEWLINE_xXDocumented infections or oral temperature > 38.2 degree Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance therapy; however, if these problems resolve, the start of treatment can be initiated on a delayed scheduleXx_NEWLINE_xXTreatment with alemtuzumab or other T cell-depleting antibodies within 6 months of T cell therapyXx_NEWLINE_xXHave received treatment with any form of therapy with CYP17 inhibitory activity such as ketoconazole, aminoglutethimide, or an antiandrogen such as bicalutamide within 6 months of study treatment initiationXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT ONLY: Patients who have had prior treatment with olaparib or other camptothecin inhibitorsXx_NEWLINE_xXmCRPC EXPANSION COHORT: Patients who have had prior treatment with olaparib or other camptothecin inhibitorsXx_NEWLINE_xXmCRPC EXPANSION COHORT: The patient has received radionuclide treatment within 6 weeks prior to the first dose of the study treatmentXx_NEWLINE_xXHistologically documented squamous cell head and neck cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatmentXx_NEWLINE_xXIf a curative treatment option in the form of chemoradiation exists in a patient with unresectable disease, this has to be attempted first and must have failed, unless the patient has documented refusal of curative treatmentXx_NEWLINE_xXAvailability of curative treatment option for the patient’s cancer, whether surgery, chemotherapy, radiation, or combination thereof, unless the patient has documented refusal of curative treatmentXx_NEWLINE_xXIf a subject is currently receiving bisphosphonates, the subject must have received the bisphosphonates for at least four weeks prior to the first dose of ARQ 751. a. Initiation of bisphosphonates during the study may be allowed provided the subject completes the first cycle of treatment without any dose limiting toxicity (DLT) and the Investigator rules out tumor progression.Xx_NEWLINE_xXPrevious treatment with AKT inhibitors (e.g., ARQ 092, MK-2206, GSK2141795, AZD5363)Xx_NEWLINE_xXPrior treatment with venetoclax or ibrutinibXx_NEWLINE_xXPrevious treatment with investigational gene or cell therapy medicine productsXx_NEWLINE_xXPrior chemotherapy or other systemic anticancer therapy within 4 weeks prior to start of olaparib treatment, 6 weeks for nitrosoureas or mitomycin. Exceptions include: Anti-hormonal treatment for ER positive or PR positive breast cancer is allowed until 7 days prior to treatment with olaparib, exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to start of olaparib treatment is not allowed, prior receipt of biologics targeting T cell co-regulatory proteins and/or immune checkpoints is not allowed. Examples include MEDI4736 or other PD1 or PD-L1 or PD-L2 inhibitors or anti-CTLA4 therapy, previous treatment with a PARP inhibitor, is not allowed.Xx_NEWLINE_xXReceived prior treatment or receiving current treatment for this malignancyXx_NEWLINE_xXPulmonary conditions - any of the following:\r\n* Respiratory condition that required any oxygen supplementation =< 6 months prior to registration\r\n* Prior or current pneumonitis\r\n* Clinically significant pulmonary hypertension =< 12 months prior to registration\r\n* Lung infection requiring treatment =< 3 months prior to registration\r\n* Pulmonary embolism requiring treatment =< 6 months prior to registration\r\n* Pleural effusion requiring drainage =< 12 months prior to registrationXx_NEWLINE_xXTreatment-naive systemic ALK-positive ALCL patientsXx_NEWLINE_xXPatients with options for treatment that are known to be curative are not eligibleXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXHave failed prior treatment within 6 months of consent dateXx_NEWLINE_xXIf the patient has been using the Optune™ device, it will be discontinued before initiating treatment with either study medication, and per inclusion criterion listed above, the patient must have recovered from all treatment-related toxicities to Grade 1 or less.Xx_NEWLINE_xXPatients with a known sensitivity to any of the products to be administered during treatmentXx_NEWLINE_xXAny concurrent treatment that would compromise the study including but not limited to continuous high dose corticosteroids (>0.5mg/kg), lymphodepleting antibodies or cytotoxic agents.Xx_NEWLINE_xXAny prior treatment with: ipilimumabXx_NEWLINE_xXPatients treated with any Cyp17-lyase inhibitor, any 2nd generation AR antagonist (e.g. enzalutamide), cabazitaxel or carboplatin whose disease progressed while on treatment or within 3 months of its discontinuation; patients who have received any of these treatments more than 12 months from study entry and whose disease did not progress while on treatment or within 3 months of its discontinuation are allowed on studyXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Available autologous T cells with ? 15% expression of CD30CAR determined by flow cytometry required prior to treatment with ATLCAR.CD30 cellsXx_NEWLINE_xXTreatment plan that includes regional nodal irradiationXx_NEWLINE_xXPatients who are participating in a concurrent treatment protocolXx_NEWLINE_xXHad treatment with a short course of corticosteroids (> 10mg daily prednisone equivalents) for symptom relief within 1-week prior to screening.Xx_NEWLINE_xXPrior treatment with paclitaxel in the metastatic setting is not allowed (patients who received neoadjuvant paclitaxel can be included)Xx_NEWLINE_xXPatients who are participating in a concurrent treatment protocolXx_NEWLINE_xXPatients will be required to have received prior treatment with azithromycin for at least 3 months prior to enrollment, unless there is evidence of progression or unsatisfactory response while on azithromycin prior to 3 months of treatment, as deemed by the treating or referring physician; patients who are on azithromycin will need to discontinue for at least 2 weeks prior to enrollmentXx_NEWLINE_xXThere is no limit on the number of prior treatment regimensXx_NEWLINE_xXAny previous treatment with AZD1775 or allergic reactions to excipients of AZD1775Xx_NEWLINE_xXUse of any active treatment for relapse/refractory AML including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs; use of hydroxyurea up to 6g per day for cytoreduction is allowed for a maximum of 15 days prior treatmentXx_NEWLINE_xXPatient is a candidate for, and agrees to proceed with additional bevacizumab treatment.Xx_NEWLINE_xXHas received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery; prior treatment with Gliadel wafers will be excludedXx_NEWLINE_xXIn first or subsequent relapse, or refractory to the last treatment (defined as less than a complete metabolic response to the last treatment, or within 6 months from the last treatment).Xx_NEWLINE_xXHistory of grade 4 rash associated with thalidomide treatmentXx_NEWLINE_xXBlasts in peripheral blood < 20,000 (treatment with hydroxyurea is permitted up to 24 hrs prior to LY251092 administration to achieve blast counts < 20,000 prior to enrollment)Xx_NEWLINE_xXPatients who have been previously treated for metastatic melanoma may be included (e.g. prior treatment with v-raf murine sarcoma viral oncogene homolog B [BRAF] inhibitors and/or ipilimumab will be allowed), provided that they have had a three week ‘washout’ prior to signing consent and have not been treated with a PD-1 blocking antibodyXx_NEWLINE_xXNo available curative treatment options, a limited prognosis of several months to < 2 years anticipated survival with currently available therapies, and progressive or relapsed diseaseXx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXDisease staging approximately within one month of treatmentXx_NEWLINE_xXPrior treatment with murine and hu3F8 is allowed; patients with prior humanizing murine IgG3 anti-GD2 antibody m3F8 (m3F8), hu3F8, ch14.18 or hu14.18 treatment must have human anti-human antibody (HAHA) antibody titer < 1300 enzyme-linked immunosorbent assay (ELISA) units/ml; human anti-mouse antibody positivity is allowedXx_NEWLINE_xXMay have had up to 24 months of ADT (testosterone suppression therapy) in the nonmetastatic setting and are at least 12 months removed from treatmentXx_NEWLINE_xXPatient must have completed a frontline induction therapy (minimum of 2 treatment cycles); NOTE: Standard therapies/therapeutic agents are defined as those listed in the National Comprehensive Cancer Network (NCCN) guidelines for treatment of CLL; also, patients who received induction regimen as part of a clinical trial and is not necessarily mentioned in the NCCN guidelines, will also be eligible as long as the patient has completed at least 2 treatment cycles of induction regimen, achieved a clinical response (PR or CR) and is able to meet all other criteria for the study; however, patients who have previously received ibrutinib or have been randomized to ibrutinib containing arms in a clinical trial will not be eligible for this studyXx_NEWLINE_xXPatients who have been off of FOLFIRINOX or gemcitabine/abraxane therapy for more than 49 days prior to treatment on studyXx_NEWLINE_xXPatients who require treatment with UGT1A1 inhibitors during the period of investigational treatment with DFP-13318.Xx_NEWLINE_xXPatients must not be pregnant at the time of SRS treatmentXx_NEWLINE_xXRadiologic evidence of first recurrence after initial treatment (including surgery, radiation, and temozolomide) or tumor refractory to initial treatment without subsequent treatment in glioblastoma or gliosarcoma (WHO Grade IV). Transformation from a lower grade glioma previously treated with radiation and/or temozolomide to glioblastoma will be considered first recurrence for the purpose of this trialXx_NEWLINE_xXPlanned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the study drugs; if such drugs have been used, patients must have discontinued these agents at least 2 weeks (or as noted below) prior to initiating study treatment; examples include:\r\n* STRONG CYP3A4 inducers \r\n* Immunosuppressants (e.g., tacrolimus, leflunomide, tofacitinib, roflumilast, pimecrolimus)\r\n* NSAIDs\r\n** Note: NSAIDs must be discontinued within 5 days prior to initiating study treatmentXx_NEWLINE_xXPatients must demonstrate progressive disease at the time of treatment\r\n*Note: patients who have received tyrosine kinase inhibitors (e.g. vemurafenib) may be treated if they present with stable disease at the time of treatmentXx_NEWLINE_xXPatients must require systemic treatmentXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXScheduled to undergo radioembolization for treatment of intrahepatic metastasesXx_NEWLINE_xXThe predominant burden of disease lies in an arterial distribution which is accessible for transarterial chemoperfusion treatmentXx_NEWLINE_xXThis study permits the re-enrollment of a patient who has discontinued the study for a reason other than treatment failure or adverse event(s) of the study treatment; the patient must be re-consented and assigned a new subject numberXx_NEWLINE_xXCurrent use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatmentXx_NEWLINE_xXHas received an investigational therapeutic drug within the last 4 weeks prior to start of study treatment, or is scheduled to receive one during the treatment periodXx_NEWLINE_xXConcurrent use of other anticancer agents or treatments, with the following exceptions:\r\n* Ongoing treatment with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists, denosumab (Prolia) or bisphosphonate (eg, zoledronic acid) is allowed; ongoing treatment should be kept at a stable schedule; however, if medically required, a change of dose, compound, or both is allowedXx_NEWLINE_xXPrevious therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago \r\n* Note: previous myeloablative autologous transplant is permitted but not requiredXx_NEWLINE_xXMale who is expecting to father a child during the treatment periodXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physicianXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physicianXx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physicianXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Patients with central nervous system (CNS) involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed; the use of seizure prophylaxis is allowed as long as patients are taking non enzyme-inducing anti-epileptic drugs (non-EIAEDs); if patients were previously on EIAEDs and these have been discontinued, they must have been discontinued for at least 2 weeks prior to the start of entrectinib treatment; if patients require an anti-epileptic medication, a CYP3A4 non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate, or lacosamide; moderate inducers of CYP450, such as dexamethasone or other glucocorticoids, may be used at the discretion of the investigator; patients requiring steroids must be at a stable or decreasing doses for at least 2 weeks prior to the start of entrectinib treatmentXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physicianXx_NEWLINE_xXPatients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this studyXx_NEWLINE_xXPrior treatment with anthracyclinesXx_NEWLINE_xXPatient received investigational treatment within 2 weeks or immunotherapy or antibody therapy within 28 days prior to initiation of treatment with Toca 511, and/or has not recovered from toxicities associated with such treatment.Xx_NEWLINE_xXScheduled to undergo either partial or radical nephrectomy as part of treatment planXx_NEWLINE_xXPatients with KPS < 70 and/or unable to tolerate potentially longer treatment timesXx_NEWLINE_xXNo implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator’s opinionXx_NEWLINE_xXImplanted hardware which limits treatment planning or delivery (determined by the investigator)Xx_NEWLINE_xXReceived prior treatment of TAS3681Xx_NEWLINE_xXParticipants must have received at least one but no more than six prior treatment regimens. Prior treatment with an anti-CD20 agent, either alone or in combination, is allowed.Xx_NEWLINE_xXFor Part 2 and Part 3 of the study, patients with primary refractory DLBCL (defined as progression of disease within 24 weeks after first line of treatment).Xx_NEWLINE_xXEither: \r\n* Relapsed after or refractory to prior treatment with at least two regimens or lines of treatment\r\n* Prior failure of at least one regimen or line of treatment, with poor cytogenetic or other risk factors, and ineligible for other clinical trialsXx_NEWLINE_xXNo more than 2 prior induction regimens (excluding prior HSCT) in their first line treatment and one must have included cytarabine with an anthracycline (or anthracenedione)Xx_NEWLINE_xXPrior treatment with an Murine Double Minute 2 (MDM2) antagonistXx_NEWLINE_xXConcurrent treatment with another anti-estrogenXx_NEWLINE_xXCOHORT II: Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment)Xx_NEWLINE_xXPrior treatment with EGFR-targeted therapy, including, but not limited to, the following examples: Gilotrif (afatinib),Tarceva (erlotinib), Erbitux (cetuximab), Iressa (gefitinib), Vectibix (panitumumab), Caprelsa (vandetanib), Tykerb (lapatinib), CDX110, D2C7-immunotoxin)Xx_NEWLINE_xXWillingness to provide a fresh biopsy prior to study enrollment and after 2 cycles of treatment as clinically appropriate per PI discretionXx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment regimenXx_NEWLINE_xXMust consent to study-specific biopsies at two separate timepoints: pre-treatment (Screening) and post-treatment (Day 28 or EOS).Xx_NEWLINE_xXFor hypomethylating failure cohorts, treatment for MDS with any other drug not being an HMA with the following exceptions: prior treatment with growth factors and/or lenalidomide is allowed for any cohortXx_NEWLINE_xXPatients who have received previous anti-angiogenic treatment (experimental or marketed: bevacizumab, thalidomide, CP-547632, sunitinib, sorafenib or others)Xx_NEWLINE_xXPrior RT to the same region within 12 months (Phase Ia, Arm A; subjects with tumors localized in the head and neck region or thorax) or at any time previously (Phase Ia, Arm B; treatment-naïve subjects with SCCHN and Phase Ib; treatment-naïve subjects with Stage III A/B NSCLC or SCCHN)Xx_NEWLINE_xXNo prior treatment of current HCC; however, recurrent HCC after resection may be includedXx_NEWLINE_xXPrior treatment with carfilzomibXx_NEWLINE_xXHypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causesXx_NEWLINE_xXCognitive or mental health impairment that inhibits group treatmentXx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXCohort 5: Treatment-naïve patients with cMET dysregulationXx_NEWLINE_xXPatients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study:Xx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 2 weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXNo prior systemic treatment for acute GVHD except for a maximum of 3 days of prednisone (or IV methylprednisolone) ? 2 mg/kg/day; topical skin steroid treatment, non-absorbable oral steroid treatment for gastrointestinal (GI) GVHD, and resumption of GVHD prophylaxis agents (e.g., calcineurin inhibitors) are permissible; patients enrolled in BMT CTN 1501 who randomized to sirolimus are also eligibleXx_NEWLINE_xXUse of other drugs for the treatment of acute GVHDXx_NEWLINE_xXPrevious assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteriaXx_NEWLINE_xXSubjects who experience a disease response per RECIST 1.1 criteria followed by subsequent progression will be required to have a post-treatment biopsy if feasible and safeXx_NEWLINE_xXHave a history of intolerance, hypersensitivity, or treatment discontinuation due to severe immune adverse events on prior immunotherapy, or documented presence of neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects who discontinued prior immunotherapies for immune-related adverse events that are well-controlled with appropriate treatment may be enrolled if approved by the Medical Monitor.Xx_NEWLINE_xXHave current second malignancy at other sites, which requires treatment, or in the judgement of the Investigator, may require treatment within the next year. Concurrent malignancies that do not require treatment and are clinically stable are allowed. A past history of other malignancies is allowed as long as the subject is not receiving specific treatment other than hormonal therapy, and, in the judgement of the Investigator, is unlikely to have a recurrence.Xx_NEWLINE_xXMust have undergone prior treatment with ?2 treatment lines of anti-myeloma therapy and failed last line of treatment (disease progression ?60 days of completion of last therapy)Xx_NEWLINE_xXPrevious treatment with farletuzumab or other folate receptor targeting agentsXx_NEWLINE_xXFor subjects being enrolled to receive PLD plus carboplatin, prior treatment with anthracyclines or anthracenodionesXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (Note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXPatients with a prior history of treatment with histone deacetylase (HDAC) inhibitors (e.g., SNDX-275/entinostat, LAQ-824, LBH589, PXD-101/belinostat, etc); patients who have received valproic acid will be excluded from this studyXx_NEWLINE_xXPrior treatment with CCR2 and/or CCR5 inhibitorsXx_NEWLINE_xXInclusion Criteria: All subjects\n\n          1. Age ? 18 years old.\n\n          2. Confirmed diagnosis of glioblastoma (WHO Grade IV).\n\n          3. Ability to undergo serial MRIs.\n\n          4. ECOG status ? 1.\n\n          5. Adequate bone marrow function.\n\n          6. Adequate renal and hepatic function.\n\n          7. Females of childbearing potential and non-sterile males must agree to use highly\n             effective methods of birth control throughout the course of study and at least up to\n             90 days after last dosing.\n\n          8. Ability to swallow whole capsules.\n\n             Subjects in Arms A and B (not Arm C) must also meet inclusion criteria 8 - 10:\n\n          9. No previous treatment for GB except surgery.\n\n         10. Able to start radiation therapy ? 49 days after surgery but ? 14 days after a biopsy\n             or ?28 days after an open biopsy or craniotomy with adequate wound healing.\n\n         11. Documented unmethylated MGMT promoter status.\n\n             Subjects in Arm C must also meet inclusion criteria # 12 - 14:\n\n         12. No prior systemic chemotherapy other than TMZ for GB.\n\n         13. Progressive disease > 2 months after completion of first line therapy.\n\n         14. At least one measurable lesion by mRANO.\n\n             Subjects in Arm C Phase 2, Cohort C1 must also meet criteria # 15. This is not\n             applicable to subjects enrolled in Arm C, Ph 1b.\n\n         15. Documentation of unmethylated MGMT promoter status.\n\n             Subjects in Arm C Phase 2, Cohort C2 must also meet Criteria #16. This is not\n             applicable to subjects enrolled in Arm C Phase 1b.\n\n         16. Documentation of methylated MGMT promoter status.\n\n        Exclusion Criteria: All subjects\n\n          1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ?21 days\n             prior to start of study treatment.\n\n          2. Toxicity of ? Grade 2 from prior therapy.\n\n          3. Major surgery or significant other injury ? 4 weeks prior to start of study treatment.\n\n          4. History of other active malignancies within 2 years with exception of (i) adequately\n             treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii)\n             localized adequately treated cancer with curative intent or malignancy diagnosed > 2\n             years ago with no evidence of disease and no treatment ? 2 years prior to study\n             treatment.\n\n          5. Uncontrolled seizure disorder.\n\n          6. Active infection requiring systemic treatment.\n\n          7. Known human immunodeficiency virus (HIV) or active viral hepatitis.\n\n          8. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease,\n             ventricular arrhythmia or CVA ? 6 months prior to start of treatment.\n\n          9. Active clinically significant gastrointestinal disease.\n\n         10. Active bleeding disorder ? 6 months prior to start of treatment.\n\n         11. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.\n\n         12. Use of any medications or food known to be strong or moderate cytochrome P450, family\n             3, subfamily A (CYP3A) inhibitors or strong inducers.\n\n         13. Pregnant or nursing females.\n\n         14. Significant intercurrent illness that may result in subject's death prior to death\n             from glioblastoma.\n\n         15. Known hypersensitivity to any component of TMZ or decarbazine (DTIC). [Subjects in\n             Arms B and C only.]Xx_NEWLINE_xXSubjects must not: have active herpetic skin lesions or prior complications of herpetic infection (eg, herpetic keratitis or encephalitis); require treatment with an antiherpetic drug; have received live-virus vaccination within 30 days of planned treatment start; have previous therapy with talimogene laherparepvec, oncolyic viruses, or tumor vaccine.Xx_NEWLINE_xXPrior treatment with leflunomideXx_NEWLINE_xXNeeding valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPrior treatment with chemotherapy or immunotherapy within 14 days prior to enrollment. Subjects receiving palliative radiation to CNS disease within 7 days may be eligible with PI approval. If the most recent treatment line is an EGFR-TKI, the washout period is a minimum of 3 days before the start of paclitaxel/selumetinib (i.e. treatment with the EGFR-TKI may continue until 3 days before start of study treatment). For other targeted therapy agents, the washout period will be 5 half-lives, prior to start of treatment on study.Xx_NEWLINE_xXPrior treatment with other anti-GD2 antibodies is allowed (prior treatment with hu3F8 is NOT allowed), but human anti-human antibody (HAHA) antibody titer must be =< 1300 enzyme-linked immunosorbent assay (ELISA) units/mLXx_NEWLINE_xXTURNSTILE II - TREATMENT:Xx_NEWLINE_xXTURNSTILE II - TREATMENTXx_NEWLINE_xXPrior treatment with abiraterone or enzalutamide is permitted, but patients must have been off prior corticosteroid treatment for at least 3 monthsXx_NEWLINE_xXFor those patients who are sexually active, they must be willing to use barrier contraceptive methods during the period of treatment on this trial (and for four weeks after the last DNA immunization treatment for patients in Arm 1)Xx_NEWLINE_xXPatients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studiesXx_NEWLINE_xXPatients are allowed to receive, but are not required to receive, biologic/targeted therapy as part of their primary treatment regimen; patients are allowed to receive, but are not required to receive, up to 5 biologic/targeted therapies as part of their treatment regimen for recurrent disease (either alone or in combination with chemotherapy)Xx_NEWLINE_xXNo previous treatment with vandetanib; previous or ongoing treatment with metformin is allowedXx_NEWLINE_xXBrain metastases or spinal cord compression that requires treatment, unless the treatment ended at least 4 weeks before starting protocol therapy and the condition has been stable without steroid treatment for at least 10 daysXx_NEWLINE_xXActive treatment-refractory diarrhea that may affect the ability of the patient to absorb the trial agents or tolerate further diarrheaXx_NEWLINE_xXPre-treatment Fridericia's correction formula (QTcF) > 480 msecsXx_NEWLINE_xXPatients with a history of prior radiation to the orbit if re-treatment would exceed known orbital toleranceXx_NEWLINE_xXSystemic oral corticosteroid treatment within 28 days prior to initiating treatment on study except as detailed aboveXx_NEWLINE_xXNo radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as suchXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior radiation > 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, both kidneys) within 1 year of the treatment dateXx_NEWLINE_xXSubjects in whom treatment planning constraints cannot be metXx_NEWLINE_xXSubjects in whom treatment planning constraints cannot be metXx_NEWLINE_xXThere is no limit to the number of prior systemic treatment regimensXx_NEWLINE_xXIf a subject is currently receiving bisphosphonates or denosumab, the subject must have received the bisphosphonates or denosumab for at least four weeks before starting study treatment. (Initiation of bisphosphonates or denosumab during the study may be allowed provided the subject completes the first cycle of treatment without any DLT and the Investigator rules out tumor progression.)Xx_NEWLINE_xXPrevious treatment with AKT inhibitors (e.g., MK-2206, GSK2141795, AZD5363)Xx_NEWLINE_xXContraindications to treatment with:Xx_NEWLINE_xXPrior treatment with anti-androgens other than enzalutamide is acceptableXx_NEWLINE_xXPrior treatment with enzalutamideXx_NEWLINE_xXSubject has any underlying conditions, which would contraindicate therapy with study treatmentXx_NEWLINE_xXMust have had prior abiraterone treatmentXx_NEWLINE_xXMajor active medical or psychosocial problems that could be exacerbated by the study treatmentXx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Major active medical or psychosocial problems that could be exacerbated by this treatmentXx_NEWLINE_xXOne or more evaluable or measurable lesions that have progressed based on RECIST 1.1, within 12 months of 131 iodine therapy, despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning. These participants must not be eligible for possible curative surgery; orXx_NEWLINE_xXPrior treatment with TRC105Xx_NEWLINE_xXHistory of hemorrhage or hemoptysis (> 1/2 teaspoon bright red blood) within 3 months of starting study treatmentXx_NEWLINE_xXPatients with documented contraindication to anticoagulation therapy such as heparin induced thrombocytopenia or a documented coagulopathy or hematologic disorder that would contraindicated undergoing treatment and use of the associated anticoagulant agents required during treatmentXx_NEWLINE_xXPatients with LVEF =< 40% from treatment with anthracyclines for all malignancies at any dose without evidence of other causes of cardiomyopathyXx_NEWLINE_xXTrastuzumab treatment within the last 3 monthsXx_NEWLINE_xXReceived ? 1 typical regime for the treatment of ITP. Splenectomy is considered one standard ITP treatmentXx_NEWLINE_xXAny prior treatment with rituximab or any other anti-CD20 agent must have been > 6 months prior to the first dose of PRTX-100Xx_NEWLINE_xXAt least two sites of measurable disease as defined by RECIST 1.1; one of which must be amenable to treatment with SAR and accessible for optional pre- and post- treatment biopsy; if a pulmonary nodule is being considered for SAR it must range in size from 1-5 cmXx_NEWLINE_xXHave provided written consent for mandatory pre- and post-treatment biopsy (expansion cohort only)Xx_NEWLINE_xXPrior treatment with crenolanib with progression on treatmentXx_NEWLINE_xXPrior treatment with talazoparibXx_NEWLINE_xXTREATMENT: Pulse oximetry of > 90% on room airXx_NEWLINE_xXPatients with curative treatment optionsXx_NEWLINE_xXNo prior treatment for myelofibrosis (for cohort 1 only)Xx_NEWLINE_xXNo prior treatment with agents targeting BRAF mutant tyrosine kinases or MEK inhibitors or radiation of target lesionsXx_NEWLINE_xXhave had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing treatment ORXx_NEWLINE_xXProgression free interval or treatment free interval of less than 12 months since the last rituximab containing treatment (including rituximab maintenance). For patients considered unwilling/unfit to receive chemotherapy : progression free interval or treatment free interval of less than 6 months since the last rituximab containing treatment (including rituximab maintenance), as assessed by the investigatorXx_NEWLINE_xXDocumented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors.Xx_NEWLINE_xXPrior treatment with copanlisibXx_NEWLINE_xXHormonal treatment within 2 weeks prior to start of study treatmentXx_NEWLINE_xXPatients must be registered prior to the start of treatmentXx_NEWLINE_xXProlymphocytic leukemia (PLL) T-cell (T)-CLL\r\n* T-PLL: treatment failure after Campath-1H and at least one other regimen\r\n* B-PLL: treatment failure after fludarabine and at least one other salvage regimenXx_NEWLINE_xXPlanned ongoing treatment with other drugs thought to potentially adversely interact with study drugs; if such medications have been used, patients must be off of these agents for >= 2 weeks prior to initiation of treatment:\r\n* Anticoagulants at therapeutic doses\r\n* Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimusXx_NEWLINE_xXNo requirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior chemotherapy treatment for AML within 21 days from the initiation of HCT conditioning; Note, use of hydroxyurea or other low intensity treatment not intended to induce remission are acceptableXx_NEWLINE_xXPatients must agree to pre- and post-treatment biopsiesXx_NEWLINE_xXPatients who previously received agents targeting c-MET and/or EGFR T790M Note: Previous treatment with afatinib may be allowable after discussions between Novartis and Investigator.Xx_NEWLINE_xXRelapsed or refractory B-cell ALL or CML in lymphoid blast phase; Philadelphia chromosome must be present at screening (as determined by cytogenetic analysis, fluorescence in situ hybridization [FISH], or polymerase chain reaction [PCR] [i.e., BCR-ABL positive]); Note: patients with CML who have received treatment with tyrosine kinase inhibitors for their CML, and have progressed to lymphoid blast phase are eligible for frontline treatment; Frontline Ph+ ALL or CML-lymphoid blast phase (LBC) Cohort: Patients with newly-diagnosed Ph+ ALL or CML-LBC, who have received no or minimal treatment (minimal treatment is defined as treatment with steroids/hydroxyurea of =< 2 week duration; vincristine =< 2 doses; tyrosine kinase inhibitor of =< 4 week duration; =< 2 doses of cytarabine) and are >= 60 years or older are eligible; patients must have bone marrow blasts > 5% at the time of screeningXx_NEWLINE_xXPrevious treatment with any anti-CD22 directed therapyXx_NEWLINE_xXPrior chemotherapy/radiotherapy/investigational therapy within 2 weeks before the start of study drugs with the following exceptions: \r\n* To reduce the circulating lymphoblast count or palliation: steroids, hydroxyurea; no washout necessary for these agents \r\n* For ALL maintenance/CML treatment: mercaptopurine, methotrexate, vincristine, single-agent, single-dose of cytarabine and/or tyrosine kinase inhibitors; these agents should be discontinued at least 48 hours prior to start of study drugs; (Note: the interval of time from last dose of any approved tyrosine kinase inhibitor [TKI] to start of protocol treatment is 48 hours regardless of the indication for treatment with the TKI)Xx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXReceived radionuclide treatment (i.e. iodine [I]-131 meta-iodo-benzyl guanidine) within 6 months of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following: a. clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment, b. hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment, c. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPrior treatment of cancer (chemotherapy, radiation therapy, and surgery) is allowed if completed at least 3 weeks prior to start of treatment with nintedanib and if all treatment-related toxicities are resolvedXx_NEWLINE_xXPrior treatment with VEGFR tyrosine kinase inhibitorsXx_NEWLINE_xXPatient will have opted for SBRT among definitive treatment choicesXx_NEWLINE_xXPatients who have received sorafenib or other systemic therapies for treatment of HCC in the pastXx_NEWLINE_xXAny condition that requires or is likely to require treatment with systemic corticosteroids within the core study period and short term follow-upXx_NEWLINE_xXSubjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study)Xx_NEWLINE_xXPatients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-upXx_NEWLINE_xXProtocol treatment is to begin within 2 working days of patient randomizationXx_NEWLINE_xXPatients who have not received any prior treatmentXx_NEWLINE_xXInterested in treatment that might change smoking behaviorXx_NEWLINE_xXEnrolled in another treatment protocolXx_NEWLINE_xXPrior bevacizumab for treatment of glioblastoma or high grade gliomaXx_NEWLINE_xXHistory of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physicianXx_NEWLINE_xXPatients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment; steroid use for management of refractory pain or for contrast induced allergy is allowedXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXCurrent use of a prohibited medication or requires any of these medications during treatment with study drugXx_NEWLINE_xXPatient are eligible if they have received one or more prior treatmentXx_NEWLINE_xXPrior treatment with topotecan.Xx_NEWLINE_xXTreatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar, ketoconazole, ritonavir, saquinavir.Xx_NEWLINE_xXPatients must have received a taxane as part of their prior treatmentXx_NEWLINE_xXPrior treatment with cytotoxic and biological agents is permissible; there should be at least a 2-week break between prior treatment and the protocol treatmentXx_NEWLINE_xXOne prior single fraction radiosurgical procedure within the treatment field is acceptable if V12 < 5 cc (V12 is the volume of normal brain [outside gross tumor volume (GTV)] receiving 12 or more Gy); additional radiosurgical procedures outside of the treatment area are acceptableXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPatients who are simultaneously enrolled in any other treatment studyXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; note: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on sonidegib study treatmentXx_NEWLINE_xXPrior treatment with cabozantinib or other c-MET directed therapyXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXThe subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment; Note: Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within 2 years of the start of study treatment may be included in the studyXx_NEWLINE_xXPrior treatment with bevacizumabXx_NEWLINE_xXBe an appropriate candidate for receiving RFA as a medically indicated treatment as evaluated by the following factors:Xx_NEWLINE_xXHave previously received therapeutic treatment for HCC outside the study protocol or is expected to receive concomitant HCC treatment prior to PFS event.Xx_NEWLINE_xXHave body temperature >101ºF (38.3ºC) immediately prior to study treatment.Xx_NEWLINE_xXBaseline laboratories (repeat lab tests are permitted to evaluate eligibility during the Screening Period. Lab results must be within protocol range prior to study treatment.)Xx_NEWLINE_xXNo active graft versus host disease (GVHD) or immunosuppression for prevention or treatment of GVHD within two weeks of study entryXx_NEWLINE_xXFor Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically)Xx_NEWLINE_xXFor Cohort A (enzalutamide) and Cohort B (abiraterone acetate): prior treatment with up to 2 additional second line hormone therapies, including ketoconazole is allowedXx_NEWLINE_xXFor Cohort C (castration-only):\r\n* Patients must continue on castrating therapy throughout BAT treatment\r\n* No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort CXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; nota bene (NB): muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXKnown allergies to any of the components of the investigational treatment regimen or required ancillary treatmentsXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\r\n* The following concomitant medications are not allowed during navitoclax administration: warfarin, clopidogrel (Plavix), ibuprofen, tirofiban (Aggrastat), and other anticoagulants, drugs, or herbal supplements that affect platelet function are excluded, with the exception of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitorXx_NEWLINE_xXOther cardiac or pulmonary disease that, at the investigators discretion, can impair treatment safetyXx_NEWLINE_xXPrevious treatment with sunitinib or valproic acid for uveal melanomaXx_NEWLINE_xXActive treatment with valproic acid for non-oncological conditions, if this cannot be safely switched to an alternative agentXx_NEWLINE_xXPrior treatment with the following agents known to have endocrine effects on prostate cancer: GnRH agonist, GnRH antagonist, anti-androgen (bicalutamide, nilutamide, flutamide), ketoconazole, diethylstilbestrol, estrogen, abiraterone acetate; concurrent use of 5-alpha-reductase inhibitors finasteride or dutasteride is permitted for patients who have been already receiving either of these treatments for at least 1 month at the time of study enrollment; baseline PSA must have been obtained in such patients after at least 1 month on 5-alpha-reductase treatment; initiation of treatment with 5-alpha-reductase inhibitors is not permitted within the first 12 months of study participationXx_NEWLINE_xXTreatment with androgens within 6 months prior to study enrollmentXx_NEWLINE_xXSubjects who received prior treatment with immune checkpoint inhibition, consisting of ipilimumab, tremelimumab, nivolumab, pembrolizumab or other antibody to CTLA4 or PD-1.Xx_NEWLINE_xXConcomitant administration of investigational drugs is not allowed; if investigational drugs were given, their use should be completed as guided by that protocol prior to initiation of cytoreduction on this protocol; if the patient is being treated for secondary (treatment related) myelodysplasia after treatment for a non-hematologic malignancy (e.g. Sarcoma), the primary disease should be in remission for at least 6 months after completing primary therapy; patients with secondary myelodysplasia after treatment of a lymphoma, may proceed with treatment with the lymphoma responding or stable but not progressingXx_NEWLINE_xXNo prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride), fluorouracil or capecitabineXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXUGT1A1 genotyping prior to treatmentXx_NEWLINE_xXOngoing treatment with cytotoxic therapyXx_NEWLINE_xXParticipation in another concurrent treatment protocolXx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment regimenXx_NEWLINE_xXResected patients should begin treatment within 24 weeks of surgery, once adequately healed as determined by the treating physiciansXx_NEWLINE_xXLocal-regional treatment sites must be able to be encompassed within a reasonable radiation therapy treatment volumeXx_NEWLINE_xXPatients must agree to have a biopsy at baseline and on treatmentXx_NEWLINE_xXPatient who has had prior treatment with demethylating agentsXx_NEWLINE_xXDisease progression during or after treatment with gemcitabine (alone or in combination with other agents; at regular, not radiosensitizing, doses)Xx_NEWLINE_xXAny medical history, concurrent disease or concomitant medication which could reasonably predispose the patient to renal insufficiency while on study treatmentXx_NEWLINE_xXParticipation in another concurrent treatment protocolXx_NEWLINE_xXWilling to withdraw from selective serotonin reuptake inhibitors and tricyclic antidepressants prior to treatment initiationXx_NEWLINE_xXPrior use of venlafaxine specifically for treatment of pain (prior use for treatment of other indications, such as hot flashes, is permitted)Xx_NEWLINE_xXReceived no more than 1 prior treatment for ALL/LBLXx_NEWLINE_xXNote: Patients who have received transplant during 1st remission are excluded since this would be considered a 2nd treatmentXx_NEWLINE_xXPresenting with a general or visceral contraindication to intensive treatment including:Xx_NEWLINE_xXHistory of Grade 3 or higher allergic reaction with prior asparaginase treatment,Xx_NEWLINE_xXPatient receiving treatment likely to cause hemolysis or under phenytoin treatment.Xx_NEWLINE_xXPatients who receive treatment with antiepileptic medications must have a two week history of stable dose of antiepileptic without seizures prior to dosingXx_NEWLINE_xXHistory of arrhythmia requiring pharmacological or electrical treatmentXx_NEWLINE_xXPatients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities; patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as suchXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPatients who have received radiotherapy, surgery, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents, immunotherapy, or any other anti-cancer therapy of any kind, or any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXOnly patients that have not received any prior treatment for pancreas cancer are eligible for this treatment protocolXx_NEWLINE_xXPatient must be eligible for HD IL-2 treatmentXx_NEWLINE_xXRelapsed/refractory MCL: Prior treatment with ibrutinibXx_NEWLINE_xXNewly diagnosed MCL: Prior treatment with ibrutinibXx_NEWLINE_xXPrior treatment with capecitabine or lapatinibXx_NEWLINE_xXPrior treatment with omacetaxineXx_NEWLINE_xXFor Phase I/Ib enrollment, patients with a CLIA confirmed EGFR mutation may be treatment naive; all other patients must have received at least one previous line of therapy; there will be no limits to prior lines of treatment for the Phase 1 portionXx_NEWLINE_xXThere will be no limits to prior lines of treatmentXx_NEWLINE_xXPatients must have discontinued all previous biologic therapies and recovered from side effects due to biologic treatment for more than 14 days prior to starting on treatmentXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXPatients who have had prior treatment with 131I-MIBG who do not meet the re-treatment criteriaXx_NEWLINE_xXPrior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permittedXx_NEWLINE_xXAny condition that would prohibit patient from initiating valproic acid; current or prior valproic acid treatment is allowed (do not need to be >= lower limit of normal [LLN] for laboratory for enrollment)Xx_NEWLINE_xXPatients must be willing to participate in all stages of treatmentXx_NEWLINE_xXPatient is currently benefiting from the treatment with pasireotide, as determined by the investigatorXx_NEWLINE_xXPatient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reasonXx_NEWLINE_xXHistory of treatment with canakinumab within the 12 months prior to study initiationXx_NEWLINE_xXRequires treatment with other medications that cannot be stopped and for which there is a known contraindication to co-administration of one or more of the study drugs.Xx_NEWLINE_xXBreasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.Xx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior treatment with murine and humanized 3F8 is allowed; patients with prior m3F8, hu3F8, ch14.18 or hu14.18 treatment must have human anti-human antibody (HAHA) antibody titer =< 1300 enzyme-linked immunosorbent assay (Elisa) units/ml; human anti-mouse antibody positivity is allowedXx_NEWLINE_xXAble to receive outpatient treatment and follow-up at the treating institution.Xx_NEWLINE_xXReceived 3 or more prior myelotoxic treatment regimensXx_NEWLINE_xXPrior treatment with eribulinXx_NEWLINE_xXAllocated to receive Gemcitabine + nab-Paclitaxel as first line treatment.Xx_NEWLINE_xXCOHORT 3: ATOPIC DERMATITIS PATIENTS: Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)Xx_NEWLINE_xXCOHORT 3: ATOPIC DERMATITIS PATIENTS: Use of topical or oral CAM agents within 4 weeks of initiation of treatmentXx_NEWLINE_xXUnresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatmentXx_NEWLINE_xXPatients will be excluded if they have < 4 lesions, or > 15 lesions at enrollment or > 20 lesions at the time of treatment (note: patients who qualify for enrollment based on having 4-15 lesions, but who are discovered to have up to 20 lesions on the volumetric MRI used for treatment planning will be allowed to continue on study)Xx_NEWLINE_xXAll patients (dose escalation and dose expansion phases) must be willing to undergo pre- and post-treatment biopsiesXx_NEWLINE_xXNutritional and general physical condition must be considered compatible with the proposed radiation +/- chemotherapy treatmentXx_NEWLINE_xXPatients assessed at presentation as requiring interstitial brachytherapy treatmentXx_NEWLINE_xXPatients must not have had prior treatment with floxuridine (FUDR)Xx_NEWLINE_xXHowever, abnormalities of specific organs will not be considered grounds for exclusion if they are the result of the EBV+ malignancy or its treatment (e.g. a renal allograft recipient with an EBVLPD may be on dialysis because the allograft was rejected when the immune suppression was stopped as a first approach to treatment of the EBVLPD); a the discretion of the investigator, patients with elevated but stable creatinine will not be precluded from treatment on studyXx_NEWLINE_xXAble to tolerate pre / post - procedure steroid treatmentXx_NEWLINE_xXPatients may not have previously failed treatment with salvage temozolomideXx_NEWLINE_xXConcurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXOxygen saturation >= 90% on room air, measured prior to treatmentXx_NEWLINE_xXPrior history of treatment with ponatinibXx_NEWLINE_xXTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigatorXx_NEWLINE_xXPrior treatment with murine 3F8 is allowed; patients with prior m3F8, chimeric (ch)14.18 or hu14.18 treatment must have human anti-hu3F8 antibody (HAHA) antibody titer less than the upper limit of normal (defined as mean + 3*standard deviation [SD] of normal volunteers)Xx_NEWLINE_xXPrior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)Xx_NEWLINE_xXSubjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of mCRPC.Xx_NEWLINE_xXPrior treatment with a third-generation EGFR TKI (i.e. rociletinib)Xx_NEWLINE_xXPrior treatment with agents targeting the VEGF pathway, including bevacizumabXx_NEWLINE_xXPrior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.Xx_NEWLINE_xXHas been treated with an Somatostatin analogs (SSA) at any time prior to randomization, except if that treatment was for less than 15 days (e.g. peri-operatively) of short acting SSA or one dose of long acting SSA and the treatment was received more than 6 weeks prior to randomizationXx_NEWLINE_xXPatients must have an ECOG PS of 0-1 at screening and on the day prior to treatment.Xx_NEWLINE_xXNot currently a candidate for curative treatmentXx_NEWLINE_xXHistory of severe eczema (as determined by the Investigator) requiring medical treatmentXx_NEWLINE_xXReceived an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.Xx_NEWLINE_xXMust not have experienced an immune-related adverse event (irAE) where the irAE was the reason for permanent discontinuation of prior immunotherapy in the most recent prior treatment regimenXx_NEWLINE_xXHas undergone ?3 previous regimens (depending on treatment arm) of cytoreductive therapies including, but not limited to, platinum-based compounds, taxanes, or 5-fluorouracil. for B7, no prior systemic treatments should have been received for RM SCCHNXx_NEWLINE_xXArms B1-B6: Has undergone 1-3 previous regimens of cytoreductive chemo-therapies Arm B7: with no prior exposure to anti-PD-(L)1 therapies and have received no prior systemic treatment for RM SCCHNXx_NEWLINE_xXSpinal cord compression unless asymptomatic and not requiring steroids for at least 4 weeks before the start of study treatment. - Presently has a second malignancy other than SCCHN, or history of treatment for invasive cancer other than SCCHN in the past 3 years. Exceptions areXx_NEWLINE_xXAdults with AML in need of treatmentXx_NEWLINE_xXTreatment with proton pump inhibitors (PPIs) within 7 days prior to enrollment.Xx_NEWLINE_xXUnable to receive prophylactic treatment for pneumocystisXx_NEWLINE_xXTREATMENT:Xx_NEWLINE_xXPrior treatment with irinotecan and/or bevacizumabXx_NEWLINE_xXPatient must live within 30 minutes of the treating physician’s office during outpatient treatmentXx_NEWLINE_xXPatients may have had any number of prior treatment regimens (including biologic) before or after radiotherapy; patients may not have previously been treated with bevacizumab or lapatinib. Gliadel wafers must be approved by CERN Principal Investigator (PI) (Project Leader, Co-Leader and Protocol PI)Xx_NEWLINE_xXWillingness to participate in rigorous neurocognitive evaluations at baseline and serially following treatmentXx_NEWLINE_xXPatients who are participating in a concurrent treatment protocolXx_NEWLINE_xXTreatment plan that includes regional nodal irradiationXx_NEWLINE_xXPatients must be registered prior to the start of treatmentXx_NEWLINE_xXActive pneumonia within 1 month prior to starting treatmentXx_NEWLINE_xXSubjects with hepatocellular carcinoma must have received sorafenib as one of the standard treatment options prior to being enrolled into the studyXx_NEWLINE_xXPatients who have had any form of prior prostate treatment (radical prostatectomy, radiotherapy, cryotherapy, high intensity focused ultrasound) will not be eligibleXx_NEWLINE_xXNo implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator’s opinionXx_NEWLINE_xXNo hormone ablation for two months prior to enrollment, or during treatmentXx_NEWLINE_xXSystemic oral corticosteroid treatment within 28 days prior to initiating treatment on studyXx_NEWLINE_xXPrior treatment with other immunotherapy, including antibodies, is allowedXx_NEWLINE_xXPatients cannot take any additional vitamin D supplementation during study treatment; patients taking > 2000 IU per day prior to treatment will be ineligibleXx_NEWLINE_xXAdditional treatment for NHL administered from time of autologous SCT through registrationXx_NEWLINE_xXPatients must be or have been ambulatory within a week prior to treatmentXx_NEWLINE_xXPatients who have received >= 2 cycles of multiagent chemotherapy within the 3 months previous to UCBT; patients who have had previous autologous transplant within 12 months of UCBT are excluded regardless of history of recent treatmentXx_NEWLINE_xXPatients must be willing to participate in all stages of treatmentXx_NEWLINE_xXSubjects must have an indication for treatment as defined by the NCI Working Group GuidelinesXx_NEWLINE_xXLife expectancy reasonably adequate for evaluating the treatment effectXx_NEWLINE_xXPatients must be geographically accessible and willing to participate in all stages of treatmentXx_NEWLINE_xXPregnancy testing will be performed within 7 days prior to treatment (Turnstile II)Xx_NEWLINE_xXAchieves PR or CR in response to B-RAF treatment (Cohort C)Xx_NEWLINE_xXPatients with rapidly advancing systemic disease, especially those without good options of systemic treatment for their disease outside the CNS (Cohort D)Xx_NEWLINE_xXPrior treatment with idelalisibXx_NEWLINE_xXPatients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have declined treatmentXx_NEWLINE_xXSerious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.Xx_NEWLINE_xXagree not to try to become pregnant during the study and for 6 months after the final study treatment administration,Xx_NEWLINE_xXActive malignancies (that is, requiring treatment change in the last 24 months) other than urothelial cancer (except skin cancers within the last 24 months that are considered completely cured)Xx_NEWLINE_xXConcurrent medical condition requiring the use of systemic immunosuppressive treatment within 28 days before the first dose of study treatment.Xx_NEWLINE_xXPrevious treatment with gene therapyXx_NEWLINE_xXPatient has had previous treatment with poziotinib.Xx_NEWLINE_xXArms A/B – eligible for treatment with ifosfamide, carboplatin, and etoposide (+/- rituximab)Xx_NEWLINE_xXOngoing or previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors including rogaratinib or FGFRspecific antibodies) or with taxanes or vinflunineXx_NEWLINE_xXPrevious treatment with ixazomib, or participated in a blinded study with ixazomibXx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment regimenXx_NEWLINE_xXTreatment with rituximab monotherapy within 3 months or rituximab combination therapies (eg, with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollmentXx_NEWLINE_xXRefractory to first or later treatment, orXx_NEWLINE_xXgreater than 5 years ago but has active graft versus host disease (GvHD) requiring systemic treatment.Xx_NEWLINE_xXPrevious treatment with any anti-CD40 antibody.Xx_NEWLINE_xXProviders and patients must be willing to defer new systemic or cutaneous topical treatment of aGvHD for at least 36 hours after administration of Neihulizumab.Xx_NEWLINE_xXPrior treatment with anti-lymphocyte globulin or anti-thymocyte globulinXx_NEWLINE_xXPatients are eligible unless their treatment is to be guided by a higher priority protocolXx_NEWLINE_xXPatients previously treated with TLR-7/8 agonist treatment.Xx_NEWLINE_xXProtocol treatment is to begin within 5 working days of patient enrolment.Xx_NEWLINE_xXPatients who have received prior treatment with PTK7-ADC (PF-06647020)Xx_NEWLINE_xXCurrent treatment of at least 3 months with pembrolizumab or nivolumab (no more than 1 cycle / 6 weeks of treatment interruption immediately prior to study enrollment)Xx_NEWLINE_xXPatients in which treatment with pembrolizumab and nivolumab is contraindicatedXx_NEWLINE_xXPatients must have received prior treatment with an immunomodulatory drug (IMiD) (for ?2 cycles or ?2 months of treatment) and a proteasome inhibitor (PI) (for ?2 cycles or ?2 months of treatment).Xx_NEWLINE_xXInclusion Criteria:\n\n        Cohort A (Solid Tumours)\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP (Good Clinical\n             Practice and local legislation prior to admission to the trial\n\n          -  WHO/ECOG (World Health Organization / Eastern Cooperative Oncology Group) performance\n             status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Male or female patients ready and able to use highly effective methods of birth\n             control during the study and for 12 weeks following the last dose of abemaciclib per\n             ICH (International Conference on Harmonization) M3(R2) that result in a low failure\n             rate of less than 1% per year when used consistently and correctly. A list of\n             contraception methods meeting these criteria is provided in the patient information.\n             Women of childbearing potential must have a negative serum pregnancy test at\n             screening.\n\n          -  Patients with histologically or cytologically confirmed diagnosis of advanced and/or\n             metastatic, measurable or evaluable, non-resectable solid tumours\n\n          -  Patients must have received and failed, or have been intolerant to, all treatment\n             known to confer clinical benefit or have no therapeutic options available as deemed\n             appropriate by their treating physician\n\n          -  Life expectancy >= 3 months in the opinion of the investigator assessed at screening;\n\n        Cohorts B, C, D, F (Breast Cancer):\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP and local legislation\n             prior to admission to the trial\n\n          -  WHO/ECOG performance status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Women who have postmenopausal status due to either surgical/natural menopause or\n             chemical ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1)\n             with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or\n             radiation-induced ovarian suppression\n\n               -  postmenopausal status defined as meeting one of the following conditions:\n\n                    -  prior bilateral oophorectomy\n\n                    -  age >= 60 years\n\n                    -  age < 60 years and amenorrheic (non-treatment-induced amenorrhea secondary\n                       to tamoxifen, toremifene, ovarian suppression, or chemotherapy) for at least\n                       12 months; and follicle stimulating hormone (FSH) and estradiol within the\n                       postmenopausal range as per institutional reference ranges.\n\n               -  Postmenopausal status due to radiation-induced ovarian suppression must be\n                  confirmed by FSH and estradiol level in the postmenopausal range\n\n          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of\n             locally advanced or metastatic disease not amenable to resection or radiation\n\n          -  HR+ (local lab results at screening or, if not available, at the time of diagnosis) To\n             fulfil the requirement of HR+ disease, the primary tumour or metastatic lesion of the\n             breast cancer must express at least one of the hormone receptors (estrogen receptor\n             [ER] or progesterone receptor [PgR]) by immunohistochemistry (IHC). Estrogen receptor\n             and PgR assays are considered positive if there are at least 1% positive tumour nuclei\n             in the sample as defined in the relevant American Society of Clinical Oncology\n             (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).\n\n          -  HER2 negative (local lab results at screening or, if not available, at the time of\n             diagnosis) as defined by the most recent American Society of Clinical Oncology\n             (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).\n\n          -  Previous adjuvant and neoadjuvant chemotherapy is permitted. 0-2 prior lines of\n             chemotherapy for the metastatic setting are allowed.\n\n          -  At least 1 lesion (measurable or non-measurable) that can be accurately assessed at\n             baseline with CT or MRI or PET-CT (CT portion of diagnostic quality) and which is\n             suitable for accurate repeated measurement. For Cohort F only: patients should have at\n             least one measurable lesion.\n\n          -  Cohort B, C, D, F Must be eligible for the corresponding hormonal therapy (letrozole,\n             anastrozole or fulvestrant). For Cohorts B and C previous treatment with fulvestrant\n             or exemestane is allowed. For Cohort D and F prior therapy with non steroidal\n             aromatase inhibitors (anastrozole, letrozole) or exemestane are permitted\n\n          -  Cohort F only: Postmenopausal with locally advanced or metastatic HR+ breast cancer\n             and refractory to aromatase inhibitors therapy and CDK4/6 inhibitor treatment (e.g.,\n             palbociclib or ribociclib) for locally advanced or metastatic breast cancer.Resistance\n             to aromatase inhibitors therapy is defined as the following:\n\n               -  disease recurrence while on, or within 12 months of end of adjuvant treatment\n                  with letrozole, anastrozole, or exemestane;\n\n               -  or disease progression while on, or within one month of end of letrozole,\n                  anastrozole, or exemestane.\n\n        Cohort E (NSCLC (Non-Small Cell Lung Cancer)):\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP and local legislation\n             prior to admission to the trial\n\n          -  WHO/ECOG performance status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Male or female patients ready and able to use highly effective methods of birth\n             control during the study and for 12 weeks following the last dose of abemaciclib per\n             ICH M3 (R2) that result in a low failure rate of less than 1% per year when used\n             consistently and correctly. A list of contraception methods meeting these criteria is\n             provided in the patient information. Women of childbearing potential must have a\n             negative serum pregnancy test at screening.\n\n          -  Histologically or cytologically confirmed diagnosis of stage IV NSCLC.\n\n          -  The participant must have progressed after platinum-based chemotherapy AND\n             immunotherapy (unless deemed inappropriate candidates for immunotherapy by their\n             treating physician) AND have received a maximum of 2 other prior chemotherapy for\n             advanced and/or metastatic disease OR must be judged by the physician as ineligible\n             for further standard second-line chemotherapy. Prior treatment with epidermal growth\n             factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and anaplastic lymphoma kinase\n             (ALK) inhibitors is mandatory in participants whose tumour has EGFR-activating\n             mutations or ALK translocations. Prior targeting agents and neoadjuvant/adjuvant\n             therapies are permitted.\n\n          -  Have adequate organ function including haematology, renal, and liver.\n\n          -  Have measureable disease per Response Evaluation Criteria In Solid Tumours (RECIST)\n             1.1.\n\n        Exclusion Criteria:\n\n        All cohorts:\n\n          -  Any documented active or suspected malignancy or history of malignancy, other than the\n             disease under study, within 3 years prior to screening, except appropriately treated\n             basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or ductal\n             carcinoma in situ (DCIS) if properly treated in opinion of the investigator.\n\n          -  Patients who must or wish to continue the intake of restricted medications or any drug\n             considered likely to interfere with the safe conduct of the trial\n\n          -  Previous treatment in this trial\n\n          -  Currently enrolled in another investigational device or drug study, or less than 21\n             days since ending another investigational device or drug study(s), or receiving other\n             investigational treatment(s).\n\n          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,\n             makes them an unreliable study subject or unlikely to complete the trial\n\n          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.\n             Men who plan to father a child while in the trial.\n\n          -  Prior chemotherapy, biological or radiation therapy, androgens, thalidomide, other\n             anticancer agents, or any investigational drug within 21 days; and/or three half-lives\n             for immunotherapy, before starting any of the trial drugs.\n\n          -  Prior anti CDK (Cyclin-dependent Kinase) agents (except cohort F)\n\n          -  Prior radiotherapy to >= 25% of bone marrow regardless of when it was received\n\n          -  Unresolved treatment related toxicity from previous therapy of > CTCAE grade 1 at\n             study entry (except for stable sensory neuropathy ? CTCAE grade 2 and alopecia)\n\n          -  Previous treatment with IGF (Insulin-like Growth Factor)-1R targeting compounds\n\n          -  Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or\n             leptomeningeal disease, as indicated by clinical symptoms, cerebral oedema, and/or\n             progressive growth. History of CNS metastases or cord compression are eligible if they\n             have been definitively treated (e.g. radiotherapy, stereotactic surgery) and are\n             clinically stable, off anticonvulsants and steroids for at least 4 weeks. Patients\n             with brain metastases are eligible if they are asymptomatic or treated at a stable\n             dose of steroids for at least 4 weeks. Patients are not eligible if they have spinal\n             cord compression.\n\n          -  Any evidence of severe or uncontrolled systemic disease as judged by the Investigator.\n\n          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following: ANC < 1.5 x 109/L, platelets < 100 x 109/L, haemoglobin <90g/L, ALT > 2.5 x\n             ULN or > 5 x ULN in the presence of liver metastases, total bilirubin >1.5 x ULN or >3\n             x ULN in patients with Gilbert's Syndrome, serum creatinine > 1.5 x ULN concurrent\n             with creatinine clearance <= 50 mL/min.\n\n          -  Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi\n             Syndrome or renal tubular acidosis\n\n          -  Refractory nausea and vomiting, chronic GI diseases, inability to swallow the product,\n             or previous significant bowel resection that would preclude adequate absorption of\n             abemaciclib or resulting in baseline Grade 2 or higher diarrhoea.\n\n          -  History of hypersensitivity to active or inactive excipients of xentuzumab,\n             abemaciclib or letrozole/anastrozole/fulvestrant, or loperamide hydrochloride, or\n             drugs with similar chemical structures\n\n          -  Patients with Diabetes Type I or uncontrolled Type II (defined by HgBA1C > 8%)\n\n          -  Patients with advanced/metastatic, symptomatic, visceral spread, that are at risk of\n             life threatening complications in the short term including patients with massive\n             uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and\n             over 50% of liver involvement in metastases.\n\n          -  Prior hematopoietic stem cell or bone marrow transplant\n\n          -  Have a personal history of any of the following conditions: syncope of either\n             unexplained or cardiovascular etiology, ventricular arrhythmia (including but not\n             limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac\n             arrest. Subjects with controlled atrial fibrillation for >30 days prior to study\n             treatment are eligible.\n\n          -  Erythropoietin, G-CSF, and GM-CSF are not allowed within 2 weeks prior to study. The\n             primary prophylactic use of G-CSF is not permitted but it may be used to treat\n             treatment emergent neutropenia.\n\n          -  Have had major surgery (excluding biopsy) < 28 days of the initial dose of any of the\n             study drugs or planned major surgery during study participation.\n\n          -  Have active bacterial, fungal, and/or known viral infection (for example, human\n             immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen, or hepatitis C\n             antibodies). Screening is not required for enrolment.\n\n          -  Patients with baseline Grade >=2 hyperglycaemia or patients with baseline Grade >= 2\n             diarrhoea\n\n          -  Patients needing treatment with CYP3A4 inhibitors/inducers cannot be included in the\n             trial.Xx_NEWLINE_xXLoco-regional treatment within 4 weeks prior to initiation of study treatment.Xx_NEWLINE_xXPrior treatment with a HER3 antibodyXx_NEWLINE_xXHas disease that is suitable for local treatment administered with curative intent.Xx_NEWLINE_xXPatients must have received prior systemic sorafenib treatment for HCC with documented progression during or after discontinuation of sorafenib treatment (for France only: patients must have received at least 8 weeks of prior sorafenib treatment), or are intolerant to sorafenib (defined as documented Grade 3 or 4 adverse events that led to sorafenib discontinuation),.Xx_NEWLINE_xXPatient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason.Xx_NEWLINE_xXPrimary hepatic dysfunction including known cirrhosis or active hepatitis. Patients with biliary obstruction must be stented prior to initiating treatment.Xx_NEWLINE_xXTreatment with third generation EGFR inhibitorsXx_NEWLINE_xXPrevious treatment for NHLXx_NEWLINE_xXCurrent or recent treatment with any other investigational medicinal product or deviceXx_NEWLINE_xXMust be maintained on a stable or decreasing corticosteroid regimen (no increase for 7 days) prior to the start of treatmentXx_NEWLINE_xXTreatment with drugs that have the potential to interfere with metabolism or excretion of mibefradilXx_NEWLINE_xXMust not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatmentXx_NEWLINE_xXPrevious discontinuation of treatment with deferiprone or deferoxamine due to adverse events;Xx_NEWLINE_xXPatients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.Xx_NEWLINE_xXPatient is currently benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol.Xx_NEWLINE_xXPatient has been permanently discontinued from everolimus study treatment in the parent study.Xx_NEWLINE_xXUp to one prior treatment for metastatic non clear cell carcinoma is allowed prior to registration as long as the agent used to treat was not pazopanibXx_NEWLINE_xXPatient has been permanently discontinued from imatinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.Xx_NEWLINE_xXHistory of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up.Xx_NEWLINE_xXInclusion Criteria:\n\n        -Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development &\n        Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the\n        parent study -Patient is currently benefiting from the treatment with nilotinib, as\n        determined by the investigator -Patient has demonstrated compliance, as assessed by the\n        investigator, with the parent study protocol requirements -Willingness and ability to\n        comply with scheduled visits, treatment plans and any other study procedures -Written\n        informed consent obtained prior to enrolling in roll-over study\n\n        Exclusion Criteria:\n\n        - Patient has been permanently discontinued from nilotinib treatment in the parent study\n        due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or\n        any other reason - Patient has participated in a Novartis sponsored combination trial where\n        nilotinib was dispensed in combination with another study medication and patient is still\n        receiving combination therapy -Patients who are currently receiving treatment with any\n        medications that have the potential to prolong the QT interval or inducing Torsade de\n        Pointes and the treatment cannot be either safely discontinued at least one week prior to\n        nilotinib treatment or switched to a different medication prior to start of nilotinib\n        treatment and for the duration of the study -Pregnant or nursing (lactating) women, where\n        pregnancy is defined as the state of a female after conception and until the termination of\n        gestation, confirmed by a positive hcG laboratory test. -Women of child-bearing potential,\n        defined as all women physiologically capable of becoming pregnant, unless they are using\n        highly effective methods of contraception during the study and for 30 days after the final\n        dose of nilotinib.Xx_NEWLINE_xXPrior Temozolomide treatmentXx_NEWLINE_xXCurrent treatment with the following antiarrythmic drugs: flecainide, moricizine or propafenoneXx_NEWLINE_xXTreatment with chronic immunosuppressantsXx_NEWLINE_xXPrior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloidXx_NEWLINE_xXAble to communicate sensations during the ExAblate MRgFUS treatmentXx_NEWLINE_xXMore than 3 painful lesions or more than 2 requiring immediate localized treatmentXx_NEWLINE_xXPatient with any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events Previous treatmentXx_NEWLINE_xXChange in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within 4 weeks prior to baselineXx_NEWLINE_xXPrevious or current treatment with mitotane or other antineoplastic drugs for ACCXx_NEWLINE_xXPatients with contraindication for treatment by laparoscopyXx_NEWLINE_xXPatients who have completed the End of Treatment assessments in their originating study. Every effort should e made to conduct the End of Treatment visit such that the patient does not have any interruption in sorafenib dosing.Xx_NEWLINE_xXPatients who are on current long term treatment (? 4 consecutive weeks) with Aspirin, NSAID or Cox-2 inhibitorsXx_NEWLINE_xXPatient on active current treatment of antiplatelet agents (i.e. off-study Aspirin, clopidogrel, ticlopidine)Xx_NEWLINE_xXCurrently tolerating treatment in the parent protocol.Xx_NEWLINE_xXHas been permanently discontinued from study treatment in the parent study for any reason.Xx_NEWLINE_xXSubjects cannot be simultaneously enrolled on other treatment studiesXx_NEWLINE_xX105 For DLBCL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments., with at least one treatment consisting of standard multiagent chemotherapy containing an anthracycline AND an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP (14 or 21), R-CHOEP, and DA-REOCH. For FL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments, with at least one treatment consisting of a standard chemotherapy containing an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP, R-CVP, and BR. For MCL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments, with at least one treatment consisting of a standard chemotherapy containing an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP, BR and hyper-CVAD alternating with R-MTX/Ara-C. For subjects with refractory B-NHL and who have received radiotherapy, PET positivity should be demonstrated no less than 6 weeks after the last dose of radiotherapyXx_NEWLINE_xXPatients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatmentXx_NEWLINE_xXPatients requiring treatment with a receptor activator of nuclear factor kappa-? ligand (RANKL) inhibitor (e.g., denosumab) who cannot discontinue it before initiation of study treatmentXx_NEWLINE_xXPrevious treatment must include treatment with a single line of chemoimmunotherapy containing an anthracycline and a CD20-targeted agentXx_NEWLINE_xXPrevious treatment with CD19-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatmentXx_NEWLINE_xXParticipants with newly diagnosed GBM: has received prior chemotherapy or radiotherapy for cancer of the head and neck region; has received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment.Xx_NEWLINE_xXHad prior treatment with napabucasin.Xx_NEWLINE_xXNo prior treatment with wee1 kinase inhibitionXx_NEWLINE_xXPrior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic diseaseXx_NEWLINE_xXMust not require concomitant treatment with anticoagulantsXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Prior treatment with cetuximab or EGFR inhibitors in any treatment settingXx_NEWLINE_xXPrevious intravesical immunotherapy less than 3 months before study entry; Note: if a patient is eligible for the study but has had intravesical immunotherapy within the past 3 months, they can enroll in the study and initiation of treatment of the drug will be delayed until a minimum of 90 days has passed since the previous treatmentXx_NEWLINE_xX\Acquired\ resistance to commercially available anti-EGFR mAbs approved for the treatment of mCRC must have:Xx_NEWLINE_xXProgressive disease (PD) documented by imaging or clinical findings less than or equal to 6 calendar months after cessation of previous anti-EGFR mAb treatmentXx_NEWLINE_xXPrior treatment with TAS-102 or regorafenibXx_NEWLINE_xXAdditional Exclusion Criteria for subjects Assigned to Treatment A: Subjects unable to tolerate antithrombotic prophylaxis must be excluded; Discontinuation of prior treatment with lenalidomide due to intolerable AEs.Xx_NEWLINE_xXAdditional Exclusion Criteria for Subjects Assigned to Treatment B: Unacceptable AEs from previous bortezomib treatment; Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis.Xx_NEWLINE_xXPrior toxicity to anti-FGFR-directed or anti-PI3K-directed therapies leading to treatment discontinuation (previous exposure is allowed in other circumstances).Xx_NEWLINE_xXHas received previous treatment with another agent targeting the Lymphocyte-activation gene 3 (LAG-3) receptorXx_NEWLINE_xXPrior treatment with sipuleucel-t and Ra-223 is permitted, provided there has been a two-week washout from the last doseXx_NEWLINE_xXOngoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)Xx_NEWLINE_xXPrevious treatment with idelalisib at any time (ZYDELIG®)Xx_NEWLINE_xXDose level 2 (20 mg) and higher: willing to provide baseline and on treatment tumor biopsies (3 weeks after RXDX-106 treatment initiation), provided the procedure is clinically feasible and not deemed unsafe by the investigator.Xx_NEWLINE_xXAvailability of production capacities for the patient's IMA202 product prior to the leukapheresis TREATMENT SCREENING:Xx_NEWLINE_xXHistory of or current immunodeficiency disease or prior treatment compromising immune functionXx_NEWLINE_xXPatients with EGFR, ALK or ROS-1 mutations who are eligible for treatment with a TKI and who have not received such treatmentXx_NEWLINE_xXNo limits to the prior lines of treatmentXx_NEWLINE_xXPredicted time to first treatment of ?3 years according to MDACC nomogram.Xx_NEWLINE_xXWillingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire studyXx_NEWLINE_xXTreatment with corticosteroids other than physiological replacement within the previous week or treatment with immunosuppressive medication within the previous week.Xx_NEWLINE_xX(Dose levels 1 and 2) - may have received one or more systemic treatments or regimens for metastatic RCC; (dose level 3) - cannot have received prior systemic treatment for RCCXx_NEWLINE_xXSubjects must be primary refractory or relapsed to 1st line intensive treatment for AML or refractory or relapsed after second line of treatment for AMLXx_NEWLINE_xXPatients having received prior radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the 2 weeks prior to treatment with CPI-613, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)Xx_NEWLINE_xXPatient is deemed by the investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up)Xx_NEWLINE_xXSubjects planning on embarking on a new strenuous exercise regimen after first dose of study treatment that can result in significant increases in plasma CK levelsXx_NEWLINE_xXUsing any systemic treatment for BCC (e.g. vismodegib), or any topical treatment for their BCC tumors, unless discontinued at least one month priorXx_NEWLINE_xXReceived at least one prior treatment regimen;historically documented CD20-positivity is acceptable;Xx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participationXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patients must have been on a stable dose of the TKI for the last 3 months before prior to pre-registrationXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Institution has received central BCR-ABL test results confirming MRD positive status following Step 1 treatmentXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participationXx_NEWLINE_xXPrior PARP therapy could have been administered as either treatment for recurrent disease or as maintenance following prior treatment.Xx_NEWLINE_xXPatients with prior treatment with idelalisib.Xx_NEWLINE_xXPrevious treatment with talimogene laherparepvec or any other oncolytic virusXx_NEWLINE_xXSexually active subjects and their partners unwilling to use a male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXSubjects in expansion cohort only: Willing to undergo pre- and on-treatment biopsiesXx_NEWLINE_xXPatients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not; (NOTE: prior ibrutinib treatment is allowed as per: patients with prior exposure to ibrutinib will be allowed if they do not have disease refractory to ibrutinib; patient receiving ibrutinib will be allowed on this trial if they have measurable disease and did not have disease progression while receiving ibrutinib; prior bortezomib treatment is allowed as per: patients with prior exposure to bortezomib will be allowed if they do not have disease refractory to bortezomib)Xx_NEWLINE_xXPrior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is > 3 years.Xx_NEWLINE_xXEvidence of severe concurrent disease requiring treatment.Xx_NEWLINE_xXPrior treatment with therapeutic dose of radioactive iodine (> 50 mCi) with evidence of RAI uptake on delayed scan, with progression within 12 months of RAIXx_NEWLINE_xXPrior treatment with trabectedin or trabectedin analogXx_NEWLINE_xXPrior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignmentXx_NEWLINE_xXPatient requiring chronic treatment with BCRP inhibitors (cyclosporine, eltrombopag)Xx_NEWLINE_xXHas had prior treatment with idelalisibXx_NEWLINE_xXRENAL COHORT: Any number of prior treatment lines is allowed on studyXx_NEWLINE_xXBLADDER: The patient must be systemic treatment naive, previous intra-vesicle therapy is allowedXx_NEWLINE_xXRENAL COHORT: Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 2 weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatmentXx_NEWLINE_xXKnown brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant GI bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXConcurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXPrevious assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the studyXx_NEWLINE_xXPatients must undergo surgery and must not have further treatment. (For MTD expansion cohort only)Xx_NEWLINE_xXHas received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel wafers will be excluded. Concomitant use of the Optune device will also be excluded.Xx_NEWLINE_xXFor study cohort A, has not had prior treatment with cetuximab, panitumumab, or other anti-EGFR therapyXx_NEWLINE_xXFor study cohort B, must have had previous treatment with cetuximab or panitumumab with disease control (defined as complete response, partial response, or stable disease) lasting for ? 4 months in durationXx_NEWLINE_xXPrior treatment with drug targeting cyclin-dependent kinase (CDK) familyXx_NEWLINE_xXAll patients must consent to pre-treatment biopsy of the tumor if it can be done safely (as judged by the investigator) during screening. Week 10 on-treatment biopsies will be required for a minimum 10 patients. After 10 paired biopsies have been obtained then week 10 on-treatment biopsy will be made optional.Xx_NEWLINE_xXNeed for ongoing treatment with an immunosuppressive agentXx_NEWLINE_xXAntibiotic allergies that would preclude treatment for a C. novyi-NT infectionXx_NEWLINE_xXENROLLMENT: Patient must have fully recovered (i.e. returned to baseline) from the clinically significant acute treatment-related toxicities of all prior treatments prior to beginning treatment on this protocol with exceptions of cytopenias resulting from persistent disease, hearing loss and alopecia.Xx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their cancer with a primary goal of improving survival within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXPatients must have adequate labs within 7 days of treatment unless cytopenia is thought to be due to underlying diseaseXx_NEWLINE_xXPrior systemic treatmentXx_NEWLINE_xXOngoing or active infection requiring systemic treatment (must be afebrile for >= 48 hours prior to study registration)Xx_NEWLINE_xXSubject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 4 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within 4 months after the last dose of any component of the treatment regimenXx_NEWLINE_xXWillingness to undergo fluoroscopy-guided SGB or sham treatmentXx_NEWLINE_xXAny anti-lymphoma treatment within 6 months of treatment initiation.Xx_NEWLINE_xXPrevious treatment with cetuximab with evidence of clinical benefit, as defined by complete response, partial response, or prolonged stable disease with 16 or more weeks of treatment without radiographic progression, as assessed by the treating physician and documented in the medical record; this treatment may have occurred at any point in the patient’s clinical course for treatment of metastatic colorectal cancerXx_NEWLINE_xXUltimate progression through previous treatment with cetuximab, with documented clinical progression; patients who discontinued cetuximab for any other reason, such as decline in performance status, hypersensitivity, or other adverse effects of therapy, are not eligibleXx_NEWLINE_xXUncontrolled infection not responding to appropriate antimicrobial treatment after 7 days; study chair is the final arbiterXx_NEWLINE_xXTrastuzumab treatment within the last 3 monthsXx_NEWLINE_xXResective surgery within 2 months prior to the initial pre-treatment AMT-PET scanXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXIn the case of malignant glioma patients, they must have previously undergone standard-of-care treatment including surgery, radiation, and first line adjuvant chemotherapy prior to the experimental treatment (WP1066); in the case of melanoma patients with brain metastasis, they may have previously undergone a resection (with radiographic evidence of progression), have undergone gamma knife radiosurgery (with radiographic evidence of progression), or have been treated with other systemic therapies that failedXx_NEWLINE_xXPrior treatment with an investigational agent is allowed but must have been completed >= 28 days prior to randomization with resolution of all treatment-related toxicities to grade =< 1.Xx_NEWLINE_xXSubjects must agree to undergo two research-directed biopsies during treatmentXx_NEWLINE_xXAll patients must be deemed by investigator to have the initiative and means to be compliant with the study protocol (treatment and follow-up)Xx_NEWLINE_xXStarted or planning to start on strenuous exercise regimen after first dose of study treatment (i.e., muscular activities, such as strenuous exercise, that can result in significant increase in plasma CK levels should be avoided while on trametinib treatment)Xx_NEWLINE_xXUnable to obtain confirmation of payment coverage (insurance or other) for either possible treatmentXx_NEWLINE_xXHave received any prior treatment for AML with the exception of hydroxyurea.Xx_NEWLINE_xXClinical indication for treatment with azacitidine.Xx_NEWLINE_xXHydroxyurea within 48 hours prior to first day of study treatment.Xx_NEWLINE_xXCurrent unstable arrhythmia requiring treatment.Xx_NEWLINE_xXSubjects must have failed prior therapy with abiraterone, enzalutamide, or both: has completed at least 12 weeks of prior continuous therapy with abiraterone or enzalutamide; has not been without abiraterone or enzalutamide treatment for >30 days prior to initiation of study treatment; lead-in dosing period for enzalutamide only will be required under the following circumstance:Xx_NEWLINE_xXTreatment with medications known to cause QTc interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor; use of ondansetron is permitted for treatment of nausea and vomitingXx_NEWLINE_xXPrior treatment: Treated with two or more lines of prior therapy, with disease refractory to both a proteasome inhibitor and an immunomodulatory agent, and disease progression (as defined by International Myeloma Working Group (IMWG) criteria) following treatment with an anti-CD38 monoclonal antibody given as monotherapy or in combination therapy. The most recent treatment regimen must have contained an anti-CD38 monoclonal antibody.Xx_NEWLINE_xXPatient has received prior treatment with any PI3K inhibitorsXx_NEWLINE_xXPatient has documented pneumonitis which is active and requiring treatmentXx_NEWLINE_xXTreatment with abiraterone within 2 weeks prior to study treatmentXx_NEWLINE_xXNo active symptoms related to carcinoid syndrome during the last 3 months prior to start of study treatment.Xx_NEWLINE_xXWell-differentiated NET group: Disease progression while on/or after the last treatment, and this progression must have been observed within 6 months prior to start of study treatment (i.e. maximum of 24 weeks from documentation of progression until study entry). Disease must show evidence of radiological disease progression based on scans performed not more than 12 months apart.Xx_NEWLINE_xXPoorly-differentiated GEP-NEC group: Disease progression while on or after prior treatment.Xx_NEWLINE_xXPretreatment with interferon as last treatment prior to start of study treatment.Xx_NEWLINE_xXPrior treatment for study indication with:Xx_NEWLINE_xXPhase 2 only: Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsyXx_NEWLINE_xXPrior treatment with CD47 or signal regulatory protein alpha (SIRP?) targeting agentsXx_NEWLINE_xXHave a current CMV infection that is considered refractory or resistant due to inadequate adherence to prior anti-CMV treatment, to the best knowledge of the Investigator.Xx_NEWLINE_xXRequire ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions other than CMV when study treatment is initiated (example: herpes simplex virus (HSV) coinfection requiring use of any of these agents after the randomization) or would need a coadministration with maribavir for CMV infection. NOTE: A subject who is not continuing with the same anti-CMV drug(s) (ganciclovir, valganciclovir or foscarnet) for the study treatment (if randomized to the investigator assigned anti-CMV treatment arm), must discontinue their use before the first dose of study drug. If subject is currently being treated with cidofovir and is assigned another anti-CMV therapy by the investigator, the subject must discontinue its use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment.Xx_NEWLINE_xXHave severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of study treatment that would preclude administration of oral/enteral medication.Xx_NEWLINE_xXSubjects who may still be sensitive to repeated treatment with decitabine or azacitidine such as subjects who had response to prior decitabine or azacitidine treatment, but relapsed >6 months after stopping treatment with these agents.Xx_NEWLINE_xXPrior treatment with guadecitabine.Xx_NEWLINE_xXHave experienced disease progression during treatment with an anti-PD1/L1 antibody as the treatment regimen immediately prior to accrual to this study or disease progression within 6 months of adjuvant anti-PD1 antibodyXx_NEWLINE_xXAllogeneic stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least four weeks prior to initiation of study treatment and who are currently dependent on such treatment; patients may also not have active graft versus (v.) host diseaseXx_NEWLINE_xXHave received prior treatment with trastuzumab.Xx_NEWLINE_xXInclusion Criteria:\n\n        Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Subject is ? 18 years of age the time of signing the informed consent form (ICF).\n\n          2. Subject must understand and voluntarily sign an ICF prior to any study-related\n             assessments/procedures being conducted.\n\n          3. Subject is willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n          4. Subject has newly diagnosed, primary (ie, de novo) or secondary (progression of MDS or\n             myeloproliferative neoplasms [MPN], or therapy-related) AML according to the WHO\n             classification with ? 20% leukemic blasts in the bone marrow: -Have an Isocitrate\n             dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) gene mutation (R132, R140,\n             or R172)\n\n               -  IDH mutational status will be assessed locally; for sites without local testing\n                  capabilities, a referral lab will be identified.\n\n                    -  By the investigator's assessment who are not candidates to receive intensive\n                       Inductive chemotherapy (IC).\n\n          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or\n             2.\n\n          6. Subject has adequate organ function defined as:\n\n               -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase\n                  (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x ULN, unless considered\n                  due to leukemic organ involvement.\n\n               -  Serum total bilirubin < 1.5 x ULN. Higher levels are acceptable if these can be\n                  attributed to ineffective erythropoiesis, 3 times the upper limit of normal for\n                  Gilbert's syndrome (eg, a gene mutation in UGT1A1), or leukemic organ\n                  involvement.\n\n               -  Serum creatinine < 2 x ULN or creatinine clearance > 30 mL/min based on the\n                  Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):\n\n             GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if\n             African American)\n\n          7. Agree to serial bone marrow aspirate/biopsies.\n\n          8. Females of childbearing potential (FCBP)* may participate, providing they meet the\n             following conditions:\n\n               -  Agree to practice true abstinence ** from sexual intercourse or to use highly\n                  effective contraceptive methods (eg, combined [containing estrogen and\n                  progestogen] or progestogen only associated with inhibition of ovulation, oral,\n                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral\n                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or\n                  male partner sterilization [note that a vasectomized partner is a highly\n                  effective birth control method provided that partner is the sole sexual partner\n                  of the FCBP trial participant and that a vasectomized partner has received\n                  medical assessment of the surgical success]) at screening and throughout the\n                  study, and for at least 4 months following the last study treatment; and\n\n               -  Have a negative serum ?-subunit of human chorionic gonadotropin (?-hCG) pregnancy\n                  test (sensitivity of at least 25 mIU/mL) at screening; and\n\n               -  Have a negative serum or urine (investigator's discretion under local\n                  regulations) ?-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72\n                  hours prior to the start of study treatment in the Treatment Period (note that\n                  the screening serum pregnancy test can be used as the test prior to the start of\n                  study treatment in the Treatment Period if it is performed within the 72-hour\n                  timeframe).\n\n          9. Male subjects must agree to practice true abstinence from sexual intercourse or agree\n             to the use of highly effective contraceptive methods (as described above) with\n             non-pregnant female partners of child bearing potential at screening and throughout\n             the course of the study and should avoid conception with their partners during the\n             course of the study and for at least 4 months following the last study treatment (6\n             months following last dose of azacitidine in Canada). Furthermore, the male subject\n             must agree to use a condom while treated with azacitidine and for at least 4 months\n             following the last azacitidine dose.\n\n        Exclusion Criteria:\n\n        - The presence of any of the following will exclude a subject from enrollment:\n\n          1. Subject is suspected or proven to have acute promyelocytic leukemia based on\n             morphology, immunophenotype, molecular assay, or karyotype.\n\n          2. Subject has AML secondary to chronic myelogenous leukemia (CML).\n\n          3. Subject has received a targeted agent against an Isocitrate dehydrogenase 1 (IDH1) or\n             Isocitrate dehydrogenase 2 (IDH2) mutation.\n\n          4. Subject has received prior systemic anticancer therapy, HSCT, or radiotherapy for AML.\n\n             Note: Hydroxyurea is allowed prior to enrollment for the control of peripheral\n             leukemic blasts in subjects with leukocytosis. (however, hydroxyurea should not be\n             given within 72 hours prior to and after administration of azacitidine). For subjects\n             with secondary AML (eg, MDS or MPN) treatment for prior cancer is not exclusionary;\n             full treatment information will be collected within the CRF. The use of all trans\n             retinoic acid (ATRA) for suspected APL is not exclusionary provided it is discontinued\n             prior to initiation of treatment in the protocol.\n\n          5. Subject has received more than 1 cycle of prior treatment with azacitidine, or subject\n             has received any prior treatment with decitabine for Myelodysplastic syndromes (MDS).\n\n             - Clarification: Subjects with newly diagnosed Acute myeloid leukemia (AML) who are\n             currently receiving their 1st cycle of azacitidine (7 days) can be screened for the\n             study. On study, Cycle 1 must be started at 28 days (+/- 3 days) after initiation of\n             the pre-study azacitidine.\n\n          6. Subject has or is suspected of having central nervous system (CNS) leukemia.\n             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is\n             suspected during screening.\n\n          7. Subject has immediate life-threatening, severe complications of leukemia such as\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\n             intravascular coagulation.\n\n          8. Subject has significant active cardiac disease within 6 months prior to the start of\n             study treatment, including New York Heart Association (NYHA) class III or IV\n             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left\n             ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated\n             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment.\n\n          9. Subject has prior history of malignancy, other than MDS, Myeloproliferative neoplasm\n             (MPN), or AML, unless the subject has been free of the disease for ? 1 year prior to\n             the start of study treatment. However, subjects with the following history/concurrent\n             conditions are allowed:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix\n\n               -  Carcinoma in situ of the breast\n\n               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,\n                  node, metastasis clinical staging system)\n\n         10. Subject is known seropositive for or has active viral infection with human\n             immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or\n             hepatitis C virus (HCV)\n\n         11. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other\n             conditions that limit the ingestion or gastrointestinal absorption of drugs\n             administered orally\n\n         12. Subject has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or\n             diastolic BP > 100 mmHg)\n\n         13. Subject is taking the following sensitive CYP substrate medications that have a narrow\n             therapeutic range are excluded from the study unless the subject can be transferred to\n             other medications at least 5 half-lives prior to the start of study treatment:\n             phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and\n             tizanidine (CYP1A2).\n\n         14. Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive\n             substrate rosuvastatin; subject should be excluded from the study unless he/she can be\n             transferred to other medications at least 5 half-lives prior to the start of study\n             treatment.\n\n         15. Subject has active uncontrolled systemic fungal, bacterial, or viral infection\n             (defined as ongoing signs/symptoms related to the infection without improvement\n             despite appropriate antibiotics, antiviral therapy, and/or other treatment).\n\n         16. Subject has known or suspected hypersensitivity to any of the components of study\n             therapy.\n\n         17. Subject is taking medications that are known to prolong the QT interval unless he/she\n             can be transferred to other medications within ? 5 half-lives prior to the start of\n             study treatment.\n\n         18. Subject has Heart rate-corrected QT (QTc) interval (ie, Fridericia's correction\n             [QTcF]) ? 450 ms or other factors that increase the risk of QT prolongation or\n             arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval\n             syndrome) at screening.\n\n         19. Female subject who is pregnant or lactating.\n\n         20. Subject has any significant medical condition, laboratory abnormality, or psychiatric\n             illness that would prevent the subject from participating in the study.\n\n         21. Subject has any condition, including the presence of laboratory abnormalities that\n             places the subject at unacceptable risk if he/she were to participate in the study.\n\n         22. Subject has any condition that confounds the ability to interpret data from the study.Xx_NEWLINE_xXPatients who have received previous treatment for antecedent hematological disorders (AHD) with 5-azacitidine, decitabine, or low dose cytarabine will be excludedXx_NEWLINE_xXNOTE: Patients proceeding to transplant are allowed up to one cycle of consolidation treatmentXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXTreatment with medications known to cause QTc interval prolongation within 7 days of study day 1 unless is not permitted unless approved by the sponsor; use of ondansetron is permitted for treatment of nausea and vomitingXx_NEWLINE_xXThe subject must have stable disease after treatment of radiation with concurrent chemotherapy or in case of progression that the disease is controlled with another treatment typeXx_NEWLINE_xXPresence of biopsiable disease and patient able to undergo pre-treatment and on-treatment biopsyXx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXConcomitant systemic treatment with chronic use of anti-histamine or non-steroidal anti-inflammatory drugs and other platelet inhibitory agents and patients on oral anticoagulant (e.g. warfarin)Xx_NEWLINE_xXPatients with prior treatment with hypomethylating agentsXx_NEWLINE_xXPrevious treatment with talimogene laherparepvec (T-VEC) or any other oncolytic virusXx_NEWLINE_xXPrior treatment with a CD123xCD3 bispecific agent, T cells expressing CD123 specific chimeric antigen receptor, or toxin-conjugated to CD123 antibodies; prior treatment with naked anti-CD123 monoclonal antibody is permittedXx_NEWLINE_xXProgression at any time after initiation of azacitidine or decitabine treatment ORXx_NEWLINE_xXMust not have received prior treatment for MDS with any hypomethylating agentXx_NEWLINE_xXPatients with hypothyroidism that is clinically stable and have normal TSH levels with hormone replacement, or patients with vitiligo or psoriasis not requiring treatment remain eligible for the studyXx_NEWLINE_xXAny concurrent treatment that would compromise the study including but not limited to:Xx_NEWLINE_xXT-ALL: T-ALL patients must be enrolled on AALL08B1 or Project:EveryChild (APEC14B1, if open for the classification of ALL patients) prior to treatment and enrollment on AALL1231Xx_NEWLINE_xXTREATMENT: Patients with a history of seizures are not eligible to receive veliparib, but patients with a history of CNS metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for >= 4 weeks will be eligible for other study agents; enzyme inducing anticonvulsants are contraindicatedXx_NEWLINE_xXTREATMENT: Patients who have received prior carboplatin or AZD1775 (MK-1775) would not be excluded unless the two drugs were administered in combination; patients who have received prior carboplatin in combination with AZD1775 (MK-1775) would still be eligible to receive other study treatment regimens based on identified genetic mutation(s), other than carboplatin plus AZD1775 (MK-1775)Xx_NEWLINE_xXSubjects must be willing to undergo 2 sets of core needle biopsies (pre-treatment and on-treatment), if there are lesions amenable to biopsy; an optional core biopsy will be requested at progressionXx_NEWLINE_xXConcurrent investigational agent or anticancer therapy\r\n* Note: megestrol [Megace] if used as an appetite stimulant is allowed\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXPrior systemic therapy directed at advanced RCC is not allowed for patients enrolled to the expansion cohort, treatment naive arm; if prior (neo)adjuvant treatment given as part of a clinical trial, this would be allowed as long as last dose was > 1 year prior to start of treatmentXx_NEWLINE_xXPrior treatment with pomalidomideXx_NEWLINE_xXPlanning to embark on a new strenuous exercise regimen after first dose of study treatment; NOTE: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on binimetinib treatmentXx_NEWLINE_xXPatients who have received prior treatment with tyrosine kinase inhibitors (e.g. erlotinib), or anti-EGFR agents (e.g. cetuximab, panitumumab)Xx_NEWLINE_xXPrevious treatment with TAS-102 or TMZXx_NEWLINE_xXPrior treatment with fluoropyrimidines (applicable to Part 1 only)Xx_NEWLINE_xXActive infection requiring treatment at the time of study treatment initiationXx_NEWLINE_xXSubjects for whom a potential 29-day delay in treatment will interfere with the subject’s potential therapeutic optionsXx_NEWLINE_xXHas prior treatment with Gliadel unless it was administered as first line treatment and at least 3 months prior to study treatmentXx_NEWLINE_xXNo hormonal therapy is allowed within 1 week of initiating study treatmentXx_NEWLINE_xXAny previous treatment with vosaroxinXx_NEWLINE_xXPatient must have received 2 or more prior lines of systemic therapy for myeloma; patients must be off last treatment for at least 2 weeks (wks) by the beginning of treatment on this protocolXx_NEWLINE_xXPatients that have previously progressed on pomalidomide treatmentXx_NEWLINE_xXCurrent treatment with anti-androgen is allowed for a maximum of one month to prevent flare response with ADTXx_NEWLINE_xXFor enrollment in the first stage of Cohort B, patients must have accessible pre-treatment and post-treatment (4-6 weeks) tumor for biopsyXx_NEWLINE_xXStable, continuous antiretroviral treatment for at least three months before enrollment, defined as a multi-drug regimen (excluding azidothymidine [AZT])Xx_NEWLINE_xXPatients for whom there is a plan to receive ipilimumab, vemurafenib, or other treatment for advanced melanomaXx_NEWLINE_xXHistory within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic eventXx_NEWLINE_xXPrior treatment, involving interferon, anakinra, imatinib, steroids, chemotherapy with, but not limited to cladribine, vinblastine, 6-mercaptopurine and etoposide, or other medications used empirically for the treatment of ECD, will be acceptable; these therapies should have been completed and discontinued 4 weeks or more prior to enrollment in this studyXx_NEWLINE_xXA treatment regimen containing a therapeutic anti-CD20 antibody (e.g., rituximab, ofatumumab, obinutuzumab) ANDXx_NEWLINE_xXA treatment regimen containing ibrutinib unless patient is not a candidateXx_NEWLINE_xXAll treatment regimens must have been administered for ?2 cycles unless patient is immediately allergic or intolerant to the regimenXx_NEWLINE_xXPrior treatment with histone deacetylase inhibitors or mammalian target of rapamycin (mTOR) inhibitorsXx_NEWLINE_xXPrior treatment with TPI 287Xx_NEWLINE_xXSubjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatmentXx_NEWLINE_xXNo implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment deliveryXx_NEWLINE_xXThe subject has started treatment with drugs used to control loss of bone mass (eg, bisphosphonates or denosumab) within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXSubject has had prior treatment with cabozantinibXx_NEWLINE_xXTime from last anti-tumor treatment to first radiation treatment at least 1 weekXx_NEWLINE_xXA patient is eligible to participate if she is not pregnant, not breast-feeding, and at least one of the following conditions applies: a.) Not a woman of childbearing potential (WOCBP) OR b.) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 30 days after the last dose of study treatmentXx_NEWLINE_xXPrior treatment with radium-223Xx_NEWLINE_xXTreatment with chronic immunosuppressantsXx_NEWLINE_xXDisease progression confirmed by radiologic assessment while receiving treatment with\n             the first single agent EGFR-TKIXx_NEWLINE_xXTreatment with prohibited medications less than or equal to 14 days prior to\n             treatment with rociletinibXx_NEWLINE_xXPrior treatment with rociletinib, or other drugs that target T790M positive mutant\n             EGFR with sparing of wild type EGFRXx_NEWLINE_xXPrior treatment with anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) monoclonal antibodies or prior CTLA-4 inhibitor or agonist or prior clusters of differentiation (CD)137 agonist or prior interferon-alfa is not allowed; other forms of prior treatment for melanoma (e.g., aldesleukin [IL-2], anti-tumor vaccine, chemotherapy) are allowed if given before the resection(s) that make(s) the patient eligible for this trial, but these must have been completed at least 4 weeks prior to randomizationXx_NEWLINE_xXChronic treatment with steroids or any other immunosuppressant drugsXx_NEWLINE_xXWomen who are currently or planning to breastfeed during protocol treatmentXx_NEWLINE_xXPatients who are taking any of the prohibited medications; if a patient is willing to discontinue such a medication in order to participate in the study, then there must be an appropriate washout period, based on the half-life of the particular drug, prior to the start of the study treatmentXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXAny line of treatment (first line versus beyond first line)Xx_NEWLINE_xXPrior treatment with 5-fluorouracil, irinotecan or oxaliplatinXx_NEWLINE_xXUse of drugs that inhibit renal tubular secretion (e.g. probenecid and cimetidine) within 2 weeks before the start of study treatmentXx_NEWLINE_xXHCV treatment experienced or naive\r\n* HCV treatment naive: no prior exposure to any IFN, ribavirin (RBV), or other approved or experimental HCV-specific direct acting antivirals (DAA)\r\n* HCV treatment-experienced: virologic failure after treatment with polyethylene glycol (PEG)- IFN + RBV, NS3 protease inhibitor plus PEG-IFN + RBV, or regimen of sofosbuvir (SOF) +/- RBV +/- PEG-IFN regimenXx_NEWLINE_xXAny HCV treatment which uses pegylated interferonXx_NEWLINE_xXHCV genotype 3 treatment experienced with cirrhosisXx_NEWLINE_xXOn a prohibited medication which cannot be stopped during the duration of HCV treatmentXx_NEWLINE_xXPatients must be neurologically stable and with stable dose steroids and anticonvulsants for at least 1 week prior to obtaining the baseline MRI of the brain, and/or at least 1 week prior to beginning study treatmentXx_NEWLINE_xXPrevious treatment with eribulin mesylateXx_NEWLINE_xXPrior treatment with other second line hormone therapy is allowed (e.g. flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, ARN-509); patients must be off these therapies for at least 4 weeks prior to starting treatmentXx_NEWLINE_xXPrior treatment with Xofigo (223Radium), Provenge, mitoxantrone and cabazitaxel is allowedXx_NEWLINE_xXAvailable for long-term follow-up of their disease after treatmentXx_NEWLINE_xXSubject has previously been treated with nab-paclitaxel\t\r\n* NOTE: Subjects who have had previous treatment with nab-paclitaxel will NOT be excluded if given in the adjuvant or neoadjuvant setting\r\n* Only in the metastatic setting, will subjects previously treated with nab-paclitaxel be excluded from this trial; exceptions may be made for subjects who discontinued treatment with a previous nab-paclitaxel inhibitor for reasons other than progression and as long as it has been > 12 months since discontinuation of the previous nab-paclitaxel; this exception will require prior approval from the study principal investigator (PI) at University of Kansas Medical Center (KUMC)Xx_NEWLINE_xXSubjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or agree to begin such treatment and remain on treatment until after completion of therapy and until the cluster of differentiation (CD)4 cells are greater than 200/mm^3Xx_NEWLINE_xXDeoxyribonucleic acid (DNA) methyltransferase inhibitors (azacitidine or decitabine) must have been stopped at least 3 weeks prior to day 1 of treatment on the studyXx_NEWLINE_xXPrior treatment with ErwinazeXx_NEWLINE_xXHyperleukocytosis with > 50,000 blasts/ul; hydroxyurea for blast count control is permitted before starting treatment and up to maximum of 4 days after starting treatment on the study; the white blood cell (WBC) need not reach 50,000/ul to start hydroxyurea during protocol; the decision to start hydroxyurea during this time is at the discretion of the treating physician; patients will be withdrawn from the study if > 50,000 blasts/ul persists on hydroxyurea or recur >= 5 days after starting treatment on the studyXx_NEWLINE_xXPatients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medicationsXx_NEWLINE_xXPatients who have a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment are not eligibleXx_NEWLINE_xXPrior treatment with any cytotoxic chemotherapy for treatment of pancreatic cancer except as an adjuvant therapy; patient should not have received gemcitabine within 6 months of starting the study treatment; 5-flourouracil or radiation treatment should be received more than 4 weeks prior to receiving the study drugXx_NEWLINE_xXFor all stage 2 participants, no prior treatment with mTOR, PI3 kinase or Akt inhibitors; prior treatment with mTOR, PI3 kinase or Akt inhibitors allowed in stage 1 onlyXx_NEWLINE_xXChronic treatment with immunosuppressant drugsXx_NEWLINE_xXPrevious radiotherapy to the lesion(s) of interest, including prior treatment with whole-brain radiation therapy (WBRT); (prior treatment with SRS is allowed if the index lesion[s] is in a different, non-contiguous location than the previously treated lesion)Xx_NEWLINE_xXPrior treatment with dasatinib, imatinib or nilotinibXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug; if an alternative medication that does not risk QT prolongation can safely be used in the opinion of the treating physician and the treatment is changed to that medication, the patient may be enrolledXx_NEWLINE_xXConcomitant systemic treatment with corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs; any cyclooxygenase-2 (COX-2) inhibitors are permittedXx_NEWLINE_xXPROCEEDING TO TREATMENT WITH 5-FC:Xx_NEWLINE_xXUrgent need of treatment to prevent acute neurologic deteriorationXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to enrollment; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* Concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXOther non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-upXx_NEWLINE_xXHave previously completed or withdrawn from this study or any other study investigating dasatinib; prior treatment with other tyrosine kinases, including afatinib, is acceptableXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s Wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXPatients may not have received any prior carfilzomib treatmentXx_NEWLINE_xXConcurrent chemotherapy (except hydroxyurea) or interleukin-2 (IL-2) therapy or anticipated need during the study treatment for 1 week after the last dose of ALT-803-hydroxyurea is permitted at any time to control blast countXx_NEWLINE_xXNo prior radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vemurafenib, breastfeeding must be discontinued prior to treatment day 1 of the studyXx_NEWLINE_xXNo radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as suchXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior treatment with an anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist, or a combination of the twoXx_NEWLINE_xXPregnant or lactating women are excluded from this study because temsirolimus and sorafenib are drugs with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temsirolimus or sorafenib, breastfeeding should be discontinued if the mother is receiving temsirolimus/sorafenib treatmentXx_NEWLINE_xXPatients who exceed the weight/size limits of the treatment table or CT scannerXx_NEWLINE_xXAt screening, patients may be included if the largest lesion is > 1 cm or > 3 in number, if the patient has underdone treatment with surgery and/or radiation therapy and there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatmentXx_NEWLINE_xXPrior treatment with trastuzumabXx_NEWLINE_xXPatients with an active infection or with a fever >= 101.3 F within 3 days of the first scheduled day of protocol treatmentXx_NEWLINE_xXPatients with an active infection or with a fever >= 101.3 degrees Fahrenheit (F) within 3 days of the first scheduled day of protocol treatmentXx_NEWLINE_xXCurrent treatment or treatment within 4 weeks of screening with bisphosphonates.Xx_NEWLINE_xXHistory of prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blocking antibodyXx_NEWLINE_xXPatients with concurrent primary head and neck tumors that will be resected as part of treatment plan are considered eligibleXx_NEWLINE_xXSubjects with an indication for AHCT for the treatment of PCM as determined by the principal investigator (PI) or lead associate investigator (LAI)\r\n* Subjects following induction treatment for PCM\r\n* Subjects with recurrent or persistent evaluable disease who have not undergone AHCT for the treatment of the PCMXx_NEWLINE_xXDisease progression confirmed by radiologic assessment while on treatment with EGFR-\n             TKI OrXx_NEWLINE_xXDisease progression confirmed by radiologic assessment while on treatment with the\n             first single agent EGFR TKI andXx_NEWLINE_xXPatients on treatment for rheumatoid arthritis or systemic lupus erythematosusXx_NEWLINE_xXMust not be taking hydroxychloroquine for treatment or prophylaxis of malariaXx_NEWLINE_xXPatients who have relapsed from their initial doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) or similar standard treatment regimen and have not received any other chemotherapy or salvage systemic treatmentXx_NEWLINE_xXPatients must have had prior treatment with bilateral orchiectomy or androgen\n             deprivation therapy with an LHRH-blocker with evidence of treatment failureXx_NEWLINE_xXPrior treatment with veliparib (ABT-888) or other PARP inhibitors (e.g., olaparib)Xx_NEWLINE_xXRequire therapeutic anticoagulation treatment, especially with CoumadinXx_NEWLINE_xXAT TIME OF TREATMENT:Xx_NEWLINE_xXAT TIME OF TREATMENT:Xx_NEWLINE_xXNo prior treatment with systemic anti-EGFR inhibitors or pemetrexed is permittedXx_NEWLINE_xXFollicular lymphoma\r\n* Patients will be eligible in >= first CR/PR (if treatment is delayed until clinically required)\r\n* Patients who are treated at diagnosis (without clinical symptoms necessitating treatment, such as B symptoms, bulky disease, marrow or other organ compromise) will be eligible in >= second CR/PRXx_NEWLINE_xXAt least one of the following indications for treatment:Xx_NEWLINE_xXNo prior treatment with LMB-2Xx_NEWLINE_xXPatients must not be planning to receive any other investigational agents during the course of protocol treatmentXx_NEWLINE_xXPrior treatment with IMGN853Xx_NEWLINE_xXPrior treatment with adenovirus-based drugsXx_NEWLINE_xXPatients with recurrent disease may have received prior treatment with carboplatin/paclitaxel but must have had a treatment free interval of > 6 monthsXx_NEWLINE_xXPatients with recurrent disease may not have received more than three prior chemotherapies for treatment of their uterine cancerXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXPretransplant treatment with sorafenib tosylate (sorafenib) not > 12 months (not exceeding 12 months of treatment, total)Xx_NEWLINE_xXUse of T cell depleting agents for prevention or treatment of rejection at any point prior to or after enrollment in the studyXx_NEWLINE_xXClinically active serious infection documented by positive cultures or an incomplete course of treatment for bacteremia or fungemiaXx_NEWLINE_xXConcomitant treatment with rifampin and St. John’s wortXx_NEWLINE_xXIs ineligible or inappropriate for other treatment regimens known to have effective potentialXx_NEWLINE_xXCohort A (asymptomatic): Subjects must be free of neurologic signs and symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy within 10 days prior to first treatment. Cohort B (symptomatic): Subjects with neurologic signs and symptoms related to metastatic brain lesions are eligible per Amendment 02. Subjects with neurologic signs and symptoms may be treated with a total daily dose of no more than 4 mg of dexamethasone that is stable or tapering for 10 days prior to first treatment. Subjects with neurologic signs and symptoms who are not being treated with steroids are eligible for Cohort B and should have no experience of seizure within 10 days prior to first treatment.Xx_NEWLINE_xXPatients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle #2Xx_NEWLINE_xXPatients undergoing pre-treatment surgery for purposes other than cytoreduction may also participate provided they meet eligibility; patients randomized to arms containing bevacizumab must wait a minimum of 28 days since that procedure to begin protocol treatment; patients who undergo an uncomplicated port placement must wait a minimum of 7 days to begin protocol treatmentXx_NEWLINE_xXPrior treatment with quizartinib or participated in a prior quizartinib study.Xx_NEWLINE_xXPrior treatment with imetelstatXx_NEWLINE_xXPrior treatment with eribulinXx_NEWLINE_xXTreatment with any systemic chemotherapy or investigational agents within 3 weeks of the start of study treatment; endocrine treatment must be stopped prior to initiating study treatment; subjects must have recovered from toxicities of prior therapyXx_NEWLINE_xXHas documented objective radiographic progression during or after treatment with sorafenib or intolerance to sorafenib.Xx_NEWLINE_xXPrior treatment with CD19 directed agents unless CD19 expression is confirmed after completion of CD19-directed treatmentXx_NEWLINE_xXPatient is to receive bevacizumab as maintenance treatmentXx_NEWLINE_xXCohort 1: Subjects with CIS with or without associated papillary disease whose disease is determined to be refractory or relapsed within 6 months of the last dose of adequate BCG treatment.Xx_NEWLINE_xXCohort 2: Subjects with CIS with or without associated papillary disease whose disease is determined to be refractory or relapsed more than 6 months but within 11 months of the last dose of adequate BCG treatment.Xx_NEWLINE_xXHistory of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day 1 until resolution of the UTI (even if this extends the screening period requirements to start of Vicinium treatment).Xx_NEWLINE_xXMore than one relapse, secondary glioblastoma and prior treatment with bevacizumab are excluded. An interval of at least 12 weeks from the completion of radiation therapy to start of study treatment is required.Xx_NEWLINE_xXDisease progression during or after the last treatment regimen and within 6 months before study entry.Xx_NEWLINE_xXTreatment with immunotherapy against PCa within the previous 6 months prior to randomizationXx_NEWLINE_xXRadiographic evidence of recurrent NSCLC prior to afatinib treatmentXx_NEWLINE_xXReceipt of any experimental treatment within 30 days of start of treatment with afatinib until the end of treatment visitXx_NEWLINE_xXPrior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last 2 yearsXx_NEWLINE_xXFor Cohort B: Has received prior treatment with either abiraterone acetate or enzalutamide (but not both) in the prechemotherapy mCRPC state. Participants in Cohort B must have received at least 4 weeks of either abiraterone or enzalutamide treatment (but not both) who failed treatment or became intolerant of the drugXx_NEWLINE_xXFor Cohort C: Has received prior treatment with abiraterone acetate in the pre-chemotherapy mCRPC state without prior enzalutamide. Participants in Cohort C must have received at least 4 weeks of abiraterone treatment who failed treatment or become intolerant of the drug.Xx_NEWLINE_xXHas had a prior radium treatment or treatment with other therapeutic radiopharmaceuticals for prostate cancerXx_NEWLINE_xXFor Cohort C: Has received treatment with 5-? reductase inhibitors (e.g., finasteride, dutasteride), estrogens, and/or cytproterone within 4 weeks of the screening visitXx_NEWLINE_xXRadiotherapy within the 2 weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than 2 weeks before treatment initiation may be considered with medical monitor approvalXx_NEWLINE_xXCurrently active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatmentXx_NEWLINE_xXPreviously exposed to rituximab as part of prior lines of treatment.Xx_NEWLINE_xXRelapsed or refractory Richter syndrome and has received ?1 previous treatment for RS.Xx_NEWLINE_xXSubjects enrolling in the primary refractory or relapsed melanoma must be willing to undergo mandatory pretreatment and on-treatment biopsies.Xx_NEWLINE_xXMust have received > or = 1 prior treatment regimen.Xx_NEWLINE_xXPatient receiving an immunosuppressive treatment for GvHD treatment due to a previous allograft at the time of screeningXx_NEWLINE_xXThey have other medical problems that could get much worse with this treatment.Xx_NEWLINE_xXParticipant treated with any prior systemic therapy with the exception of the following:\r\n* Treatment by localized radiotherapy for a specific indication within 2 weeks of initiation of treatment\r\n* Treatment with corticosteroids, not to exceed the equivalent of 160 mg of dexamethasone over a four-week period before initiation of protocol therapyXx_NEWLINE_xXAny prior treatment with dalantercept or any other agent targeting ALK1 pathway.Xx_NEWLINE_xXAny prior treatment with axitinib.Xx_NEWLINE_xXDuring cohort expansion, subjects with various solid tumors that have received at least one and no more than 5 prior treatment regimensXx_NEWLINE_xXPatient who have had previous treatment with pazopanib or with weekly gemcitabine for recurrent or persistent diseaseXx_NEWLINE_xXPatients assessed at presentation as requiring interstitial brachytherapy treatmentXx_NEWLINE_xXDisease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.Xx_NEWLINE_xXPatients with prior trastuzumab treatmentXx_NEWLINE_xXPatients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting.Xx_NEWLINE_xXAll other significant diseases might impair the subject's tolerance of trial treatmentXx_NEWLINE_xXPatients with gliomas who have had prior treatment with bevacizumab (Avastin) are excludedXx_NEWLINE_xXPatients must agree to blood samples during screening and at the end of treatment for cytogenetic analysis.Xx_NEWLINE_xXSubject must have received no prior treatment for AML with the exception of hydroxyureaXx_NEWLINE_xXPrior treatment with CD137 agonists or immune checkpoint blockade therapies.Xx_NEWLINE_xXThe subject has disease that is not amenable to a curative treatment approach.Xx_NEWLINE_xXProgression following at least 1 prior systemic treatment for HCC.Xx_NEWLINE_xXPrior cabozantinib treatment.Xx_NEWLINE_xXIf the subject has RS, the subject must have had ?1 prior treatment with a combination chemoimmunotherapy regimen.Xx_NEWLINE_xXMust have failed last line of treatment (refractory to last line of treatment).Xx_NEWLINE_xXHas received prior treatment with daratumumab or other anti-CD38 therapies previouslyXx_NEWLINE_xXInclusion Criteria:\n\n        Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Subject is ? 18 years of age the time of signing the informed consent form (ICF).\n\n          2. Documented diagnosis of MDS according to World Health Organization (WHO)/French\n             American British (FAB) classification that meets IPSS R classification of very low,\n             low, or intermediate risk disease, and:\n\n        Ring sideroblast ? 15% of erythroid precursors in bone marrow or ? 5% (but < 15%) if SF3B1\n        mutation is present.\n\n          -  < 5% blasts in bone marrow\n\n          -  Peripheral blood WBC count < 13,000/µL 3. Requires red blood cell RBC transfusions 4.\n             Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 5. Subjects who are\n             refractory/intolerant/ineligible to prior ESA treatment, defined as:\n\n          -  Refractory to prior Erythropoiesis- stimulating agents(ESA) treatment: documentation\n             of non-response or response that is no longer maintained to prior ESA-containing\n             regimen, either as single agent or combination (eg, with G-CSF); ESA regimen must have\n             been either recombinant human erythropoietin (rHu EPO) ? 40,000 IU/wk for at least 8\n             doses or equivalent OR darbepoetin alpha ? 500 ?g Q3W for at least 4 doses or\n             equivalent\n\n          -  Intolerant to prior ESA treatment: documentation of discontinuation of prior\n             ESA-containing regimen, either as single agent or combination (eg, with G-CSF), at any\n             time after introduction due to intolerance or an adverse event\n\n          -  ESA ineligible: low chance of response to ESA base on endogenous serum erythropoietin\n             level > 200 U/L for subjects not previously treated with ESAs\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a subject from enrollment:\n\n          1. Prior therapy with disease modifying agents for underlying MDS disease.\n\n          2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)\n\n          3. MDS associated with del 5q cytogenetic abnormality\n\n          4. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury\n             or treatment with chemotherapy and/or radiation for other diseases.\n\n          5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies,\n             or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding\n\n             - iron deficiency to be determined by serum ferritin less than or equal to 15 ug/L and\n             additional testing if clinically indicated (eg, calculated transferrin saturation\n             [iron/total iron binding capacity less than or equal to 20%] or bone marrow aspirate\n             stain for iron).\n\n          6. Prior allogeneic or autologous stem cell transplant\n\n          7. Known history of diagnosis of Acute myeloid leukemia (AML)\n\n          8. Use of any of the following within 5 weeks prior to randomization:\n\n               -  anticancer cytotoxic chemotherapeutic agent or treatment\n\n               -  corticosteroid, except for subjects on a stable or decreasing dose for ? 1 week\n                  prior to randomization for medical conditions other than MDS\n\n               -  iron-chelating agents, except for subjects on a stable or decreasing dose for at\n                  least 8 weeks prior to randomization\n\n               -  other RBC hematopoietic growth factors (eg, Interleukin-3)\n\n               -  investigational drug or device, or approved therapy for investigational use. If\n                  the half-life of the previous investigational product is known, use within 5\n                  times the half-life prior to randomization or within 5 weeks, whichever is longer\n                  is excluded.\n\n          9. Prior history of malignancies, other than MDS, unless the subject has been free of the\n             disease (including completion of any active or adjuvant treatment for prior\n             malignancy) for ? 5 years. However, subjects with the following history/concurrent\n             conditions are allowed:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix\n\n               -  Carcinoma in situ of the breast\n\n               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,\n                  nodes, metastasis [TNM] clinical staging system)\n\n         10. Major surgery within 8 weeks prior to randomization. Subjects must have completely\n             recovered from any previous surgery prior to randomizationXx_NEWLINE_xXMust have undergone prior treatment with ?2 treatment lines of anti-myeloma therapy and must have failed last line of treatment (refractory to last line of treatment)Xx_NEWLINE_xXEligibility based on prior treatment with immunomodulatory agents depends on the mechanistic class of the drug and the cohort for which the participant is being consideredXx_NEWLINE_xXFor RCC, prior treatment with everolimus or temsirolimusXx_NEWLINE_xXFor urothelial carcinoma, prior treatment with any taxaneXx_NEWLINE_xXFor CRC, prior treatment with cetuximab or panitumumabXx_NEWLINE_xXPatients must have marrow function and organ function as defined below\r\n* Note: to remain on treatment, any abnormal lab values allowed by the PI must remain stable or improve during treatment; similar off treatment rules will be applied to all patients, except the following: the grade of any abnormal laboratory (lab) value allowed by the protocol principal investigator (P.I.) at enrollment will be considered the patient’s baseline for potentially resuming therapy after modification/holding of therapy when off treatment criteria are appliedXx_NEWLINE_xXLife expectance of greater than two months to allow completion of study treatment and assessment of dose-limiting toxicityXx_NEWLINE_xXPatients must not have received any prior treatment for AMLXx_NEWLINE_xXInclusion:\n\n          1. Male or female 1 to 21 years of age at the time of consent\n\n          2. Steroid-refractory grade B-D aGvHD.\n\n               -  Steroid-refractory is defined as a failure to respond to steroid treatment, with\n                  failure to respond defined as any grade B-D (IBMTR grading) aGvHD that shows\n                  progression ? 3 days, or no improvement by 5 days of treatment with 12 mg/kg/day\n                  methylprednisolone or equivalent in subjects with lower GI or liver disease, or\n                  skin disease associated with bullae. Grade D organ involvement will be limited to\n                  skin and liver.\n\n               -  Steroid refractory may also be defined as a failure to respond to 1 mg/kg/day of\n                  methylprednisolone or equivalent in subjects with disease confined to upper GI\n                  disease or lesser degrees of skin GvHD.\n\n               -  Subjects with lack of complete response after 2 weeks of steroid treatment.\n\n          3. A Lansky scale Performance Status score ? 30.\n\n          4. Laboratory values are within the following limits, assessed within 3 days of the first\n             study treatment:\n\n               -  Absolute neutrophil count > 0.5 × 10^9/L.\n\n               -  Creatinine level < 2 times the upper limit of normal.\n\n          5. For patients with isolated upper GI symptoms, pre-Screening biopsy results to confirm\n             diagnosis of aGvHD.\n\n          6. Female patients of childbearing potential and nonsterilized males who are sexually\n             active with a female partner must be practicing highly effective, reliable, and\n             medically approved contraceptive regimen throughout their participation in the study\n             and for 3 months following the last ECP treatment. Or, for the US only, abstinence may\n             be used in place of an approved contraceptive regimen. Females of childbearing\n             potential are those who have reached the onset of menarche, or 8 years of age,\n             whichever comes first. Approved contraceptive methods for female patients of\n             childbearing potential or nonsterilized males who are sexually active with a female\n             partner are as follows:\n\n               -  Barrier methods of contraception: condom or occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n\n               -  Established use of oral, injectable, or implanted hormonal methods of\n                  contraception.\n\n               -  Placement of an intrauterine device or intrauterine system.\n\n          7. Signed informed consent/assent is obtained before conducting any study procedures; the\n             parent, legal guardian, or legally authorized representative of a minor must also\n             provide written informed consent.\n\n        Exclusion:\n\n          1. Currently enrolled in another clinical trial for the treatment of aGvHD.\n\n          2. Use of any experimental regimens or medication(s) for aGvHD treatment.\n\n          3. Treatment with > 2.0 mg/kg/day of methylprednisolone equivalents for aGvHD within 30\n             days prior to the first study treatment.\n\n          4. Overt signs of relapse of the underlying condition.\n\n          5. Uncontrolled viral, fungal, or bacterial infection.\n\n          6. Platelet count < 20.0 × 10^9/L, despite platelet transfusion.\n\n          7. Inability to tolerate the extracorporeal volume shifts associated with ECP treatment.\n\n          8. Uncontrolled GI bleeding.\n\n          9. Veno-occlusive liver disease.\n\n         10. Life expectancy < 4 weeks.\n\n         11. Patient requires invasive ventilation or vasopressor support.\n\n         12. Known human immunodeficiency virus (HIV) or hepatitis B or C virus infection (proof of\n             seronegativity within 6 months of screening is required).\n\n         13. Known allergy or hypersensitivity to methoxsalen, Uvadex, or its excipients.\n\n         14. Known hypersensitivity and allergy to heparin and Anticoagulant Citrate Dextrose\n             Formula-A (ACD-A).\n\n         15. Co-existing photosensitive disease (e.g., porphyria, systemic lupus erythematosus,\n             albinism) or aphakia.\n\n         16. Coagulation disorders that cannot be corrected with simple transfusion.\n\n         17. Co-existing melanoma, basal cell, or squamous cell skin carcinoma.\n\n         18. Previous splenectomy.\n\n         19. White blood cell count greater than 25,000 mm3.\n\n         20. Currently being treated with any systemic immunosuppressive or biologic therapy for\n             the treatment of a medical condition other than aGvHD.\n\n         21. Female patient is breastfeeding or pregnant.\n\n         22. Any medical concerns that may pose risk to the patient.\n\n         23. Any psychological, familial, sociological, and/or geographical condition that may\n             potentially hamper compliance with the study protocol and follow-up schedule.Xx_NEWLINE_xXConcurrent treatment with any medical that prolongs QT interval and may induce torsades de pointes, and which cannot be discontinued at least 2 weeks before treatment with ASTX660. [Applies to Phase 1 only].Xx_NEWLINE_xXFor Dose Expansion Cohort A: patient must 1) have progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) have biopsy of tumor taken after progression on erlotinib, gefitinib or afatinib which must be EGFR-T790M negative confirmed by central testing prior to treatment (if EGFR-T790M status is unknown, patients may consent for trial and for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial), and 3) be treatment naive to 3rd generation EGFR-TKI (rociletinib, EGFR inhibitor HM61713 [HM61713] and AZD9291) and EGFR monoclonal antibodiesXx_NEWLINE_xXTreatment with 5-? reductase inhibitors (finasteride, dutasteride) within 4 weeks of randomization;Xx_NEWLINE_xXPrevious treatment with investigational agents that inhibit MDM2 or MDMX activity (some MDM2-treated patients may be eligible)Xx_NEWLINE_xXENTRY CRITERIA:\n\n        DISEASE CHARACTERISTICS:\n\n          -  Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell\n             carcinoma high-grade subtype.\n\n               -  Patients are eligible if the diagnostic biopsy was done within 3 months of\n                  treatment start and a cystoscopy demonstrating no resectable disease was done\n                  within 6 weeks of treatment start. Patients with high-grade Ta and/or T1 disease\n                  should have complete resection before study treatment.\n\n               -  Upper tract imaging within 6 months prior to study entry must not be suspicious\n                  for upper tract malignancy.\n\n          -  No history of or evidence of muscle-invasive, locally advanced, metastatic and/or\n             extravesical bladder cancer or presence of any other cancer.\n\n        PRIOR/CONCURRENT THERAPY:\n\n          -  No prior BCG treatment or known hypersensitivity to BCG. Patients who have received\n             more than a single-dose post-operative treatment of mitomycin-C or gemcitabine are\n             excluded.\n\n          -  No concurrent use of other investigational agents.\n\n        PATIENT CHARACTERISTICS:\n\n        Performance Status • ECOG 0, 1, or 2. Bone Marrow Reserve\n\n          -  Absolute neutrophil count (AGC/ANC) ? 1,000/uL\n\n          -  Platelets ? 100,000/uL\n\n          -  Hemoglobin ? 8g/dL Renal Function\n\n          -  Glomerular Filtration Rate (GFR) > 40mL/min or serum creatinine ? 1.5 x ULN Hepatic\n             Function\n\n          -  Total bilirubin ? 2.0 X ULN\n\n          -  AST, ALT, ALP ? 3.0 X ULN Cardiovascular\n\n          -  No symptomatic congestive heart failure Class III or IV.\n\n          -  No severe/unstable angina pectoris < 6 months.\n\n          -  No myocardial infarction < 6 months. Pulmonary\n\n          -  Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction.\n\n        Other\n\n          -  Currently eligible for intravesical BCG therapy.\n\n          -  Negative serum pregnancy test if female and of childbearing potential.\n\n          -  No women who are pregnant or nursing.\n\n          -  Subjects, both females and males, with reproductive potential must agree to use\n             effective contraceptive measures for the duration of the study.\n\n          -  No known positive HIV status.\n\n          -  No history or evidence of uncontrollable CNS disease.\n\n          -  No psychiatric illness/social situation that would limit compliance with study\n             requirements.\n\n          -  No other illness that in the opinion of the investigator would exclude the patient\n             from participating in this study.\n\n          -  Must provide signed informed consent and HIPPA authorization and agree to comply with\n             all protocol-specified procedures and follow-up evaluations.\n\n          -  No active systemic infection requiring parenteral antibiotic therapy.\n\n          -  No ongoing chronic systemic steroid therapy required.\n\n          -  No concurrent febrile illness, active urinary tract infection, active tuberculosis, a\n             history of hypotension or anaphylactic reactions.Xx_NEWLINE_xXConsolidation and/or maintenance (including SCT) may have been given in CR/CRi, but are not counted as a line of treatment.Xx_NEWLINE_xXHydroxyurea will not be considered a prior line of treatment.Xx_NEWLINE_xXConsolidation and/or maintenance (including SCT) may have been given in CR/CRi, but are not counted as a line of treatment.Xx_NEWLINE_xXHydroxyurea will not be considered a prior line of treatment.Xx_NEWLINE_xXThe patient has previously received treatment with SL-401.Xx_NEWLINE_xXThe patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (? 10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade ? 2 GVHD.Xx_NEWLINE_xXPhase II only: \r\n* Arm 1: disease progression after at least one cycle of prior treatment with cisplatin or carboplatin for incurable disease; prior treatment with cetuximab for incurable disease is not permitted\r\n* Arms 2 and 3: disease progression after at least one cycle of treatment with cetuximab for incurable diseaseXx_NEWLINE_xXPhase II, arm 1 only: prior treatment with cetuximabXx_NEWLINE_xXHistologically and/or cytologically confirmed and radiographically measurable KRAS and NRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment; in addition, for the monotherapy MET Amplified cohort, subjects must have received prior treatment with anti-EGFR therapy (either panitumumab or cetuximab)Xx_NEWLINE_xXFor Combination Expansion cohort only: prior treatment with cetuximab or panitumumabXx_NEWLINE_xXRadionuclide treatment, including yttrium-90 treatment, within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXPreviously experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPlanned treatment with biological agents within 28 days prior to receiving TheraSphere (may resume after Y-90 treatment or immediately if in control arm)Xx_NEWLINE_xXToxicities due to prior cancer therapy that have not resolved before the initiation of study treatment, if the Investigator determines that the continuing complication will compromise the safe treatment of the patientXx_NEWLINE_xXTreatment with chemotherapy less than or equal to (</=) 3 weeks before study treatmentXx_NEWLINE_xXTreatment with kinase inhibitors </= 2 weeks before study treatmentXx_NEWLINE_xXPrevious radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerancesXx_NEWLINE_xXAt least 6 months since prior treatment with curative intent and recurrenceXx_NEWLINE_xXMust have received at least 2 prior lines of therapy for the treatment of current histology; there are no treatment options available known to provide clinical benefit. Refer to National Comprehensive Cancer Network (NCCN) guidelines of each respective histology for guidance.Xx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXMen and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after treatment;\r\n* NOTE: patient with < 6 moths of life expectancy will be treated with palliative QUAD shot radiotherapy and those with > 6 moths of life expectancy will be treated with conventionally fractionated full dose re-irradiation approach; additional other factors determining which patients will be treated with Quad shot therapy rather than full dose are if the patients have poor performance status, bulky or diffuse disease, significant medical co-morbidities, and significant metastatic disease burdenXx_NEWLINE_xXFor the most recently received VEGFR-targeting TKI there must have been progression of disease as determined by the treating physician either (i) during treatment or (ii) within 6 mo following completion of at least 4 weeks of treatment with the TKIXx_NEWLINE_xXPrior treatment with mTOR inhibitors (everolimus or temsirolimus) or CB-839Xx_NEWLINE_xXPhase 1: Subjects who have disease progression after treatment with available therapies.Xx_NEWLINE_xXRecurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.Xx_NEWLINE_xXPrior treatment with TRC105Xx_NEWLINE_xXPrior treatment with a VEGFR TKI (including pazopanib) (Phase 2 only)Xx_NEWLINE_xXHistory of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatmentXx_NEWLINE_xXHistory of peptic ulcer within the past 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatmentXx_NEWLINE_xXRelapsed or relapsed and refractory MM after receiving at least 2 previous therapies, including an immunomodulator and bortezomib and had either no response or documented disease progression (according to IMWG criteria) to the most recent treatment regimenXx_NEWLINE_xXPrior treatment:\r\n* No radiotherapy within 90 days prior to pre-registration\r\n* No prior treatment with any anti-angiogenic agent targeting the vascular endothelial growth factor (VEGF) pathway including but not limited to bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept or sorafenib\r\n* No prior treatment with HSPPC-96 or other investigational immunotherapy\r\n* Must have received prior treatment with radiotherapy and temozolomide for histologically confirmed GBM at initial diagnosis\r\n* No tumor directed therapy for most recent progression\r\n* No prior Gliadel wafersXx_NEWLINE_xXProgressive disease during or after last treatment regimen.Xx_NEWLINE_xXAppropriate treatment history for histological entity.Xx_NEWLINE_xXPrior treatment with TMZ for low grade glioma or glioblastoma.Xx_NEWLINE_xXPrior treatment with prolifeprospan 20 with carmustine wafer.Xx_NEWLINE_xXUse of 5-alpha reductase inhibitors (5-ARIs) or hormone therapy within 3 months prior to the baseline visit. Baseline PSA must be established after a minimum of 3 months following 5-ARIs discontinuation. Additionally, use of 5-ARIs is not permitted following treatment during the study follow-up period.Xx_NEWLINE_xXDocumented clinical prostatitis requiring therapy within 6 months prior to TreatmentXx_NEWLINE_xXSTEP 2 TO MEDI4736 RE-TREATMENT REGISTRATION:Xx_NEWLINE_xXPatient must have progressed following 12 months of treatment with MEDI4736; patients who discontinue MEDI4736 prior to the completion of 12 months (for any reason) are not eligible; patients who have already completed two 12-month periods of treatment are not eligibleXx_NEWLINE_xXPatients must not have received any treatment after discontinuing MEDI4736 with the following exceptions; localized palliative radiation therapy is allowed for symptom management, provided and treatment is completed >= 14 days prior to RE-TREATMENT registration; local treatment for brain metastases is allowedXx_NEWLINE_xXSubject must have received sorafenib treatment and either:Xx_NEWLINE_xXHave two negative pregnancy tests as verified by the investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence2 from heterosexual contact.Xx_NEWLINE_xXSubjects with psoriasis not requiring systemic treatment;Xx_NEWLINE_xXCentral review of pathology is required for study participation, but not required prior to enrollment or start of treatment in order to avoid delay. If the results of central pathology review are not available prior to the start of study treatment, the confirmation of diagnosis of ATC at the local laboratory is mandatory prior to scheduled start of treatment with lenvatinib.Xx_NEWLINE_xXWillingness to provide pretreatment and on-treatment biopsies.Xx_NEWLINE_xXHistory of listeriosis or previous treatment with a listeria-based immunotherapyXx_NEWLINE_xXFor treatment-naïve subjects only:Xx_NEWLINE_xXPatients must have disease amenable to biopsy and must be willing to undergo a paired biopsy for correlative analyses (the first biopsy within 28 days prior to start of treatment and the second biopsy while on treatment)Xx_NEWLINE_xXPatients who previously received gemcitabine for the treatment of recurrent diseaseXx_NEWLINE_xXPrior treatment with entrectinib.Xx_NEWLINE_xXPart C (CPI-Treated Expansion): Subject must have received prior treatment with a CPI in the metastatic settingXx_NEWLINE_xXPrior treatment for lymphoid malignancy requiring treatment for progressive diseaseXx_NEWLINE_xXSecondary or hypoplastic MDS or other subtype with eligibility for treatment with immunotherapyXx_NEWLINE_xXOngoing medically significant adverse events from previous treatment, regardless of the time periodXx_NEWLINE_xXPrior treatment with PARP inhibitors (Patients in Cohort A1)Xx_NEWLINE_xXPrior treatment with PM01183 or trabectedin.Xx_NEWLINE_xXPost resection serum cancer antigen (CA)19-9 =< 180 units/mL AND prior to any systemic treatmentXx_NEWLINE_xXPatients who are already on prescribed treatment for paronychia who are not willing to discontinue this treatment and only use study drug (no washout period required)Xx_NEWLINE_xXIneligible for intensification treatment due to age or significant comorbidityXx_NEWLINE_xXRefused intensification treatment and/or ASCTXx_NEWLINE_xXParticipant for whom treatment with monotherapy chemotherapy such as gemcitabine or capecitabine is a reasonable choice.Xx_NEWLINE_xXSubjects with psoriasis not requiring systemic treatmentXx_NEWLINE_xXPrevious cytotoxic, cytostatic, hormonal, biological or immunological treatment (ESA with or without G-CSF and iron chelating therapy and hydroxyurea are allowed under certain conditions, see exclusion criterion #5) or biologic treatment for AML.Xx_NEWLINE_xXPrevious treatment with ibrutinibXx_NEWLINE_xXSubject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an investigational agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).Xx_NEWLINE_xXRelapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatmentXx_NEWLINE_xXPrior treatment with pomalidomideXx_NEWLINE_xXMust have undergone prior treatment with ?2 treatment lines of anti-myeloma therapyXx_NEWLINE_xXMust have failed last line of treatment (refractory to last line of treatment).Xx_NEWLINE_xXMust have achieved at least a stable disease (SD) for at least 1 cycle of treatment to at least 1 prior anti-myeloma regimen before developing Progressive disease (PD) (relapsed)Xx_NEWLINE_xXAny concurrent therapy for BM other than the specified treatment in this studyXx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment line.Xx_NEWLINE_xXTreatment with herbal cancer therapy within 1 week prior to initiation of study drugXx_NEWLINE_xXCurrent treatment with therapeutic anticoagulantsXx_NEWLINE_xXPrior participation in an afatinib clinical study, even if not assigned to afatinib treatmentXx_NEWLINE_xXSingle dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.Xx_NEWLINE_xXFollicular low-grade NHL: either treatment naïve (except for France) or relapsed or refractory following at least one prior treatment. In Part 1 Dose Escalation only, in addition to follicular NHL, marginal zone B cell lymphomas: either treatment naïve or relapsed or refractory following at least one prior treatment.Xx_NEWLINE_xXAdults with ALL in need of treatmentXx_NEWLINE_xXPrior treatment with nintedanibXx_NEWLINE_xXPrior treatment with regorafenibXx_NEWLINE_xXNo prior treatment with GDC-0810 (allowed only during dose expansion stage)Xx_NEWLINE_xXCurrent treatment with any systemic anti-cancer therapies for advanced disease or any systemic experimental treatment on another clinical trialXx_NEWLINE_xXSubjects enrolled in the current study must start treatment with the single hormone agent either within 15 days prior to randomization or after randomization (before or simultaneously to the first injection of Ra-223/placebo).Xx_NEWLINE_xXConcurrent treatment with a non permitted drugXx_NEWLINE_xXPatients must have no non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with protocol therapyXx_NEWLINE_xXPreviously untreated and not receiving any other agent that would be considered as a treatment for the lymphoma; for subjects with severe systemic symptoms, compressive disease, or rapidly progressing symptomatic adenopathy, are allowed for lymphoma associated symptom treatment with up to 1 mg/kg/day prednisone, or equivalent, for a maximum of 7 days is permitted prior to beginning the treatment, at the discretion of the investigator; a washout period does not applyXx_NEWLINE_xXTreatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physicianXx_NEWLINE_xXHave a clinical indication for treatment as determined by the investigatorXx_NEWLINE_xXNo prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids, cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar punctureXx_NEWLINE_xXNo prior treatment with cetuximabXx_NEWLINE_xXFor men: Must be surgically sterile or compliant with a contraceptive regimen during and for 3 months after the treatment periodXx_NEWLINE_xXDocumented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.Xx_NEWLINE_xXPrior treatment with the following:Xx_NEWLINE_xXPatient is currently deriving clinical benefit from the study treatment, as determined by the investigator.Xx_NEWLINE_xXHas mesothelioma (pleural, peritoneal, pericardial, tunica vaginalis) of any histology that is relapsed or refractory after treatment with at least one pemetrexed-containing regimenXx_NEWLINE_xXHave received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.Xx_NEWLINE_xXNo prior systemic treatment for ES-SCLCXx_NEWLINE_xXPatients who have any option for other treatment for B-cell NHL at the current state of disease.Xx_NEWLINE_xXRelapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigatorXx_NEWLINE_xXContraindication to treatment for TE prophylaxisXx_NEWLINE_xXPrior treatment with sorafenib or tivozanib.Xx_NEWLINE_xXSubject must be deriving benefit from continued treatment without any persistent intolerable toxicity from continued treatment of ASP2215.Xx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXMore than one chemotherapeutic regimen given for R/M disease. Prior treatment with immunotherapy is allowed.Xx_NEWLINE_xXProgressive disease within 3 months after completion of curatively intended treatment for locoregionally advanced SCCHN.Xx_NEWLINE_xXAnti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of first dose of BBI608 and BBI503. Patients may begin BBI608 and BBI503 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 7 days since last receiving anti-cancer treatment, provided that all treatment-related adverse effects have resolved or have been deemed irreversibleXx_NEWLINE_xXPrior treatment with either BBI608 or BBI503Xx_NEWLINE_xXMust have a documented diagnosis of MM and have relapsed or relapsed-and-refractory disease. All patients must have relapsed after having achieved at least stable disease (SD) for at least 1 cycle of treatment to at least 1 prior regimen and then developed progressive disease (PD). Relapsed-and-refractory patients also have documented evidence of PD during or within 60 days of completing last treatmentXx_NEWLINE_xXPatients who have had previous treatment with:Xx_NEWLINE_xXTreatment directed against the resected melanoma that is administrated after the surgeryXx_NEWLINE_xXPrior treatment with fulvestrantXx_NEWLINE_xXNo prior treatment with MRZ or any other proteasome inhibitors or any other anti-angiogenic agents.Xx_NEWLINE_xXRequire treatment with any of the exclusionary medications listed in Appendix D.Xx_NEWLINE_xXPatients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 14 days since last receiving anti-cancer treatment which did not include BBI608, provided that all treatment-related adverse events have resolved or have been deemed irreversible (except for alopecia).Xx_NEWLINE_xXPatients who previously received BBI608 for treatment of PDAC on the BBI608-118 (BBI608-201PANC) study may continue with BBI608 in monotherapy between discontinuation of the first chemotherapy backbone and start of the second chemotherapy backbone. Patients may begin chemotherapy backbone on a date determined by the investigator and medical monitor for the sponsor after a minimum of 14 days and a maximum of 30 days since last receiving anti-cancer treatment which included BBI608, provided that all treatment-related adverse events have resolved or have been deemed irreversible (except for alopecia).Xx_NEWLINE_xXPrior irinotecan treatmentXx_NEWLINE_xXPrevious treatment with Samarium-153 or Strontium-89.Xx_NEWLINE_xXThe subject has had a hypoglycemic episode requiring medical intervention while on insulin (or other anti-diabetic) treatment within 12 months before Day 1.Xx_NEWLINE_xXConcurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Subjects must have discontinued use of such agents prior to beginning study treatment.Xx_NEWLINE_xXTreatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-0610. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of CPI-0610 may be permitted in patients with rapidly progressive or aggressive subtypes of lymphoma following discussion with the medical monitor.Xx_NEWLINE_xXTreatment with medications that are known to carry a risk of Torsades de Pointes.Xx_NEWLINE_xXPrior treatment with rigosertib;Xx_NEWLINE_xXAny number of prior treatment regimens (in the phase I portion only); prior erlotinib is allowed in the dose finding phase and expansion cohort A; (only EGFR mutated patients are eligible)Xx_NEWLINE_xXEXCLUSION FOR TREATMENT: Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observationXx_NEWLINE_xXEXCLUSION FOR TREATMENT: Patients will be excluded if they have isolated extra-medullary relapse of ALLXx_NEWLINE_xXEXCLUSION FOR TREATMENT: Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapyXx_NEWLINE_xXPrevious treatment with exemestane or mTOR inhibitors* (Note: Patients with disease refractory to prior LEE011 are excluded for dose expansion Group 3 only).Xx_NEWLINE_xXGroup 1 - Patients must not have received prior treatment with any CDK4/6 inhibitorsXx_NEWLINE_xXPrior treatment with TRC105 or axitinib or any agent targeting the endoglin pathway (including a fusion protein that binds bone morphogenic protein)Xx_NEWLINE_xXHistory of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months of starting study treatmentXx_NEWLINE_xXHistory of peptic ulcer disease within 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatmentXx_NEWLINE_xXEligible for curative treatment (ablation or transplantation)Xx_NEWLINE_xXPrior yttrium-90 microsphere treatment to the liverXx_NEWLINE_xXPrior treatment with transarterial chemoembolization (TACE) or bland embolization >2 months prior to randomization and must have been applied to a treatment field and/or lobe not targeted for treatment under this protocolXx_NEWLINE_xXPrior systemic treatment for the treatment of HCC, including sorafenibXx_NEWLINE_xXPatients who have received prior chemoradiation, radiation, and/or surgery in the potentially curative setting are eligible as long as 3 months has elapsed since the end of the potentially curative treatment endedXx_NEWLINE_xXPatients must have relapsed after having achieved at least stable disease for at least one cycle of treatment to at least one prior regimen and then developed PD.Xx_NEWLINE_xXPatients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease).Xx_NEWLINE_xXPatient has received other investigational drugs with 14 days before treatment of treatment with bortezomib + rituximabXx_NEWLINE_xXContinued treatment with bevacizumab with documented evidence of disease progression on a bevacizumab-containing regimenXx_NEWLINE_xXTreatment for the studied cancer within 28 days prior to initiation of study treatmentXx_NEWLINE_xXPrior treatment with plitidepsin.Xx_NEWLINE_xXAll patients who disagree to refrain from donating blood while on study treatment and for 4 weeks after discontinuation from this study treatment.Xx_NEWLINE_xXPrior treatment with any drug that targets T cell co-stimulation pathways(such as checkpoint inhibitors)Xx_NEWLINE_xXDocumented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.Xx_NEWLINE_xXTreatment Naive MCL patients requiring treatment with no exposure to prior therapies. Relapsed/Refractory patients defined as disease relapsed or been refractory to ? 1 prior therapies for MCL and requiring further treatment. Patient who discontinued any prior treatment for MCL for tolerability reasons can also be enrolled.Xx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXFor Cohort 1: has documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenibXx_NEWLINE_xXPrior treatment with lenvatinib.Xx_NEWLINE_xXHas received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment)Xx_NEWLINE_xXSexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXRequires intermittent or chronic treatment with antiherpetic drugs, except for topical agentsXx_NEWLINE_xXPatients who are known sensitive to any of the products or components to be administered during treatment with talimogene laherparepvecXx_NEWLINE_xXHas progressed on more than 2 prior treatment regimens for acute GVHD.Xx_NEWLINE_xXSubject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, has not been treated). If re-enrolled, the subject must be re-consented.Xx_NEWLINE_xXPrevious treatment with decitabine or azacitidine or other hypomethylating agent.Xx_NEWLINE_xXLive vaccines should ideally not be administered to any patients undergoing treatment with chemotherapy or immunotherapy, but if need be, they should be administered >4 months prior to the initiation of treatment or >4 months after the completion of all treatmentXx_NEWLINE_xXPrior treatment with PI3K? or Bcl-2 inhibitors.Xx_NEWLINE_xXConcomitant treatment with:Xx_NEWLINE_xXFor participants enrolled in the safety run-in phase: lymphoma classified as either relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen or previously untreated Grade 1, 2, or 3a FL that requires treatmentXx_NEWLINE_xXFor women who are not postmenopausal or surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than [<] 1 percent [%] per year during the treatment period and for at least 18 months after the last dose of study treatment for participants in the Atezo-G-benda and Atezo-G-CHOP treatment groups or for at least 12 months after the last dose of study treatment for participants in the Atezo-R-CHOP treatment groupXx_NEWLINE_xXPrevious systemic chemotherapy is permitted if administered as induction treatment (=< 2 cycles) before definitive chemoradiotherapy for early stage disease and there is no evidence of tumor progression during or after treatment completionXx_NEWLINE_xXPatients requiring a treatment by oral vitamin K antagonistsXx_NEWLINE_xXExperienced an investigator-determined confirmed cutaneous or radiographic disease progression after stopping their initial treatment with MK-3475Xx_NEWLINE_xXAny concurrent chemotherapy, biologic, or hormonal therapy for cancer Treatment; 2. History of leptomeningeal carcinomatosis; 3. Active or prior documented autoimmune or inflammatory disorders; 4. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 14 days prior to study treatment start; 5. QT interval corrected for heart rate using Fridericia's formula (QTcF) ?470 ms; 6. Known allergy or hypersensitivity to IP or any IP excipientXx_NEWLINE_xXRelapsed or refractory disease. Relapse is defined as progression of disease after an initial response to previous treatment, more than 60 days after cessation of treatment. Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatmentXx_NEWLINE_xXRecent infection requiring systemic treatment that was completed =< 14 days before starting treatment on the studyXx_NEWLINE_xXMain inclusion criteria:\n\n          1. Female patient, with histologically or cytologically confirmed advanced / metastatic\n             epithelial ovarian cancer either :\n\n               -  refractory to first line platinum treatment (defined as progressive disease while\n                  receiving or persistent disease after platinum-based therapy, according to GOG),\n                  or\n\n               -  candidate to third line treatment.\n\n          2. Patient has recovered of all acute toxic side effects of prior therapy or surgical\n             procedures to grade ?1 National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE\n             v4.02), except for the laboratory values\n\n          3. Patient has at least one target lesion that can be measured in one dimension,\n             according to the Response Evaluation Criteria in Solid Tumors (RECIST)\n\n          4. ECOG Performance status ? 2\n\n          5. Patient with adequate organ function per laboratory tests evaluations\n\n          6. Patient with life expectancy > 3 months\n\n          7. Patient weight > 40 kg and BMI > 18\n\n          8. Female patient ? 18 years\n\n          9. Patient with nutritional risk index (NRI) ? 83.5, i.e. with no or moderate\n             malnutrition;\n\n         10. Female patient of childbearing potential (entering the study after a menstrual period\n             and who have a negative pregnancy test), who agrees to use two methods (one for the\n             patient and one for the partner) of medically acceptable forms of contraception during\n             the study and for 3 months after the last treatment intake.\n\n        Main exclusion criteria:\n\n          1. Patient intolerant to gemcitabine\n\n          2. Patient who has not recovered from any significant treatment toxicities prior to\n             baseline (?Grade 2)\n\n          3. Patient presenting with serious cardiac disorders defined in the protocol\n\n          4. Pregnant or nursing female patient\n\n          5. Patient with active central nervous system (CNS) metastasis or with history of CNS\n             metastasis\n\n          6. Patient treated for a cancer other than epithelial ovarian cancer within 5 years\n             before enrolment, with the exception of basal cell carcinoma or cervical cancer in\n             situ\n\n        WASH-OUT:\n\n          1. Patient is at least 4 weeks from any major surgery (at baseline/W0)\n\n          2. Patient treated with any investigational agent within 4 weeks prior baseline\n\n          3. Patient who had systemic chemotherapy within 4 weeks before baseline\n\n          4. Patient who had radiotherapy within 4 weeks before baselineXx_NEWLINE_xXAnti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of first dose of BBI608. Patients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 7 days since last receiving anti-cancer treatment, provided that all treatment-related adverse events (AEs) have resolved or have been deemed irreversibleXx_NEWLINE_xXPrior treatment with a therapeutic agent targeting CD19 and/or CD3Xx_NEWLINE_xXA clinical indication for treatment as determined by the investigatorXx_NEWLINE_xXPrevious assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.Xx_NEWLINE_xXPrevious antiangiogenic treatmentXx_NEWLINE_xXPatients who have received any treatment with ibrutinib prior to study entryXx_NEWLINE_xXPatients must not have plans to receive concomitant chemotherapy, other biological or immune therapies, or radiation therapy for the treatment of prostate cancer during the period of study treatmentXx_NEWLINE_xXSubjects with active HBV infection need to be on anti-HBV suppression ?3 months, throughout treatment and for 6 months afterXx_NEWLINE_xXConcurrent treatment with anticoagulation medication, unless approved by SponsorXx_NEWLINE_xXAny prior treatment with carfilzomibXx_NEWLINE_xXPrior treatment with carfilzomib or oprozomibXx_NEWLINE_xXPhase Ib only: documented progression of disease according to RECIST v1.1 while on continuous treatment with EGFR TKI (e.g.: erlotinib, gefitinib or afatinib).Xx_NEWLINE_xXPhase II Group 4 (EGFRmut, any T790M, any c-MET, 1L (treatment-naïve), 2//3L antineoplastic): All patients must harbor an EGFR activating mutation and 2/3L patients must have failed (defined as intolerance to treatment or documented disease progression) a maximum of 2 prior lines of antineoplastic therapy in the advanced settingXx_NEWLINE_xXMore than one previous treatment line with erlotinib, gefitinib or afatinibXx_NEWLINE_xXPrevious treatment with any investigational agent known to inhibit EGFR (mutant or wild-type)Xx_NEWLINE_xXMore than 1 previous treatment line with 1st or 2nd generation EGFR TKI (e.g. erlotinib, gefitinib, afatinib) in the advanced settingXx_NEWLINE_xXPrevious treatment with an investigational or marketed 3rd generation EGFR TKI (e.g. AZD9291, CO-1686, ASP8273, EGF816)Xx_NEWLINE_xXMore than two previous treatment lines of systemic antineoplastic therapies in the advanced settingXx_NEWLINE_xXPrevious treatment with an investigational or marketed 3rd generation EGFR TKI (e.g. AZD9291, CO-1686, ASP8273, EGF816)Xx_NEWLINE_xXInclusion Criteria:\n\n        All patients must meet all of the following inclusion criteria:\n\n          1. Histologically or cytologically confirmed metastatic or unresectable locally advanced\n             NSCLC with radiological progression on the most recent therapy received\n\n          2. Documented evidence of a tumor with 1 or more EGFR activating mutations excluding exon\n             20 insertion\n\n          3. Disease progression confirmed by radiological assessment while receiving treatment\n             with single agent EGFR-TKI (e.g., erlotinib, gefitinib, afatinib, or dacomitinib) or\n             EGFR-TKI in combination with other targeted therapy (e.g. bevacizumab, immunotherapy)\n\n          4. Multiple lines of prior treatment are permitted and there is no specified order of\n             treatment, but in the course of their treatment history, patients must have received\n             and have radiologically documented disease progression following:\n\n             At least 1 line of prior treatment with a single-agent EGFR-TKI (e.g., erlotinib,\n             gefitinib, afatinib, or dacomitinib)\n\n             If EGFR-TKI is a component of the most recent treatment line, the washout period for\n             the EGFR-TKI is a minimum of 3 days before the start of study drug treatment\n\n             AND\n\n             A platinum-containing doublet chemotherapy (either progressed during therapy or\n             completed at least 4 cycles without progression with subsequent progression after a\n             treatment-free interval or after a maintenance treatment).\n\n             If cytotoxic chemotherapy is a component of the most recent treatment line, treatment\n             with chemotherapy should have been completed at least 14 days prior to start of study\n             treatment. When an EGFR-TKI is given in combination with platinum-containing doublet\n             chemotherapy, treatment with the EGFR-TKI may continue until at least 3 days before\n             start of treatment.\n\n          5. Have undergone a biopsy of either primary or metastatic tumor tissue within 60 days\n             prior to start of treatment and have tissue sent to the central laboratory prior to\n             randomization\n\n          6. Measureable disease according to RECIST Version 1.1\n\n          7. Life expectancy of at least 3 months\n\n          8. ECOG performance status of 0 to 1\n\n          9. Age ? 18 years (in certain territories, the minimum age requirement may be higher\n             e.g., age ? 20 years in Japan and Taiwan, age ? 21 years in Singapore)\n\n         10. Patients should have recovered to National Cancer Institute (NCI) Common Terminology\n             Criteria for Adverse Events (CTCAE) Grade ? 1 from any significant\n             chemotherapy-related toxicities\n\n         11. Adequate hematological and biological function\n\n         12. Written consent on an Institutional Review Board (IRB)/Independent Ethics Committee\n             (IEC)-approved ICF before any study specific evaluation\n\n        Exclusion Criteria:\n\n        Any of the following criteria will exclude patients from study participation:\n\n          1. Any other malignancy associated with a high mortality risk within the next 5 years and\n             for which the patients may be (but not necessarily) currently receiving treatment\n\n             Patients with a history of malignancy that has been completely treated, with no\n             evidence of that cancer currently, are permitted to enroll in the trial provided all\n             chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 years\n             prior\n\n          2. Known pre-existing interstitial lung disease\n\n          3. Tumor small cell transformation by local assessment, irrespective of presence of\n             T790M+ component\n\n          4. Patients with leptomeningeal carcinomatosis are excluded. Other central nervous system\n             (CNS) metastases are only permitted if treated, asymptomatic, and stable (not\n             requiring steroids for at least 2 weeks prior to randomization and the patient is\n             neurologically stable i.e. free from new symptoms of brain metastases)\n\n          5. Patients who are currently receiving treatment with any medications that have the\n             potential to prolong the QT interval and that treatment cannot be either discontinued\n             or switched to a different medication (known to have no effect on QT) before starting\n             protocol-specified treatment (see http://crediblemeds.org/ for a list of QT-prolonging\n             medications)\n\n          6. Prior treatment with rociletinib, or other drugs that target T790M+ mutant EGFR with\n             sparing of WT-EGFR including but not limited to osimertinib, HM61713, and TAS-121\n\n          7. Any contraindications for therapy with pemetrexed, paclitaxel, gemcitabine or\n             docetaxel unless a contraindication with respect to one of these drugs will not affect\n             the use of any of the others as a comparator to rociletinib\n\n          8. Any of the following cardiac abnormalities or history:\n\n               1. Clinically significant abnormal 12-lead ECG, QT interval corrected using\n                  Fridericia's method (QTCF) > 450 msec\n\n               2. Inability to measure QT interval on ECG\n\n               3. Personal or family history of long QT syndrome\n\n               4. Implantable pacemaker or implantable cardioverter defibrillator\n\n               5. Resting bradycardia < 55 beats/min\n\n          9. Non-study related surgical procedures ? 7 days prior to randomization. In all cases,\n             the patient must be sufficiently recovered and stable before treatment administration\n\n         10. Females who are pregnant or breastfeeding\n\n         11. Refusal to use adequate contraception for fertile patients (females and males) while\n             on treatment and for 6 months after the last dose of study treatment (rociletinib and\n             chemotherapy irrespective of single cytotoxic agent used)\n\n         12. Presence of any serious or unstable concomitant systemic disorder incompatible with\n             the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including\n             uncontrolled diabetes, active infection, arterial thrombosis, and symptomatic\n             pulmonary embolism)\n\n         13. Any other reason the investigator considers the patient should not participate in the\n             study\n\n         14. Treatment with live vaccines initiated less than 4 weeks prior to randomizationXx_NEWLINE_xXPatients with metastatic malignant solid tumors who received treatment in the past 6 months are excludedXx_NEWLINE_xXHas prior treatment with Gliadel (carmustine) unless it was administered as first line treatment and at least 3 months prior to study treatmentXx_NEWLINE_xXUncontrolled infection; to be eligible, patients receiving treatment for an infection (antibiotic, antifungal or antiviral treatment) must be afebrile (< 38.3 degrees Celsius [C]) and without hemodynamic instability or dyspnea from pneumonia for > 48 hours (hrs) prior to the start of induction therapyXx_NEWLINE_xXPatient has received previous treatment with histone deacetylase (HDAC) inhibitorsXx_NEWLINE_xXSubject is taking warfarin at start of treatment or within 6 months prior to start of study treatmentXx_NEWLINE_xXOn treatment with eculizumab (Soliris®) for at least 3 monthsXx_NEWLINE_xXHave received prior treatment with everolimusXx_NEWLINE_xXknown or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment),Xx_NEWLINE_xXIn Part B-BM expansion, patients must have not received any EGFR TKI and have asymptomatic brain metastasis, either found during screening process which does not require local treatment in the opinion of the investigator or local treatment has been given (surgery or radiation), patient must be stable without corticosteroid and/or anti-convulsants treatment for at least 2 weeks before study enrollment. For Part B-LM expansion, patients who received previous EGFR TKI treatment must have stable extracranial disease;EGFR TKI treatment naïve patients can also be enrolled into AZD9291 cohorts, or AZD3759 cohorts if efficacy signal seen in Part A and agreed by Safety Review Committee.Xx_NEWLINE_xXIn Part B-AZD9291 LM expansion (sub-cohort of T790M+ LM patients), patients must have central confirmation of T790M+ mutation status from a sample taken after documented progression on the last treatment administered prior to enrolling in the study. Patients must have received prior therapy with an EGFR TKI and may also have received additional lines of treatment. Stable extracranial disease is not required.Xx_NEWLINE_xXAny cytotoxic chemotherapy,or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen within 14 days of the first dose of study treatmentXx_NEWLINE_xXPatients who have received a taxane based treatment or abiraterone, within 4 weeks before start of study treatment.Xx_NEWLINE_xXCurrent treatment with steroidsXx_NEWLINE_xXPatients who have a history of alcohol or drug abuse in the 6 month period prior to study treatment.Xx_NEWLINE_xXPrior treatment with temozolomide, dacarbazine or procarbazineXx_NEWLINE_xXPrior treatment with poly ADP ribose polymerase (PARP) inhibitors (eg., olaparib, ABT-888)Xx_NEWLINE_xXCurrent use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug.Xx_NEWLINE_xXRegistration to Step 3 Crossover must be within 28 days of discontinuation of Arm 1 protocol treatment; patients going off treatment for any other reason are not eligibleXx_NEWLINE_xXHave chosen a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment optionsXx_NEWLINE_xXReceived systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocolXx_NEWLINE_xXReceived 3 or more prior myelotoxic treatment regimensXx_NEWLINE_xXSubject must have received ? 1 prior treatment regimen(s)Xx_NEWLINE_xXTreatment with Coumadin; patients who recently received Coumadin must be off Coumadin for at least 7 days prior to start of the studyXx_NEWLINE_xXNeed of treatment for relapsed, progressed or refractory disease as assessed by the investigator.Xx_NEWLINE_xXPatients who have received any treatment with SGN-35 prior to study entryXx_NEWLINE_xXPrior treatment with bleomycinXx_NEWLINE_xXPrevious treatment with SB-485232 or ofatumumabXx_NEWLINE_xXPatients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligibleXx_NEWLINE_xXOngoing treatment with chronic immunosuppressants.Xx_NEWLINE_xXSubjects previously treated with anti-program death-1 (PD1) or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibodies must not have discontinued therapy due to any treatment-related adverse events including immune-related adverse events. Prior treatment-related adverse events should also be fully resolved and not requiring treatment for at least 28 days prior to randomization.Xx_NEWLINE_xXTreatment-naïveXx_NEWLINE_xXPatients must have been previously treated, as defined by treatment with at least one prior cytotoxic regimen or agentXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXUncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. Treatment of pre-existing invasive fungal infections must be completed prior to starting treatment.Xx_NEWLINE_xXSubject has an advance directive to withhold life-sustaining treatment.Xx_NEWLINE_xXSubject has had previous treatment with ART-123.Xx_NEWLINE_xXCurrently tolerating imatinib 400mg QD. Patients with prior imatinib treatment interruption or dose reductions are required to be on treatment with 400 mg imatinib for two weeks immediately prior to randomization to ensure tolerance to imatinibXx_NEWLINE_xXAny prior melanoma treatment other than surgery or regional irradiationXx_NEWLINE_xXAutoimmune disorders confined to the skin (e.g. psoriasis) are eligible, and topical steroids are allowed for the treatment of such skin disorders.Xx_NEWLINE_xXTREATMENTXx_NEWLINE_xXTREATMENTXx_NEWLINE_xXPatient under medications that can affect PSA for the last 3 months prior to MRgFUS treatment (Androgen Deprivation Treatment; alpha reductase inhibitors)Xx_NEWLINE_xXPatients who received PDGFR inhibitors (imatinib, sunitinib, nilotinib, etc.) previously are excluded (patients who received PDGFR antibody based treatment however are allowed)Xx_NEWLINE_xXAn infection requiring antibiotic treatment within seven days of starting study treatment (day -1)Xx_NEWLINE_xXDisease staging approximately within one month of treatmentXx_NEWLINE_xXPrior mTOR inhibitors for the treatment of cancer.Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]Xx_NEWLINE_xXPrior treatment with irinotecan, topotecan, or dinutuximab.Xx_NEWLINE_xXSubject must agree to undergo two research-directed biopsies during treatmentXx_NEWLINE_xXPrior treatment with compounds with the same mode of action as proposed for HDM201, i.e. an inhibition of the interaction of TP53 with HDM2, e.g. RG7112 or CGM097Xx_NEWLINE_xXPrior receipt of antiangiogenic treatment, including but not limited to bevacizumab, is optional. If used, it can be used in the first line or recurrent setting.Xx_NEWLINE_xXPrior treatment with other agents targeting the HGF/c-Met pathwayXx_NEWLINE_xXResolution of treatment-related toxicities except alopeciaXx_NEWLINE_xXConditions that could interfere with treatment or protocol-related proceduresXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXPreemptive treatment with retinoic acid prior to exclusion of APL ? 7 daysXx_NEWLINE_xXSubject has cholesterol panel and triglyceride done before first treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting treatment; granisetron may be administered, but antiemetics associated with QT prolongation (e.g., ondansetron) are not allowedXx_NEWLINE_xXPrior treatment with IMGN779Xx_NEWLINE_xXPrior treatment with neratinibXx_NEWLINE_xXHave a central venous catheter line in place prior to study treatment administrationXx_NEWLINE_xXThe interval between last PD-(L)1 directed treatment and start of study treatment should be at least 21 days.Xx_NEWLINE_xXThose with BRAF wild type may have had a maximum of two previous systemic regimens for the treatment of melanoma.Xx_NEWLINE_xXThose with a BRAF mutation may have had a maximum of three previous systemic regimens for the treatment of melanoma.Xx_NEWLINE_xXPatients who have received systemic treatment with IFN-? within the previous 6 months prior to enrolling into this study.Xx_NEWLINE_xXPatients who previously had a severe reaction to treatment with a human antibody.Xx_NEWLINE_xXOngoing treatment with chronic, therapeutic dosing of anti-coagulants.Xx_NEWLINE_xXTreatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresisXx_NEWLINE_xXPrior treatment with imetelstatXx_NEWLINE_xXPatients may not have been included in any prior IMCgp100 trial, regardless of treatment cohortXx_NEWLINE_xXInclusion Criteria:\n\n          -  Age >= 18 years\n\n          -  Indicated and planned to receive primary radiation therapy for prostate cancer\n\n          -  Histologically confirmed adenocarcinoma of an intact prostate, and 1 of the following\n             at diagnosis: 1) Gleason score >=8 and >=cT2c, 2) Gleason score >=7, PSA >=20 nanogram\n             per milliliters (ng/mL), and >=cT2c\n\n          -  Charlson index (CCI) <=3\n\n          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade of 0 or 1\n\n          -  Adequate organ function: (1) aspartate aminotransferase (AST), alanine\n             aminotransferase (ALT), within normal limits (WNL), (2) serum creatinine less than (<)\n             1.5 milligram/deciliter (mg/dL) (<133 micromoles/Liter [mcmol/L]), (3) platelets\n             greater than or equal to (>=)140,000/microLiter (mcL), independent of transfusion\n             and/or growth factors within 3 months prior to randomization, (4) Hemoglobin >= 12.0\n             gram/deciliter (g/dL) (7.4 millimloes [mmol], independent of transfusion and/or growth\n             factors within 3 months prior to randomization\n\n          -  Participants who are sexually active (even men with vasectomies) and willing to use a\n             condom and agree not to donate sperm during the trial\n\n          -  Signed, written, informed consent\n\n          -  Be able to swallow whole study drug tablets\n\n        Exclusion Criteria: -\n\n          -  Presence of distant metastasis, (clinical stage M1). Isolated pelvic nodal disease\n             below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of\n             distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal\n             disease (clinical N stage; N1 versus N0) will be assessed by central radiological\n             review. Patients are considered eligible only if the central radiological review\n             confirms clinical stage M0.\n\n          -  Prior treatment with gonadotropin releasing hormone (GnRH) analogue or anti-androgen\n             or both for >3 months prior to randomization\n\n          -  Bilateral orchiectomy\n\n          -  History of pelvic radiation\n\n          -  Prior systemic (example [e.g.], chemotherapy) or local (e.g. radical prostatectomy,\n             cryotherapy) treatment for prostate cancer\n\n          -  History of seizure or any condition that may predispose to seizure (including, but not\n             limited to prior stroke, transient ischemic attack or loss of consciousness <= 1 year\n             prior to randomization; brain arteriovenous malformation; or intracranial masses such\n             as schwannomas and meningiomas that are causing edema or mass effect)\n\n          -  Prior treatment with enzalutamide, abiraterone acetate, orteronel, galeterone,\n             ketoconazole, aminoglutethimide, estrogens, megestrol acetate, and progestational\n             agents (including cyproterone acetate) for prostate cancer\n\n          -  Prior treatment with radiopharmaceutical agents (e.g., strontium-89) or immunotherapy\n             (e.g., sipuleucel-T) for prostate cancer\n\n          -  Prior treatment with systemic glucocorticoids ?4 weeks prior to randomization or is\n             expected to require long-term use of corticosteroids during the study\n\n          -  Use of 5-alpha reductase inhibitors (e.g., dutasteride, finasteride) <=4 weeks prior\n             to randomization\n\n          -  Use of any investigational agent <=4 weeks prior to randomization\n\n          -  Current chronic use of opioid analgesics for >=3 weeks for oral or >7 days for\n             non-oral formulations\n\n          -  Major surgery <=4 weeks prior to randomization\n\n          -  Current or prior treatment with anti-epileptic medications for the treatment of\n             seizures\n\n          -  Gastrointestinal conditions affecting absorption\n\n          -  Known or suspected contraindications or hypersensitivity to apalutamide, bicalutamide\n             or GnRH agonists or any of the components of the formulations\n\n          -  Any condition for which, in the opinion of the investigator, participation would not\n             be in the best interest of the subjectXx_NEWLINE_xXConcurrent treatment with non-permitted drugs and other interventionsXx_NEWLINE_xXPrior progesterone treatment for either diagnosis is ALLOWEDXx_NEWLINE_xXInclusion Criteria:\n\n        Signed informed consent; Histologically confirmed gastric, esophageal, or gastro-esophageal\n        junction adenocarcinoma; disease that is locally advanced (unresectable), metastatic, or\n        locally recurrent disease; Measurable or non-measurable, but radiologically evaluable\n        disease, according to RECIST; ErbB2 (HER2)positive; Age =18 years; ECOG Performance status\n        = 2; Adequate organ function, including adequate hematologic, renal and liver function;\n        Cardiac ejection fraction within institutional range of normal as measured by\n        echocardiogram; Able to swallow and retain oral medications, and/or receive enteral\n        medications via gastrectomy feeding tube; Women and men with potential to have children\n        must be willing to practice acceptable methods of birth control during the study; Prior\n        gastric surgery is permitted if > 3 weeks prior and recovered; Prior chemotherapy for\n        non-gastric malignancy if > than 5 years; Prior neoadjuvant and/or adjuvant chemotherapy\n        for early stage gastric cancer if > 6 months since completion; At least 4 weeks since prior\n        radiotherapy; Prior biologic, hormonal, or immunologic cancer treatment if > 5 years since\n        treatment.\n\n        Exclusion Criteria:\n\n        Pregnant or lactating females; Known history of active CNS disease; Uncontrolled ascites;\n        Concurrent anti-cancer therapy; Gastric carcinoid, epidermoid, sarcomas, or squamous cell\n        carcinoma; Prior palliative chemotherapy for the treatment of gastric cancer; Prior\n        treatment with oxaliplatin < 12 months; Malabsorption syndrome or uncontrolled inflammatory\n        gastrointestinal disease; Known history of uncontrolled or symptomatic angina, arrhythmias,\n        or congestive heart failure; Pre-existing grade = 2 motor or sensory neuropathy;\n        Uncontrolled infection; Concurrent disease or condition that would make the subject\n        inappropriate for study participation or any serious medical condition that would interfere\n        with the subject''s safety; Active hepatic or biliary disease; History of other malignancy\n        except if disease-free for 5 years, a history of completely resected non-melanoma skin\n        cancer, or a successfully treated in situ carcinoma; Unresolved or unstable serious\n        toxicity from prior administration of another investigational drug and/or prior cancer\n        treatment; Dementia, altered mental status, or any psychiatric condition that would\n        prohibit the understanding or rendering of informed consent; Known history of DPD\n        deficiency; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n        chemically related to lapatinib, capecitabine, fluorouracil, platins or their excipients;\n        Use of any investigational drug within 30 days prior randomization; Use of concurrent\n        prohibited medications that would interact with study medicationsXx_NEWLINE_xXPatients must have not received previous treatment with any of the study medications or similar drugsXx_NEWLINE_xX?1 prior systemic hematologic therapy for a free light chain (FLC) producing hematologic malignancy underlying the initial diagnosis of AL amyloidosis with at least a partial FLC response (PR, VGPR, CR) to treatment deemed stable and not requiring further treatmentXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma creatine kinase (CK) levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXIf the patient has been using the Optune™ device, it will be discontinued at least four days prior to commencing treatment with VAL-083, and the patient must have recovered from all treatment-related toxicities to Grade 1 or less.Xx_NEWLINE_xXPatients with a known sensitivity to any of the products to be administered during treatment and assessments.Xx_NEWLINE_xXPrior treatment with letrozole is allowed if the patient meets the washout period of 10 days.Xx_NEWLINE_xXCapecitabine and bevacizumab considered appropriate treatment for the patientXx_NEWLINE_xXHistory of pulmonary hemorrhage or hemoptysis within 6 months of starting study treatmentXx_NEWLINE_xXPre-treatment with other mTOR inhibitors may be allowed and should be discussed with the medical monitorXx_NEWLINE_xXPrevious meningioma progression during treatment with other mTOR complex 1 (C1)/2 inhibitors (but not mTORC1 inhibitors such as everolimus or other rapalogues)Xx_NEWLINE_xXPrevious treatment with ibrutinibXx_NEWLINE_xXPrevious treatment with an EGFR monoclonal antibody (except for past treatment for squamous cell carcinoma of head and neck or metastatic colorectal cancer).Xx_NEWLINE_xXPrevious treatment with osimertinib or third generation EGFR TKIs.Xx_NEWLINE_xXRepeat palliative RT will be permitted for the treatment of isolated, non-target lesionsXx_NEWLINE_xXFor obinutuzumab + Atezo + Pola treatment group: relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-Cluster of Differentiation (CD)20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigatorXx_NEWLINE_xXPatients must have disease progressing after treatment with at least one line of therapy including mitotane and/or chemotherapy; Note: Patients who are deemed ineligible to receive first line treatment with mitotane and/or chemotherapy or who decline first line treatment may be eligible for this study after discussion with the principal investigator (PI)Xx_NEWLINE_xXFOCBP and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment periodXx_NEWLINE_xXHave completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the SponsorXx_NEWLINE_xXAML participants ? 60 years old in first relapse with a disease-free interval < 12 months, or further relapse. First relapse is also applicable to AML post-MDS patients who have received prior treatment for MDS, but have not received prior treatment for AML.Xx_NEWLINE_xXNo more than 3 years of ADT is allowed, with the most recent ADT treatment having occurred greater than 6 months prior to enrollmentXx_NEWLINE_xXPatient is participating in a concurrent treatment protocolXx_NEWLINE_xXSubjects who have started oral or parenteral anticoagulation therapy within 2 weeks before the start of anetumab ravtansine until end of treatment visit.Xx_NEWLINE_xXPrevious treatment with specific chemotherapy (cytarabine, idarubicin, daunorubicin) or hypomethylating drug (decitabine or azacitidine) for a hematological disorder; EXCEPTIONS: prior hydroxyurea allowed; secondary AML is allowedXx_NEWLINE_xXPrevious local therapy (e.g., chemoembolization or bland embolization) is allowed if completed > 6 weeks prior to study entry; for such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entryXx_NEWLINE_xXTreatment with short-acting somatostatin analogs less than 3 days and Sandostatin depot injection less than 5 weeks before scanning and treatmentXx_NEWLINE_xXPrevious treatment with any other compound that targets CD40Xx_NEWLINE_xXPrior treatment with fulvestrantXx_NEWLINE_xXTreatment with any additional Food and Drug Administration (FDA)-approved biologic agent (i.e. bevacizumab, cetuximab, or panitumumab) is allowed according to standard practiceXx_NEWLINE_xXPrior treatment with oxaliplatinXx_NEWLINE_xXNo active brain metastases (e.g. stable for < 4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before treatment); no leptomeningeal diseaseXx_NEWLINE_xXHave two negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the participant practices true abstinence* from heterosexual contact.Xx_NEWLINE_xXNo prior treatment with carmustine wafersXx_NEWLINE_xXStable or decreasing dose of corticosteroids prior to treatment with a goal of 4 mg or less of dexamethasoneXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXReceived double-blind enzalutamide study treatment during the main study.Xx_NEWLINE_xXHistory of topotecan treatment for SCLCXx_NEWLINE_xXNew systemic immune suppressive agent added for the treatment of chronic GVHD within 2 weeks prior to enrollment\r\n* Addition of a new systemic immune suppressive treatment simultaneously with ixazomib is also prohibitedXx_NEWLINE_xXChronic treatment with glucocorticoids within one yearXx_NEWLINE_xXRadiologically confirmed disease progression after at least one line of treatment with an EGFR-TKIXx_NEWLINE_xXPatients who have received prior treatment with GEN-1.Xx_NEWLINE_xXRadiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.Xx_NEWLINE_xXThe participant has not received any previous treatment with anthracyclines.Xx_NEWLINE_xXPrior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.Xx_NEWLINE_xXBone only disease if there are lytic lesions is also allowed and treatment response will be evaluated based on the MD Anderson criteriaXx_NEWLINE_xXActively breastfeeding women unless it is interrupted during treatment and at least 6 weeks after treatment discontinuationXx_NEWLINE_xXbiologic therapy (e.g., bevacizumab) as part of their primary treatment regimen or part of their treatment for management of recurrent or persistent disease.Xx_NEWLINE_xXPrior treatment with dasatinibXx_NEWLINE_xXPrior treatment with PM01183, trabectedin, or with both PLD and topotecan.Xx_NEWLINE_xXAny prior treatment with T-DM1 (trastuzumab emtansine) or any trastuzumab therapyXx_NEWLINE_xXNonresponsive to most recent therapy (stable disease only or PD while on treatment), orXx_NEWLINE_xXPrior treatment with either carfilzomib or oprozomibXx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 1: Ninety days must have passed since the last doses of radiation or chemoradiation treatment involving lung tissue or thorax prior to T cell infusion (to avoid confounding pneumonitis)Xx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 2: Patients must express HLA-A*0201Xx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 2: Ninety days must have passed since the last definitive doses of radiation or chemoradiation treatment prior to T cell infusion (to avoid confounding pneumonitis)Xx_NEWLINE_xXDocumented infections or known oral temperature > 38.2 degrees Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance; the start of treatment may be delayedXx_NEWLINE_xXPatients willing to have regular blood draws, one before treatment and four during or after treatmentXx_NEWLINE_xXProgression or recurrence after treatmentXx_NEWLINE_xXIs newly diagnosed with a curative treatment option available.Xx_NEWLINE_xXPrior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the CRPC setting for the treatment of prostate cancer or participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless treatment was placebo);Xx_NEWLINE_xXInitiation of new treatment with denosumab, bisphosphonates, or systemic corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;Xx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXSubject has received prior treatment with fulvestrant.Xx_NEWLINE_xXPrevious use of pexidartinib or any biologic treatment targeting CSF-1 or the CSF-1R; previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, are allowed.Xx_NEWLINE_xXPatients must be refractory to the last rituximab-based treatment, defined as no response or response lasting < 6 months after completion of treatment. Time interval to assess refractoriness will be calculated between the end date (last day) of the last rituximab-containing regimen and the day of diagnosis confirmation of the subsequent relapse.Xx_NEWLINE_xXPrior treatment with regorafenibXx_NEWLINE_xXHistory of myocardial infraction (MI) within 6 month prior to starting study treatmentXx_NEWLINE_xXHas progressive disease (PD) within six (6) months of completion of curatively intended systemic treatment for locoregionally advanced HNSCCXx_NEWLINE_xXPresence of biopsiable disease and willingness to undergo pre-treatment biopsyXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment\r\n* Prophylactic use of bisphosphonates in patients without bone disease, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, cannabis, St. John’s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\r\n* Raloxifene is allowed for patients taking it for bone healthXx_NEWLINE_xXHypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causesXx_NEWLINE_xXPatients who have received EGFR tyrosine kinase inhibitors within 72 hours of initiation of study treatment, or treatment with other anti-cancer agents within 21 days of study treatmentXx_NEWLINE_xXPrior treatment with ibrutinibXx_NEWLINE_xXAny number of prior treatment regimens is allowedXx_NEWLINE_xXPrevious treatment with a camptothecin derivative (eg., irinotecan, topotecan, and investigational agents including but not limited to exatecan, rubitecan, gimatecan, karenitecan, SN38 investigational agents, EZN 2208, SN 2310, and AR 67) is not allowedXx_NEWLINE_xXCurrent treatment or known prior treatment with ribavirinXx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXPrior treatment with an EGFR-TKI.Xx_NEWLINE_xXPrior treatment with cetuximab or panitumumabXx_NEWLINE_xXInclusion Criteria:\n\n          -  Histologically or cytologically documented diagnosis of Stage IIIB not amenable to\n             radical treatment or Stage IV NSCLC (pathological characterization must determine the\n             non-squamous or squamous histological subtype as well as adenocarcinoma subtype\n             classification)\n\n          -  HER2 status of IHC 2+ or 3+ as determined by a Sponsor-designated central laboratory\n\n          -  Prior treatment with at least one regimen of platinum-based (cisplatin or carboplatin)\n             chemotherapy in the locally advanced or metastatic setting/recurrent NSCLC with\n             documented disease progression by investigator assessment\n\n          -  Participants with a known anaplastic lymphoma kinase (ALK) fusion oncogene (must be\n             documented in the participant's chart) must have also experienced disease progression\n             or intolerance with a first-line ALK Tyrosine Kinase Inhibitor (TKI) approved for the\n             treatment of ALK fusion oncogene NSCLC (for example, crizotinib). Disease progression\n             or intolerance must be documented\n\n          -  Participants with a known mutation in the epidermal growth factor receptor (EGFR) gene\n             (must be documented in the participant's chart) must have also experienced disease\n             progression or intolerance with an EGFR TKI approved for the treatment of EGFR-mutant\n             NSCLC (for example, gefitinib, erlotinib, afatinib). Disease progression or\n             intolerance must be documented\n\n          -  Measurable disease determined as per the RECIST v1.1\n\n          -  Life expectancy of at least (>/=) 12 weeks\n\n          -  Adequate organ function\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Left ventricular ejection fraction (LVEF) >/= 50 percent (%) by either echocardiogram\n             (ECHO) or multiple-gated acquisition (MUGA) scan\n\n          -  Use of highly effective contraception\n\n        Exclusion Criteria:\n\n        Cancer-Related Criteria:\n\n          -  Any approved anti-cancer therapy less than or equal to (</=) 21 days (including\n             chemotherapy or hormonal therapy) before the first study treatment; the following\n             exceptions are allowed: (1) TKIs approved for the treatment of NSCLC must be\n             discontinued greater than (>) 7 days prior to the first study treatment on D1C1 (The\n             baseline computed tomography [CT] scan must be completed after discontinuation of\n             TKIs); (2) Hormone-replacement therapy or oral contraceptives; (3) Anti-emetics,\n             Granulocyte-colony stimulating factor (GCS-F), and prophylactic antibiotics according\n             to local standards\n\n          -  Investigational therapy participation in another clinical study with therapeutic\n             intent </= 21 days before first study treatment\n\n          -  Previous irradiation is permitted if >/=14 days since the last fraction of\n             radiotherapy have elapsed before the first study treatment on Day 1 as long as a\n             sufficient number of target lesions remain to allow for measurable disease as per\n             RECIST v1.1\n\n          -  Participants who have untreated brain metastases or are symptomatic; participants with\n             treated brain metastases must have discontinued corticosteroid therapy and not have\n             any neurological symptoms\n\n          -  History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity\n             to trastuzumab or murine proteins or any excipient of the product\n\n          -  History of exposure to the following cumulative doses of anthracyclines: Doxorubicin\n             or liposomal doxorubicin > 500 milligram per meter-square (mg/m^2); Epirubicin > 900\n             mg/m^2; Mitoxantrone > 120 mg/m^2. If another anthracycline, or more than one\n             anthracycline, has been used, the cumulative dose must not exceed the equivalent of\n             500 mg/m^2 doxorubicin\n\n          -  Peripheral neuropathy of Grade >/= 3 per the National Cancer Institute Common Toxicity\n             Criteria for Adverse Events Version 4.0 (NCI CTCAE v. 4.0)\n\n          -  History of other malignancy within the last 5 years, except for appropriately treated\n             carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer,\n             or other cancers with a similar outcome as those mentioned above\n\n        Cardiopulmonary Function Criteria:\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures\n\n          -  Severe dyspnea at rest due to complications of advanced malignancy or requiring\n             current continuous oxygen therapy\n\n          -  Clinical history of active hemoptysis\n\n          -  Evidence of active pneumonitis during screening\n\n          -  Current unstable ventricular arrhythmia requiring treatment\n\n          -  History of symptomatic congestive heart failure (CHF) New York Heart Association\n             (NYHA) classes II-IV\n\n          -  History of myocardial infarction or unstable angina within 6 months of enrollment\n\n          -  History of a decrease in LVEF to <50%\n\n        General Criteria:\n\n          -  Current severe, uncontrolled systemic disease (for example, clinically significant\n             cardiovascular, pulmonary, or metabolic disease)\n\n          -  Major surgical procedure or significant traumatic injury within 28 days before\n             enrollment or anticipation of the need for major surgery during the course of study\n             treatment\n\n          -  Current pregnancy or lactation\n\n          -  Current known active infection with human immunodeficiency virus (HIV), hepatitis B\n             virus (HBV), or hepatitis C virus (HCV)Xx_NEWLINE_xXSubject must have received no prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Subject may have been treated for prior Myelodysplastic Syndrome.Xx_NEWLINE_xXPatient plans to receive treatment at MD AndersonXx_NEWLINE_xXPatients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatmentXx_NEWLINE_xXAt least 4 weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiationXx_NEWLINE_xXPatients who have had previous treatment with selinexorXx_NEWLINE_xXPatients are allowed to have received prior treatment with mFOLFOX6; if patients are currently receiving treatment with mFOLFOX6, the subject must have documented disease progression; patients must also be able to tolerate standard mFOLFOX6; reduced dosing of mFOLFOX6 at enrollment is exclusionaryXx_NEWLINE_xXPatient has had a prior monoclonal antibody for treatment of MCCXx_NEWLINE_xXInclusion Criteria: Provision of signed and dated, written informed consent prior to any\n        mandatory study specific procedures, sampling and analyses. Aged at least 18 years. Any\n        menopausal status. Pre- or peri-menopausal women must have commenced treatment with an LHRH\n        agonist at least 4 weeks prior to starting study treatment and must be willing to continue\n        to receive LHRH agonist therapy for the duration of the trial. Histological or cytological\n        confirmation of adenocarcinoma of the breast. ER-positive according to local laboratory;\n        HER-2 negative. Metastatic disease or locoregionally recurrent disease which is not\n        amenable to treatment with curative intent. Disease progression after at least 6 months of\n        endocrine therapy for ER+ breast cancer. Radiological or objective evidence of progression\n        on or after the last systemic therapy prior to starting study treatment. Receipt of ?2\n        lines of prior chemotherapy for advanced disease. Females of child-bearing potential must\n        agree to use adequate contraceptive measures, must not be breast feeding and must have a\n        negative pregnancy test prior to start of dosing. Eastern Cooperative Oncology Group (ECOG)\n        performance status 0-1 with no deterioration over the previous 2 weeks and minimum life\n        expectancy of 12 weeks.\n\n        Exclusion Criteria: Any cytotoxic chemotherapy, investigational agents or other anti-cancer\n        drugs for the treatment of advanced breast cancer from a previous treatment regimen or\n        clinical study within 14 days of the first dose of study treatment. Any unresolved\n        toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events\n        (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia.\n        Presence of life-threatening metastatic visceral disease, uncontrolled central nervous\n        system metastatic disease or symptomatic pulmonary lymphangitic spread. Any evidence of\n        severe or uncontrolled systemic diseases, including uncontrolled hypertension, active\n        bleeding diatheses, or active infection. Unexplained symptomatic endometrial disorders.\n        Uncontrolled symptomatic thyroid dysfunction. Inadequate bone marrow reserve or organ\n        functionXx_NEWLINE_xXPatients on immunosuppressive agents (e.g., TNF pathway inhibitors, phosphoinositide 3 [PI3] kinase inhibitors) within 7 days of study treatmentXx_NEWLINE_xXHave rapidly progressing disease, as judged by the investigator (e.g., rapid progression through prior treatment[s])Xx_NEWLINE_xXThere is no limit on the number or type of prior chemotherapies except:\r\n* Patients must not have received prior treatment with convection enhanced delivery, other catheter based intra-tumoral treatment, or carmustine (BCNU)/Gliadel wafers\r\n* Patients with prior therapy that included stereotactic radiosurgery (including gamma-knife or cyber-knife) during therapy for newly diagnosed or recurrent disease, or re-irradiation of any type, must have confirmation of true progressive disease rather than radiation necrosis based upon surgical documentation of recurrent/progressive disease; imaging with magnetic resonance (MR)Spectroscopy, MRPerfusion, positron emission tomography (PET), or other techniques is not adequate to exclude radiation necrosis for this study\r\n* Patients may not have received prior treatment with an agent designed to inhibit mTOR or PI3K/AKT including, but not limited to, temsirolimus, rapamycin (sirolimus), RAD001 (everolimus), other rapalogs, BKM120, or perifosine; any question regarding the definition of an agent designed to inhibit mTOR or PI3K/AKT targeting should be discussed with the sponsor\r\n* Patients may not have received prior treatment with direct VEGF/VEGFR inhibitors such as bevacizumab (Avastin), aflibercept (VEGF-Trap), cediranib (AZD2171), trebananib (AMG 386), or XL-184 (Cabozantinib)Xx_NEWLINE_xXPatients with a history of prior intratumoral bleeding must be evaluated with a non-contrast head CT to exclude acute blood prior to start of treatmentXx_NEWLINE_xXPatients must not have a known diagnosis of hepatitis B or C; patients with the following risk factors must have hepatitis screening pre-treatment:\r\n* Blood transfusions prior to 1990\r\n* Current or prior intravenous (IV) drug users\r\n* Current or prior dialysis\r\n* Household contact with a hepatitis B or C patient\r\n* Current or prior high-risk sexual activity\r\n* History of jaundiceXx_NEWLINE_xXConcurrent radiotherapy is not permitted for disease progression on treatment on protocol; however, symptomatic treatment for pre-existing non-target lesions would be allowed with approval from the principal investigatorXx_NEWLINE_xXPrior treatment with bosutinib.Xx_NEWLINE_xXPrior treatment with ponatinib.Xx_NEWLINE_xXPrior treatment with TNFRSF agonists including OX40, CD27, CD137 (4-1BB), CD357 (GITR) .Xx_NEWLINE_xXPrior treatment with pertuzumab, Lapatinib, and/or Trastuzumab emtansine is allowed; however, the last treatment for MBC must not include Trastuzumab in combination with pertuzumab.Xx_NEWLINE_xXNo limit on number or type of prior therapies\r\n* Prior treatment with docetaxel is permitted but not required\r\n* Prior treatment with ketoconazole, estrogens, abiraterone or novel antiandrogens allowed, including past enzalutamide\r\n* Require at least a 6 week withdrawal period from the last dose of bicalutamide, or nilutamide or 4 weeks from last flutamide or enzalutamide dose\r\n** Must have a documented PSA rise after stopping the antiandrogen\r\n* Will require a 2 week washout period from last dose of ketoconazole, chemotherapy, radiation (including radium-223), or prior investigational systemic agentsXx_NEWLINE_xXPrior treatment with c-Met inhibitorsXx_NEWLINE_xXConcurrent treatment with any systemic chemotherapeutic agentXx_NEWLINE_xXTransfusion of blood products are not allowed to normalize blood parameters within 4 weeks of the first radium treatmentXx_NEWLINE_xXPrior treatment with enzalutamideXx_NEWLINE_xXFor inclusion in the study patient should fulfil the following criteria:\n\n          1. Male or female, aged at least 18 years.\n\n          2. Histological or cytological confirmation diagnosis of NSCLC.\n\n          3. Radiological documentation of disease progression while on a previous continuous\n             treatment with an EGFR TKI, eg gefitinib, afatinib or erlotinib. In addition, other\n             lines of therapy may have been given. All patients must have documented radiological\n             progression on the last treatment administered prior to enrolling in the study.\n\n          4. Confirmation that the tumour harbours an EGFR mutation known to be associated with\n             EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration\n             over the previous 2 weeks (Appendix G).\n\n          6. Patients must have a life expectancy of ?12 weeks as estimated at the time of\n             screening.\n\n          7. Females should be using adequate contraceptive measures and must have a negative\n             pregnancy test prior to start of dosing if of child-bearing potential, or must have\n             evidence of non-child-bearing potential by fulfilling one of the following criteria at\n             screening: Post-menopausal defined as aged more than 50 years and amenorrhoeic for at\n             least 12 months following cessation of all exogenous hormonal treatments; women under\n             50 years old would be considered post-menopausal if they have been amenorrhoeic for 12\n             months or more following cessation of exogenous hormonal treatments and with LH and\n             FSH levels in the post-menopausal range for the institution; documentation of\n             irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or\n             bilateral salpingectomy, but not tubal ligation.\n\n          8. Male patients should be willing to use barrier contraception, ie, condoms, until 6\n             months after last study drug is taken.\n\n        Exclusion criteria:\n\n          1. Participation in another study with an IP during the last 14 days (or a longer period\n             depending on the defined characteristics of the agents used).\n\n          2. Treatment with any of the following: Treatment with an EGFR TKI (eg, erlotinib or\n             gefitinib) within 8 days or approx. 5 x half-life, whichever is the longer, of the\n             first dose of study treatment; any cytotoxic chemotherapy, investigational agents or\n             other anticancer drugs from a previous treatment regimen or clinical study within 14\n             days of the first dose; major surgery (excluding placement of vascular access) within\n             4 weeks of the first dose of study treatment; radiotherapy with a limited field of\n             radiation for palliation within 1 week of the first dose of study treatment, with the\n             exception of patients receiving radiation to more than 30% of the bone marrow or with\n             a wide field of radiation which must be completed within 4 weeks of the first dose;\n             patients currently receiving (or unable to stop use prior to receiving the first dose\n             of study treatment) medications or herbal supplements known to be potent inhibitors of\n             CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior).\n             All patients must avoid concomitant use of any medications, herbal supplements and/or\n             ingestion of foods with known inducer/inhibitory effects on CYP3A4.\n\n          3. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of\n             starting study treatment with the exception of alopecia and Grade 2, prior\n             platinum-therapy related neuropathy.\n\n          4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges within 7 days of the first\n             administration of the IP until the final PK sample collection on Day 32 of Part A.\n\n          5. Spinal cord compression or brain metastases unless asymptomatic, stable and not\n             requiring steroids for at least 4 weeks prior to start of study treatment.\n\n          6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled\n             hypertension and active bleeding diatheses, which in the PI's opinion makes it\n             undesirable for the patient to participate in the study or which would jeopardise\n             compliance with the protocol, or active infection including hepatitis B, hepatitis C,\n             and HIV. Screening for chronic conditions not required.\n\n          7. Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following laboratory values: ANC <1.5 x 10^9/L; platelet count <100 x 10^9/L;\n             haemoglobin <90 g/L; ALT >2.5 times ULN if no demonstrable liver metastases or >5\n             times ULN in the presence of liver metastases; Aspartate aminotransferase (AST) >2.5\n             times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver\n             metastases; total bilirubin >1.5 times ULN if no liver metastases or >3 times ULN in\n             the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or\n             liver metastases; creatinine >1.5 times ULN concurrent with creatinine clearance <50\n             ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of\n             creatinine clearance is only required when creatinine is >1.5 times ULN.\n\n          8. Any of the following cardiac criteria: mean resting corrected QT interval corrected\n             for heart rate using Fridericia's correction factor (QTcF) >470 msec obtained from 3\n             ECGs; any clinically important abnormalities in rhythm, conduction or morphology of\n             resting ECG eg, complete left bundle branch block, third degree heart block, second\n             degree heart block, PR interval >250 msec; any factors that increase the risk of QTc\n             prolongation or risk of arrhythmic events such as heart failure, hypokalaemia,\n             congenital long QT syndrome, family history of long QT syndrome or unexplained sudden\n             death under age of 40 or any concomitant medication known to prolong the QT interval.\n\n          9. Patients unable to swallow oral medication or patients with GI disorders or\n             significant GI resection likely to interfere with the absorption of AZD9291.\n\n         10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required\n             steroid treatment, or any evidence of clinically active ILD.\n\n         11. Women who are breastfeeding.\n\n         12. Patients with a known hypersensitivity to AZD9291, simvastatin, or any of the\n             excipients of the products.\n\n         13. Concomitant medication contraindicated for use with simvastatin due to drug\n             interaction associated with increased risk of rhabdomyolysis (including, but not\n             limited to): itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin,\n             telithromycin, HIV protease inhibitors (eg, nelfinavir), nefazodone, cyclosporine,\n             danazol, gemfibrozil, amiodarone, amlodipine.\n\n         14. 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)-reductase inhibitors, such as\n             lovastatin and simvastatin.\n\n         15. For optional genetic research: Previous allogenic bone marrow transplant or\n             non-leukocyte depleted whole blood transfusion within 120 days of the date of the\n             genetic sample collection.Xx_NEWLINE_xXCurrent treatment with sirolimus AND either cyclosporine or tacrolimus.Xx_NEWLINE_xXPatients with single or multiple lung metastases at diagnosis or that develop over the course of treatmentXx_NEWLINE_xXA confirmed diagnosis of WM, which requires treatment.Xx_NEWLINE_xXPrevious treatment with pomalidomideXx_NEWLINE_xXUntreated or previously treated for Waldenström's macroglobulinemia. Previously treated subjects must have either documented disease progression or had no response (stable disease) to the most recent treatment regimen.Xx_NEWLINE_xXRituximab treatment within the last 12 months before the first dose of study drug.Xx_NEWLINE_xXPatients who have received no more than 1 prior cytotoxic treatment regimen.Xx_NEWLINE_xXSubjects must have received at least one prior treatment regimen\r\n* Subjects that have received a prior Bruton’s agammaglobulinemia tyrosine kinase (BTK) inhibitor or cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition are ineligible\r\n* Subjects that have undergone prior allogeneic stem cell transplantation will only be eligible if the transplant occurred at least 1 year prior to study entry, the patient is no longer taking any immunosuppressive therapy, and there are no significant ongoing transplant-related adverse effects\r\n* Subjects must not have received chemotherapy =< 21 days prior to first administration of study treatment, monoclonal antibody =< 6 weeks prior to first administration of study treatment, and/or radiotherapy or other investigational agents =< 4 weeks prior to first administration study treatment unless the subjects’ tumor has progressed on the previous therapy and the investigator believes that the patient should not postpone further therapy and, all treatment-related toxicities have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5 =< grade 1; subjects may be receiving equivalent to prednisone at a maximum dose of 20 mg/day orallyXx_NEWLINE_xXSubjects should be willing to undergo a research related biopsy prior to treatment and at the time of progressionXx_NEWLINE_xXUnable to receive prophylactic treatment for pneumocystisXx_NEWLINE_xXRadiological documentation of disease progression following 1st line EGFR TKI Treatment without any further treatmentXx_NEWLINE_xXTreatment with more than one prior line of treatment for advanced NSCLCXx_NEWLINE_xXTreatment with an approved EGFR-TKI (e.g.,erlotinib, gefitinib, afatinib) within 8 days or approximately 5x half-life of the first dose of study treatmentXx_NEWLINE_xXPrevious treatment with AZD9291, or a 3rd generation EGFR TKI For subjects who cross-over to AZD9291:Xx_NEWLINE_xXSubject has relapsed/refractory disease with an indication for treatmentXx_NEWLINE_xXPatients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225 treatment; patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment, should also be excluded; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatmentXx_NEWLINE_xXPrior treatment with any agent specifically targeting T-cell co-stimulation or checkpoint pathwaysXx_NEWLINE_xXAny prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up to 6 months prior to study entry (signature of ICF) if suitably approved for use in the subject's region.Xx_NEWLINE_xXPatients with one of the following diagnoses:\r\n* Intermediate, high and very high risk (per International Prognostic Scoring System [IPSS]-revised [R]) untreated MDS or any MDS with >= 5% marrow blasts (by French American British [FAB] and World Health Organization [WHO] diagnostic criteria); NOTE: MDS/MPN overlap is allowed\r\n* CMML requiring treatment per doctor of medicine (MD) judgment\r\n* Low and very low risk MDS patients symptomatic and/or transfusion dependent, (>= 4 U red blood cells [RBC] over the preceding 12 week period) who have failed erythropoietin-stimulating agents (ESAs) or who have a low likelihood of responding to ESAs\r\n* MDS and CMML patients relapsed/refractory to hypomethylating agents as evidenced by one of the following:\r\n** Progressed at any time during treatment with hypomethylating agents\r\n** Failed to achieve a response after 6 cycles of 5-azacytidine or 4 cycles of decitabine\r\n** Progressed after treatment with hypomethylating agents had been discontinued\r\n*** NOTE: MDS/MPN overlap is allowed\r\n* Relapsed or refractory AML exposed to =< 3 prior regimens (note, induction and consolidation including stem cell transplantation count as one regimen)\r\n* For exploratory phase I LDE225 days 1-7 with azacitidine or LDE225 days 1-28 with decitabine cohorts only: untreated AML/CMML/MDS/MPN overlap or relapsed/refractory AML/CMML/MDS/MPN overlap WITHOUT prior exposure to a hypomethylating agent (HMA)\r\n* Elderly (age >= 60) untreated AML and not a candidate for induction therapy\r\n* Untreated AML < 60 year of age who are not candidates to undergo standard induction chemotherapy\r\n* Primary myelofibrosis (PMF) and post essential thrombocytopenia (ET)/polycythemia vera (PV) MF with a Dynamic International Prognostic Scoring System (DIPSS)-plus score of intermediate or high, or a > 10% blasts in the marrow and who are in need of therapy and who have failed previous treatment with a janus kinase 2 (JAK2) inhibitor and, if appropriate, have failed Interferon based treatmentXx_NEWLINE_xXAny previous treatment with LDE225 or allergic reactions to excipients of LDE225Xx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; NOTE: muscular activities, such as strenuous exercise, that can result in significant increases in plasma creatine kinase (CK) levels should be avoided whilst on LDE225 treatmentXx_NEWLINE_xXTreatment naïve or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.Xx_NEWLINE_xXSerious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.Xx_NEWLINE_xXPrior treatment with a cancer vaccine for this indicationXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXExpansion cohort only (if conducted in the study): men with mCRPC and disease progression as defined by PCWG2 within 6 months (primary resistance); or after at least 6 months of treatment (acquired resistance) of starting treatment with abiraterone acetate; at least 4 weeks must have elapsed from the last dose of abiraterone acetateXx_NEWLINE_xXPrior treatment with apalutamide or phosphatidylinositol-3 kinase (PI3K)/mTOR pathway inhibitorsXx_NEWLINE_xXPrevious treatment with 2 or more courses of decitabine (all stages) or azacitidine (Dose Confirmation stage only)Xx_NEWLINE_xXPrior treatment with nab-paclitaxel.Xx_NEWLINE_xXRequirement for RBC transfusion while on ruxolitinib treatment, ORXx_NEWLINE_xXDose adjustment of ruxolitinib to < 20 mg twice daily at start of or during ruxolitinib treatment AND at least one of the following while on ruxolitinib treatment:Xx_NEWLINE_xXPrior treatment with MMBXx_NEWLINE_xXHistory of allergic reaction or intolerance to statin treatmentXx_NEWLINE_xXEvidence of an active optic glioma or other low-grade glioma, requiring treatment with chemotherapy or radiation therapy; subjects not requiring treatment are eligible for this protocolXx_NEWLINE_xXInclusion:\n\n          -  Aged at least 18 years. Japan patients aged at least 20 years.\n\n          -  Locally advanced/metastatic NSCLC not amenable to curative surgery or radiotherapy\n\n          -  Radiological documentation of disease progression:\n\n        following 1st line EGFR TKI treatment but who have not received further treatment OR\n        following prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy.\n        Patients who received prior EGFR TKI and platinum-based doublet chemotherapy may have also\n        received additional lines of treatment. All patients must have documented radiological\n        progression on the last treatment administered prior to enrolling in the study.\n\n          -  Disease progression following 1st line EGFR TKI treatment or following prior EGFR TKI\n             and platinum-containing doublet chemotherapy.\n\n          -  Confirmation that the tumour harbours an EGFR mutation known to be associated with\n             EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q). Patients must\n             have central confirmation of tumour T790M mutation positive status from a biopsy\n             sample taken after confirmation of disease progression on the most recent treatment\n             regimen.\n\n          -  World Health Organisation (WHO) performance status 0-1 with no deterioration over the\n             previous 2 weeks and a minimum life expectancy of 12 weeks.\n\n          -  At least one lesion, not previously irradiated and not chosen for biopsy during the\n             study screening period, that can be accurately measured at baseline as ? 10mm in the\n             longest diameter (except lymph nodes which must have short axis ? 15mm) with\n             computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for\n             accurate repeated measurements.\n\n          -  Females of child-bearing potential using contraception; negative pregnancy test.\n\n        Exclusion:\n\n          -  Treatment with an EGFR-TKI within 8 days of study entry; any cytotoxic chemotherapy,\n             investigational agents or other anticancer drugs within 14 days of study entry;\n             previous treatment with AZD9291 (or 3rd generation TKIs); major surgery within 4\n             weeks; radiotherapy treatment to more than 30% of the bone marrow or with a wide field\n             of radiation within 4 weeks; current treatment with potent inhibitors of CYP2C8 and\n             potent inhibitors/inducers of CYP3A4.\n\n          -  Unresolved toxicities from prior therapy.\n\n          -  Unstable spinal cord compression/brain metastases.\n\n          -  Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding\n             diatheses or infection.\n\n          -  Refractory nausea/vomiting, chronic gastrointestinal diseases or bowel resection.\n\n          -  Cardiac disease.\n\n          -  Past history of ILD, drug-induced ILD, radiation pneumonitis which required steroid\n             treatment, or any evidence of clinically active interstitial lung disease.\n\n          -  Inadequate bone marrow reserve or organ function.Xx_NEWLINE_xXPatients must have received treatment with either enzalutamide and/or abiraterone prior to study entryXx_NEWLINE_xXPrior treatment with PI3K/mTOR pathway inhibitorsXx_NEWLINE_xXPatients with prior or current treatment of sorafenib are excludedXx_NEWLINE_xXPrior failed treatment with mTOR inhibitorsXx_NEWLINE_xXPrior or concomitant use of megestrol acetate for the treatment of hot flashes is allowedXx_NEWLINE_xXTreatment with concurrent 5-alpha reductase inhibitors (finasteride, dutasteride), estrogens, and/or cyproteroneXx_NEWLINE_xXPrior treatment with bortezomibXx_NEWLINE_xXMale and female, ages 18 and above, with relapsed or refractory FL lymphoma after > or =2 prior treatment lines; each of the 2 prior treatment lines must include at least CD20 antibody and/or an alkylating agentXx_NEWLINE_xXPatients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this studyXx_NEWLINE_xXInclusion Criteria\n\n        Patients must meet the following criteria to be eligible for the study:\n\n          1. Metastatic breast cancer, documented as HER2+ by fluorescence in situ hybridization\n             (FISH) and/or 3+ staining by immunohistochemistry (IHC).\n\n          2. Progressive disease, with a history of prior treatment with both trastuzumab and T-DM1\n             (unless deemed intolerant to or ineligible for T-DM1 by the investigator) for\n             metastatic disease.\n\n          3. ? 18 years at time of consent.\n\n          4. If female and of child-bearing potential, has negative pregnancy test within 14 days\n             prior to treatment.\n\n          5. If a sexually active male or a sexually active female of child-bearing potential,\n             agrees to use dual (two concurrent) forms of medically accepted contraception from the\n             time of consent until 6 months after the last dose of ONT-380, capecitabine, or\n             trastuzumab, whichever is longest.\n\n          6. Signed an informed consent document that has been approved by an institutional review\n             board or independent ethics committee (IRB/IEC).\n\n          7. Must have target or non-target lesions as per Response Evaluation Criteria In Solid\n             Tumors (RECIST) 1.1.\n\n          8. All toxicity related to prior cancer therapies must have resolved to ? Grade 1, with\n             the following exceptions: alopecia; neuropathy, which must have resolved to ? Grade 2;\n             and congestive heart failure (CHF), which must have been ? Grade 1 in severity at the\n             time of occurrence and must have resolved completely.\n\n          9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.\n\n         10. In the opinion of the Investigator, life expectancy > 6 months.\n\n         11. Adequate hematologic function as defined by:\n\n               1. Hemoglobin ? 9 g/dL\n\n               2. Absolute neutrophil count (ANC) ? 1000 cells/?L\n\n               3. Platelets ? 100,000/?L\n\n         12. Adequate hepatic function as defined by the following:\n\n               1. Total bilirubin ? 1.5 X upper limit of normal (ULN), unless a known history of\n                  Gilbert's disease\n\n               2. Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase\n                  [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase\n                  [ALT/SGPT]) ? 2.5 X ULN (< 5 X ULN if liver metastases are present)\n\n         13. International normalized ratio (INR) and activated partial thromboplastin time (aPTT)\n             ? 1.5 X ULN unless on medication known to alter INR and aPTT.\n\n         14. Creatinine clearance ? 50 mL/min.\n\n         15. Left ventricular ejection fraction (LVEF) must be within institutional limits of\n             normal as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)\n             documented within 4 weeks prior to first dose of study drug.\n\n        Exclusion Criteria\n\n        Patients will be excluded from the study for any of the following reasons:\n\n          1. Medical, social, or psychosocial factors that, in the opinion of the Investigator,\n             could impact safety or compliance with study procedures.\n\n          2. Patient is breastfeeding.\n\n          3. Previous treatment with any experimental agent within 14 days or five half-lives of\n             study treatment, whichever is greater.\n\n          4. Previous treatment with trastuzumab or other antibody-based therapy within three weeks\n             of starting study treatment or with chemotherapy or hormonal cancer therapy within two\n             weeks of starting study treatment.\n\n          5. Previous treatment with cumulative dose of doxorubicin > 360 mg/m2 or previous\n             treatment with another anthracycline with cumulative dose equivalent to > 360 mg/m2\n             doxorubicin.\n\n          6. Previous treatment with:\n\n               1. Capecitabine for metastatic disease at any time, for patients assigned to cohorts\n                  using capecitabine plus ONT-380 (Combination 1) or capecitabine plus trastuzumab\n                  plus ONT-380 (Combination 3). However, patients who have previous treatment with\n                  capecitabine for metastatic disease are eligible for enrollment into cohorts\n                  using trastuzumab plus ONT-380 (Combination 2). Patients who have received\n                  capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to\n                  starting study treatment are eligible to enroll into all cohorts (Combination 1,\n                  2, or 3).\n\n               2. Any small molecule HER2 inhibitors including (but not limited to) lapatinib,\n                  neratinib, or afatinib within the last 4 weeks prior to initiation of study\n                  therapy.\n\n          7. CNS disease:\n\n               1. Patients with leptomeningeal disease are excluded.\n\n               2. Dose escalation and expansion cohorts: Patients with symptomatic CNS metastases\n                  are excluded. Patients with treated CNS metastases or untreated asymptomatic CNS\n                  metastases not requiring immediate local therapy may be eligible. Enrollment of\n                  patients with metastases must be approved by the study medical monitor.\n\n               3. Optional CNS disease expansion cohorts: Patients with untreated asymptomatic CNS\n                  metastases not requiring immediate local therapy or patients with progressive CNS\n                  disease following local therapy may be eligible with medical monitor approval.\n\n          8. History of allergic reactions to compounds of similar chemical or biological\n             composition to capecitabine (for patients assigned to Combination 1 or 3 only),\n             trastuzumab (for patients assigned to Combination 2 or 3 only), or ONT-380, except for\n             a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab, which has\n             been successfully managed.\n\n          9. Patients with uncorrectable electrolyte abnormalities.\n\n         10. Known to be HIV positive. HIV testing is not required for those patients who are not\n             known to be positive.\n\n         11. Known carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).\n\n         12. Known liver disease, autoimmune hepatitis, or sclerosing cholangitis.\n\n         13. Inability to swallow pills or any significant gastrointestinal diseases, which would\n             preclude adequate absorption of oral medications.\n\n         14. Use of a strong CYP3A4 inhibitor or inducer within three elimination half-lives of the\n             inhibitor or inducer prior to the start of study treatment.\n\n         15. Use of a strong CYP2C8 inducer or inhibitor within three elimination half-lives of the\n             inducer or inhibitor prior to the start of study treatment. (See Appendix F).\n\n         16. Radiotherapy within 14 days of first dose of ONT-380; patient must have recovered from\n             acute effects of radiotherapy to baseline.\n\n         17. Known impaired cardiac function or clinically significant cardiac disease such as\n             ventricular arrhythmia requiring therapy, congestive heart failure, and uncontrolled\n             hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood\n             pressure > 100 mmHg on antihypertensive medications).\n\n         18. Myocardial infarction or unstable angina within 6 months prior to the first dose of\n             study drug.\n\n         19. Patient with known dihydropyrimidine dehydrogenase deficiency (for patients assigned\n             to Combination 1 or 3 only).\n\n         20. Patient requiring warfarin therapy with known history of difficulty in management of\n             maintaining INR within therapeutic range. Patients on warfarin may be included if on a\n             stable dose with a therapeutic INR.Xx_NEWLINE_xXAdvanced unresectable, metastatic or recurrent colorectal carcinoma (CRC) for which treatment with FOLFOX6 with or without bevacizumab, FOLFIRI with or without bevacizumab, CAPOX, or regorafenib would be acceptable as determined by the Investigator. FOLFIRI-refractory patients with CRC enrolling on the FOLFIRI study arm must have failed treatment with one FOLFIRI with or without bevacizumab regimen for unresectable or metastatic disease. Treatment failure is defined as progression of disease (clinical or radiologic) during treatment with FOLFIRI with or without bevacizumab or < 3 months after the last dose of treatment with FOLFIRI with or without bevacizumab. Patients with CRC enrolling on the regorafenib arm of this study will have previously received at least two previous lines of therapy for advanced colorectal cancer, and will have previously received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients with K-ras wild type tumors enrolling on the regorafenib arm will also have previously received either cetuximab or panitumumab.Xx_NEWLINE_xXHepatocellular carcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.Xx_NEWLINE_xXPancreatic adenocarcinoma for which treatment with FOLFOX6, CAPOX, FOLFIRI, or irinotecan would be acceptable as determined by the Investigator.Xx_NEWLINE_xXCholangiocarcinoma for which treatment with FOLFOX6 or CAPOX would be acceptable as determined by the Investigator.Xx_NEWLINE_xXPrior treatment with BBI608.Xx_NEWLINE_xXPrior treatment with radium-223 dichlorideXx_NEWLINE_xXUnstable brain metastases or spinal cord compression that requires treatment, unless the treatment ended at least 4 weeks before starting treatment and the condition has been stable without steroid treatment for at least 10 daysXx_NEWLINE_xXPrior hypomethylating agent treatment for MDSXx_NEWLINE_xXNot have received bacillus Calmette-Guérin (BCG) or have completed previous BCG treatment > 12 months prior to the baseline staging procedure.Xx_NEWLINE_xXPrior treatment with a cancer vaccine for this indicationXx_NEWLINE_xXHistory of prior venetoclax treatmentXx_NEWLINE_xXPrior treatment of any duration with pomalidomideXx_NEWLINE_xXPrior treatment with clusters of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, systemic immunostimulatory agents, or systemic immunosuppressive medicationsXx_NEWLINE_xXPrevious laser therapy within one year prior to protocol treatmentXx_NEWLINE_xXPrevious treatment with T-DM1 at any time; or previous treatment with any small molecule HER2 inhibitors including (but not limited to) lapatinib, neratinib, or afatinib within the last 4 weeks prior to initiation of study therapy.Xx_NEWLINE_xXPrior or concurrent treatment with Avastin (bevacizumab)Xx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXHave been informed of other treatment options.Xx_NEWLINE_xXAt least 1 prior treatment with a CD20 antibody combination chemo-immunotherapy regimenXx_NEWLINE_xXPrevious treatment in the present study.Xx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXNo prior treatment with erlotinib, gefitinib, or other EGFR tyrosine kinase inhibitorsXx_NEWLINE_xXPatients are allowed to receive, but are not required to receive, one additional prior treatment regimen (including a single chemotherapeutic, a combination of chemotherapeutics, or biologic drugs such as bevacizumab) for management of their recurrent or persistent diseaseXx_NEWLINE_xXPatients must not have received prior treatment with pazopanib or topotecanXx_NEWLINE_xXPrior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)Xx_NEWLINE_xXActive graft?versus?host disease requiring systemic treatmentXx_NEWLINE_xXPatients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames:Xx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXEmergency treatment for hyperleukocytosis with hydroxyurea for ? 10 days;Xx_NEWLINE_xXPreemptive treatment with retinoic acid prior to exclusion of APL ? 7 days;Xx_NEWLINE_xXPatients must have received primary treatment with radical prostatectomyXx_NEWLINE_xXPatients must agree to have a biopsy at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)Xx_NEWLINE_xXConcurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might be allowed for pre-existing non-target lesions with approval from the principal investigator of the trialXx_NEWLINE_xXAdditional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment; 89Zr-trastuzumab use as imaging agent for 89Zr-trastuzumab PET permittedXx_NEWLINE_xXPatients who have received =< 1 cycle of therapy after most recent progression/relapse are eligible to enroll on study\r\n* Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted\r\n* Bisphosphonates are permitted\r\n* Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted\r\n* Prior treatment with radiotherapy is permitted\r\n* Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 4 weeks from last dose (on a trial or outside a trial) are eligibleXx_NEWLINE_xXConcomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosphonates are permitted without restriction even during protocol treatment.Xx_NEWLINE_xXPatient with extensive systemic disease and without reasonable systemic treatment options.Xx_NEWLINE_xXPrevious radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.Xx_NEWLINE_xXAt least 1 prior treatment (no restriction to number of prior therapies)Xx_NEWLINE_xXWillingness to undergo pre- and on-treatment biopsies unless not clinically feasible while on treatmentXx_NEWLINE_xXPregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last dose of sorafenibXx_NEWLINE_xXTreatment with systemic immunostimulatory agentsXx_NEWLINE_xXChronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)Xx_NEWLINE_xXHas a previous treatment with irinotecanXx_NEWLINE_xXProgression following treatment with fluoropyrimidine/oxaliplatin/bevacizumab-regimen in the metastatic setting.Xx_NEWLINE_xXInclusion Criteria: All subjects\n\n          1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator.\n\n          2. Confirmed diagnosis of CD20-positive CLL or SLL.\n\n          3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment.\n\n          4. ECOG performance status of 0, 1 or 2.\n\n          5. Life expectancy ? 6 months.\n\n          6. Adequate bone marrow function.\n\n          7. Adequate renal and hepatic function.\n\n          8. Females of childbearing potential and non-sterile males must agree to use highly\n             effective methods of birth control throughout the course of study\n\n          9. Male patients are eligible if vasectomized or if they agree to use of barrier\n             contraception with other methods described above throughout the course of study.\n\n         10. Written informed consent.\n\n        Exclusion Criteria: All subjects\n\n          1. Previous systemic treatment for CLL/SLL.\n\n          2. Known prolymphocytic leukemia or history of or suspected Richter's transformation.\n\n          3. Clinically significant cardiovascular disease.\n\n          4. Prior malignancy within the past 3 years, except for curatively treated basal or\n             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the\n             cervix of breast.\n\n          5. Major surgery or significant injury ? 4 weeks prior to start of study treatment.\n\n          6. History of severe bleeding disorder.\n\n          7. History of stroke or intracranial hemorrhage within 6 months before the first dose of\n             study drug.\n\n          8. Severe or debilitating pulmonary disease.\n\n          9. Inability to swallow capsules or disease affecting gastrointestinal function.\n\n         10. Known central nervous system involvement by leukemia or lymphoma.\n\n         11. Active infection requiring systemic treatment.\n\n         12. Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C\n             infection.\n\n         13. Vaccination with live vaccine within 35 days prior to the first dose of study drug.\n\n         14. Known hypersensitivity to BGB-3111, bendamustine, or rituximab or any other\n             ingredients of the study drugs.\n\n         15. Requires ongoing treatment with strong CYP3A inhibitor or inducer.\n\n         16. Pregnant or nursing females.\n\n         17. Concurrent participation in another therapeutic clinical trial.Xx_NEWLINE_xXSubjects (other than those in the ibrutinib + JCAR017 combination therapy cohort) must have received previous treatment as follows:Xx_NEWLINE_xXPrior treatment with second generation anti-androgensXx_NEWLINE_xXPrior treatment with CYP17 inhibitorsXx_NEWLINE_xXConcurrent treatment with a non-permitted drugXx_NEWLINE_xXPrior treatment with enzalutamideXx_NEWLINE_xXPrior treatment with abiraterone acetate or enzalutamideXx_NEWLINE_xXNo acute toxicities from previous treatment higher than grade 1 at the start of treatment with CPI-613Xx_NEWLINE_xXTreatment with any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613Xx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior treatment with Aurora A-targeted agents, including MLN8237Xx_NEWLINE_xXPrior treatment with irinotecan or aurora A-targeted agents, including MLN8237Xx_NEWLINE_xXPatients with a diagnosis of chronic hepatitis B are ineligible due to the possibility of immunosuppression on study treatmentXx_NEWLINE_xXPatients who are simultaneously enrolled in other treatment studiesXx_NEWLINE_xXSubjects who are refractory to initial induction or re-induction treatmentXx_NEWLINE_xXPrevious treatment with MLN1117 and/or MLN0128; previous treatment with dual mTORC1/2 or dual PI3K-mTOR inhibitorsXx_NEWLINE_xXPreviously treated SCLC with only one prior treatment regimen (cyclophosphamide/doxorubicin/vincristine [CAV] alternating with etoposide/cisplatin [EP] is acceptable)Xx_NEWLINE_xXThe most recent treatment prior to enrollment must be one of the following (duration of treatment >= 2 weeks), and must have been adequately tolerated according to the treating physician's judgment\r\n* Letrozole\r\n* Exemestane\r\n* Exemestane + everolimus (everolimus must be discontinued for >= 3 weeks prior to starting study treatment)\r\n* Letrozole or exemestane in combination with an experimental agent(s) on a clinical trial, provided that the experimental agent(s) is not a PI3K inhibitor or v-akt murine thymoma viral oncogene homolog 1 (AKT) inhibitor (experiment agent[s] must be discontinued for >= 3 weeks prior to starting study treatment)Xx_NEWLINE_xXPrior treatment with doxorubicin and/or bevacizumabXx_NEWLINE_xXPrior treatment with Gliadel wafer is allowed if it has been at least 3 months from placementXx_NEWLINE_xXSuitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.Xx_NEWLINE_xXProgressive disease on prior treatmentXx_NEWLINE_xXPrevious assignment to treatment during this studyXx_NEWLINE_xXOn beta-blocker treatment; if discontinued, patients must have been off beta-blockers for at least 3 monthsXx_NEWLINE_xXPatients receiving concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea; however, prior treatment with DNMTi therapy (i.e., decitabine or azacitidine) for MDS or other antecedent hematologic malignancy is allowed\r\n* NOTE: if the patient has been initiated on the protocol defined regimen (i.e. decitabine without a FLT3 inhibitor) before the FLT3 mutation status was known, the patient may be registered on the protocol and start midostaurin on day 11Xx_NEWLINE_xXPatients must have, in the opinion of the investigator, clinical complete response or partial response and have no clinical evidence of disease progression on the post treatment scan or rising CA-125 level, following completion of this chemotherapy course. Patients with stable disease on the post-treatment scan at completion of first line platinum-containing therapy are not eligible for the study.Xx_NEWLINE_xXStable disease or progressive disease on the post-treatment scan or clinical evidence of progression at the end of the patient's first line chemotherapy treatment.Xx_NEWLINE_xXTreatment naïve patientsXx_NEWLINE_xXKnown allergies to any of the components of the investigational treatment regimen or required ancillary treatmentsXx_NEWLINE_xXPrior treatment with sorafenib as single agent or in combination, with no less than 200 mg once every other day dose of sorafenib, with radiologic evidence of progression of diseaseXx_NEWLINE_xXSubjects with active hepatitis B or C on anti-viremic compounds may remain on such treatment, except for interferonXx_NEWLINE_xXConcomitant treatment with rifampin or St. John's Wort; patients should discontinue these drugs at least 4 weeks prior to starting protocol treatmentXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior treatment with eribulinXx_NEWLINE_xXPrior sipuleucel-T treatment or investigational immunotherapy.Xx_NEWLINE_xXSubjects may be receiving anti-cancer treatment, but this treatment should be have been instituted at least 4 weeks prior to enrollment, and may not change during the study periodXx_NEWLINE_xXPrior treatment with doxorubicin (doxorubicin hydrochloride) up to 400 mg/m^2Xx_NEWLINE_xXPrevious treatment with chemotherapy (cytarabine, idarubicin, daunorubicin) for a hematological disorder; Exceptions: patients with prior diagnosis of myelodysplastic syndrome (MDS) and/or treatment with hypomethylating agent (azacytidine or decitabine) are not excluded, prior hydroxyurea allowedXx_NEWLINE_xXRadiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib (with the exception of 1st line expansion cohort). In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.Xx_NEWLINE_xXPrevious treatment with a single-agent EGFR TKI (e.g. gefitinib or erlotinib).Xx_NEWLINE_xXTreatment with an EGFR TKI (erlotinib or gefitinib) within 8 days (approximately 5x half-life) of the first dose of study treatment.Xx_NEWLINE_xXPrior treatment with letrozole is allowedXx_NEWLINE_xXPrior use of Gliadel wafers or any other intratumoral or intracavitary treatment.Xx_NEWLINE_xXThere is no limit on the number of prior chemotherapy regimens allowed; any prior treatment (with the exception of lanreotide or octreotide) must be completed at least 4 weeks prior to initiation of treatmentXx_NEWLINE_xXPrior treatment with embolization of ablative therapies is allowed if measurable disease remains outside of the treated area or if there is definite progression of the treated lesions; there is no limit on the number of prior proceduresXx_NEWLINE_xXPrior treatment with everolimus, other mammalian target of rapamycin (mTOR) inhibitors, or anti-VEGF drug (sunitinib, bevacizumab)Xx_NEWLINE_xXPrior treatment with pemetrexed < 6 months prior to starting study drugXx_NEWLINE_xXFor men: Must be surgically sterile, or compliant with a contraceptive regimen during and for 3 months after the treatment periodXx_NEWLINE_xXUse of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within 28 days of the first day of study drug treatmentXx_NEWLINE_xXPrevious treatment with any HER2-directed therapy, at any time, for any durationXx_NEWLINE_xXAngina pectoris requiring treatmentXx_NEWLINE_xXRefractory NSCLC: Defined as achieving less than a complete response and having residual measurable disease by RECIST criteria after prior treatment with chemotherapy, targeted or small molecules, monoclonal antibodies or any combination of these.Xx_NEWLINE_xXFailure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within 10 weeks after the last treatment with sorafenib.Xx_NEWLINE_xXPrior systemic treatment for HCC, except sorafenib.Xx_NEWLINE_xXPrior treatment with trastuzumab emtansineXx_NEWLINE_xXPrior treatment with bevacizumabXx_NEWLINE_xXRefractory to or relapsed after at least 1 prior treatment regimen;Xx_NEWLINE_xXPrevious treatment with FGFR inhibitorsXx_NEWLINE_xXTreating physician must deem that SRS is appropriate treatment for the metastatic spinal lesion(s)Xx_NEWLINE_xXTreatment initiation with BST no longer than 6 months prior to randomizationXx_NEWLINE_xXPatients with a prior history of grade 4 rash associated with thalidomide treatmentXx_NEWLINE_xXPrior treatment with KW-0761 or vorinostat.Xx_NEWLINE_xXPatient who has had any prior radiotherapy to the treatment site(s); as in, definitive therapy for lesion of interest; field overlap from previous treatment is permitted at the discretion of the treating investigatorXx_NEWLINE_xXPatient is participating in a concurrent treatment protocolXx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: treatment to central nervous system lesions, such as the brain or spine (prior to first line systemic therapy), or symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization, in which case the patient would be randomized to treatment of other metastatic sites or the primary sites (based on the disease remaining after first-line treatment); these treated lesions should be counted towards the total number of metastases at the time of enrollmentXx_NEWLINE_xXPatient is eligible for Low-Dose Cytarabine (LDAC) treatment.Xx_NEWLINE_xXObjective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimensXx_NEWLINE_xXAny treatment in a BMS-936558 (Nivolumab) trialXx_NEWLINE_xXPrior treatment with an anti-angiogenic agent is not an exclusion criterion.Xx_NEWLINE_xXPrior treatment with MEK or BRAF inhibitorsXx_NEWLINE_xXDepending upon patient prior treatment the following apply:Xx_NEWLINE_xXPrior treatment with CYP17 inhibitors or AR antagonists (e.g. abiraterone, TAK-700, ARN-509, ketoconazole*, enzalutamide, or galeterone) - Treatment naïve onlyXx_NEWLINE_xXPrior treatment with CYP17 inhibitors (e.g. TAK-700, ketoconazole*) or AR antagonists (e.g. enzalutamide, ARN-509,) or galeterone - abiraterone refractory onlyXx_NEWLINE_xXPrior treatment with CYP17 inhibitors (e.g. abiraterone, TAK-700, ketoconazole*) or AR antagonists (e.g. ARN -509) or galeterone - enzalutamide refractory onlyXx_NEWLINE_xXPrior treatment with Alpharadin® (Xofigo®)Xx_NEWLINE_xXPatients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studiesXx_NEWLINE_xXPrevious treatment with mTOR inhibitors.Xx_NEWLINE_xXPatient has at least 2 years of nilotinib treatment prior to study entry.Xx_NEWLINE_xXPatient ever attempted to permanently discontinue imatinib or nilotinib treatmentXx_NEWLINE_xXCurrent treatment with nitratesXx_NEWLINE_xXHistory of hypotension and/or blindness during prior treatment with tadalafil or other PDE-5 inhibitorsXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANOBINOSTAT treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPrior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural killer (NK) cell inhibitors.Xx_NEWLINE_xXNeed to be able to undergo metformin treatment for a duration of 12 weeks (+/- 7 days) prior to repeat endometrial biopsyXx_NEWLINE_xXoff rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.Xx_NEWLINE_xXPrevious treatment with an anti-CD19 antibody or fragmentsXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks prior to the first dose of the study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant hematemesis or gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPatients may receive hydroxyurea, steroids, or leukapheresis as necessary until day 5 of treatmentXx_NEWLINE_xXReceiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edemaXx_NEWLINE_xXPatient must not have received any previous treatment with any aurora-kinase inhibitors (MTD expansion cohort only)Xx_NEWLINE_xXRequire immediate treatment for progressive CTCLXx_NEWLINE_xXAre unable to discontinue current treatment for CTCL due to risk of progressionXx_NEWLINE_xXWithin 8 weeks of treatment initiation (day 0), have received treatment with:\r\n* Imiquimod\r\n* Total body electron beam radiation\r\n* Investigational drugs or treatmentsXx_NEWLINE_xXWithin 2 weeks of treatment initiation (day 0), have received at or adjacent to the target treatment lesions:\r\n* Any surgical procedures other than biopsies related to CTCL diagnosis or follow up\r\n* Any topical treatment other than bland moisturizers (creams, lotions, emollients, etc)Xx_NEWLINE_xXHave other concurrent cutaneous conditions in the treatment area or immediately adjacent to the treatment area that would be exacerbated by resiquimod or interfere with assessmentsXx_NEWLINE_xXNo more than 3 total prior systemic treatment regimens in the advanced or metastatic setting, and evidence of progression on or after last treatment regimen received and within 6 months of enrollmentXx_NEWLINE_xXPrior treatment with PI3K inhibitorsXx_NEWLINE_xXPrior crenolanib treatment for a non-leukemic indicationXx_NEWLINE_xXPatients must not have prior, current or planned treatment as defined below:\r\n* Previous treatment with > 2 anticancer regimens\r\n* Any prior radiotherapy to the pelvis or abdomen\r\n* Surgery (including open biopsy) within 4 weeks prior to the start of study, or anticipation of the need for major surgery during study treatment\r\n* Minor surgery procedures, within 24 hours prior to the first study treatment\r\n* Current or recent (within 10 days prior to the first study drug dose) chronic daily treatment with aspirin (> 325 mg/day)\r\n* Current or recent treatment with another investigational drug within 30 days of first study treatment dosing or earlier participation in this study\r\n* Chronic daily treatment with corticosteroids (dose > 10 mg/day methylprednisolone equivalent), excluding inhaled steroidsXx_NEWLINE_xXMust not be taking hydroxychloroquine for treatment or prophylaxis of malariaXx_NEWLINE_xXPatients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the studyXx_NEWLINE_xXTreatment with BT062 in previous studiesXx_NEWLINE_xXSubjects receiving other investigational agents thirty days prior to study treatment or during treatmentXx_NEWLINE_xXBiological agents (antibodies, immune modulators, cytokines, or vaccines) or radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXSymptomatic or uncontrolled brain metastasis or epidural disease requiring current treatment including steroids and anti-convulsantXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXTreatment plan to include delivery of concurrent chemoradiotherapyXx_NEWLINE_xXSubjects with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents)Xx_NEWLINE_xXCurrent use of a prohibited medication or requires any of these medications during treatment with lapatinib prior to study entryXx_NEWLINE_xXPrior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior randomization in any other clinical study evaluating ibrutinibXx_NEWLINE_xXPatients previously treated with a bendamustine-containing regimen who did not achieve a response or who relapsed and required treatment within 24 months of treatment with that regimenXx_NEWLINE_xXCriteria that need to be met to participate in this study:\n\n          -  Patients must be > 12 months and < 30 years of age when registered on study.\n\n          -  Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than\n             a partial response to standard treatment or persistent neuroblastoma that had at least\n             a partial response to standard treatment. All patients must have at least ONE site of\n             evaluable disease.\n\n             o Patients who have at least a partial response to standard treatment who still have\n             neuroblastoma that can be seen on CT/MRI or MIBG scans must have a surgical biopsy\n             done of the tumor to confirm that it is neuroblastoma. Patients with relapsed or\n             refractory neuroblastoma do not need to have a biopsy done to enter on study.\n\n          -  Patients must have adequate heart, kidney, liver and bone marrow function. Patients\n             who have bone marrow disease must still have adequate bone marrow function to enter\n             the study.\n\n          -  MLN8237 must be swallowed as whole tablets. Therefore, patients must be able to\n             swallow pills to be eligible for study. One tablet is the size of small breath mint,\n             or baby aspirin. Due to the size of MLN8237 tablets, patients must have a body surface\n             area of at least 0.38 m2 to be eligible for study. A body surface area is a\n             combination of a patient's height and weight. An example of a child with a BSA of 0.45\n             is a child that is 25 inches tall and weighs 25 pounds.You can use the link below to\n             calculate your child's body surface area and determine if they are too small for this\n             trial.\n\n        Patients cannot participate in the study if:\n\n          -  Patients who have received prior MLN8237 are excluded from all phases of the study.\n             Patients previously treated with irinotecan and/or temozolomide will be eligible if\n             they have not had documented progressive disease during treatment with a regimen\n             containing these agents.\n\n          -  They have other medical problems that could get much worse if they had this treatment.\n\n          -  They are on dialysis for bad kidney function.\n\n          -  They are pregnant or breast feeding.\n\n          -  They have active infections such as hepatitis or fungal infections.\n\n          -  They have an allergy to treatment with cefixime and cefpodixime.\n\n          -  They have brain metastasis at study entry, or have received cranial spinal radiation.\n\n          -  They have had an allogeneic stem cell transplant (received stem cell from someone\n             else).\n\n          -  They can't cooperate with the special precautions that are needed for this trial.Xx_NEWLINE_xXPrior treatment with eribulinXx_NEWLINE_xXComplete initial work-up within 8 days prior to treatment that allows definite stagingXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXThe participant has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXPrior bevacizumab as 1st line treatment for GB (if treatment was concluded 12 months prior to enrollment, the patient may be eligible to participate in the trial)Xx_NEWLINE_xXPrior therapies for treatment of HL including involved field radiation therapy or any prior treatment for any malignancy with anthracyclinesXx_NEWLINE_xXAny patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of 177Lu-DOTA0-Tyr3-Octreotate, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of 177Lu-DOTA0-Tyr3-Octreotate, unless the tumour uptake on target lesions observed by OctreoScan® imaging during continued Octreotide LAR treatment is at least as high as normal liver uptake observed by planar imaging.Xx_NEWLINE_xXTreatment with any Food and Drug Administration (FDA) approved or experimental cancer treatment following progression on EGFR-TKI (e.g., radiation or chemotherapy; supportive regimens such as denosumab or zoledronic acid will not result in exclusion)Xx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXParticipants who relapsed from their previous treatment(s) but were not refractory to any previous treatment.Xx_NEWLINE_xXPrior treatment with fulvestrantXx_NEWLINE_xXCurrently benefitting from continued treatment and have an acceptable safety profile with GSK2110183 as determined by the investigator following previous treatment with GSK2110183 either as monotherapy or as part of a combination treatment regimen.Xx_NEWLINE_xXThe patient has not received an investigational chemotherapy within the last 28 days prior to the screening visit and has never received investigational immunotherapy. In addition, the patient must not receive treatment for AML (including treatment with IL-2 or IFN?) in the interval of time between the screening visit and initiation of pre-infusion preparative therapyXx_NEWLINE_xXCurrently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.Xx_NEWLINE_xXComplete initial work-up within 8 days prior to treatment that allows definite staging.Xx_NEWLINE_xXPatients who provide consent for placement of the IP port system, if randomized to Regimen II (Study treatment: dd-TCip therapy)Xx_NEWLINE_xXPatients expected to receive the first protocol treatment within 8 weeks after the comprehensive staging surgeryXx_NEWLINE_xXPatients expected to survive longer than 3 months from the start date of the protocol treatmentXx_NEWLINE_xXPatients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as hydroxymethyl glutaryl coenzyme A (HMG CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225 treatmentXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; note that muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on LDE225 treatmentXx_NEWLINE_xXEither no previous trans-hepatic arterial treatment or progressive hepatic metastasis after prior regional treatment with trans-arterial embolization; embolization of hepatic artery with different types of medication will be considered to be one regional treatmentXx_NEWLINE_xXPresence of life-limiting extra-hepatic metastasis that requires a systemic treatment within 3 months; patients with extra-hepatic metastasis that can be controlled with a loco-regional treatment are eligibleXx_NEWLINE_xXPrevious treatment with isolated hepatic perfusionXx_NEWLINE_xXRadiotherapy prior to initiation of therapy is allowed to a limited area (e.g., palliative treatment for painful bone metastases), if it is not the sole site of disease; subjects must have completed treatment at least one week prior to starting study drugs, and must have recovered from all treatment-related toxicitiesXx_NEWLINE_xXCannot have received radionuclide treatment within 6 weeks of first dose of study treatmentXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients who are unwilling to stop the use of herbal remedies while on the treatment phase of the studyXx_NEWLINE_xXTime lapse of 21 to 56 days between the end of onco-specific treatment and start of vaccination. Patients must have recovered from any acute toxicity produced by previous therapy.Xx_NEWLINE_xXFertile patients of either sex who do not use adequate contraceptive methods while on treatmentXx_NEWLINE_xXPatients are eligible even if they have not received prior treatment; they are also eligible if they have received prior treatment, and any number of treatments is allowedXx_NEWLINE_xXMust be at least 21 days since treatment with chemotherapy, biochemotherapy, surgery, radiation, or immunotherapy, and recovered from any clinically significant toxicity experienced during treatmentXx_NEWLINE_xXPrior treatment with an anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody if treatment failure was due to adverse events (AEs); if a subject was discontinued from the prior anti-CTLA-4 treatment due to an AE or serious adverse event (SAE), regardless of the type of event, that discontinuation constitutes an exclusion criterion; if AEs were serious enough to require a subject’s withdrawal from prior treatment, the subject should be excluded from this studyXx_NEWLINE_xXPrevious treatment with agents that target the IGF receptorXx_NEWLINE_xXNo prior treatment with cytarabine or clofarabine; prior hydroxyurea for control of leukocytosis or use of hematopoietic growth factors (eg, filgrastim [G-CSF], sargramostim [GM-CSF], Procrit, Aranesp, thrombopoietins) is allowed at any time prior to or during study if considered to be in the best interest of the patientXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatient is willing to have two biopsies while on treatment for correlative studiesXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on sonidegib treatmentXx_NEWLINE_xXPatients must not have any disease that will obscure toxicity or dangerously alter drug metabolism; patients with a history of psychosis/schizophrenia or cardiac disease requiring beta-blocker treatment (unable to change medication to non-beta blocker), anti-malarial drugs, or quinine or quinidine will not be eligible for enrollment to a mefloquine containing arm; patients who are on active treatment with one of the study drugs at the time of evaluation will not be eligible for enrollment to an arm containing that study drugXx_NEWLINE_xXDose Expansion phase: Previous treatment with RAF or MEK inhibitorsXx_NEWLINE_xXChronic treatment with systemic steroids or another immuno-suppressive agentXx_NEWLINE_xXPrior treatment with intracystic P-32, intracystic bleomycin or radiosurgeryXx_NEWLINE_xXIs on any specifically prohibited medication or requires any of these medications during treatment with pazopanibXx_NEWLINE_xXPrevious treatment for APL, except tretinoin, which may be given for up to 7 days prior to study entryXx_NEWLINE_xXReceiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edemaXx_NEWLINE_xXUse of potassium wasting diuretics during study treatmentXx_NEWLINE_xXPatients who have been treated for at least two weeks with stable doses of corticosteroids to address conditions unrelated to their malignancy will be allowed to continue this treatment during enrollment on the current trialXx_NEWLINE_xXPatients currently being treated with a gonadotropin-releasing hormone (GnRH agonist), bicalutamide or with bisphosphonates may continue treatment while on clinical trial PU-H71 as long as the treatment has been initiated before the study start; GnRH agonist must have been well tolerated for at least three monthsXx_NEWLINE_xXFor patients with MPN: Ruxolitinib treatment requirements will be waived for patients who have failed this treatment in the past or for whom this treatment is otherwise contraindicatedXx_NEWLINE_xXDocumented fungal disease that is progressive despite treatmentXx_NEWLINE_xXPrior treatment with radiosurgeryXx_NEWLINE_xXPrior disease progression/recurrence during or immediately following treatment with bevacizumab; any questions should be directed to the PIXx_NEWLINE_xXMust have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment) requiring 2nd or 3rd line therapyXx_NEWLINE_xXHas demonstrated compliance during the parent study with study treatment(s), treatment visit schedules, and the requirements and restrictions listed in the consent form.Xx_NEWLINE_xXIs currently receiving clinical benefit as determined by the investigator from previous treatment with GSK1120212 either as monotherapy or as part of a combination treatment regimen.Xx_NEWLINE_xXAny unresolved toxicity that meets the study treatment discontinuation or study withdrawal criteria from the parent study at the time of transition to this study.Xx_NEWLINE_xXBlood and urine samples must be provided from all subjects for biomarker analysis before and during treatment with pazopanibXx_NEWLINE_xXPart B only: Prior treatment with agents targeting both mammalian target of rapamycin (mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex 1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.Xx_NEWLINE_xXNo prior radiation treatment to the affected spine, or sacral region; prior chemotherapy is allowed within 30 days of start of treatmentXx_NEWLINE_xXPatients cannot have concurrent enrollment on other phase I, II, or III investigational treatment studiesXx_NEWLINE_xXPatients who have had prior chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C); patients must be off treatment with temozolomide for at least 23 days; patients who received non-cytotoxic drug therapy must be off treatment for at least 2 weeks; for patients enrolling in Part 1 or Part 3 AND who have progressed on a prior bevacizumab-containing regimen, patients may continue treatment with bevacizumab 10 mg/kg monotherapy, with last dose of bevacizumab administered no fewer than 14 days from start of plerixafor and bevacizumab; for participants enrolling in Part 1 or Part 3 AND who have progressed on a prior anti-VEGF(R) (other than bevacizumab) containing regimen, patients must be off anti-VEGF(R) treatment for at least 28 days before receiving plerixafor and bevacizumab; for patients enrolled in Part 2 (surgical substudy) AND who have progressed on a prior bevacizumab or other anti-VEGF(R) containing regimen, patients must be off anti-VEGF(R) treatment for at least 28 days prior to surgery; NOTE: participants must have recovered to a grade 0 or 1 from the toxic effects of prior therapy (with the exception of lymphopenia, which is common after therapy with temozolomide); for any patient who received prior bevacizumab or an anti-VEGF(R) therapy, patient must NOT have discontinued that treatment regimen due to a treatment-related toxicityXx_NEWLINE_xXCurrent use of a prohibited medication or expected to require any of these medications during treatment with study treatment.Xx_NEWLINE_xXPrevious treatment with dacarbazine (DTIC) or TMZXx_NEWLINE_xXE 18. Contraindications to the use of corticosteroid treatment.Xx_NEWLINE_xXPatients requiring treatment with any other systemic glucocorticoid; NOTE: this restriction regarding choice of glucocorticoid does not apply should patient need < 2 week course of glucocorticoid for treatment of non-infectious pneumonitis during studyXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baselineXx_NEWLINE_xXPrior treatment with treatment doses of capecitabine (prior radio-sensitizing doses of capecitabine are allowed as long as the patient did not progress on capecitabine)Xx_NEWLINE_xXPrior treatment with regorafenibXx_NEWLINE_xXUse of formalin or hyperbaric oxygen treatmentXx_NEWLINE_xXAt least one prior HMTA treatment with either azacitidine or decitabine and subsequent loss of response to HMTA, progression while on HMTA, or no response to HMTA, defined as failure to achieve at least hematologic improvement (HI) after 4 cycles of treatmentXx_NEWLINE_xXTreatment with drugs interacting with S-1, 5-FU, or cisplatin.Xx_NEWLINE_xXPrior treatment with lapatinib or trastuzumab are allowed, provided that the agents have never been given in combinationXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXUsing medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatients must have had FISH evaluation of leukemia cells within 3 months without intervening treatment demonstrating deletion 11q22-23Xx_NEWLINE_xXFor Parts A & B: Have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment. For Part C: not received previous systemic treatment. For Part D: have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment or have not received prior systemic treatment.Xx_NEWLINE_xXHave received more than 1 line of systemic treatment in Parts A, B and DXx_NEWLINE_xXPatients receiving treatment with 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) within 90 days prior to preregistration are not eligible; treatment with these agents during the protocol intervention is not permittedXx_NEWLINE_xXHas demonstrated compliance with study drug(s), treatment visit schedules, and the requirements and restrictions listed in the consent formXx_NEWLINE_xXCurrently has no evidence of progressive disease, as determined by the investigator, following previous treatment with GSK2118436 (either as monotherapy or as part of a combination treatment regimen)Xx_NEWLINE_xXReceived randomized double-blind treatment in PREVAIL;Xx_NEWLINE_xXTreatment of any bone lesion is permissible if it is anticipated that the dosimetry guidelines can be metXx_NEWLINE_xXPrior treatment with MDV3100Xx_NEWLINE_xXPrior treatment with abirateroneXx_NEWLINE_xXPrior treatment with ketoconazoleXx_NEWLINE_xXConcurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.Xx_NEWLINE_xXPatients with AML and ALL should have received at least 1 prior treatment regimen and either failed to achieve response or relapsed on treatmentXx_NEWLINE_xXSubject has any underlying conditions, which would contraindicate therapy with study treatment (or allergies to reagents used in this study)Xx_NEWLINE_xXSubjects who have progressed on Bevacizumab treatmentXx_NEWLINE_xXPatients requiring treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumabXx_NEWLINE_xXReceived prior treatment with a hypomethylating agent, except as allowed in Exclusion Criterion 7.bXx_NEWLINE_xXConcurrent treatment with a non-permitted drug.Xx_NEWLINE_xXPrior treatment with HAI FUDRXx_NEWLINE_xXHas completed treatment (eg, whole brain radiation treatment [WBRT], stereotactic radiosurgery, or equivalent) ?14 days prior to the first dose of study treatment,Xx_NEWLINE_xXPrevious treatment with palbociclib, abemaciclib, ribociclib or other investigational CDK4/6 inhibitorsXx_NEWLINE_xXPatients who have received treatment with IFN-? within the previous 6 months prior to enrollment.Xx_NEWLINE_xXa. Indication A - ASPS: Prior treatment with cediranib.Xx_NEWLINE_xXPatients must have achieved PR to primary treatment and not be refractory to prior treatmentXx_NEWLINE_xXReceiving sirolimus for treatment of chronic GVHD (sirolimus for prophylaxis or treatment of acute GVHD is acceptable).Xx_NEWLINE_xXPatients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCTXx_NEWLINE_xXPatients with > 10 pack years of smoking history and/or currently a smoker at the time of treatmentXx_NEWLINE_xXThere is no limit on the number of prior treatment regimensXx_NEWLINE_xXIndolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimenXx_NEWLINE_xXPrior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 monthsXx_NEWLINE_xXTreatment with anti-CD20 monoclonal antibody within 3 months of randomizationXx_NEWLINE_xXPrior use of any monoclonal antibody (other than anti-CD20) within 3 months prior to the start of Cycle 1, prior treatment with obinutuzumab was not allowedXx_NEWLINE_xXKnown treatment with systemic corticosteroid within one week prior to the first administration of study drugXx_NEWLINE_xXPrior treatment with fludarabine or alemtuzumab based regimens.Xx_NEWLINE_xXPatients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baselineXx_NEWLINE_xXHistory of scleroderma and systemic lupus erythematosus which increases the risk of toxicity from radiation treatmentXx_NEWLINE_xXPatients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not metXx_NEWLINE_xXFertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatmentXx_NEWLINE_xXPatients who have demonstrated relapse to 3 or more prior regimens of SM treatment (not including those given for supportive care)Xx_NEWLINE_xXNewly diagnosed, treatment naive CP-CML (Cohort 3)Xx_NEWLINE_xXGrade 4 rash due to prior thalidomide treatmentXx_NEWLINE_xXINCLUSION CRITERIA\n\n        PART 1:\n\n          -  confirmed pathologic diagnosis of a solid tumor not curable with available therapies\n             for which neratinib plus capecitabine is a reasonable treatment option.\n\n        PART 2:\n\n          -  confirmed histologically and/or cytologically confirmed diagnosis of breast cancer,\n             metastatic or locally advanced.\n\n          -  erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+\n             with FISH or CISH confirmation), based on local testing, or based on centralized FISH\n             testing prior to day 1.\n\n          -  disease progression on or following at least 1 prior trastuzumab containing treatment\n             regimen (at least 6 weeks) for metastatic or locally advanced disease. (Prior adjuvant\n             trastuzumab is allowed but not required). A 2 week period is required between the last\n             dose of trastuzumab treatment and first dose of the test article.\n\n          -  Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, and/or\n             metastatic disease treatment setting.\n\n        PARTS 1 and 2:\n\n          -  At least 1 measurable lesion as defined by RECIST criteria.\n\n          -  LVEF within institutional range of normal as measured by multi-gated acquisition\n             (MUGA) or echocardiogram (ECHO).\n\n        EXCLUSION CRITERIA\n\n        PART 2:\n\n          -  prior treatment with capecitabine, lapatinib (20 subjects with prior lapatinib\n             exposure will be enrolled) or any erbB-2 targeted agents except trastuzumab. Treatment\n             with erbB-2 targeted therapy must exceed 2 weeks (14 days) in order to be\n             exclusionary.\n\n          -  prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater\n             than 400 mg/m², epirubicin dose of greater than 800 mg/m², or the equivalent dose for\n             other anthracyclines.\n\n        PARTS 1 and 2:\n\n          -  Subjects with bone as the only site of disease.\n\n          -  Active uncontrolled or symptomatic central nervous system (CNS) metastases, as\n             indicated by clinical symptoms, cerebral edema, and/or progressive growth. Subjects\n             with a history of CNS metastases or cord compression are allowable if they have been\n             considered definitively treated and are off anticonvulsants and steroids for at least\n             4 weeks before the first dose of test article.\n\n          -  Any other cancer within 5 years prior to screening with the exception of adequately\n             treated cervical carcinoma in situ, or adequately treated basal or squamous cell\n             carcinoma of the skin.Xx_NEWLINE_xXPrior treatment with vinorelbine for metastatic setting, or prior treatment with any ErbB-2 targeted agents except trastuzumab (part 2 only). Up to 20 subjects with ErbB-2-overexpressing metastatic breast cancer who have been previously exposed to lapatinib but are not refractory to lapatinib may be enrolled in part 2.Xx_NEWLINE_xXBoth naive and previous systemically treated patients are included \r\n* Prior chemotherapy or immunotherapy is permitted\r\n* Prior investigational agents are permitted, however, no prior treatment with targeted therapies directed to c-KIT/PDGFR allowed (e.g., imatinib or sunitinib)\r\n* Limb perfusion allowed\r\n* If radiation has been administered to a lesion, there must be radiographic evidence of progression of that lesion in order for that lesion to constitute measurable disease or to be included in the measured target lesionsXx_NEWLINE_xXPatients must begin treatment as outlined in the protocol within 31 days of definitive surgeryXx_NEWLINE_xXPatients with extraneural metastasis are eligible for treatment on the high-risk armXx_NEWLINE_xXPrior treatment with isotretinoin is allowed because the trial is based on the hypothesis that HDAC inhibition will potentially overcome resistance to retinoids.Xx_NEWLINE_xXPatients must not have: a) active infection; b) disease that will obscure toxicity or dangerously alter drug metabolism, especially liver disease; c) serious intercurrent medical illness; d) prior treatment with HDAC inhibitors. However, patients who have received anticancer agents for non-therapeutic purposes (for eg., as part of a pharmacology study without therapeutic intent) will remain eligible for enrollment into the study.Xx_NEWLINE_xXPrior treatment with bevacizumab is not allowed.Xx_NEWLINE_xXPatients on previous treatment with carboplatin.Xx_NEWLINE_xXFor patients who are Her2 positive and will be treated on the trastuzumab + mDCF cohort, prior trastuzumab treatment is not allowedXx_NEWLINE_xXThe patient has progressed within 6 months after completion of curative intent (definitive) treatment for localized/locoregionally advanced disease.Xx_NEWLINE_xXPrior cytotoxic or cyclosporin treatment for HLH.Xx_NEWLINE_xXPrevious ZD6474 treatmentXx_NEWLINE_xXEvidence of an optic glioma requiring treatmentXx_NEWLINE_xXTreatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigatorXx_NEWLINE_xXPrior history of treatment with dasatinibXx_NEWLINE_xXPrior treatment with Herceptin (Arm B only)Xx_NEWLINE_xXNewly diagnosed, AL amyloidosis treatment naïveXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXSubject has received a prior treatment with a therapeutic agent targeting EGFR (e.g., afatinib, dacomitinib, ASP8273, etc).Xx_NEWLINE_xXCurrent immunosuppressive treatment for graft versus host diseaseXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (Note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\r\n** Note: for proliferative disease, hydroxyurea will be allowed during weeks 1 and 2 of cycle 1 of study; hydroxyurea may be started or the dose changed during that 2-week period if it is clinically indicated; if a subject not previously on a stable dose of hydroxyurea needs to begin hydroxyurea or a subject on a stable dose needs to have their dose increased during the first 2 weeks, the investigator will notify the clinical team that this has been initiatedXx_NEWLINE_xXReceived systemic agents other than corticosteroids for treatment of acute GvHD. GvHD prophylaxis agents (example, calcineurin inhibitors) may be continued.Xx_NEWLINE_xXEligible for and agree to BM aspirate prior to treatment startXx_NEWLINE_xXPrior treatment with any anti-androgens, including but not limited to, enzalutamide and bicalutamideXx_NEWLINE_xXTreatment with any of the following hormone replacement therapies, unless discontinued at least 14 days prior to the first dose of study treatment:Xx_NEWLINE_xXMale subjects must not donate sperm during the Screening and Treatment periods, and for at least 3 months after the last dose of ALXN1007.Xx_NEWLINE_xXKey Inclusion Criteria for Tumor Collection:\n\n          1. Diagnosis or clinical signs of advanced RCC\n\n          2. Scheduled for cytoreductive or partial nephrectomy\n\n        Key Exclusion Criteria for Tumor Collection:\n\n          1. Known inability to undergo sunitinib treatment as currently labeled, due to\n             pre-existing medical conditions\n\n          2. Requirement for systemic chronic immunosuppressive drugs or corticosteroids\n\n          3. Evidence of brain metastases prior to nephrectomy\n\n        Key Inclusion Criteria for Treatment Study:\n\n          1. Advanced disease, histologically assessed as RCC, with predominantly clear cell\n             histology\n\n          2. Metastatic disease (measurable or non-measurable) that can be monitored throughout the\n             course of the study participation per RECIST 1.1\n\n          3. Subjects who are candidates for standard first-line therapy initiating with sunitinib\n\n          4. Time from diagnosis to treatment < 1 year\n\n          5. Karnofsky performance status (KPS) ? 70%\n\n          6. Life expectancy of 6 months or greater\n\n          7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to\n             Grade ? 1 according to National Cancer Institute Common Terminology Criteria for\n             Adverse Events Version 4.0\n\n          8. Adequate hematologic, renal, hepatic, and coagulation function\n\n          9. Negative serum pregnancy test for female subjects with reproductive potential, and\n             agreement of all male and female subjects of reproductive potential to use a reliable\n             form of contraception during the study and for 12 weeks after the last dose of study\n             drug\n\n         10. Normal ECG or clinically non-significant finding(s) at Screening\n\n         11. Able to abstain from taking prohibited drugs, either prescription or non-prescription,\n             during the treatment phase of the study\n\n         12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures\n\n        Key Exclusion Criteria for Treatment Study:\n\n          1. Prior systemic therapy (including adjuvant or neoadjuvant) of any kind for RCC,\n             including immunotherapy, chemotherapy, hormonal, or investigational therapy\n\n          2. Prior history of malignancy within the preceding 3 years, except for adequately\n             treated in situ carcinomas or non-melanoma skin cancer, adequately treated early stage\n             breast cancer, superficial bladder cancer, and non-metastatic prostate cancer with a\n             normal PSA\n\n          3. History of or known brain metastases, spinal cord compression, or carcinomatous\n             meningitis, or evidence of brain or leptomeningeal disease\n\n          4. Patients with 4 or more of the following risk factors:\n\n               1. Hgb < LLN\n\n               2. Corrected calcium > 10.0 mg/dL\n\n               3. KPS < 80%\n\n               4. Neutrophils > ULN\n\n               5. Platelets > ULN\n\n          5. Planned or elective surgical treatment post-nephrectomy for the direct management of\n             RCC, within 28 days before Visit 1 (Week 0)\n\n          6. NCI CTCAE Grade 3 hemorrhage < 28 days before Visit 1 (Day 0)\n\n          7. Clinically significant cardiovascular conditions within 3 months prior to\n             Randomization\n\n          8. Significant gastrointestinal abnormalities\n\n          9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in\n             the normal range with medication\n\n         10. Active autoimmune disease or condition requiring chronic immunosuppressive therapy\n\n         11. Clinically significant infections, including human immunodeficiency virus, syphilis,\n             and active hepatitis B or C\n\n         12. Current treatment with an investigational therapy on another clinical trial\n\n         13. Pregnancy or breastfeeding\n\n         14. Any serious medical condition or illness considered by the investigator to constitute\n             an unwarranted high risk for investigational treatmentXx_NEWLINE_xXPrior treatment with gemcitabineXx_NEWLINE_xXPatient meets the FDA-approved indication for Atezolizumab treatment in NSCLC.Xx_NEWLINE_xXNo prior treatment for ALL, except steroids or hydroxyurea (stopped within 24 hours before start of protocol treatment)Xx_NEWLINE_xXReceived more than one treatment course of enzalutamide or abirateroneXx_NEWLINE_xXPrior treatment with investigative androgen receptor (AR) agentsXx_NEWLINE_xXPrior treatment with regorafenib.Xx_NEWLINE_xXPrevious assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.Xx_NEWLINE_xXPatients who have had previous treatment with topotecanXx_NEWLINE_xXHistory of treatment with a murine-derived biological product other than blinatumomab unless subject has been shown to be negative for human-anti-mouse-antibodies (HAMA) prior to or during screeningXx_NEWLINE_xXTreatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresisXx_NEWLINE_xXPrior HDAC, deacetylase (DAC), heat shock protein (HSP)90 inhibitors or valproic acid for treatment of cancerXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting treatmentXx_NEWLINE_xXPrevious treatment with anthracycline antibiotics (e.g. Doxorubicin) or sorafenib.Xx_NEWLINE_xXRandomized cohort: resistant or intolerant to prior ruxolitinib therapy. Documentation by the Investigator that the patient has exhausted available treatment options (eg, resistant or intolerant to hydroxyurea, etc).Xx_NEWLINE_xXActive graft versus host disease (GVHD) with other than grade 1 skin involvement or GVHD requiring immunosuppressive treatment.Xx_NEWLINE_xXTreatment with prohibited medications less than or equal to 14 days prior to first day of study treatmentXx_NEWLINE_xXPrior treatment with EGFR TKIs (e.g. erlotinib, gefitinib, neratinib, afatinib, AZD9291, or dacomitinib), rociletinib or other drugs that target mutant EGFRXx_NEWLINE_xXPrior treatment with temozolomide, dacarbazine or procarbazine.Xx_NEWLINE_xXPrior treatment with poly ADP ribose polymerase (PARP) inhibitors (e.g., olaparib, ABT-888).Xx_NEWLINE_xXCurrent use of a prohibited medication or expected to require any of these medications during treatment with the investigational drugXx_NEWLINE_xXPrior irinotecan treatment.Xx_NEWLINE_xXTreatment must start not more than 15 days from diagnosis of metastatic retinoblastomaXx_NEWLINE_xXReceived previous treatment with rituximab that was not effective.Xx_NEWLINE_xXFor subjects receiving neoadjuvant therapy only, time between start of neoadjuvant treatment and randomization must be ? 8 weeks and subjects must be scheduled to undergo definitive treatment (including surgery and/or radiotherapy) with curative intent within approximately 9 months of starting neoadjuvant treatmentXx_NEWLINE_xXOsteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six monthsXx_NEWLINE_xXStudy treatment must begin within 30 days of surgical resection or adjuvant treatment; this timeline may be extended if further time for recovery from treatment related toxicities is requiredXx_NEWLINE_xXPalliative radiation for treatment of painful bone metastasis, control of hemoptysis or treatment of small asymptomatic brain metastasis that become symptomatic during on protocol treatment is allowed; protocol treatment will be delayed until recovery from radiation at the discretion of the treating physicianXx_NEWLINE_xXWilling to undergo or must have had a lower GI biopsy within 7 days of informed consent to confirm GI GvHD. Biopsy results are not needed to initiate treatment; however, if biopsy results are not consistent with aGvHD, treatment with GLASSIA will be discontinued.Xx_NEWLINE_xXParticipant receiving GvHD treatment other than continued prophylaxis (eg, cyclosporine and/or mycophenolate mofetil, etc) or corticosteroid therapy. In addition, a participant who received the first dose of corticosteroid therapy for acute GvHD with lower GI involvement more than 72 hours before the first dose of study treatment is not eligible for the studyXx_NEWLINE_xXAny prior history of treatment with maytansine (DM1 or DM4)-based ADCXx_NEWLINE_xXPatient have received anti-cancer therapies within the following time frames prior to the first dose of study treatment:Xx_NEWLINE_xXWeekly paclitaxel must be an acceptable treatment optionXx_NEWLINE_xXPrior treatment with antiPD-1, or antiPD-L1 therapeutic antibody or pathway targeting agentsXx_NEWLINE_xXPatients who have received prior treatment with antiCTLA-4 may be enrolled, provided the following requirements are met:Xx_NEWLINE_xXPrior treatment with abiraterone acetateXx_NEWLINE_xXPrior treatment with cabazitaxelXx_NEWLINE_xXPatients whose tumors have progressed on first-line treatmentXx_NEWLINE_xXPrior treatment with ibrutinibXx_NEWLINE_xXAnti-leukemia treatment within14 days of study drug (other than hydroxyurea or 6-mercaptopurine), immunosuppressive therapy (except for GVHD treatment/prophylaxis in Part B), or investigational agentsXx_NEWLINE_xXReceipt of treatment known to potentially affect the course of AA within last monthXx_NEWLINE_xXTreatment with a non-EGFR targeting regimen following progression on anti-EGFR plus irinotecan-based therapyXx_NEWLINE_xXUse of drugs known to inhibit UDP glycosyltransferase 1 family, polypeptide A1 gene (UGT1A1), such as Atazanavir, Gemfibrozil, Indinavir, or Ketoconazole while on study treatment; (patients using these drugs must not take these drugs on the day study treatment begins and for the duration of study treatment)Xx_NEWLINE_xXDocumented complete response to HCC treatment.Xx_NEWLINE_xXSubject is not expected to show a therapeutic response to existing available treatment.Xx_NEWLINE_xXPatients who have previously received treatment with ibrutinib (modified by amendment 1), including:Xx_NEWLINE_xXCompletion of at least 1 cycle of treatment with ibrutinib and confirmed evidence of disease progression or refractoriness to treatment orXx_NEWLINE_xXDiscontinuation of ibrutinib treatment at an earlier time due to toxicityXx_NEWLINE_xXSubjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment linesXx_NEWLINE_xXPrior treatment with second generation anti-androgens (e.g. abiraterone, enzalutamide)Xx_NEWLINE_xXTreatment with immune modulators includingXx_NEWLINE_xXPatients on treatment for rheumatoid arthritis or systemic lupus erythematosusXx_NEWLINE_xXMust not be taking hydroxychloroquine for treatment or prophylaxis of malariaXx_NEWLINE_xXMore than one prior treatment regimen for ALL or LLXx_NEWLINE_xXPrior treatment with pacritinibXx_NEWLINE_xXPrevious treatment with sunitinib.Xx_NEWLINE_xXReceiving any other therapies for cancer treatment (with the exception of gonadotropin-releasing hormone [GnRH] agonists for prostate cancer); Note: hydroxyurea is allowed before initiation of study treatment and for the first 5 days of study treatmentXx_NEWLINE_xXConcurrent non-hematologic malignancies requiring treatment.Xx_NEWLINE_xXPatients who have had prior radiation to the lung will be excluded from the study, although mediastinal irradiation will be permitted if minimal lung is in the treatment volumeXx_NEWLINE_xXFor Cohort 3 subjects, prior treatment with hypomethylating agents (eg, azacitidine, decitabine)Xx_NEWLINE_xXTreatment with chronic immunosuppressant (e.g., cyclosporine following transplantation)Xx_NEWLINE_xXSubjects must be able to receive outpatient treatment and laboratory monitoring (where specifically indicated) at the institution that administers study drug for the entire treatment periodXx_NEWLINE_xXPrior treatment for glioblastoma or gliosarcoma.Xx_NEWLINE_xXPatients with active infection or with a fever > 38.5 degrees Celsius (C) within three days prior to the first scheduled treatmentXx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXMust have a confirmed diagnosis of WM as defined by the Second International Workshop, with a clinical indication for treatment.Xx_NEWLINE_xXAccessible for treatment and follow-upXx_NEWLINE_xXAt least one previous line of treatment for the metastatic disease and the last treatment must have included cetuximab or panitumumab. Documentation of clinical benefit and subsequent progression on cetuximab or panitumumab as the most recent line of treatment is required for patients in the expansion partXx_NEWLINE_xXPrior treatment with c-MET/HGF inhibitorsXx_NEWLINE_xXTreatment with any medication that has a clinically relevant potential risk of prolonging the QT interval or inducing torsades de pointes that cannot be discontinued or switched to a different medication before starting study drug.Xx_NEWLINE_xXTreatment with any medication that has a clinically relevant potential risk of prolonging the QT interval or inducing torsades de pointes that cannot be discontinued or switched to a different medication before starting study drug.Xx_NEWLINE_xXPatients who are known purified protein derivative (PPD) positive will be screened for active tuberculosis prior to starting treatment with BCGXx_NEWLINE_xXFor Phase I: Locally advanced or metastatic B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E/K positive melanoma that is either treatment-naïve or treatment-experienced; for the latter, progression, or stable as best response, or intolerance to the last treatment is required; previous treatments can be local or systemic therapies; there are no limits to the number of prior therapies; for all patients, disease does not have to be measurable but must be evaluable, which is defined as one or more lesions which are known to be present, but which cannot be measured; e.g.: bony lesions, pleural effusion, ascitesXx_NEWLINE_xXA concurrent skin rash or skin condition requiring treatment with a prescription medicationXx_NEWLINE_xXRequirement for immediate palliative treatment of any kind including surgeryXx_NEWLINE_xXPrior treatment with refametinib or regorafenib.Xx_NEWLINE_xXOngoing treatment with sensitive cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) substrate or CYP1A2 substrate with narrow therapeutic range at the start of study treatmentXx_NEWLINE_xXOngoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of study treatmentXx_NEWLINE_xXPrior treatment with bortezomibXx_NEWLINE_xXParticipant must have viable alternatives to the current ART regimen in the event of drug resistance related to study treatmentXx_NEWLINE_xXAny steroid treatment except for that required for replacement therapy in adrenal insufficiency or inhaled steroids for the treatment of asthmaXx_NEWLINE_xXPrevious local therapy of any KS-indicator lesion unless the lesion has clearly progressed since treatment; any prior local treatment to indicator lesions regardless of the elapsed time is not allowed unless there is evidence of clear-cut progression of said lesionXx_NEWLINE_xXPrior treatment with any investigational or targeted therapiesXx_NEWLINE_xXPrior treatment with regorafenib.Xx_NEWLINE_xXPrevious treatment with rituximab or other monoclonal antibodies, or temozolomide.Xx_NEWLINE_xXChronic treatment with steroids or other immunosuppressive agents for medical conditions other than cancer. Patients who require steroids for treatment of tumor-associated cerebral edema are eligible.Xx_NEWLINE_xXPrior treatment with an anti-4-1BB antibodyXx_NEWLINE_xXPatients must discontinue any medication that causes a strong CYP3A4 inhibition 1 week prior to treatment initiation; patients who are not able to discontinue these drugs are considered ineligibleXx_NEWLINE_xXCurrent use of a prohibited medication per protocol or expected to require any of these medications during treatment with study drug.Xx_NEWLINE_xXPatients on active treatment for hypo- or hyperthyroidism that is uncontrolled, requiring new medication, treatment intervention (such as thyroid ablation or surgery), or a > 30% medication dose adjustment within the previous 3 months; patients on stable doses of thyroid hormone replacement for hypothyroidism or thyroid suppression for hyperthyroidism can participateXx_NEWLINE_xXPrior treatment with more than 2 JAK2 inhibitors or with pacritinibXx_NEWLINE_xXConcomitant treatment with other anti-neoplastic agents, with the exception of hydroxyureaXx_NEWLINE_xXPrior treatment with histone deacetylase inhibitors or mammalian target of rapamycin (mTOR) inhibitorsXx_NEWLINE_xXPrior treatment with TPI 287Xx_NEWLINE_xXPatients who have received any previous carfilzomib treatmentXx_NEWLINE_xXPrior treatment with small molecule inhibitors of the MET pathway.Xx_NEWLINE_xXSystemic drug treatment to induce ovarian suppression if woman is premenopausalXx_NEWLINE_xXSubject currently participating in a clinical investigation that includes an active treatment armXx_NEWLINE_xXReceived gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatmentXx_NEWLINE_xXDocumented progression on or after treatment with sorafenib, confirmed by the Investigator upon review of appropriate imaging documentationXx_NEWLINE_xXIndication for any possible curative treatment after multidisciplinary assessment (surgery, ablation, transplantation)Xx_NEWLINE_xXPrevious treatment with sorafenib for more than 4 weeks during the previous 2 months; prior sorafenib-related toxicityXx_NEWLINE_xXPrior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.Xx_NEWLINE_xXMust have received the following treatment for glioblastoma: •Prior treatment with radiotherapy and temozolomide; Note: A maximum of two prior chemotherapy/antibody regimens (including bevacizumab or other direct VEFG/VEGFR inhibitors) for recurrent disease are permitted.Xx_NEWLINE_xXPrior treatment with a PI3K and/or mTOR inhibitors for glioblastoma or for pre-existing neoplasm transformed to glioblastoma (applicable for combination treatment arm only)Xx_NEWLINE_xXReceiving treatment with long acting proton pump inhibitors, and cannot be discontinued 3 days prior to the start of INC280 treatment and during the course of the study.Xx_NEWLINE_xXPatient has received previous treatment with any AKT, mTOR inhibitors or PI3K pathway inhibitors;Xx_NEWLINE_xXPatients with previous anti-cancer chemotherapy, immunotherapy or investigational agents =< 3 weeks prior to the first day of study defined treatment; NSCLC patients with EGFR mutation can enroll within 7 days of discontinuing EGFR-TKI; palliative radiation < 1 week before the start of treatment (lesions subjected to radiotherapy may not be used as target lesions); patients who receive gamma knife radiosurgery for brain metastases within 1 week prior to treatment startXx_NEWLINE_xXPatient must have failed (progressed on or been intolerant of) prior treatment with cabozantinib or vandetanibXx_NEWLINE_xXHave been informed of other treatment options.Xx_NEWLINE_xXPatients should NOT have had prior therapy for primary myelofibrosis. This includes treatment with cytoreductive drugs (Hydroxyurea), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), JAK2 inhibitors, or other therapies specifically for myelofibrosis. If they received these classes of drugs for indications other than PMF, treatment should be discontinued at least 6 weeks prior to randomization.Xx_NEWLINE_xXHistory of depression or active treatment for depressionXx_NEWLINE_xXPatients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this studyXx_NEWLINE_xXUnable to comply with treatment with the NovoTTF-100A deviceXx_NEWLINE_xXMinimum pre-treatment online neurocognitive function (tNCF) score >= 70Xx_NEWLINE_xXPrior treatment with cabozantinib and other met inhibitorsXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXFor Phase II, Arms 1 and 2, prior cetuximab or other EGFR-targeted antibody therapy is allowed only if administered in the induction setting, or concurrently with radiation in the curative setting, with the last dose of cetuximab administered at least 12 months prior to starting the study treatment. For Arm 3, prior cetuximab must have been administered in the curative, recurrent or metastatic disease setting and disease progression documented within 9 months of the last dose of cetuximab administered in that setting. This regimen (including both platinum and cetuximab) must be the most recent anti-neoplastic treatment regimen administered.Xx_NEWLINE_xXPrior treatment with PI3K-inhibitorsXx_NEWLINE_xXPatients receiving chronic daily treatment with aspirin (> 325 mg/day) or nonsteroidal anti- inflammatory agents known to inhibit platelet function; treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and/or cilostazol (Pletal) is also not allowedXx_NEWLINE_xXInclusion Criteria:\n\n        Subjects shall be screened according to the following inclusion criteria. An answer of \no\\n        to any inclusion criterion disqualifies a subject from participating in this study.\n\n          -  Patients age: > 18 years\n\n          -  Subject has documented diagnosis of Barrett's esophagus, maximum endoscopic length of\n             no more than C2M5 (i.e. no more than 2cm of circumferential extent and no more than\n             5cm of tongues) containing HGD/EC as follows:\n\n          -  HGD or EC documented on biopsy within previous 6 months from enrollment\n\n          -  Histology slides reviewed at central pathology service for ERADICATE Trial confirm\n             HGD/EC.\n\n          -  Endoscopically visible lesion/area/pattern in a patient with HGD/EC either by high\n             definition white light endoscopy, narrow band imaging, confocal laser endomicroscopy,\n             or another enhanced imaging tool.\n\n          -  Ability to take oral proton pump inhibitor\n\n          -  For female subjects of childbearing potential, a negative urine pregnancy test within\n             2 weeks of enrollment and any subsequent endoscopy encounter\n\n          -  Subject is eligible for treatment and follow-up endoscopy and biopsy as required by\n             the investigational plan\n\n          -  Ability to discontinue aspirin/NSAIDs/Clopidogrel 7 days before and after all ablation\n             procedures\n\n          -  Ability of provide written, informed consent and understands the responsibilities of\n             trial participation NOTE: At the Kansas City Veterans Hospital, participants must be\n             eligible for care at the VA in order to be enrolled. Other sites listed are able to\n             enroll non-veterans.\n\n        Exclusion Criteria:\n\n        Subjects shall be screened according to the following exclusion criteria. An answer of\n        \yes\ to any exclusion criterion disqualifies a subject from participating in this study.\n\n          -  Extent of BE >C2M5\n\n          -  The subject is pregnant or planning a pregnancy during the study period (12 months\n             after treatment)\n\n          -  Esophageal stricture preventing passage of endoscope or catheter\n\n          -  Active erosive esophagitis\n\n          -  History of malignancy of the esophagus, esophageal varices or coagulopathy\n\n          -  Prior radiation therapy to the esophagus, except head and neck region radiation\n             therapy.\n\n          -  Any previous ablation therapy within the esophagus (photodynamic therapy, multipolar\n             electrocoagulation, argon plasma coagulation, laser treatment, or other)\n\n          -  Any previous EMR in the esophagus\n\n          -  Any previous esophageal surgery, including fundoplication\n\n          -  Evidence of esophageal varices during treatment endoscopy\n\n          -  Subject has a life-expectancy of less than two years due to an underlying medical\n             condition\n\n          -  Subject has a known history of unresolved drug or alcohol dependency that would limit\n             ability to comprehend or follow instructions related to informed consent,\n             post-treatment instructions, or follow-up guidelines\n\n          -  Subject has an implantable pacing device (examples: Implantable cardiac defibrillator,\n             neurostimulator, cardiac pacemaker) and has not received clearance for enrollment in\n             this study by specialist responsible for the pacing device\n\n          -  The subject is currently enrolled in an investigational drug or device trial that\n             clinically interferes with the ERADICATE trial.\n\n          -  Subject suffers from psychiatric or other illness deemed by the investigator as an\n             inability to comply with protocolXx_NEWLINE_xXIf there is a history of prior malignancies other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.Xx_NEWLINE_xXPatients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to the start of the study treatment (i.e., D1 of Cycle 1)Xx_NEWLINE_xXPrior treatment with drugs of the immunotoxin classXx_NEWLINE_xXTREATMENT: Patients with no more than 3 intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for the study, provided there is no evidence of active disease for at least 2 months and no requirement for anticonvulsant therapy or steroids following treatmentXx_NEWLINE_xXTREATMENT:Xx_NEWLINE_xXHas never received cetuximab or panitumumab, and has not received any treatment for colorectal cancer within 30 days prior to the first dose of study treatment under this protocol;Xx_NEWLINE_xXENROLLMENT INTO THE TREATMENT ARMS:Xx_NEWLINE_xXDocumented progression on (a) at least one prior hormone treatment, which must have incorporated LH-RH agonist therapy AND (b) at least one chemotherapy regimen, which must have been taxane based; progression may be demonstrated by ) or radiologic criteria (defined by radiologic documentation of a new lesion or a >= 20% increase in the sum of the diameters of previously noted measurable lesions) or by PSA (defined by a 25% increase in the PSA from its most recent treatment nadir, confirmed with a second measurement at least 4 weeks later) only if accompanied by new or worsening symptoms (pain progression)Xx_NEWLINE_xXPresence of an active infection or fever >= 38.5 C within 3 days of the first scheduled protocol treatmentXx_NEWLINE_xXPrior treatment with AN-152Xx_NEWLINE_xXParticipants may be treatment naive, refractory to or intolerant of one or more prior therapies, or treated with prior systemic treatment including but not limited to liposomal doxorubicinXx_NEWLINE_xXAny steroid treatment except for that required for replacement therapy in adrenal insufficiency, topical or injected testosterone for hypogonadism, or inhaled steroids for the treatment of asthmaXx_NEWLINE_xXPrevious local therapy of any KS-indicator lesion unless the lesion has clearly progressed since that local treatment; any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesionXx_NEWLINE_xXParticipants with diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months, or any other intercurrent medical condition that contraindicates treatment with sEphB4-HSA or places the participant at undue risk for treatment related complicationsXx_NEWLINE_xXTreatment with therapeutic oral or IV antibiotics within 2 weeks prior to the first dose of study treatmentXx_NEWLINE_xXHistory of prior significant toxicity or intolerance to BCG requiring discontinuation of treatmentXx_NEWLINE_xXPrior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapiesXx_NEWLINE_xXPrevious treatment with mTOR inhibitors, or exemestane for advanced disease.Xx_NEWLINE_xXPatients on the Phase II portion only must be willing to undergo pre- and post-treatment biopsies and have at least one lesion amenable to biopsyXx_NEWLINE_xXHave received at least one prior course of treatment for ccRCC. Part C only: Prior treatment must include at least 1 course of VEGF-directed therapy.Xx_NEWLINE_xXReceived an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.Xx_NEWLINE_xXFor obinutuzumab + polatuzumab vedotin + venetoclax treatment group, relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cluster of differentiation 20 (CD20) (anti-CD20) monoclonal antibody (mAb) and for which no other more appropriate treatment option exists, as determined by the investigatorXx_NEWLINE_xXFor rituximab + polatuzumab vedotin + venetoclax treatment group, relapsed or refractory DLBCL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 mAb and for which no curative option exists as determined by the investigatorXx_NEWLINE_xXPrior treatment with bicalutamide will not be allowedXx_NEWLINE_xXInclusion Criteria:\n\n        Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Subject is ? 60 years of age at the time of signing the ICF\n\n          2. Subject has primary (ie, de novo) or secondary (progression of MDS or\n             myeloproliferative neoplasms ([MPN], or therapy-related) AML according to WHO\n             classification (Appendix B)\n\n          3. Subject has received second- or third-line of AML therapy (see Appendix G for the\n             definition of prior AML line; note that, for subjects having AML secondary to prior\n             higher risk [Intermediate-2 or High risk according to the International Prognostic\n             Scoring System] MDS treated with a hypomethylating agent [eg, azacitidine or\n             decitabine], the hypomethylating therapy can be counted as a line if there is disease\n             progression to AML during or shortly [eg, within 60 days] after the hypomethylating\n             therapy.)\n\n          4. Subject has the following disease status:\n\n               1. Refractory to or relapsed after second- or third-line of intensive therapy for\n                  AML (eg, the \7 + 3\ regimen):\n\n                  at least 5% leukemic blasts in bone marrow (the minimum number of treatment\n                  cycles of the intensive therapy is per the investigator's discretion); or\n\n               2. Refractory to or relapsed after second- or third-line low-intensity AML therapy\n                  (eg, LDAC, azacitidine or decitabine):\n\n             at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles\n\n          5. Subject is eligible for and willing to receive the pre-selected CCR treatment option,\n             according to the investigator's assessment (Note: Subjects with degenerative and toxic\n             encephalopathies, especially after the use of methotrexate or treatment with ionizing\n             radiation, should not receive cytarabine.)\n\n          6. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n             (Appendix D)\n\n          7. Subject has IDH2 gene mutations tested centrally (using the \investigational use\n             only\PCR assay, Abbott RealTime IDH2) in samples of bone marrow aspirate and\n             peripheral blood, and confirmed positive in bone marrow aspirate and/or peripheral\n             blood. (Note: in the event that the central laboratory result is delayed and precludes\n             acute clinical management of a subject who has confirmed IDH2 gene mutation by local\n             evaluation, the subject may be eligible for randomization with approval by the Medical\n             Monitor.)\n\n          8. Subject has adequate organ function defined as:\n\n               -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT)\n                  and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ? 3\n                  x upper limit of normal (ULN), unless considered due to leukemic organ\n                  involvement, following review by the Medical Monitor; and\n\n               -  Serum total bilirubin ? 1.5 x ULN, unless considered due to Gilbert's syndrome\n                  (eg, a gene mutation in UGT1A1) or leukemic organ involvement, following review\n                  by the Medical Monitor; and\n\n               -  Creatinine clearance > 30 mL/min based on the Modification of Diet in Renal\n                  Disease (MDRD) glomerular filtration rate (GFR):\n\n             GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-1.154 × (Age)-0.203 × (0.742 if\n             female) × (1.212 if African American)\n\n          9. Females of childbearing potential (FCBP)* may participate, providing they meet the\n             following conditions:\n\n               -  Agree to practice true abstinence from sexual intercourse or to use highly\n                  effective contraceptive methods (eg, combined [containing estrogen and\n                  progestogen] or progestogen-only associated with inhibition of ovulation, oral,\n                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral\n                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or\n                  male partner sterilization [note that vasectomized partner is a highly effective\n                  birth control method provided that partner is the sole sexual partner of the FCBP\n                  trial participant and that the vasectomized partner has received medical\n                  assessment of the surgical success]) at screening and throughout the study, and\n                  for 4 months following the last study treatment (6 months following the last dose\n                  of cytarabine); and\n\n               -  Have a negative serum ?-subunit of human chorionic gonadotropin (?-hCG) pregnancy\n                  test (sensitivity of at least 25 mIU/mL) at screening; and\n\n               -  Have a negative serum or urine (investigator's discretion under local\n                  regulations) ?-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72\n                  hours prior to the start of study treatment in the Treatment Phase (note that the\n                  screening serum pregnancy test can be used as the test prior to the start of\n                  study treatment in the Treatment Phase if it is performed within the 72-hour\n                  timeframe).\n\n         10. Male subjects must agree to practice true abstinence from sexual intercourse or to the\n             use of highly effective contraceptive methods (as described above) with non-pregnant\n             female partners of childbearing potential at screening and throughout the course of\n             the study, and should avoid conception with their partners during the course of the\n             study and for 4 months following the last study treatment (6 months following the last\n             dose of cytarabine; 6 months following the last dose of azacitidine in Canada)\n\n         11. Subject must understand and voluntarily sign an ICF prior to any study-related\n             assessments/procedures being conducted\n\n         12. Subject is willing and able to adhere to the study visit schedule and other protocol\n             requirements\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a subject from enrollment:\n\n          1. Subject is suspected or proven to have acute promyelocytic leukemia based on\n             morphology, immunophenotype, molecular assay, or karyotype\n\n          2. Subject has AML secondary to chronic myelogenous leukemia\n\n          3. Subject has received a targeted agent against an IDH2 mutation\n\n          4. Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to\n             the start of study treatment. Note that hydroxyurea is allowed prior to the start of\n             study treatment for the control of leukocytosis (however, hydroxyurea should not be\n             given within 72 hours prior to and after administration of azacitidine).\n\n          5. Subject has received non-cytotoxic or investigational agents < 14 days or 5\n             half-lives, whichever is longer, prior to the start of study treatment\n\n          6. Subject has undergone HSCT within 60 days prior to the start of study treatment, or on\n             immunosuppressive therapy post HSCT at the time of screening, or with clinically\n             significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroid\n             post-HSCT and/or topical steroids for ongoing skin GVHD is permitted.\n\n          7. Subject has persistent, clinically significant non-hematologic toxicities from prior\n             therapies\n\n          8. Subject has or is suspected of having central nervous system (CNS) leukemia.\n             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is\n             suspected during screening.\n\n          9. Subject has active uncontrolled systemic fungal, bacterial, or viral infection\n             (defined as ongoing signs/symptoms related to the infection without improvement\n             despite appropriate antibiotics, antiviral therapy, and/or other treatment)\n\n         10. Subject has immediately life-threatening, severe complications of leukemia such as\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\n             intravascular coagulation\n\n         11. Subject has significant active cardiac disease within 6 months prior to the start of\n             study treatment, including New York Heart Association (NYHA) class III or IV\n             congestive heart failure (Appendix E); acute coronary syndrome (ACS); and/or stroke;\n             or left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or\n             multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of\n             study treatment\n\n         12. Subject has prior history of malignancy, other than MDS, MPN or AML, unless the\n             subject has been free of the disease for ? 1 year prior to the start of study\n             treatment.\n\n             However, subjects with the following history/concurrent conditions are allowed:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix\n\n               -  Carcinoma in situ of the breast\n\n               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,\n                  node, metastasis clinical staging system)\n\n         13. Subject is known seropositive or active infection with human immunodeficiency virus\n             (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\n\n         14. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other\n             conditions that limit the ingestion or gastrointestinal absorption of drugs\n             administered orally\n\n         15. Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or\n             diastolic BP > 100 mmHg)\n\n         16. Subject is a pregnant or lactating female\n\n         17. Subject has known or suspected to have hypersensitivity to any of the components of\n             study treatment\n\n         18. Subject is taking those medications (listed in Section 8.2) that are known to prolong\n             QT interval unless the subject can be transferred to other medications at least 5\n             half-lives prior to the start of study treatment\n\n         19. Subject has QTc interval (ie, Fridericia's correction [QTcF]) ? 450 ms or other\n             factors that increase the risk of QT prolongation or arrhythmic events (eg, heart\n             failure, hypokalemia, family history of long QT interval syndrome) at screening\n\n         20. Subject is taking the following sensitive CYP substrate medications that have a narrow\n             therapeutic range are excluded from the study unless the subject can be transferred to\n             other medications at least 5 half-lives prior to the start of study treatment:\n             paclitaxel and docetaxel (CYP2C8), phenytoin (CYP2C9), S-mephenytoin (CYP2C19),\n             thioridazine (CYP2D6), theophylline, and tizanidine (CYP1A2)\n\n         21. Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive\n             substrate rosuvastatin should be excluded from the study unless the subject can be\n             transferred to other medications at least 5 half-lives prior to the start of study\n             treatment\n\n         22. Subject has any significant medical condition, laboratory abnormality, or psychiatric\n             illness that would prevent the subject from participating in the study\n\n         23. Subject has any condition including the presence of laboratory abnormalities, which\n             places the subject at unacceptable risk if he/she were to participate in the study\n\n         24. Subject has any condition that confounds the ability to interpret data from the studyXx_NEWLINE_xXPatients may have had treatment for an unlimited number of prior relapsesXx_NEWLINE_xXPHASE II COHORT A: Patients must have metastatic/recurrent histologically confirmed NSCLC that harbors an EGFR activating mutation (exon 21 L858R, exon 19 deletion, exon 18 G719X, exon 21 L861Q) with stable disease by RECIST 1.1 as best response on erlotinib compared to pre-treatment erlotinib imaging by RECIST 1.1 or progressive disease compared to pre-treatment imaging by RECIST 1.1 after a minimum duration of treatment on erlotinib of 12-weeks; patients must be enrolled within 6 months of initiation of erlotinibXx_NEWLINE_xXPrior treatment with albumin-bound paclitaxel or gemcitabineXx_NEWLINE_xXFor Part 3, the patient has not received prior treatment with a TKI.Xx_NEWLINE_xXMust be within 75 days of completion of first-line treatment regimen; must have achieved complete response (CR/unconfirmed complete response [CRu]) to first-line treatmentXx_NEWLINE_xXIf CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or a slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; for CRu, some patients will have a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often difficult to ascertain whether this represents a residual nidus of tumor or scar tissue; if the abnormality does not change or slowly involutes without therapy and corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeksXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\r\n* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPatients with malignant pleural disease (MPD), pathologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC) (radiographic confirmation is acceptable for screening phase eligibility), and defined as one of the following (patients who have not yet received treatment may enroll in the screening portion only):\r\n* Malignant pleural mesothelioma – previously treated with at least one prior treatment regimen\r\n* Non-small cell lung cancer metastatic to the pleura—previously treated with at least one prior treatment regimen (chemotherapy, surgery, or targeted agent) and documented progression of disease; patients with disease outside of the pleura will be discussed among study principal investigator (PI) and Co-Pls prior to considered eligible for the study; disease outside of the pleura must not require any immediate therapy per PI’s discretion\r\n* Breast cancer metastatic to the pleura— previously treated with at least one prior treatment regimen (chemotherapy, surgery or targeted agent) and documented progression of disease; patients with disease outside of the pleura will be discussed among study PI and Co-Pls prior to considered eligible for the study; disease outside of the pleura must not require any immediate therapy per PI’s discretionXx_NEWLINE_xXKnown active infection requiring antibiotic treatment before the start of treatment (day 0)Xx_NEWLINE_xXPrior treatment with enzalutamide.Xx_NEWLINE_xXSerum cholesterol < ULN with or without treatment for hyperlipidemia; if > ULN and untreated, may be rescreened for eligibility after treatmentXx_NEWLINE_xXOther non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude treatment with any of the treatment regimens or would prevent required follow-upXx_NEWLINE_xXPrior histone deacetylases (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors or valproic acid for the treatment of cancerXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPHASE II – GROUP B: Progressive disease must have occurred on abiraterone within the prior 12 months and patient has not received treatment with enzalutamideXx_NEWLINE_xXAll pre-treatment laboratory tests and scans must be performed within 14 days prior to initiation of treatmentXx_NEWLINE_xXHaving chronic hepatitis B or C will not exclude patients from participating if they are otherwise eligible; however, requiring treatment with interferon is an exclusion; patients must be stable without having received interferon in at least 4 weeksXx_NEWLINE_xXTreatment of cGVHD with anti-thymocyte globulins (ATG), or campath within 60 days of screening visit unless used for treatment of acute GVHDXx_NEWLINE_xXTreatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-0610. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of CPI-0610 may be permitted in patients with rapidly progressive myeloma, following discussion with the medical monitorXx_NEWLINE_xXTreatment with medications that are known to carry a risk of Torsades de PointesXx_NEWLINE_xXPrior treatment with MMBXx_NEWLINE_xXPatient has failed to respond to steroid treatment, with failure to respond defined as any Grade B-D (IBMTR grading) acute GVHD that shows progression within 3 days, or no improvement within 7 consecutive days, of treatment with 2 mg/kg/day methylprednisolone or equivalent.Xx_NEWLINE_xXPatient has received systemic agents other than steroids and prophylactic agents for primary treatment of acute GVHD.Xx_NEWLINE_xXPatient has had prior treatment with mesenchymal stem cells (MSCs), including remestemcel-L.Xx_NEWLINE_xXWillingness to undergo pre-treatment and on-treatment biopsy.Xx_NEWLINE_xXPrior treatment with TNFRSF agonists.Xx_NEWLINE_xXPrior treatment with more than 3 lines of cytostatic therapies for metastatic disease unless specifically agreed between investigator and sponsor. Subjects with a history of any prior Grade =/> 3 toxicity associated with taxane treatment will be excluded.Xx_NEWLINE_xXNeed for ongoing treatment with an immunosuppressive agent.Xx_NEWLINE_xXAntibiotic allergies that would preclude treatment for a C. novyi-NT infection.Xx_NEWLINE_xXPrior treatment with interferon alfa is allowedXx_NEWLINE_xXRequires initiation of daily PE treatment and has received 1 PE treatment prior to randomizationXx_NEWLINE_xXSubjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknownXx_NEWLINE_xXPatients who are on (or will require) prolonged systemic corticosteroid treatment during the study, except for:Xx_NEWLINE_xXtopical applications for treatment of e.g., rash, inhaled sprays for treatment of e.g., obstructive airways diseases, eye drops or local Protocol No. PQR309-003 Protocol Amendment 3, 23 September 2015 PIQUR Therapeutics AG - Confidential Page 15 of 108 injections (e.g., intra-articular);Xx_NEWLINE_xXPrevious treatment for MDS or MPN for dose escalation cohortsXx_NEWLINE_xXPrior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatmentXx_NEWLINE_xXPrior treatment with a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC)Xx_NEWLINE_xXHave an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment.Xx_NEWLINE_xXHave received previous treatment with ramucirumab or LY2875358, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.Xx_NEWLINE_xXTreatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;Xx_NEWLINE_xXSubject has had prior treatment with cabozantinibXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXPrior treatment with a CD33 antibodyXx_NEWLINE_xXPrior sunitinib treatment.Xx_NEWLINE_xXPrior treatment with mirvetuximab soravtansineXx_NEWLINE_xX< 60 days from ASCT; has chronic graft-versus host disease (GVHD) or requires continued treatment with systemic immunosuppressive agentsXx_NEWLINE_xXDiagnosis must be confirmed clinically at baseline with 1-2 lesions having been biopsied no sooner than 2 weeks prior to treatmentXx_NEWLINE_xXCurrently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracil, ingenol mebutate (picato) to the selected treatment lesion sitesXx_NEWLINE_xXNot a candidate for treatment with rituximab as a single-agentXx_NEWLINE_xXAny prior treatment with rituximabXx_NEWLINE_xXSubjects must be able to safely be on lithium carbonate treatment for a period of at least four weeks prior to the scheduled prostatectomyXx_NEWLINE_xXPatients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatmentXx_NEWLINE_xXConditions that could interfere with treatment and proceduresXx_NEWLINE_xXPrior treatment with ANG1005/GRN1005Xx_NEWLINE_xXReceived AT treatment within the last 3 months prior to Screening visit.Xx_NEWLINE_xXNSCLC that has failed crizotinib treatmentXx_NEWLINE_xXPrior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxelXx_NEWLINE_xXPatients must have already received or refused 1st-line treatmentXx_NEWLINE_xXPatient has had previous treatment with the study drug or other WT1-related vaccine therapy.Xx_NEWLINE_xXScheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.Xx_NEWLINE_xXScheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.Xx_NEWLINE_xXPart 3: Patients must have target (?2 cm diameter) or non-target lesion cancer that is accessible for core biopsies before starting on study and after one cycle of treatment.Xx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug.Xx_NEWLINE_xXStable brain metastasis (defined as asymptomatic and off steroids ?3 months) are permitted in subjects entering LPT112515 on second-line treatment (completed 12-24 weeks of second-line treatment with trastuzumab plus chemotherapy)Xx_NEWLINE_xXConcurrent treatment with protocol-defined prohibited medications (refer to protocol for details)Xx_NEWLINE_xXThe complete set of baseline radiographic images must be available before treatment initiation.Xx_NEWLINE_xXEligible and agreeable for percutaneous biopsy of a primary or metastatic lesion prior to treatment and after approximately 16 weeks of treatmentXx_NEWLINE_xXClinically active or unstable graft-versus-host disease (GvHD) requiring treatment which precludes administration of chemotherapy as defined in this protocolXx_NEWLINE_xXPrior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKIXx_NEWLINE_xXPrior treatment with trastuzumab, pertuzumab, and T-DM1, either alone or in combination, is required.Xx_NEWLINE_xXPatient must be eligible for treatment with enzalutamideXx_NEWLINE_xXNo previous treatment with chemotherapy for AML, other than hydroxyurea; previous treatment with hypomethylating agents is acceptableXx_NEWLINE_xXPatients with metal implants less than 5 cm from the treatmentXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXSubject has unavoidable concomitant treatment with any drug known for causing Torsades de Pointes.Xx_NEWLINE_xXProgressive disease (PD) while receiving AR targeted therapy with abiraterone acetate or enzalutamide within 12 months of treatment initiation (?12 months) by at least one of the following:Xx_NEWLINE_xXContraindications to the use of corticosteroid treatment.Xx_NEWLINE_xXPrevious treatment defined as follows:\r\n* Previous participation in this study\r\n* Previous radiotherapy to the site of vertebroplasty prior to study enrollment\r\n* Samarium therapy at any previous timeXx_NEWLINE_xXGrade 3 (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol 8400-401.Xx_NEWLINE_xXRequires administration of a prohibited medication or treatment;Xx_NEWLINE_xXPrior treatment with selinexorXx_NEWLINE_xXCurrent treatment with steroidsXx_NEWLINE_xXStudy patients must have disease that is amenable to pre and post treatment biopsy and be willing to undergo thisXx_NEWLINE_xXSubject has not received fosbretabulin treatment in the study OX4218sXx_NEWLINE_xXPhase II only: Prior treatment with RAF inhibitors, Wnt pathway inhibitors, cetuximab, panitumumab, and/or other EGFR inhibitorsXx_NEWLINE_xXPrior crenolanib treatment for a non-leukemic indicationXx_NEWLINE_xXResponse to previous RELHEM2 treatment: at least resistant disease with clinical benefit or better responseXx_NEWLINE_xXHas received prior treatment with ONT-10 or varlilumab, or prior treatment with other MUC1 vaccines or CD27-targeted agentsXx_NEWLINE_xXPrevious treatment with azacitidine (any formulation), decitabine, any other hypomethylating agent.Xx_NEWLINE_xXTherapeutic treatment with Coumadin or any other coumarin-derivative anticoagulantXx_NEWLINE_xXMust not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment.Xx_NEWLINE_xXPart A: Progression of disease (RECIST 1.1) while on continuous treatment with single EGFR TKI or for histology other than adenocarcinoma and without prior EGFR TKI treatment: progression of disease (RECIST v1.1) on platinum-based chemotherapy. Part B: Progression of disease (RECIST v1.1) while on continuous treatment with single agent of the second generation irreversible EGFR TKI (e.g. afatinib or dacomitinib)Xx_NEWLINE_xXNo intervening systemic therapy between cessation of EGFR TKI and study treatmentXx_NEWLINE_xXPart A only: For patient who has been treated with afatinib: last treatment at reduced dose below the assigned dose levelXx_NEWLINE_xXMore than 2 prior EGFR TKI treatment regimens for Part BXx_NEWLINE_xXRequiring treatment with any of the prohibited concomitant medicationsXx_NEWLINE_xXPrevious treatment with EGFR TKI which cannot be documented as either reversible or irreversible (Part B only)Xx_NEWLINE_xXPart B only: Prior treatment with third generation irreversible EGFR TKI (e.g. AZD9291 or CO-1686)Xx_NEWLINE_xXContraindication to potential treatment agentsXx_NEWLINE_xXPatients has received prior treatment with LEE011.Xx_NEWLINE_xXPrior treatment with any drugs or therapies that will be administered during the course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or the conventional molecularly targeted agent intended for use as standard of care treatment.Xx_NEWLINE_xXPatient has received prior treatment with ceritinib.Xx_NEWLINE_xXPatients must be accessible for treatment and follow up.Xx_NEWLINE_xXProtocol treatment is to begin within 2 working days of patient randomization.Xx_NEWLINE_xXPrior treatment with BBI608.Xx_NEWLINE_xXAny active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.Xx_NEWLINE_xXAble to initiate study treatment within 2 weeks of completion of last chemoradiation treatment;Xx_NEWLINE_xXParticipants with glioblastoma are eligible for this study; these will include\r\n* Those with a histologically proven diagnosis of glioblastoma who have developed new changes on MRI following primary treatment\r\n* Those who received primary treatment for a histologically proven lower grade (2 or 3) glioma and who now progress with radiographic characteristics of transformed gliomaXx_NEWLINE_xXPrevious treatment with nintedanibXx_NEWLINE_xXTherapeutic Options: Patients must be ineligible or inappropriate for other treatment regimens known to have curative potential.Xx_NEWLINE_xXPrior treatment with a compound of the same mechanismXx_NEWLINE_xXTreatment with any systemic antineoplastic therapy or investigational products within 21 days before the first dose of study treatment.Xx_NEWLINE_xXpatient had been permanently discontinued from oral dovitinib study treatment, either alone or in combination with fulvestrant, in the parent studyXx_NEWLINE_xXPatients who have neuromuscular or muscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are known to cause rhabdomyolysis (such as statins and fibrates), and that cannot be discontinued at least 2 weeks prior to starting LDE225; if it is essential that the patient stays on a statin for hyperlipidemia, only pravastatin may be used with extra caution; patients should not plan to embark on a new strenuous exercise regimen after initiation of study treatment; (nota bene [NB]: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatment)Xx_NEWLINE_xXPrevious treatment with any anti-CD30 directed therapyXx_NEWLINE_xXChemotherapy (except hydroxyurea or emergent use of single-agent cytarabine for cytoreduction), radiotherapy, biologics, and/or other treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug, unless progressive disease is documented; NOTE: hydroxyurea will be allowed during the first cycle of treatmentXx_NEWLINE_xXPrior treatment with a human DR5 agonist.Xx_NEWLINE_xXOther conditions that could interfere with treatmentXx_NEWLINE_xXTreatment with interferon within 4 weeks prior to first dose of study treatmentXx_NEWLINE_xXBrain metastasis, unless previously treated with surgery or stereotactic radiosurgery and the disease has been confirmed stable (i.e., no increase in lesion size, and stable or decreased doses of corticosteroids) for at least 6 weeks with two consecutive scans prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3). (Enzyme inducing anticonvulsants are not allowed while subjects are on study treatment. Prior whole-brain radiation as adjuvant treatment is allowed.)Xx_NEWLINE_xXAny number of prior chemotherapies or biological therapies are allowed, patients are required to have prior treatment with pertuzumab and ado-trastuzumab emtansine with the exceptions listed below: \r\n* Metastatic patients who have not received prior pertuzumab are eligible if: heavily pretreated prior to Food and Drug Administration (FDA) approval of pertuzumab (08-June-2012) for first line treatment of HER2+ MBC\r\n* Metastatic patients who have not received ado-trastuzumab emtansine are eligible if: heavily pretreated prior to FDA approval of ado-trastuzumab emtansine (22-Feb-2013) for the treatment of patients with HER2+ MBC who previously received trastuzumab and a taxane, separately or in combinationXx_NEWLINE_xXTreatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)Xx_NEWLINE_xXPatient is deemed by the investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up)Xx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXMay be systemic naïve or received up to two previous systemic treatment regimens for metastatic melanoma.Xx_NEWLINE_xXTreatment with stereotactic radiosurgery or treatment with whole-brain radiation within treatment specific timeframe.Xx_NEWLINE_xXWilling to undergo pre-treatment lesion biopsy and post-treatment lesion biopsyXx_NEWLINE_xXPrior treatment with dalantercept or other agent targeting the ALK1 pathway.Xx_NEWLINE_xXPrior treatment with sorafenib or other RAF/VEGF targeted therapies.Xx_NEWLINE_xXAny therapeutic regimen for treatment of recurrent tumor after first line treatment with surgery, radiation and temozolomide.Xx_NEWLINE_xXPrior treatment with bevacizumab or an experimental anti-angiogenic agent.Xx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXHas >= Grade 2 persistent non-hematological toxicity related to the transplant. Donor lymphocytes infusion (DLI) is not permitted <= 30 days prior to study registration or during the first cycle of treatment on the study in Cohort 1 and first two cycles of the treatment in Cohort 2Xx_NEWLINE_xXNSCLC that has progressed on prior treatmentXx_NEWLINE_xXHas the subject elected not to undergo treatment with the Gliadel® wafer?Xx_NEWLINE_xXAntimicrobial treatment active against CDAD administered for > 24 hours except for metronidazole treatment failures (MTF)Xx_NEWLINE_xXNo other drug treatment for malignant melanoma administered after completing study treatment with trametinibXx_NEWLINE_xXPatients enrolling on the retreatment cohort must have locally and systemically stable disease following the definite local treatment.Xx_NEWLINE_xXPrior treatment with RegorafenibXx_NEWLINE_xXPrior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximabXx_NEWLINE_xXKnown significant dose delays during prior treatment with a taxane due to drug-related toxicitiesXx_NEWLINE_xXPrior HER3- directed treatment (HER2- or EGFR-directed treatment is acceptable).Xx_NEWLINE_xXPrior treatment with Gliadel wafer is allowed if it has been at least 3 months from placementXx_NEWLINE_xXTime to treatment failure from doxorubicin containing regimen ? 12 months if previously treated with doxorubicin.Xx_NEWLINE_xXPrior vemurafenib treatmentXx_NEWLINE_xXHypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causesXx_NEWLINE_xXPatient has received previous treatment with PI3K inhibitors, lomustine or carboplatin.Xx_NEWLINE_xXPatient has received previous antineoplastic treatment for recurrent GBM (e.g. VEGF inhibitors, cytotoxic agents).Xx_NEWLINE_xXPrevious AML treatment (other than hydroxyurea).Xx_NEWLINE_xXCurrent and continued use during study treatment period of known Breast cancer resistance protein (BCRP) inhibitors or known P-gp inhibitors.Xx_NEWLINE_xXHistory of treatment with an asparaginase agentXx_NEWLINE_xXPrior treatment with IL2 within the last 5 yearsXx_NEWLINE_xXTreatment with any investigational products 21 days prior to treatmentXx_NEWLINE_xXFor subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:Xx_NEWLINE_xXFor subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:Xx_NEWLINE_xXPrior treatment with cabazitaxelXx_NEWLINE_xXTreatment with at least 2 months of abiraterone prior to progressionXx_NEWLINE_xXPrior history of treatment with ABT-263Xx_NEWLINE_xXPatients presenting with untreated cord compression, visceral metastases or those in need of immediate treatment are not eligible (patients with prior treatment and stability will be eligible)Xx_NEWLINE_xXPatients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-C) prior to starting study treatment.Xx_NEWLINE_xXHistory of a decrease in LVEF to < 40% or symptomatic CHF with previous trastuzumab treatmentXx_NEWLINE_xXPrevious treatment with azacitidine or decitabineXx_NEWLINE_xXActive uncontrolled infectious diseases requiring treatmentXx_NEWLINE_xXFor Subjects with recurrent GBM in Arm B, subject has received prior treatment with bevacizumab, nitrosourea, or has secondary GBMXx_NEWLINE_xXFor Subjects with recurrent GBM in Arm C, subject has received prior treatment with bevacizumab, or has secondary GBMXx_NEWLINE_xXHistory of symptomatic pulmonary disease or non-malignant pulmonary disease requiring treatment.Xx_NEWLINE_xXChemotherapy with approved or investigative anticancer therapeutics including steroid therapy within the three weeks prior to first dose (unless enrolling on this study after progression Cancer Molecular Analysis Project [CMAP] compassionate use carfilzomib protocol, in which case subject may proceed with current study treatment on next expected date of treatment)Xx_NEWLINE_xXPrior treatment with AEZS-108.Xx_NEWLINE_xXUse of LHRH agonist or antagonist treatment within 6 months prior to randomization.Xx_NEWLINE_xXConcomitant or recent treatment with other investigational drug (within 4 weeks or 5 elimination half life times prior to anticipated start of study treatment).Xx_NEWLINE_xXApplication of any topical haemostatic material on the resection surface of the liver prior to application of study treatment.Xx_NEWLINE_xXPatients must have evidence of progression of disease during or after last treatmentXx_NEWLINE_xXPatients with a history of prior treatment with ipilimumabXx_NEWLINE_xXReceived treatment with an investigational drug, which has not received regulatory approval for any indication, within 28 days of study treatment with DKN-01Xx_NEWLINE_xXPatients must meet one or more of the following indications for treatment:Xx_NEWLINE_xXPatients must have relapsed or refractory disease after ?1 prior line of treatment.Xx_NEWLINE_xXCurrent treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXPatient has received previous treatment with PI3K inhibitorsXx_NEWLINE_xXAny number of prior treatment regimens are allowedXx_NEWLINE_xXIf epidural catheter was used - the catheter must be removed prior to treatmentXx_NEWLINE_xXSerious active infection at the time of randomization, or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatmentXx_NEWLINE_xXKnown sensitivity or contraindication to any component of study treatmentXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatmentXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatmentXx_NEWLINE_xXTreatment with ritonavir at the time of first dose of study treatment.Xx_NEWLINE_xXTreatment with a cyclical chemotherapy within a period of time that is less than the cycle length used for that treatment prior to first dose of study treatment.Xx_NEWLINE_xXTreatment with any other investigational agents within a period of time that is less than the cycle length used for the treatment or within 28 days (whichever is shorter) prior to first dose of study treatment.Xx_NEWLINE_xXPrior treatment with TRC105Xx_NEWLINE_xXInclusion criteria:\n\n        Part A only:\n\n          1. Patients with histologically confirmed advanced solid tumours that are metastatic or\n             unresectable and for which standard curative or palliative measures do not exist or\n             are no longer effective. Patients who refuse standard therapy are also eligible.\n\n             Part B only:\n\n          2. Pathologically confirmed diagnosis of Stage IV (M1a or b) non-small cell lung cancer\n\n          3. Documented Epidermal Growth Factor Receptor (EGFR) T790M mutation\n\n          4. Progression of disease on a reversible tyrosine kinase inhibitor within 30 days of\n             starting study drug. Loss of exposure to prior EGFR TKI should not be >30 days; any\n             procedural delay in confirmation of progression is to be discussed with the BI\n             Clinical Monitor.\n\n             Parts A and B:\n\n          5. Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n\n          6. Age >/= to 18 years\n\n          7. Eastern Cooperative Group (ECOG) performance status 0-1\n\n          8. Adequate organ function\n\n          9. Recovered from any previous therapy-related toxicity to </= to Grade 1 at study entry\n             (except for stable sensory neuropathy </= Grade 2 and alopecia)\n\n         10. Written informed consent\n\n         11. Ability to take oral medication\n\n        Exclusion criteria:\n\n        Parts A and B:\n\n          1. Chemotherapy, biological therapy, or investigational agents (except erlotinib or\n             gefitinib) within 4 weeks prior to the start of study treatment\n\n          2. Hormonal treatment within 2 weeks prior to the start of study treatment (continued use\n             of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer is\n             permitted)\n\n          3. Radiotherapy within two weeks prior to the start of study treatment (except palliative\n             radiotherapy given for symptom control)\n\n          4. Less than 3 days from prior treatment with gefitinib or erlotinib. Patients with\n             adverse events related to gefitinib or erlotinib must recover to Grade 1 or less to be\n             eligible.\n\n          5. Major surgery within 4 weeks before starting study treatment or scheduled for surgery\n             during the projected course of the study\n\n          6. Known hypersensitivity to afatinib or the excipients of any of the trial drugs\n\n          7. History or presence of clinically relevant cardiovascular abnormalities such as\n             uncontrolled hypertension, congestive heart failure New York Heart Association\n             classification of 3, unstable angina or poorly controlled arrhythmia as determined by\n             the investigator. Myocardial infarction within 6 months prior to starting study\n             treatment\n\n          8. Women of childbearing potential and men who are able to father a child, unwilling to\n             be abstinent or use adequate contraception prior to study entry, for the duration of\n             study participation and for at least 2 months after treatment has ended.\n\n          9. Female patients of childbearing potential who are nursing; are pregnant; are not using\n             an acceptable method of birth control, or do not plan to continue using this method\n             throughout the study; and do not agree to submit to pregnancy testing required by this\n             protocol\n\n         10. Any history of or concomitant condition that, in the opinion of the investigator,\n             would compromise the patient's ability to comply with the study or interfere with the\n             evaluation of the efficacy and safety of the test drug\n\n         11. Previous or concomitant malignancies at other sites, except effectively treated\n             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ\n             or effectively treated malignancy that has been in remission for more than 3 years and\n             is considered to be cured\n\n         12. Required treatment with any of the prohibited medications listed in this protocol that\n             cannot be stopped for the duration of trial participation\n\n         13. Known pre-existing Interstitial Lung Disease\n\n         14. Any history or presence of poorly controlled gastrointestinal disorders that could\n             affect the absorption of the study drug (for example, Crohn's disease, ulcerative\n             colitis, chronic diarrhea, malabsorption) in the opinion of the investigator\n\n         15. Active hepatitis B infection (defined as the presence of Hepatitis B DNA), active\n             hepatitis C infection (defined as the presence of Hepatitis C RNA) and/or known Human\n             Immunodeficiency Virus carrier\n\n         16. Prior participation in a blinded afatinib clinical study, unless permission to unblind\n             was granted in consultation with the Clinical Monitor of the blinded study\n\n         17. Meningeal carcinomatosis\n\n         18. Patients with brain or subdural metastases are not eligible, unless they have\n             completed local therapy and have discontinued use of corticosteroids or have been on\n             stable doses of corticosteroids for at least 4 weeks before starting study treatment.\n             Any symptoms attributed to brain metastases must be stable for at least 4 weeks before\n             starting study treatment\n\n         19. QTc interval > 0.47 seconds as measured during screening proceduresXx_NEWLINE_xXSubjects treated with oral, aerosolized or intravenous (IV) ribavirin for the treatment of PIV. A forty-eight hour (48 hr) wash out period prior to randomization is allowed.Xx_NEWLINE_xXPatients with a history of prior treatment with ipilimumab or dasatinibXx_NEWLINE_xXPatients who require concurrent treatment with any medications or substances that have significant proarrhythmic potential are ineligibleXx_NEWLINE_xX3. Patients must start treatment in the extension protocol within 8 weeks of their last injection administered in the core protocol.Xx_NEWLINE_xXPatients who have received prior treatment with sorafenib are eligible, as long as the sorafenib was not given in combination with cyclosphosphamide and/or topotecan. Patients with tumor relapse/progression while on sorafinib or having dose modifications or experiencing toxicity that required sorafenib to be discontinued are also ineligible to participate in this study.Xx_NEWLINE_xXLocal treatment (e.g., surgery, cryotherapy, laser ablation) to any Study Lesion within 4 weeks of initial study treatmentXx_NEWLINE_xXMust have had no previous systemic anti-cancer treatment, though previous loco-regional therapy is allowed: a. Prior treatment with any of the following is allowed: trans-arterial embolization, trans-arterial chemo-embolization, percutaneous ethanol injection, radio-embolization, radio-frequency ablation, or other ablation techniques.Xx_NEWLINE_xXPrevious treatment with sorafenibXx_NEWLINE_xXThe patient previously received treatment with SL-401.Xx_NEWLINE_xXCompleted at least 12 weeks of prior continuous therapy with enzalutamide. A 2 week or less treatment (enzalutamide) holiday will be permitted prior to initiating study treatment.Xx_NEWLINE_xXExposure to more than 4 investigational medicinal products within 12 months prior to the first dose of study treatmentXx_NEWLINE_xX(summarized due to limitation of characters)\n\n        Inclusion Criteria:\n\n          1. Written informed consent\n\n          2. Aged at least 18 years (20 years for Japan)\n\n          3. Histological or cytological confirmation diagnosis of EGFRm+ NSCLC. Confirmation from\n             a previous archival sample that the tumour harbours an EGFRm+ known to be associated\n             with EGFR TKI sensitivity.\n\n          4. Radiological documentation of disease progression while on a previous continuous\n             treatment with an EGFR TKI (on the last treatment administered prior to enrolling in\n             the study)\n\n             Part B cMET+ve patients:\n\n               -  No prior treatment with a 3rd generation TKI: at least one prior line of therapy\n                  with 1st or 2nd generation EGFR TKI, but not a 3rd generation (T790M-directed)\n                  EGFR TKI.\n\n               -  Prior treatment with a 3rd generation TKI: at least one prior line of therapy\n                  with a 3rd generation (T790M-directed) EGFR TKI for EGFRm or T790M+ NSCLC.\n\n             Part B cMET-ve patients:\n\n               -  T790M directed EGFR TKI patients only: their immediate prior therapy before entry\n                  into this study must be a T790M directed EGFR TKI.\n\n               -  ?2nd line cohort: patients must have progressed while on treatment with an EGFR\n                  TKI (T790M directed EGFR TKIs are permitted). Other prior lines of therapy may\n                  have been given.\n\n             Part D cMET-ve patients:\n\n             No prior treatment with a 3rd generation TKI, T790M negative:\n\n             Patients must have received at least one prior line of therapy with 1st or 2nd\n             generation EGFR TKI, but not a 3rd generation (T790M directed) EGFR TKI.\n\n          5. cMET status: Prior to study entry, local confirmation of tumour cMET status is\n             acceptable, a central result will be confirmed retrospectively. If a local test is not\n             available, central confirmation of tumour cMET status must be obtained prior to study\n             entry.\n\n             T790M status: Local confirmation of tumour T790M status is acceptable, a central\n             result will be confirmed retrospectively. If local testing is performed with the\n             Cobas® EGFR Mutation Test, the central confirmation is not required.\n\n          6. At least one lesion, not previously irradiated, not biopsied during the screening\n             period, that can be accurately measured at baseline as ?10 mm in the longest diameter\n             (except lymph nodes which must have short axis ?15 mm) with CT or MRI which is\n             suitable for accurate repeated measurements\n\n          7. WHO performance status 0-1 with no deterioration over the previous 2 weeks and minimum\n             life expectancy of 12 weeks\n\n          8. Females should be using adequate contraceptive measures, must not be breast feeding\n             and must have a negative pregnancy test prior to start of dosing if of child-bearing\n             potential or must have evidence of non-child-bearing potential.\n\n        Exclusion Criteria (summary):\n\n          -  Treatment with an EGFR TKI within approximately 5x half-life of the first dose of\n             study treatment. Any cytotoxic chemotherapy, investigational agents or other\n             anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen\n             or clinical study within 14 days of the first dose of study treatment. Patients\n             currently receiving (or unable to stop use) medications or herbal supplements known to\n             be potent inducers of CYP3A4 (at least 3 weeks prior). For AZD6094 patients currently\n             receiving (or unable to stop use at least 2 weeks) prior to receiving the first dose,\n             medications known to be strong inhibitors of CYP1A2. Prior AZD9291 dosing in the\n             present study. Prior or current treatment with AZD6094 or another cMET inhibitor (if\n             allocated to AZD9291 + AZD6094). Radiotherapy with a limited field of radiation for\n             palliation within 1 week of the first dose of study treatment, with the exception of\n             patients receiving radiation to more than 30% of the bone marrow or with a wide field\n             of radiation which must be completed within ?4 weeks of the first dose of study\n             treatment. Major (or anticipated major) surgical procedure (excluding placement of\n             vascular access) or significant traumatic injury within 4 weeks of the first dose of\n             study treatment. Currently receiving treatment with warfarin sodium.\n\n          -  With the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy,\n             any unresolved toxicities from prior therapy and/or pre-study biopsies greater than\n             CTCAE Grade 1 at the time of starting study treatment.\n\n          -  Spinal cord compression or brain metastases unless asymptomatic, stable and not\n             requiring steroids for at least 2 weeks prior to start of study treatment.\n\n          -  Severe or uncontrolled systemic diseases; known serious active infection; active\n             hepatitis B or C; cardiac disease; inadequate bone marrow reserve or organ function or\n             coagulation parameters; inadequate liver or renal function; GI events that would\n             preclude adequate absorption, distribution, metabolism or excretion of AZD9291,\n             AZD6094 or selumetinib; hipersensitivity to IP or similar drugs\n\n          -  Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation\n             pneumonitis which required steroid treatment, or any evidence of clinically active\n             ILD.Xx_NEWLINE_xXAny medications for treatment of left ventricular systolic dysfunction.Xx_NEWLINE_xXPrior treatment with floxuridine (FUDR)Xx_NEWLINE_xXPatients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatmentXx_NEWLINE_xXThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXPrior treatment with cabozantinibXx_NEWLINE_xXPrior treatment with HAI floxuridine (FUDR)Xx_NEWLINE_xXPatients must be accessible for treatment and follow-up; investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-upXx_NEWLINE_xXIn accordance with CCTG policy, protocol treatment is to begin within 3 weeks of patient randomizationXx_NEWLINE_xXRefractory graft versus host disease (GvHD) not responding to treatmentXx_NEWLINE_xXHave received any prior treatment with bevacizumab (Avastin).Xx_NEWLINE_xXTreatment with approved or investigational cancer therapy within 14 days prior to treatment initiationXx_NEWLINE_xXPatient must agree to complete PROs (quality of life [QoL] questionnaire) throughout the study, including after study treatment discontinuation.Xx_NEWLINE_xXPrior treatment with immunomodulators, including toll-like receptor (TLR) agonists, inhibitors of indoleamine 2,3-dioxygenase (IDO)/ tryptophan-2,3-dioxygenase (TDO), or agonists of OX40, is allowed provided that at least 5 half-lives of the drug or a minimum of 3 weeks have elapsed between the last dose of the prior treatment and the proposed Cycle 1, Day 1, with the exception as specified in protocolXx_NEWLINE_xXPhase 1: Subjects who have disease progression after treatment with available therapies.Xx_NEWLINE_xXPrior treatment with AIsXx_NEWLINE_xXPrevious treatment with PI3K inhibitors, AKT inhibitors or fulvestrantXx_NEWLINE_xXHyper sensitivity to fulvestrant treatment excipientsXx_NEWLINE_xXNo prior treatment with temsirolimus or an agent specifically targeting met proto-oncogene (c-Met)Xx_NEWLINE_xXAll patients must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load > 400 copies/mL who have been on antiretroviral therapy for more than 4 months can be enrolled if an alternative ART regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment historyXx_NEWLINE_xXPrevious treatment with vemurafenibXx_NEWLINE_xXPatients who are on concomitant treatment with drugs that are contraindicated in this study and that cannot be discontinued within the time framesXx_NEWLINE_xXPatients who are receiving treatment with statins that are known to cause rhabdomyolysis and that cannot be discontinued at least 2 days prior to starting LDE225 treatmentXx_NEWLINE_xXMentally, physically, and geographically able to undergo treatment and follow upXx_NEWLINE_xXConcurrent or previous treatment with inhibitors of DLL4Xx_NEWLINE_xXHistory of prior significant toxicity from a same class of agents as GDC-0575 or gemcitabine requiring discontinuation of treatmentXx_NEWLINE_xXPatients may not have had more than 7 days of treatment with ketoconazole by mouth in the past 6 monthsXx_NEWLINE_xXProgression on or after endocrine treatmentXx_NEWLINE_xXPrevious treatment with fulvestrantXx_NEWLINE_xXSubjects enrolled into the previously untreated subject cohort must also meet all of the following criteria: No prior treatment for CLL (prior corticosteroid immunosuppression treatment for autoimmune hemolytic anaemia and idiopathic thrombocytopenic purpura (ITP) is permitted); Be considered inappropriate for fludarabine-based therapy for reasons that include, but are not limited to, advanced age or presence of co-morbidities.Xx_NEWLINE_xXDesire to quit smoking, with at least one prior failed quit attempt and willingness to participate in a treatment studyXx_NEWLINE_xXPrevious treatment with any anti-CD30 antibodyXx_NEWLINE_xXTreatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)Xx_NEWLINE_xXPatient may have received initial treatment for GBM as follows:Xx_NEWLINE_xXPatient has received previous treatment with PI3K and/or mTOR inhibitors for GBM or for pre-existing neoplasm transformed to GBM. Patient has received any prior anti-neoplastic therapy for BKM, except for the treatment allowed in inclusion criteriaXx_NEWLINE_xXPrevious treatment with AKT inhibitorsXx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXSerious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatmentXx_NEWLINE_xXRelapsed from or refractory to at least one treatment containing rituximab or another anti-CD20 based immunotherapy combined with anthracycline- or anthracenedione-based chemotherapyXx_NEWLINE_xXAs per national or local treatment guidelines, endocrine therapy (i.e., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not necessary for participants, at time of entry into the study.Xx_NEWLINE_xXPrior treatment with PM01183.Xx_NEWLINE_xXHave previously been enrolled in Study C0328T03 or CNTO328MCD2001 (either treatment arm)Xx_NEWLINE_xXUnmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab studyXx_NEWLINE_xX> 4 weeks since discontinuation of tivozanib treatment on a previous protocolXx_NEWLINE_xXNo treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatmentXx_NEWLINE_xXOne of the following:\r\n* Cytotoxic chemotherapy, alemtuzumab, or an adequate course of 5-azacitidine or decitabine within 3 months prior to start of conditioning; or\r\n* Previous BMT within 6 months prior to start of conditioning\r\n** Note: Patients who have received treatment outside of these windows may be eligible if it is deemed sufficient to reduce graft rejection risk; this will be decided on a case-by-case basis by the PI or co-PIXx_NEWLINE_xXAny number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted.Xx_NEWLINE_xXPrior treatment with pazopanib.Xx_NEWLINE_xXAny serious concomitant illness or infectious disease requiring treatment, or infectious disease not requiring treatment, but with significant risks for myelosuppressive complications associated with chemotherapy.Xx_NEWLINE_xXDISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed\n\n          -  Locally advanced or metastatic non-hematologic malignancies\n\n          -  Measureable\n\n          -  Refractory to standard therapies or single agent gemcitabine is indicated as a\n             standard treatment option\n\n        PRIOR/CONCURRENT THERAPY:\n\n          -  No concurrent radiotherapy, chemotherapy, immunotherapy or other investigational\n             agents\n\n          -  Must have recovered from side effects of prior therapies\n\n        PATIENT CHARACTERISTICS:\n\n        Life expectancy\n\n          -  > 12 weeks\n\n        Performance Status\n\n          -  ECOG 0 or 1\n\n        Bone Marrow Reserve\n\n          -  Absolute Neutrophil count (AGC/ANC) ? 1,500/uL\n\n          -  Platelets ? 100,000/uL\n\n          -  Hemoglobin > 9 g/dL\n\n        Renal Function\n\n          -  Calculated Glomerular filtration rate (GFR) > 59mL/min/1.73M^2\n\n        Hepatic Function\n\n          -  Total bilirubin ? 1.5 X ULN\n\n          -  AST, ALT, and ALP ? 3 X ULN or ? 5.0 x ULN, if liver metastasis exists\n\n          -  PT INR ? 1.5 X ULN\n\n        Cardiovascular\n\n          -  No history of clinically significant vascular disease\n\n          -  No New York Heart Association (NYHA) Class > II heart failure\n\n        Hematologic\n\n          -  No history of bleeding disorders\n\n          -  No evidence of bleeding diathesis or coagulopathy\n\n          -  No presence of clinically significant hemoptysis or hematuria, presence of serious\n             non-healing wound or ulceration, or signs of other bleeding\n\n          -  No evidence of a tumor invasion of any major blood vessel\n\n          -  No trauma with increased risk of life-threatening bleeding or history of severe head\n             trauma or intracranial surgery within two months of study entry\n\n        Surgery/Procedures\n\n          -  No major surgery or open biopsy within 28 days before drug infusion or evidence of\n             active bleeding postoperatively\n\n          -  No plan for any major surgery during treatment period\n\n          -  No presence or requirement of an epidural catheter or lumbar puncture within 48 hours\n             prior to each dose of study treatment\n\n          -  No anticipation of receiving an epidural catheter or a lumbar puncture within 48 hours\n             after each dose of study treatment\n\n        Excluded Medications or Treatment Regimens\n\n          -  Unfractionated heparin of > 15,000 units/day within 8 hours prior to each dose of\n             study treatment\n\n          -  Low-molecular weight heparin at a higher dose than recommended for prophylactic used\n             or required within 20 hours prior to each dose of study treatment\n\n          -  Warfarin used or required within 48 hours prior to each dose of study treatment and\n             the prothrombin time (INR) exceeded the upper limit of normal range\n\n          -  Direct thrombin inhibitors or Xa inhibitors\n\n          -  Acetylsalicylic acid used or required within 72 hours prior to each dose of study\n             treatment\n\n          -  Clopidogrel bisulfate used or required within 48 hours prior to each dose of study\n             treatment\n\n          -  Anticipated requirement for anti-platelet or anti-coagulant agents excluding\n             non-aspirin NSAID within 48 hours following study treatment infusion\n\n        Other\n\n          -  No active systemic infection requiring parenteral antibiotic therapy\n\n          -  No history of or presence of a CNS disease\n\n          -  No history of allergic reactions to compounds of similar chemical or biologic\n             composition\n\n          -  Not HIV positive\n\n          -  No women who are pregnant or nursing\n\n          -  A negative serum pregnancy test if female\n\n          -  Patients, both females and males, with reproductive potential must agree to use\n             effective contraceptive measures for the duration of the study\n\n          -  No history of significant renal, endocrinologic, metabolic, immunologic or hepatic\n             disease\n\n          -  No evidence of psychiatric illness/social situations\n\n          -  Other illness that in the opinion of the investigator would exclude the patient from\n             participating\n\n          -  Must provide informed consent and HIPAA authorization and comply with\n             protocol-specified procedures and follow-up evaluationsXx_NEWLINE_xXIt must be at least 6 months since the last treatment with a \VPLD\ induction/re-induction type regimen (i.e. anthracycline, steroid, asparaginase and vincristine)Xx_NEWLINE_xXPatients in this study may not use vaccines for the treatment of cancer or prevention of disease unless indicated as a component of the protocol regimen (including those for common medical conditions) for up to one month pre and post dosing with ipilimumabXx_NEWLINE_xXSubjects must have undergone prior treatment with ? 2 treatment lines of anti-myeloma therapyXx_NEWLINE_xXSubjects with conditions requiring chronic steroid or immunosuppressive treatmentXx_NEWLINE_xXAt least two prior treatment regimens for chronic lymphocytic leukaemia.Xx_NEWLINE_xXConcurrent treatment with relevant doses of systemic glucocorticosteroids.Xx_NEWLINE_xXAny infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.Xx_NEWLINE_xXPrior treatment with BI 836826.Xx_NEWLINE_xXSubjects who have received prior bendamustine are eligible if they achieved a response (CR/PR) which lasted > 6 months after the end of bendamustine containing treatment.Xx_NEWLINE_xXPrevious treatment with ofatumumab.Xx_NEWLINE_xXPart A2: Unable to swallow tablets. Intolerant of therapy with erlotinib. Concomitant treatment with the cytochrome P450 3A (CYP3A) modulators. Must not have received treatment with any of these modulators within 14 days of study treatment.Xx_NEWLINE_xXReceived previous treatment with any c-MET experimental therapeutic.Xx_NEWLINE_xXCurrent or previous treatment with angiopoietin inhibitors, or inhibitors of Tie1 or Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820Xx_NEWLINE_xXPrior treatment of NSCLC with EGFR TKIs or monoclonal antibodies targeting EGFRXx_NEWLINE_xXPatients who have previously received treatment with LY2940680Xx_NEWLINE_xXInclusion Criteria:\n\n          1. Pathologically documented Stage IV malignant melanoma or unresectable Stage III\n             melanoma for which no standard effective therapy exists or for which an appropriate\n             window exists between alternative therapeutic options. Patients for whom early\n             treatment with vemurafenib is indicated e.g. rapidly progressing or symptomatic\n             disease, are excluded from this trial.\n\n          2. Previous surgery (other than resection of skin metastases), radiotherapy,\n             chemotherapy, immunotherapy or experimental therapy completed >4 weeks before and all\n             adverse events resolved to ? grade 1. In cases where localised radiotherapy has been\n             applied, treatment with IMCgp100 can be commenced after a two week period.\n\n          3. HLA A2 positive.\n\n          4. ? 18 years old.\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status ?1.\n\n          6. Measurable disease according to RECIST 1.1 criteria. Patients participating in the\n             dose escalation part of Arm 2 only require assessable disease.\n\n          7. Life expectancy >3 months.\n\n          8. Blood tests within the following parameters:\n\n               1. Platelet count ?100 x10?/L\n\n               2. Haemoglobin ?9g/dL (blood transfusion to achieve this level is permitted)\n\n               3. Calculated creatinine clearance ?50 mL/min using the modified Cockroft-Gault\n                  equation\n\n               4. Neutrophil count ?1x10?/L\n\n               5. Lymphocyte count ?0.5x10?/L\n\n          9. Female patients of childbearing potential must use maximally effective birth control\n             during the period of therapy, must be willing to use contraception for 6 months\n             following the last study drug infusion and must have a negative urine or serum\n             pregnancy test upon entry into this study. Otherwise, female patients must be\n             postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile.\n\n         10. Male patients must be surgically sterile or willing to use a double barrier\n             contraception method upon enrolment, during the course of the study, and for 6 months\n             following the last study drug infusion.\n\n         11. Patients with a history of adrenal insufficiency, maintained on stable replacement\n             dose corticosteroid (<10 mg/d prednisone or the equivalent) are eligible for treatment\n             with IMCgp100, unless there is a past history of adrenal crisis. Eligible patients\n             with a history of adrenal insufficiency receiving replacement dose corticosteroid must\n             receive prophylactic stress dose corticosteroid prior to dosing during the first four\n             doses of IMCgp100 treatment, regardless of weekly or daily dosing regimen.\n\n         12. Able to give informed consent.\n\n        Exclusion Criteria:\n\n        Patients meeting any of the following criteria will be excluded from the study:\n\n          1. Symptomatic brain metastases that are unstable, require steroids, or that have\n             required radiation within the last 28 days.\n\n          2. Other active malignancy in the past 5 years except carcinoma in situ, completely\n             excised nonmelanomatous skin cancer or any other malignancy that in the opinion of the\n             investigator is considered to be cured.\n\n          3. Comorbid medical condition that would increase the risk of toxicity in the opinion of\n             the investigator or sponsor. Symptomatic on-going infection must be resolved before\n             the patient can be treated in the study.\n\n          4. Uveitis\n\n          5. Had myocardial infarction within 1 year before enrolment, symptomatic congestive heart\n             failure (New York Heart Association >Class II), unstable angina or unstable cardiac\n             arrhythmia requiring medication.\n\n          6. Has an ejection fraction <50%.\n\n          7. Clinically significant electrocardiogram (ECG) changes that obscure the ability to\n             assess the RR, PR and QT intervals. Patients with QTc calculated by Bazetts or locally\n             preferred formula which is greater than 500ms.\n\n          8. Has hepatic function as follows:\n\n               1. Aspartate aminotransferase >2.5 x upper limit of normal (ULN)\n\n               2. Alanine aminotransferase >2.5 x ULN\n\n               3. Bilirubin >2.0 x ULN\n\n               4. Prothrombin time or partial thromboplastin time >1.5 x ULN\n\n          9. Bleeding diathesis.\n\n         10. Immunosuppressive condition or treatment including previous transplantation,\n             splenectomy or known HIV infection.\n\n         11. Has a history of adult seizures.\n\n         12. Patients with evidence of a raised intracranial pressure in Arm 2 of the study who\n             will have a CSF sample taken.\n\n         13. Patients receiving chronic corticosteroid treatment (longer than 8 weeks duration) for\n             management of pre-existing adverse events at any dose, or patients with a history of\n             chronic corticosteroid treatment longer than 8 weeks duration for adverse events\n             within 6 months.Xx_NEWLINE_xXTreatment-related MDSXx_NEWLINE_xXTreatment-related MDSXx_NEWLINE_xXRituximab-sensitive iNHL, defined as a partial or complete response to their last prior treatment with rituximab or a rituximab-containing regimen lasting at least 6 months following completion of rituximab treatment.Xx_NEWLINE_xXOne or more of the following indications for treatment:Xx_NEWLINE_xXPrevious treatment with ofatumumab.Xx_NEWLINE_xXPatients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drugXx_NEWLINE_xXAt least 3 months must have passed since last BCG therapy or intravesical treatment for bladder carcinoma.Xx_NEWLINE_xXsubject elected not to undergo treatment with Gliadel waferXx_NEWLINE_xXIs treatment naive or has received prior treatment for metastatic melanoma.Xx_NEWLINE_xXIf previously treated with bortezomib (alone or in combination), progression during treatmentXx_NEWLINE_xXProgression during the first 3 months of initiating treatmentXx_NEWLINE_xXPrior carfilzomib treatmentXx_NEWLINE_xXCurrent use of a prohibited medication or requires any of these medications during treatment with study drug.Xx_NEWLINE_xXFor patients >= 60 years old: at least one induction chemotherapy treatment or alternative treatment.Xx_NEWLINE_xXIn the investigator's opinion and in compliance with the Institution Hematology Tumor Board's guidances, the patient should not be eligible for any additional chemotherapy treatment before the ASCI treatment.Xx_NEWLINE_xXPatients who are participating in a concurrent treatment protocolXx_NEWLINE_xXNo prior treatment with temsirolimus or everolimus in the phase II component of the study. NOTE: Prior treatment with these agents is permitted in the phase I component of the study.Xx_NEWLINE_xXCurrent diagnosis for depression, including treatment with an SSRI.Xx_NEWLINE_xXHistory of prior treatment with chloroquine for malaria within past 24 months.Xx_NEWLINE_xXAny patient taking hydroxychloroquine for treatment or prophylaxis of malariaXx_NEWLINE_xXhypotension unresponsive to treatment (mean BP < 60 or < 5th % for age),Xx_NEWLINE_xXTreatment with highly active antiretroviral therapy (HAART) for at least 1 monthXx_NEWLINE_xXHistory of arterial thromboembolic disease within 6 months of first study treatmentXx_NEWLINE_xXprior treatment with PF-02341066Xx_NEWLINE_xXNo prior treatment (patients on \watch and wait\ may enter the study if a recent biopsy [obtained within the last 6 months] is available)Xx_NEWLINE_xXPatients must be registered in the University of California at San Francisco (UCSF) Neuro-Oncology database prior to treatment with study drugXx_NEWLINE_xXPrior treatment with taxanes or anthracyclines is required;Xx_NEWLINE_xXConcurrent treatment with bisphosphonates is permitted, however treatment must be initiated prior to the first dose of study therapy;Xx_NEWLINE_xXActive brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants). Dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)Xx_NEWLINE_xXPermanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.Xx_NEWLINE_xXThe participant has a history of treatment with other agents targeting the IGF receptorXx_NEWLINE_xXPatients must be willing to comply with the photosensitivity guidelines for a minimum of six weeks to be in the PDT treatment group (Group 1)Xx_NEWLINE_xXSuitable for either treatment regimen.Xx_NEWLINE_xXNon-malignant disease that would render the patient unsuitable for treatment according to the protocol.Xx_NEWLINE_xXInclusion Criteria:\n\n        A subject will be eligible for inclusion in this study only if all of the following\n        criteria apply:\n\n          -  Subjects must have histologically confirmed invasive breast cancer with Stage IV\n             disease at primary diagnosis or at relapse after curative-intent surgery. Where the\n             disease is restricted to a solitary lesion, the neoplastic nature of the lesion should\n             be confirmed by cytology or histology.\n\n          -  Documented amplification of ErbB2 3+ by immunohistochemistry or a positive score\n             (>2.2) by FISH using a local laboratory result (which will be considered sufficient in\n             this study with no further verification by a central laboratory).\n\n          -  Subjects must have received no more than one prior chemotherapeutic regimen in the\n             metastatic setting.\n\n          -  If a taxane had been administered in the neoadjuvant, adjuvant or metastatic setting,\n             progression must have occurred ?12 months after completion of this treatment.\n\n          -  Prior therapy with radiation for this breast cancer population is permitted if it was\n             administered in the neoadjuvant or adjuvant non metastatic setting. Radiotherapy given\n             in the metastatic setting, prior to initiation of study medication, is allowed to a\n             limited area (e.g., palliative therapy and involving less than 25% of bone marrow), if\n             it is not the sole site of disease. Subjects must have completed radiation treatment\n             and recovered from all acute radiation treatment related toxicities (e.g., bone marrow\n             suppression) prior to commencement of combination treatment.\n\n          -  The subject must have received all prior chemotherapy treatment at least 4 weeks prior\n             to enrollment in this study and must have recovered from all related toxicities.\n             Subjects who have received weekly dose of prior chemotherapy e.g. gemcitabine or\n             capecitabine may enroll 2 to 3 weeks after cessation of treatment provided that they\n             have recovered from all related toxicities.\n\n          -  Prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting is\n             permitted. The subject must have received all prior trastuzumab treatment at least 4\n             weeks prior to enrollment in this study and must have recovered from all related\n             toxicities.\n\n          -  Prior endocrine therapy is permitted in the neoadjuvant or adjuvant or metastatic\n             setting. The subject must have received all prior endocrine treatment at least 1 week\n             prior to enrollment in this study and must have recovered from all related toxicities.\n\n          -  Prior diagnosis of cancer is allowed as long as the subject is free of disease for 5\n             years. Subjects with completely resected basal or squamous cell skin cancer, thyroid\n             cancer or successfully treated cervical carcinoma in-situ will be allowed if it has\n             been 1 year or greater since definitive surgery.\n\n          -  Subjects must have measurable disease, according to Response Evaluation Criteria in\n             Solid Tumors (RECIST) guidelines; defined as at least 1 lesion that can be accurately\n             measured in at least 1 dimension (longest diameter [LD] to be recorded) by mammogram,\n             ultrasound or physical exam [Therasse, 2000].\n\n          -  Subjects with liver metastases or stable chronic liver disease are permitted into the\n             study.\n\n          -  Women ?18 years of age:\n\n          -  Non-child-bearing potential (i.e., women with functioning ovaries who have a current\n             documented tubal ligation or hysterectomy, or women who are postmenopausal); or\n\n          -  Child-bearing potential (i.e., women with functioning ovaries and no documented\n             impairment of oviductal or uterine function that would cause sterility). This category\n             includes women with oligomenorrhoea (severe), women who are perimenopausal and young\n             women who have begun to menstruate. These subjects must provide a negative serum\n             pregnancy test at Screening and agree to 1 of the following:\n\n          -  Complete abstinence from intercourse from 2 weeks prior to administration of the first\n             dose of study medication until 5 days after the final dose of study medication; or\n\n          -  Consistent and correct use of 1 of the following acceptable methods of birth control:\n\n          -  Male partner who is sterile prior to the female subject's entry into the study and is\n             the sole sexual partner for that female subject.\n\n          -  Implants of levonorgestrel.\n\n          -  Injectable progestogen.\n\n          -  Any intrauterine device with a documented failure rate of less than 1% per year.\n\n          -  Oral contraceptives (either combined or progestogen only).\n\n          -  Barrier methods, including diaphragm or condom with a spermicide.\n\n          -  Considered by the Investigator to have a life expectancy of ?6 months.\n\n          -  ECOG Performance Status (PS) of 0 or 1 (Karnofsky ?80%) [Oken, 1982].\n\n          -  Subjects must have normal organ and marrow function as defined in Table 3:\n\n        CONFIDENTIAL UM2007/00382/01 LPT111111 28\n\n          -  Table 3 Baseline Laboratory Values for Adequate Organ Function\n\n          -  Hematologic\n\n          -  Absolute neutrophil count ?1.5 × 10^9/L\n\n          -  Hemoglobin ?9 g/dL\n\n          -  Platelets ?100 × 10^9/L\n\n          -  Hepatic\n\n          -  Serum bilirubin ? upper limit of normal (ULN)\n\n          -  Aspartate aminotransferase and alanine aminotransferase\n\n          -  ?3 × ULN without liver metastases\n\n          -  ?5 × ULN if documented liver metastases\n\n          -  Renal\n\n          -  Serum creatinine ?1.5 mg/dL\n\n          -  OR -\n\n          -  Calculated creatinine clearance ?40 mL/min\n\n          -  Subjects must have a cardiac ejection fraction of >50% as measured by echocardiogram\n             (ECHO) or multigated acquisition scan (MUGA) and within the institutional range of\n             normal.\n\n          -  Subjects with stable central nervous system metastases (stable for at least 3 months)\n             as confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) or\n             evidence of leptomeningeal involvement are eligible only if they are not taking\n             steroids or enzyme-inducing anticonvulsants.\n\n          -  Subject must be free of gastrointestinal diseases that impede swallowing and retaining\n             of oral medications.\n\n          -  Signed, informed consent prior to registration.\n\n          -  Bisphosphonate therapy for bone metastases is allowed; however, treatment must be\n             initiated prior to the first dose of study medication. Prophylactic use of\n             bisphosphonates in subjects without bone disease, except for the treatment of\n             osteoporosis, is not permitted.\n\n          -  Subjects whose disease is estrogen receptor + and/or progesterone receptor + or\n             unknown status will only be included in the study if they meet the following criteria:\n\n          -  They have symptomatic visceral disease that requires chemotherapy.\n\n          -  Significant visceral organ tumor burden\n\n          -  The disease is considered by the Investigator to be progressing rapidly or is life\n             threatening.\n\n          -  Subjects who have received prior endocrine therapy and who are no longer benefiting\n             from this therapy.\n\n        Exclusion Criteria:\n\n        A subject will not be eligible for inclusion in this study if any of the following criteria\n        apply:\n\n          -  Subjects who have received more than one prior chemotherapeutic regimen in the\n             metastatic setting\n\n          -  Subjects taking treatment with medications provided in the list of restricted\n             medications and substances in the drug information section for lapatinib are not\n             eligible for the study (Section 5.11.2). This includes human immunodeficiency\n             virus-positive subjects receiving combination anti-retroviral therapy because of\n             possible pharmacokinetic interactions with lapatinib.\n\n          -  Prior treatment with lapatinib.\n\n          -  Concurrent anticancer or concomitant radiotherapy treatment;\n\n          -  Concurrent treatment with prohibited medications (Section 5.11.2);\n\n          -  Use of an investigational drug within 30 days or 5 half-lives, whichever is longer,\n             preceding the first dose of investigational treatment, or, concurrent treatment with\n             an investigational agent or participation in another clinical trial involving\n             investigational agents.\n\n          -  Known history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to lapatinib or nab-paclitaxel or excipients;\n\n          -  Known history of uncontrolled inter-current illness including, but not limited to,\n             ongoing or active infection, symptomatic congestive heart failure, unstable angina\n             pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements.\n\n          -  Have current active hepatic or biliary disease (with exception of patients with\n             Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver\n             disease per investigator assessment)\n\n          -  Concurrent disease or condition that would make the subject inappropriate for study\n             participation or any serious medical disorder that would interfere with the subject's\n             safety.\n\n          -  Pregnant or lactating females at any time during the study (due to the potential\n             teratogenic or abortifacient effects of lapatinib and breastfeeding).\n\n          -  Subjects with diseases affecting gastrointestinal function resulting in an inability\n             to take oral medication, including; malabsorption syndrome, a requirement for iv\n             alimentation, prior surgical procedures affecting absorption e.g. gastric resection\n             and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis).\n\n          -  Peripheral neuropathy of Grade 2 or greater.\n\n          -  Unresolved or unstable, serious toxicity from prior administration of another\n             investigational drug and/or of prior cancer treatment.\n\n          -  History of prior malignancy. However, subjects who have been disease-free for 5 years,\n             or subjects with completely resected basal or squamous cell skin cancer, thyroid\n             cancer or successfully treated cervical carcinoma in situ will be eligible if it has\n             been at least 1 year since definitive surgery.\n\n          -  or rendering of informed consent.\n\n        Other Eligibility Criteria Considerations:\n\n          -  To assess any potential impact on subject eligibility with regard to safety, the\n             Investigator must refer to the following document(s) for detailed information\n             regarding warnings, precautions, contraindications, AEs, and other significant data\n             pertaining to the investigational product(s) being used in this study: Clinical\n             Investigator's Brochure (IB), SPM, and the nab-paclitaxel Product Label.Xx_NEWLINE_xXLikely to continue to need treatment of OIC for the duration of participation in the study.Xx_NEWLINE_xXPrior treatment with alemtuzumab (Campath) or similar agents or procedures that depress blood T cell counts to below 50% of the lower limit of normal.Xx_NEWLINE_xXThe subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancerXx_NEWLINE_xXAll patients must have completed therapy including intensive induction followed by ASCT and radiotherapy to be eligible for ANBL0032; radiotherapy may be waived for patients who either have small adrenal masses which are completely resected up front, or who never have an identifiable primary tumor; examples of such therapies include:              \r\n* Following treatment per A3973 protocol\r\n* Following treatment per Pediatric Oncology Group (POG)-9341/9342 protocol\r\n* Following treatment per CCG3891\r\n* Following treatment on New Approaches to Neuroblastoma Therapy (NANT) 2001-02\r\n* Enrollment on or following treatment per ANBL02P1\r\n* Enrollment on or following treatment per ANBL07P1\r\n* Tandem transplant patients are eligible:                     \r\n** Following treatment on or per ANBL0532\r\n** Following treatment per POG 9640\r\n** Following treatment per COG ANBL00P1\r\n** Following treatment per CHP 594/Dana-Farber Cancer Institute (DFCI) 34-DATXx_NEWLINE_xXAt least one target lesion. In patients with prior loco-regional therapy, the target lesion(s) must be located in area(s) outside previous treatmentXx_NEWLINE_xXAlcohol consumption within 30 days of first study treatment, or refusing to abstain from alcohol for the duration of study treatmentXx_NEWLINE_xXFailure of prior intravesical treatment(s), one of which must include a course of BCG; failure is defined as evidence of TCC on cystoscopic examination and biopsy or cystoscopic examination and urine cytology at least 6 weeks from completion of last treatmentXx_NEWLINE_xXPrevious treatment with talimogene laherparepvec or any other oncolytic virusXx_NEWLINE_xXPrior treatment with CD137 agonists or immune checkpoint blockade therapiesXx_NEWLINE_xXPrior treatment with obinutuzumabXx_NEWLINE_xXProgressive disease after treatment with single-agent nivolumabXx_NEWLINE_xXAny other medical condition for which treatment with ipilimumab or nivolumab would be medically contraindicatedXx_NEWLINE_xXPrior warfarin-based therapies within 7 days of capecitabine treatmentXx_NEWLINE_xXPrior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last 2 yearsXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXSubject who developed persistent intolerable toxicity to ASP8273 treatment in the parent study.Xx_NEWLINE_xXSubject who received any other systemic anticancer treatment after parent study entry (radiation to local areas such as bone or brain if received in the parent ASP8273 study is permitted).Xx_NEWLINE_xXPatients who have been on a statin other than simvastatin within 2 weeks of starting treatment on current study; these include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, and rosuvastatin; if patient is on statin, will need to stop treatment 2 weeks prior to starting treatment on studyXx_NEWLINE_xXPrevious treatment with lenvatinib mesylate (E7080)Xx_NEWLINE_xXHave been informed of other treatment optionsXx_NEWLINE_xXPatients who have received any treatment of ponatinib prior to study entryXx_NEWLINE_xXReceived prior treatment with a standard anthracycline and therapeutic anti-CD20 monoclonal antibody-based regimen;Xx_NEWLINE_xXCarfilzomib was not part of their most recent therapy for the treatment of MM, andXx_NEWLINE_xXDid not discontinue carfilzomib treatment because of adverse effects.Xx_NEWLINE_xXPrior treatment with talazoparib or a poly(adenosine diphosphate [ADP]-ribosyl)ation (PARP)1/2 inhibitor; prior treatment with other agents that inhibit deoxyribonucleic acid (DNA) repair (i.e. WEE1 homolog [S. pombe] [WEE1] inhibitors, ataxia telangiectasia mutated [ATM] inhibitors), is allowed; if there are any questions, please contact the study's principal investigatorXx_NEWLINE_xXPrior treatment with more than two Janus kinase 2 (JAK2) inhibitors or with pacritinibXx_NEWLINE_xXThe target population for this study is patients who have participated in any REGN2810\n        clinical study.\n\n        Inclusion Criteria for Patients Receiving Re-treatment:\n\n          1. Tolerated prior treatment with REGN2810 with no unacceptable toxicity (except select\n             reversible irAEs) requiring discontinuation of REGN2810\n\n          2. Developed documented progressive disease after first demonstrating clinical benefit\n             from their initial treatment\n\n          3. Eastern Cooperative Oncology Group (ECOG) performance status ? 1\n\n          4. ?18 years old\n\n          5. Hepatic function:\n\n               -  Total bilirubin ? 1.5 x upper limit of normal (ULN; if liver metastases ? 3 x\n                  ULN)\n\n               -  Transaminases ? 3 x ULN (or ? 5.0 x ULN, if liver metastases)\n\n               -  Alkaline phosphatase (ALP) ? 2.5 x ULN (or ? 5.0 x ULN, if liver metastases)\n\n               -  For patients with hepatic metastases or hepatic malignancies, exclude patients\n                  with concomitant 3 x ULN ? aspartate aminotransferase (AST) and/or alanine\n                  aminotransferase (ALT) ? 5 x ULN and 1.5 x ULN ? total bilirubin ? 3 x ULN\n\n          6. Renal function: Serum creatinine ? 1.5 x ULN\n\n          7. Bone marrow function:\n\n               -  Hemoglobin ? 9.0 g/dL\n\n               -  Absolute neutrophil count (ANC) ? 1.5 x 10^9/L\n\n               -  Platelet count ? 75 x 10^9/L\n\n        Inclusion Criteria for Patients who Will not Receive Re-treatment:\n\n        Patients must have completed participation in any REGN2810 clinical study.\n\n        Exclusion Criteria:\n\n        A patient who meets any of the following criteria will be excluded from receiving\n        re-treatment with REGN2810:\n\n          1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that\n             required treatment with systemic immunosuppressive treatments, which may suggest risk\n             for irAEs.\n\n          2. Patients who experienced an irAE in while participating in another REGN2810 protocol\n             who were unable to have their corticosteroid dose reduced to <10 mg per day prednisone\n             equivalent within 12 weeks of toxicity.\n\n          3. Patients who developed ? Grade 2 uveitis in a prior REGN2810 protocol\n\n          4. Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within\n             4 weeks prior to the first dose of REGN2810\n\n          5. Active infection requiring therapy, including known infection with human\n             immunodeficiency virus, or active infection with hepatitis B or hepatitis C virus.\n\n          6. History of pneumonitis within the last 5 years.\n\n          7. Any investigational or antitumor treatment within 30 days prior to the initial\n             administration of REGN2810.\n\n          8. History of documented allergic reactions or acute hypersensitivity reaction attributed\n             of Grade ? 3 severity during or directly following an REGN2810 infusion\n\n          9. Known allergy to doxycycline or tetracycline. (precaution due to presence of trace\n             components in REGN2810)\n\n         10. Breast-feeding\n\n         11. Positive serum pregnancy test\n\n         12. History within the last 5 years of an invasive malignancy other than the one treated\n             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma\n             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured\n             by local treatment.\n\n         13. Acute or chronic psychiatric problems that, under the evaluation of the investigator,\n             make the patient ineligible for participation\n\n         14. Unwilling to practice adequate contraception during the study until 6 months after the\n             last dose of study drugXx_NEWLINE_xXPrevious treatment with tocilizumab (TCZ)Xx_NEWLINE_xXPatients with relapsed or persistent malignancy requiring immunosuppressive withdrawal or modulation (an example of this may be a patient who relapsed and was being treatment with DLI and then developed GvHD)Xx_NEWLINE_xXPatients who have had previous treatment with pazopanib or topotecanXx_NEWLINE_xXEvidence of recurrence of rectal cancer prior to the start of study treatmentXx_NEWLINE_xXPatient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up)Xx_NEWLINE_xXPatients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatmentXx_NEWLINE_xXPatients who have failed at least one line of a standard treatment, including bendamustine, fludarabine, ibrutinib, or alemtuzumab and require treatment within 2 years of completion of last treatment regimen or untreated with del17p by fluorescence in-situ hybridization (FISH) (high-risk) who do not have an allogeneic stem cell transplant optionXx_NEWLINE_xXCurrent treatment with steroidsXx_NEWLINE_xXHas no prostate calcification greater than 5 mm in the treatment zone, as noted by TRUS,Xx_NEWLINE_xXPrevious treatment with all of the following: lapatinib, and trastuzumab emtansine; (patients are eligible if treated with 3 or less of these agents)Xx_NEWLINE_xXPatient received previous treatment with oral AC480Xx_NEWLINE_xXWithin the 30 days before registration, no use of: 1) any pharmacologic treatment for smoking cessation, including bupropion or nicotine replacement therapy; 2) any nicotine delivery system (i.e., e-cigarettes and vape products); or 3) be enrolled in any formal behavioral treatment program for tobacco dependence as determined by patient reportXx_NEWLINE_xXPRIOR TO START OF TREATMENT:Xx_NEWLINE_xXUntreated current severe depression; currently treated depression is permitted if treatment is stableXx_NEWLINE_xXPlan to be on chemotherapy or other allowable treatment for at least 3 months (minimum 70 days) and be willing to come in for study visits\r\n* The plan for treatment should be for at least 3 months at time of study enrollment; the treatment can stop earlier during the study at the discretion of the physician and patient (e.g., due to progression as noted through imaging, toxicity, or patient preference)Xx_NEWLINE_xXPatients must not co-enroll on other treatment trialsXx_NEWLINE_xXPatient with a history of a thrombotic event within 12 months of starting nintedanib treatmentXx_NEWLINE_xXMust be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as ibrutinib or idelalisib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included)Xx_NEWLINE_xXDocumented, confirmed OIC defined as less than 3 laxations per week over a 1-week OIC confirmation period at any time during screening and prior to initial treatment period day 1Xx_NEWLINE_xXDCIS prior to index lesion or history of progressive/recurrent DCIS after treatmentXx_NEWLINE_xXCHILD: Child has completed cancer treatment and is up to 7 years post-treatmentXx_NEWLINE_xXAble to communicate sensations during the ExAblate treatmentXx_NEWLINE_xXMore than 5 painful lesions, or more than 1 requiring immediate localized treatmentXx_NEWLINE_xXPrior acupuncture treatment within 5 years of enrollmentXx_NEWLINE_xXPeople who are on long-term (> 1 year) chronic treatment are eligibleXx_NEWLINE_xXPrevious treatment with pathogen-reduced blood productsXx_NEWLINE_xXWithin 0-5 years post-active treatment for initial diagnosis or recurrenceXx_NEWLINE_xXPHASE I: Off treatmentXx_NEWLINE_xXPHASE II: Off treatment for at least 6 monthsXx_NEWLINE_xX>= 6 months post active treatmentXx_NEWLINE_xXAre receiving, or are likely to receive another intervention for the treatment of fatigue during the study period; (per provider report)Xx_NEWLINE_xXAppropriate for treatment with ADT in the opinion of the treating physicianXx_NEWLINE_xXOngoing continuous treatment with ibrutinib.Xx_NEWLINE_xXSubject must have completed all assessments in their parent protocol and want to continue treatment with ibrutinib.Xx_NEWLINE_xXMeeting any requirement in the parent protocol to permanently discontinue ibrutinib treatment.Xx_NEWLINE_xXWomen must agree not to breast feed while on abemaciclib treatment and for at least three months following the last dose of study therapyXx_NEWLINE_xXImmunosuppression as a result of underlying illness or treatment;Xx_NEWLINE_xXPatients who are platinum ineligible may be enrolled if they have received and failed an approved treatment and lack a treatment option with curative potential.Xx_NEWLINE_xXDocumented investigator-assessed relapse or progression after the last treatment is required if the participant responded and then progressed on the prior treatment.Xx_NEWLINE_xXPatients may receive hydroxyurea, steroids, or leukapheresis as necessary until day 5 of treatmentXx_NEWLINE_xXAnd for Treatment Period 2 only: 1) Patients participating in Treatment Period 1 must have had disease progression after receiving at least 4 weeks of progestin therapy or 2) Patients must be determined as PrR negative status at Screening.Xx_NEWLINE_xXPrior treatment with selinexorXx_NEWLINE_xXPatients must not have received prior treatment with talimogene laherparepvec (T-VEC) or other oncolytic virus agentsXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXSubject requires treatment with or plans to use either of the following:Xx_NEWLINE_xXNew systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.Xx_NEWLINE_xXEither treatment naive to, relapsed/refractory to, or experienced treatment failure due to other reasons with ibrutinib, idelalisib, or any other investigational B-cell receptor (BCR) pathway inhibitors not directly targeting spleen tyrosine kinase (SYK).Xx_NEWLINE_xXPrior treatment with a regimen that includes the combination drug will not necessarily exclude a participant from that cohort if the investigator views treatment with that agent as appropriate. However, a participant who has a contraindication for a particular combination agent or who has been discontinued from prior therapy with a particular agent for toxicity will not be eligible for inclusion in that particular cohort.Xx_NEWLINE_xXPrior systemic treatment with an azole drug within two weeks of start of treatmentXx_NEWLINE_xXNot amenable to treatment with curative intentXx_NEWLINE_xXThe patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma.Xx_NEWLINE_xXPrior treatment with the Optune® system.Xx_NEWLINE_xXPrior history of hypertensive crisis or hypertensive encephalopathy within the previous 3 months of first study treatmentXx_NEWLINE_xXAgree to undergo a pre-treatment and on treatment biopsy and have disease amenable to biopsy required in PK/pharmacodynamic dose expansion cohorts.Xx_NEWLINE_xXPatient has not completed a Physician Orders for Scope of Treatment (POST) formXx_NEWLINE_xXHave completed active cancer treatment at least 1 year prior to study enrollmentXx_NEWLINE_xXPatients taking Viagra must have a 1 day washout period prior to treatment.\r\n* Note: patients must agree to discontinue Viagra while on study treatment.Xx_NEWLINE_xXSevere active anemia (a hemoglobin < 8 documented by labs drawn within 3 months of first study treatment)Xx_NEWLINE_xXSubjects who are pregnant or may become pregnant during metformin administration in accordance with radioactive iodine treatment guidelinesXx_NEWLINE_xXSubjects who have received iodinated contrast dye; metformin treatment can be started the day after subjects complete iodinated contrast treatment; if a computed tomography (CT) scan with contrast is scheduled after screening and consent, the metformin treatment should be stopped the day before iodinated contrast administration; metformin can be resumed on the day after last iodinated contrast was administered to the subjectXx_NEWLINE_xXPatients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatmentXx_NEWLINE_xXChronic treatment with any inhaled steroid for > 1 month in past three monthsXx_NEWLINE_xXTreatment with montelukast or zafirukast for > 1 month in past three monthsXx_NEWLINE_xXTreatment with systemic steroids for > 1 month in past three monthsXx_NEWLINE_xXTreatment with any Food and Drug Administration (FDA) non-approved study medication within the past four weeks; off label treatment with FDA approved medication is allowedXx_NEWLINE_xXPatients will be ineligible if they are participating in an investigational drug treatment trial that requires structured symptom or toxicity reporting at the time of enrollmentXx_NEWLINE_xXPatients with any co-morbid condition which renders patients at high risk of treatment complicationXx_NEWLINE_xXPlanned treatment with any VEGF?TKI treatment with treatment has not yet begunXx_NEWLINE_xXHaving received Ayurvedic treatment within 6 months of study enrollment.Xx_NEWLINE_xXPatients that are between 1-5 years post treatmentXx_NEWLINE_xXEXCLUSION - STUDY 1: Taking medications unrelated to cancer treatment that may affect balance and gaitXx_NEWLINE_xXCurrent lymphedema treatmentXx_NEWLINE_xXPHASE 3B: PEER MENTOR ELIGIBILITY: At least 2 years from treatmentXx_NEWLINE_xXPatients will be eligible for treatment of multiple synchronous osseous sites only if those sites can be included in no more than three treatment sites; for patients with painful metastases that are contiguous but do not fit into the definition of a site listed above, those patients will still be eligible but will be considered to have two treatment sites; for example, a patient with a lesion of T4, T7 and T9 would be eligible but would be considered as two treatment sites since more than five consecutive vertebral bodies would be treated; these lesions could be treated with one field, even though the treatment is coded as two sitesXx_NEWLINE_xXTreatment plan including autologous HSCTXx_NEWLINE_xXProvides consent for his/her own treatment and proceduresXx_NEWLINE_xXRequires treatment with non-steroidal anti-inflammatory agents that cannot be stopped for one week during study participationXx_NEWLINE_xXSurvivors will have completed adjuvant chemotherapy and/or radiation treatment, with those participating in phase I within 5 years of completing treatment and those participating in phase II within three years (36 months) of completing treatmentXx_NEWLINE_xXMetal implants for the treatment extremityXx_NEWLINE_xXNo anticipated major changes in their pain treatment regimen (i.e., new class of pain medication starting or change in the class of pain medication) or enrollment on a new treatment study presumed to impact pain in the near futureXx_NEWLINE_xXSubjects who are participating in any other treatment studies, either medical or behavioral, specifically for pain managementXx_NEWLINE_xXSubjects who began a medical intervention for treatment of their disease that has a possible impact on pain (including mitogen-activated protein kinase kinase [MEK] trials) will not be eligible until after one year on the medical treatment; at that time, eligibility will be discussed with the PI of the medical study to assess the stability of the patient’s pain and whether further pain-related changes due to the medical treatment are likelyXx_NEWLINE_xXAnytime from treatmentXx_NEWLINE_xXHas initiated treatment as part of an active St. Jude Children's Research Hospital (SJCRH) treatment planXx_NEWLINE_xXCurrent treatment with pregabalinXx_NEWLINE_xXCIPN that may be associated with previous treatment with a vinca alkaloid (e.g. vincristine, vinblastine), or current treatment with a vinca alkaloidXx_NEWLINE_xXPatients whose physician-approved radiation treatment plan indicates a maximum prescription dose of less than 45 GyXx_NEWLINE_xXIf sexually active, patients will take contraceptive measures for the duration of protocol treatment and continue until two months after treatment; the effectiveness of hormonal contraceptives containing levonorgestrel has been shown to be reduced by perampanel at a 12 mg dose; therefore, alternative or back-up methods of contraception are recommendedXx_NEWLINE_xXReceiving a G-CSF for one of the following indications:\r\n* Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma\r\n* Mobilization of hematopoietic progenitor cells\r\n* Neutropenia prevention following autologous hematopoietic cell transplantXx_NEWLINE_xXTreatment for serious psychological disorders (e.g., schizophrenia) in the last 6 monthsXx_NEWLINE_xXPatients must have had a transrectal ultrasound (TRUS)/endoscopic ultrasound (TEUS) staging within two months prior to treatment startXx_NEWLINE_xXSUBJECT: A child has plans to start a new treatment for attention/memory problems in the next 3 months.Xx_NEWLINE_xXIf sexually active, patients will take contraceptive measures for the duration of protocol treatment and continue until one month after treatment; the efficacy of hormonal contraceptives during and for 28 days following the last dose of aprepitant may be reduced; alternative or back-up methods of contraception must be usedXx_NEWLINE_xXCase review by the study chair, or designate, as a case where treatment should be triedXx_NEWLINE_xXIf patients are on opioids for the treatment of cancer pain, they must have had no dose changes (> 25%) for at least 48 hours prior to study entry; change in opioid dose after study entry is allowedXx_NEWLINE_xXPost HNC primary treatmentXx_NEWLINE_xXBe receiving hospital-based treatment so that acupressure treatments and parents can be trained and monitoredXx_NEWLINE_xXReceiving treatment at UCSF Benioff Children’s Hospital San Francisco or OaklandXx_NEWLINE_xXIn early survivorship phase, defined as being post-surgery to ending of active treatment to 18 months post active treatment for stage 0-3 breast cancer (BCA)Xx_NEWLINE_xXAn episode of vomiting or retching within 24 hours before the start of the initial treatment with chemotherapyXx_NEWLINE_xX6 months post-treatment completionXx_NEWLINE_xXChild: child is in treatment remission and has completed intensive therapyXx_NEWLINE_xXPatients’ proposed post-operative treatment plan must include standard focal brain irradiation and temozolomideXx_NEWLINE_xXPatients must not be on treatment with class Ia or class III antiarrhythmic drugsXx_NEWLINE_xXOff-treatment and progression-free for at least 12 months and =< 14 years; treatment cessation is defined as the final dose of chemotherapy, the last dose (fraction) of radiation, or date of surgery, whichever occurred lastXx_NEWLINE_xXOff treatment > 14 yearsXx_NEWLINE_xXPrevious treatment with low level laser (regardless of indication)Xx_NEWLINE_xXHave already made a decision to not undergo any cancer treatment (e.g., being followed in best supportive care or hospice)Xx_NEWLINE_xXSerum creatinine acceptable for treatment with cisplatin per institutional guidelinesXx_NEWLINE_xXPatients must not require selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants during study participation; patients must have been able to taper and discontinue treatment with these medications at least 7 days prior to registration (28 days for fluoxetine), and must not be experiencing antidepressant withdrawal symptoms (e.g., dizziness, nausea, sleep disturbance, or other sensory disturbances); patients must not have previously taken the serotonin norepinephrine reuptake inhibitors (SNRI) duloxetine or milnacipran; prior venlafaxine is allowed as long as it was not taken concurrently with AI therapy and was not taken for treatment of pain (e.g., prior treatment for hot flashes is permitted)\r\n* NOTE: Patients requiring antidepressants for management of depression are not appropriate candidates for this placebo-controlled study, but those who are on antidepressants for other indications, such as hot flash management, may be able to tolerate a time off of antidepressant therapyXx_NEWLINE_xXDiabetics requiring insulin treatmentXx_NEWLINE_xXHas received the full dose of CTX over the course of their treatmentXx_NEWLINE_xXCase review by the study chair, or designate, as a case where treatment should be triedXx_NEWLINE_xXPatient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/changeXx_NEWLINE_xXTreatment expected to last no longer than 12 months (patient)Xx_NEWLINE_xXEligible after 2 months of completing all their active cancer treatment with the exception of long-term hormonal treatments or trastuzumab.Xx_NEWLINE_xXCIPN neuropathy: received neurotoxic chemotherapy in any setting as cancer treatment; including taxanes-such as paclitaxel or docetaxel; platinum-based compounds such as carboplatin or cis-platinum or oxaliplatin; or, vinca alkaloids such as vincristine, vinblastine, or vinorelbine, or proteasome inhibitors such as bortezomib\r\n* NOTE: patients should no longer be receiving the therapy that caused the CIPN, or have recently started a new treatment that may worsen CIPN; patients on a treatment that may cause CIPN for a period of time where CIPN does not appear to be worsening may be allowed at discretion at the principal investigatorXx_NEWLINE_xXPrior celiac plexus block, or other neurolytic pain control treatmentXx_NEWLINE_xXReceived treatment for breast cancer, and treatment must have been completed at least 2 weeks prior to enrollment in trial, but no longer than 2 years post-treatmentXx_NEWLINE_xXTried at least 1 prior pharmacological/non-pharmacological treatment for their genitourinary symptomsXx_NEWLINE_xXReceived filgrastim (GCSF) treatment within one month of enrollmentXx_NEWLINE_xXIf patients are on opioids for the treatment of cancer pain, they must have had no major dose change (> 25%) for at least 48 hours prior to study entry; change in opioid dose after study entry is allowedXx_NEWLINE_xXPrevious assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter studyXx_NEWLINE_xXSix to 36 months post treatmentXx_NEWLINE_xXTreatment with an anticoagulant for more than 7 days for the current blood clot, prior to randomizationXx_NEWLINE_xXTreatment of a thromboembolic event =< 6 months prior to randomizationXx_NEWLINE_xXCaregivers of patients who are receiving hospice care will be excluded; caregivers who are themselves undergoing active cancer treatment will be excluded (hormonal treatment allowed)Xx_NEWLINE_xXConcurrent cancer treatment of any kind is allowed, but the participant can also have completed all treatmentXx_NEWLINE_xXHave treatment with radical prostatectomy or radiation treatment > 3 months prior to enrollment, if receiving these treatmentsXx_NEWLINE_xXCompleted all primary treatmentXx_NEWLINE_xXDeemed appropriate for treatment in the prone position by the treating physicianXx_NEWLINE_xXPatients requiring treatment in supine positionXx_NEWLINE_xXPatients who have seen an oncologist after undergoing first line treatment imagingXx_NEWLINE_xXPATIENT: Not have completed a Physician Orders for Scope of Treatment (POST) formXx_NEWLINE_xX2 months post treatmentXx_NEWLINE_xXCompleted initial regional and systemic treatmentXx_NEWLINE_xXPrior visit to a survivorship clinic or previously provided with a treatment summary and care planXx_NEWLINE_xXOne or more significant medical conditions that in the treatment team’s judgment preclude participation in the walking interventionXx_NEWLINE_xXCurrent treatment with angiotensin converting enzyme (ACE)-inhibitors or beta blockersXx_NEWLINE_xXPrior treatment with an oxaliplatin-containing regimenXx_NEWLINE_xXPrior chemotherapy treatment, including radio-sensitization in pre- and post-operative settingsXx_NEWLINE_xXPrior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor.Xx_NEWLINE_xXPrior treatment for AML, except for the following allowances:Xx_NEWLINE_xXTreatment for hyperleukocytosis with hydroxyurea;Xx_NEWLINE_xXPrior treatment with quizartinib or other FLT3-ITD inhibitors;Xx_NEWLINE_xXShort course systemic corticosteroids is permissible for disease control, improvement of performance status or non-cancer indication if =< 10 days and must be discontinued prior to study treatmentXx_NEWLINE_xXDose escalation phase prior systemic treatment requirements:Xx_NEWLINE_xXmelanoma: at least 1 prior treatment (including immunotherapy).Xx_NEWLINE_xXOther prior malignancy active within the previous 2 years except for local or organ confined early stage cancer that has been definitively treated with curative intent or does not require treatment, does not require ongoing treatment, has no evidence of active disease and has a negligible risk of recurrence and is therefore unlikely to interfere with the endpoints of the studyXx_NEWLINE_xXPrevious treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based resulting in disease progressionXx_NEWLINE_xXPrior treatment with either obinutuzumab or ibrutinibXx_NEWLINE_xXRegional nodal irradiation is part of the treatment planXx_NEWLINE_xXProgressive disease on at least one prior EGFR-TKI (previous treatment with 3rd generation EGFR-TKI including osimertinib [AZD9291] allowed for dose escalation only)Xx_NEWLINE_xXFor the dose expansion portion ONLY, patient must: 1) have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown, patient may consent for trial for biopsy and testing for EGFR T790M will be performed as part of the initial biopsy for the trial: patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naive for 3rd generation EGFR-TKI (CO-1686 and osimertinib [AZD9291]) and mTOR inhibitorsXx_NEWLINE_xXPart B only: Prior treatment with SYK or Janus Kinase (JAK) inhibitors, except MF subjects.Xx_NEWLINE_xXHas been receiving erlotinib for treatment of NSCLC with erlotinib-related toxicities well-controlled and less than Grade 3 in severity at screeningXx_NEWLINE_xXPatients must have histologically or cytologically confirmed malignant neoplasms (not including hematological malignancies and brain tumors) untreated or previously treated requiring further treatment; patients must be refractory to, and intolerant of, established therapy known to provide clinical benefit for their condition; patients in Arm L (pembrolizumab) and Arm M (nivolumab) can be treatment naïve and do not have to fail first line nivolumab or pembrolizumab if they have disease where pembrolizumab or nivolumab are Food and Drug Administration (FDA) approved for the first-line settingXx_NEWLINE_xXPrior treatment with an agent targeting the exportinXx_NEWLINE_xXArm C1 and C2: SCNSL patients do not require one prior CNS directed treatment; newly diagnosed SCNSL patients are eligible as long as their systemic disease has been treated and does not require any active treatmentXx_NEWLINE_xXParticipant is scheduled to initiate treatment with everolimus combined with exemestane or another form of endocrine therapyXx_NEWLINE_xXMinocycline trial only: patients who have had prior treatment for pancreatic cancer within the past six months may be excluded at the discretion of the investigatorXx_NEWLINE_xXAYA has initial or relapsed cancer diagnosis and is actively on treatment and will continue to be on treatment long enough to complete the intervention and evaluation (4 to 6 weeks)Xx_NEWLINE_xXWomen who are pregnant or plan a pregnancy within 8 weeks after completion of treatment (only for patients who are going to be randomized to either therapeutic arms)Xx_NEWLINE_xXThrombocytopenia that is considered to be unrelated to treatment with TKI or accelerated phase as defined aboveXx_NEWLINE_xXSubjects must be on current treatment with tamoxifen or an aromatase inhibitor for at least two months prior to study enrollment (defined as the date of consent) and should not be planning to discontinue treatment or to change dose or type of endocrine treatment during the duration of the studyXx_NEWLINE_xXSubjects must agree to not use any medications, products, or preparations known to contain estrogen during the four weeks of treatment with topical fluocinonide creamXx_NEWLINE_xXCurrent or past treatment with fluocinonide cream for vaginal dryness, itching, or dyspareuniaXx_NEWLINE_xXSubjects who have had a venous or arterial embolic event AND who have received anti-coagulant treatment, where both the event and the treatment were within six months of the first Investigational Product administrationXx_NEWLINE_xXMinimum pre-treatment oNCF score >= 70Xx_NEWLINE_xXPatients taking drugs leading to significant QT prolongation must have an ECG prior to each treatmentXx_NEWLINE_xXKnown previous treatment failure to erythropoiesis stimulating agents (ESAs) (eg, rHuEPO, darbepoetin alfa).Xx_NEWLINE_xXinterested in behavioral sleep treatmentXx_NEWLINE_xXSexually active prior to cancer treatment (>= 17 on the Sexual Health Inventory For Men?[“SHIM”])Xx_NEWLINE_xXPatient undergoing concomitant treatment for upper extremity lymphedema, or who have received treatment within the last 14 daysXx_NEWLINE_xXPatients on diuretics solely for treatment of lymphedema are excludedXx_NEWLINE_xXPrevious acupuncture treatment for any indication within 30 days of enrollmentXx_NEWLINE_xXRadiation oncology and medical oncology consults must deem patient suitable for protocol treatmentXx_NEWLINE_xXUndergoing active treatment or in remission and undergoing active surveillanceXx_NEWLINE_xXHas active infectious disease undergoing systemic treatment excluding oral candidiasisXx_NEWLINE_xXPrevious laser treatment of telangiectasiasXx_NEWLINE_xXSubjects may be currently prescribed hormone treatment or Herceptin therapyXx_NEWLINE_xXThe subject agrees to follow-up examinations out to 6 months post-treatmentXx_NEWLINE_xXPost HNC primary treatmentXx_NEWLINE_xXPatients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225 treatment; if it is essential that the patient stays on a statin to control hyperlipidemia, only pravastatin may be used with extra caution\r\n* Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatmentXx_NEWLINE_xXNarcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollmentXx_NEWLINE_xXPrevious treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 1 monthXx_NEWLINE_xXAny topical treatment for neuropathy or other serious skin condition on the hands or feetXx_NEWLINE_xXPrevious acupuncture treatment for lymphedemaXx_NEWLINE_xXPatients who have received any systemic agents in addition to steroids for treatment of GVHDXx_NEWLINE_xXEvidence of disease progression that would necessitate a treatment in the next 2 weeksXx_NEWLINE_xXPrevious cisplatin treatmentXx_NEWLINE_xXRecent steroid treatment within the last monthXx_NEWLINE_xXActive cGVHD despite treatment with at least two immunosuppressive treatments (not including GVHD prophylaxis) in the past yearXx_NEWLINE_xXPrevious acupuncture treatment for any indication within 30 days of enrollmentXx_NEWLINE_xXPatient is willing to delay prostate biopsy for a 3-month finasteride treatmentXx_NEWLINE_xXPatient is willing to take finasteride 5 mg orally daily for 3-month treatment periodXx_NEWLINE_xXPrior treatment with finasteride or dutasteride in the past 6 monthsXx_NEWLINE_xXPatient must have a lifetime cumulative anthracycline dose of >= 250 mg/m^2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy; the anthracycline dose threshold must be met as part of the treatment of a cancer that was diagnosed at < 22 years of age\r\n* Note: Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used to document lifetime receipt of anthracycline doseXx_NEWLINE_xXPatient must have completed cancer treatment >= 2 years prior to study enrollmentXx_NEWLINE_xXMen randomized to the treatment arm should not father a baby while receiving topical treatment during this study; men who could father a child must agree to use at least one form of birth control during or continued abstinence from heterosexual intercourse if receiving topical treatment during the study, and for 2 weeks after stopping topical treatmentXx_NEWLINE_xXTreatment or removal of HSIL less than 6 months prior to randomizationXx_NEWLINE_xXParticipant has symptoms related to HSIL and would benefit more from immediate treatment than from entry into the study and potential for randomization to active monitoring armXx_NEWLINE_xXPatient must be above the age of 1 month as of the start date of study treatment.Xx_NEWLINE_xXPatient has hemodynamic instability within 24 hours before the start of study treatment.Xx_NEWLINE_xXSubjects scheduled to have > 3 Lumbar Punctures over the course of the study treatment periodXx_NEWLINE_xXAny prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFRXx_NEWLINE_xXCurrent treatment with tamoxifen or aromatase inhibitorsXx_NEWLINE_xXAny prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFRXx_NEWLINE_xXAny previous treatment for HCV =< 6 months prior to registrationXx_NEWLINE_xXHistory of autoimmunity that has not been controlled with treatment in the last 12 monthsXx_NEWLINE_xXPrevious treatment for lymphedema of either arm.Xx_NEWLINE_xXPrevious or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator).Xx_NEWLINE_xXPrevious or current treatment with GLP-1 receptor agonists (e.g. exenatide, liraglutide).Xx_NEWLINE_xXNot engaged in smoking cessation treatment other than the MD Anderson Cancer Center (MDACC) Tobacco Treatment ProgramXx_NEWLINE_xXSubject considered by the investigator an unsuitable candidate for receipt of a smoking cessation treatment or unstable to be followed up throughout the entire duration of the studyXx_NEWLINE_xXDoes not have a recent history of alcohol or drug abuse or is in treatmentXx_NEWLINE_xXCurrent sexually transmitted infection (STI) requiring treatment (women may participate after adequate treatment, at the discretion of the treating provider)Xx_NEWLINE_xXPrior treatment for cervical HSIL\r\n* Note: Cervical scarring that occurs after treatment with cryotherapy or LEEP may impact future visual evaluation of the cervix, making visual inspection with acetic acid (VIA) or colposcopy more challengingXx_NEWLINE_xXNo prior history of NMSC in the treatment fieldsXx_NEWLINE_xXNo actinic keratosis (AK)/Bowen’s disease in the treatment fields within the last 3 monthsXx_NEWLINE_xXBe willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medicationXx_NEWLINE_xXBe the only participant in his/her household on active treatment in Protocol 2016-0626 at the time.Xx_NEWLINE_xXPatient has taken phenothiazines (prochlorperazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine, etc.) for any indication within the last 48 hours prior to the start of treatment with study drugXx_NEWLINE_xXExposure to cisplatin treatment without interventionXx_NEWLINE_xXInterested in treatment that might change smoking behaviorXx_NEWLINE_xXAvailable autologous T cells with >= 15% expression of CD30CAR determined by flow-cytometry required prior to treatment with ATLCAR.CD30 cellsXx_NEWLINE_xXPatients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANO treatmentXx_NEWLINE_xXPatients must be scheduled to receive RT or CRT as definitive treatment or adjuvant RT or CRT treatment post-surgery per surgeon or Head and Neck Cancer (HNC) Tumor Board decisionXx_NEWLINE_xXPatients on treatment with tamoxifenXx_NEWLINE_xXPlans to move from Kansas City (KC) during the treatment and follow-up phaseXx_NEWLINE_xXSeeking treatment for smoking cessationXx_NEWLINE_xXParticipants must not be currently receiving or have previously received thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment and within 12 months of entryXx_NEWLINE_xXInterested in treatment that might change smoking behaviorXx_NEWLINE_xXPatient is diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of 30 mg/m^2Xx_NEWLINE_xXActive systemic treatment for graft versus host disease.Xx_NEWLINE_xXParticipants must be willing to take supplemental oral calcium 1000 mg and vitamin D3 1000 IU daily for six months (which will be supplied by the research study) after receiving denosumab treatment or no treatmentXx_NEWLINE_xXPrior or concurrent eczema or other eczemoid skin disorders or active skin condition (acute, chronic, or exfoliative) that disrupts the epidermis; persons with psoriasis are not excluded except in cases of:\r\n* any active lesion\r\n* any active lesion in the previous 6 months that required treatment, either systemic or topical\r\n* any prior episode, at any time, extensive enough or severe enough as to require systemic treatmentXx_NEWLINE_xXTreatment with other oral hypoglycemic agentsXx_NEWLINE_xXTREATMENT GROUPXx_NEWLINE_xXTREATMENT GROUPXx_NEWLINE_xXPrevious treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy;Xx_NEWLINE_xXA subject with a history or expectation of noncompliance with medications or treatment protocolXx_NEWLINE_xXAs determined by the study investigators or consenting professionals, recent prolonged antibiotic treatment as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing antianaerobic antibioticsXx_NEWLINE_xXFor Phase 2 Group A, EGFR TKI treatment-naïve and chemotherapy-naïveXx_NEWLINE_xXPrior treatment with CD137 agonists or other immune checkpoint blockade therapies, including anti-CTLA-4 therapeutic antibodiesXx_NEWLINE_xXSubjects with chronic treatment (at least twice/week for more than 3 months) with aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXCurrently undergoing treatment with photodynamic therapy, topical chemotherapy agents including imiquimod, fluorouracilXx_NEWLINE_xXAll visible papillary lesions must be macroscopically resected within 60 days of treatment initiationXx_NEWLINE_xXCurrently being treated or scheduled to have treatment with any systemic or intravesical chemotherapeutic agent during the studyXx_NEWLINE_xXAdequate course of treatment with an injectable hypomethylating agent (azacitidine for injection or decitabine) as the last therapeutic intervention for MDS (MYELODYSPLASTIC SYNDROMES) prior to beginning screening for this study. Adequate is defined as:Xx_NEWLINE_xXhaving received at least 6 consecutive 4-week treatment cycles with azacitidine for injection, orXx_NEWLINE_xXhaving received at least 4 consecutive 6-week treatment cycles with decitabine (3-day regimen) or at least 6 consecutive 4-week treatment cycles with decitabine (5-day regimen), orXx_NEWLINE_xXDocumented disease progression or stable disease as best response to treatment (or attempted treatment) with azacitidine for injection or decitabine. Those achieving an objective response to treatment regimen with an injectable Hypomethylating agent (HMA) are excluded from participation in this study. Definitions of disease progression are modified from IWG (INTERNATIONAL WORKING GROUP) 2006 criteria and include:Xx_NEWLINE_xXHave the last dose of the prior treatment regimen (injectable HMA (HYPOMETHYLATING AGENT) - azacitidine for injection or decitabine) not more than 16 weeks prior to screening for this study (date of informed consent signature).Xx_NEWLINE_xXPrior or ongoing response (IWG 2006: HI, PR, CR, or marrow CR) to treatment with azacitidine for injection or decitabine, at any time in the subject's prior history, which includes relapsed diseaseXx_NEWLINE_xXOngoing medically significant adverse events from previous treatment, regardless of the time periodXx_NEWLINE_xXSubjects with psoriasis not requiring systemic treatmentXx_NEWLINE_xXSubjects must be on therapy with bisphosphonates or denosumab for at least 1 month before start of study treatment.Xx_NEWLINE_xXSubjects who received prior treatment or are already receiving everolimus treatment prior to study entry are not eligible.Xx_NEWLINE_xXPrior history of Grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments.Xx_NEWLINE_xXPatients may continue on a daily multi-vitamin, calcium and vitamin D, but all other herbal, alternate and food supplements (i.e. PC-Spes, saw palmetto, St John wort, etc.) must be discontinued before treatment start; patients must not be planning to receive any concurrent cytotoxic chemotherapy, surgery for their prostate cancer, or radiation therapy during protocol treatmentXx_NEWLINE_xXSystemic anti-cancer treatment with a small molecule therapeutic (other than Ruxolitinib for the Combination arm) other than hydroxyurea less than 2 weeks before the first dose of CPI-0610Xx_NEWLINE_xXTreatment with medications that are known to carry a risk of Torsades de PointesXx_NEWLINE_xXPatients may have had treatment for no more than 2 prior relapsesXx_NEWLINE_xXConditions that could interfere with treatment or protocol-related proceduresXx_NEWLINE_xXSubjects with diabetes on active treatment (for subjects treated on CC-223 containing arms only)Xx_NEWLINE_xXPrior thoracic radiation allowed only if there is minimal to no overlap with the treatment area estimated at the time of consultation, and there is no cumulative esophageal dose that exceeds more than 50% of the maximal acceptable dose toleranceXx_NEWLINE_xXCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:\r\n* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)\r\n* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis\r\n* Concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John’s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)Xx_NEWLINE_xXPatients who need to continue treatment with any prohibited medicationsXx_NEWLINE_xXPatient under medications that can affect PSA for the last 3 months prior to MRgFUS treatment (Androgen Deprivation Treatment; alpha reductase inhibitors)Xx_NEWLINE_xXTreatment with systemic immunostimulatory agentsXx_NEWLINE_xXPregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the last dose of study treatmentXx_NEWLINE_xXSubject has MF with evidence of persistent disease despite ruxolitinib monotherapy treatment, consisting of:Xx_NEWLINE_xXPrior treatment with capecitabineXx_NEWLINE_xXTreatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresisXx_NEWLINE_xXPrior treatment with a drug that targets BCMA on tumor cells or any other bi specific antibody construct or chimeric antigen receptor T cell (CAR-T) infusion for the treatment of multiple myelomaXx_NEWLINE_xXSubjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physicianXx_NEWLINE_xXNo current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reasonXx_NEWLINE_xXPrior treatment with metforminXx_NEWLINE_xXPrevious enrollment or randomization of treatment in the present studyXx_NEWLINE_xXPrevious treatment with acupuncture in the last 12 monthsXx_NEWLINE_xXConditions contraindicated to progesterone treatment.Xx_NEWLINE_xXPatients in whom the lock solution application will interfere with routine treatment of the underlying diseaseXx_NEWLINE_xXPatients must be without evidence of residual disease as assessed by their treatment teamXx_NEWLINE_xXhas agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.Xx_NEWLINE_xXSubjects must not have received any form of systemic antineoplastic treatment for melanoma within the last year from day 1Xx_NEWLINE_xXExpected use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids used for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG during study followup; hepatitis C co-infected subjects should not enroll in this study if they expect to initiate treatment for hepatitis C (e.g., interferons) during this trialXx_NEWLINE_xXSerious illness requiring systemic treatment and/or hospitalization within 45 days prior to entryXx_NEWLINE_xXhas agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.Xx_NEWLINE_xXPatient must be scheduled to receive treatment with a bevacizumab containing chemotherapy regimen; patient can be treated with bevacizumab alone or in combination with other chemotherapies; patient may also be receiving treatment with OptuneXx_NEWLINE_xXCapable of making informed decisions regarding his/her treatmentXx_NEWLINE_xXPatient capable of making informed decisions regarding his/her treatmentXx_NEWLINE_xXCurrent treatment with bisphosphonates (as of time of enrollment)Xx_NEWLINE_xXCurrent treatment with the anticonvulsant depakote (at time of enrollment)Xx_NEWLINE_xXThere will be no restrictions on prior treatmentXx_NEWLINE_xXRadical prostatectomy as definitive treatment for PCaXx_NEWLINE_xXMajor invasive surgical procedure occurring between the first treatment-eligible PET/CT examination and end of radiotherapy that would affect the treatment target regionXx_NEWLINE_xXPrior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 daysXx_NEWLINE_xXPrior endoscopic treatment for BEXx_NEWLINE_xXTreatment plan for HDC-ASCTXx_NEWLINE_xXDaratumumab or other anti CD38 antibody treatment within 3 months prior to study enrollmentXx_NEWLINE_xXTreatment with another investigational drug or other intervention with 24 hours of injectionXx_NEWLINE_xXParticipants whose clinical care plan includes treatment with anti-angiogenic treatment-based therapyXx_NEWLINE_xXPatients who are planning to undergo treatment in a different institutionXx_NEWLINE_xXPatients selected for Ra-223 dichloride therapy for treatment of bone metastasis by their treating physicianXx_NEWLINE_xXPATIENT: Patients with other primary cancers requiring systemic treatmentXx_NEWLINE_xXRecipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or cytarabine more than 1 g per square meterXx_NEWLINE_xXPrior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is =< 1300 assay developed by Dr. Nai-Kong CheungXx_NEWLINE_xXPrior and current therapy:\r\n* For NF1 related benign tumor manifestations there is no standard effective medical treatment, and surgery is the only standard treatment; chemotherapy and radiation therapy are additional treatment options for malignant NF1 related tumors; for the purpose of this study subjects who have not previously received medical or surgical treatment, patients who have previously received medical or surgical treatment, and subjects who are currently receiving medical treatment and or radiation for a NF1 related manifestation will be eligible\r\n* Patients must be recovered from acute toxicities of prior therapy in order to be able to safely undergo biopsies proposed on the trial; prior and current treatment for NF1 related manifestations will be recorded on protocol 08-C-0079\r\n* Prior radiation therapy and chemotherapy in patients with MPNST must not have been administered within 4 weeks prior to enrollmentXx_NEWLINE_xXNo prior treatment for this diagnosis of NSCLCXx_NEWLINE_xXAndrogen ablation (hormone treatment) within the last 3 monthsXx_NEWLINE_xXThe patient has an orbital mass which needs further diagnostic evaluation before treatment or for monitoringXx_NEWLINE_xXSubjects may be enrolled at any point in diagnosis or treatmentXx_NEWLINE_xXPlan to receive dental treatment during the study datesXx_NEWLINE_xXPrevious or on-going radioactive iodine treatment.Xx_NEWLINE_xXPatients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consentedXx_NEWLINE_xXPatients with other primary cancers requiring systemic treatment.Xx_NEWLINE_xXPatients who are participating in a concurrent treatment protocolXx_NEWLINE_xXConcomitant medications for treatment of the target lesionXx_NEWLINE_xXPatients with other primary cancers requiring systemic treatmentXx_NEWLINE_xXSubject who is deemed by the treating physician to have a contraindication to definitive treatmentXx_NEWLINE_xXAllowable type and amount of prior therapy: patients with newly diagnosed malignancies should not have initiated treatment for their disease before participating in this study; patients with recurrent or second malignancies may have had prior therapy as appropriate for their disease, but should have completed all prior treatment at least 30 days before participation in this study and should not have initiated new treatment for the current problemXx_NEWLINE_xXParticipants undergoing active treatment, or who have completed treatment, will have radiographic abnormalities that may or may not be recurrent tumorXx_NEWLINE_xXPrior treatmentXx_NEWLINE_xXPatients that may need dose reduction to commence cycle 1 treatmentXx_NEWLINE_xXHas radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, afatinib, or osimertinibXx_NEWLINE_xXTreatment with any of the following:Xx_NEWLINE_xXPrior treatment with an anti-HER3 antibodyXx_NEWLINE_xXPrior treatment with cetuximab with tumor progression during or within 6 months after completing treatment.Xx_NEWLINE_xXPrevious treatment with CDX-3379 or other anti-ErbB3 targeted agents.Xx_NEWLINE_xXTreatment-naïve/ Unfit Cohorts: Previously untreated patients with histological confirmation of AML who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen; or previously untreated patients with intermediate, high, or very high risk MDS. Prior and concurrent therapy with hydroxyurea, oral etoposide, erythroid and/or myeloid growth factors is allowed.Xx_NEWLINE_xXPrior treatment with CD47 or signal regulatory protein alpha (SIRP?) targeting agents (with exception of Hu5F9-G4 for patients in the Rollover cohort).Xx_NEWLINE_xXTreatment-naïve/Unfit Cohorts Only: Any prior anti-leukemic therapy (excluding hydroxyurea or oral etoposide), prior treatment with hypomethylating agents and/or low dose cytarabine.Xx_NEWLINE_xXUnresolved chronic toxicity of previous AML treatmentXx_NEWLINE_xXCD123/IL3RA expression on the subject’s AML or MDS blasts, determined locally within 3 months of first protocol treatmentXx_NEWLINE_xXPrior treatment with a hypomethylating agent (including but not limited to azacitidine or decitabine), unless last treatment with hypomethylating agent was > 3 months prior to start of protocol treatment OR has received =< 2 cycles of hypomethylating agent without disease progression during those =< 2 cycles and last dose was not within 14 days of first protocol treatmentXx_NEWLINE_xXPrior treatment with SL-401Xx_NEWLINE_xXAt least 1, but no more than 5, prior treatment regimens for MCLXx_NEWLINE_xXFailure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimenXx_NEWLINE_xXPrior treatment with venetoclax or other BCL2 inhibitorsXx_NEWLINE_xXPrior treatment with bortezomib or other Proteasome Inhibitor (PI) is allowed, provided all of the following criteria are met: Best response achieved with prior bortezomib at any time was ? PR and with the last PI (PI therapy (alone or in combination) was ? PR, AND Participant did not discontinue bortezomib due to ? Grade 3 related toxicity, AND Must have had at least a 6-month PI-treatment-free interval prior to Cycle 1 Day 1 (C1D1) of study treatment.Xx_NEWLINE_xXRequires prohibited treatment (i.e., non-protocol specified anticancer pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor).Xx_NEWLINE_xXUse of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS, MDS/MPN, CMML or AML within 14 days of the first day of study drug treatmentXx_NEWLINE_xXPre-treatment with other mTOR inhibitors may be allowed and should be discussed with the medical monitorXx_NEWLINE_xXPrevious meningioma progression during treatment with other mTORC1/2 inhibitors (but not mTORC1 inhibitors such as everolimus or other rapalogs)Xx_NEWLINE_xXUnable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), and herpes zoster (varicella zoster virus [VZV]) at start of treatmentXx_NEWLINE_xXActively breastfeeding women unless it is interrupted during treatment and at least 6 weeks after treatment discontinuationXx_NEWLINE_xXAt least 4 months after HCT, either autologous or allogeneic (of any source, with any preparatory regimen, for any indication), prior to study treatment.Xx_NEWLINE_xXHas received treatment with any prescribed treatments within specified time frames prior to study drug administrationXx_NEWLINE_xXHas received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptorXx_NEWLINE_xXSubject agrees not to participate in another interventional study while on treatment.Xx_NEWLINE_xXThe patient agrees to follow-up examinations out to 5-years post-treatmentXx_NEWLINE_xXPatients with other primary cancers requiring systemic treatmentXx_NEWLINE_xXDiagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesisXx_NEWLINE_xXTREATMENT GROUP: Elect to undergo, but have not yet started tamoxifen therapyXx_NEWLINE_xXTREATMENT GROUP: Willing to avoid oral contraception use (which is not recommended while on tamoxifen treatment) for the duration of the study participationXx_NEWLINE_xXSubjects must be planned for treatment with approved treatment doses of a VEGF receptor TKI (e.g., sunitinib, pazopanib, cabozantinib, axitinib, sorafenib, lenvatinib)Xx_NEWLINE_xXPrior treatment with a VEGF receptor TKI within a time period equivalent to 5 half-lives of the prior TKI (e.g., there should be no substantial amount of TKI remaining in the patient)Xx_NEWLINE_xXSubjects who have received prior treatment for HCC (prior surgical procedures not related to HCC are allowed)Xx_NEWLINE_xXPatient undergoing current or recent treatment within past 6 weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy.Xx_NEWLINE_xXConcomitant medications for treatment of the target lesionXx_NEWLINE_xXPrior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 daysXx_NEWLINE_xXPrevious brachytherapy treatment will have occurred at least 2 years in the pastXx_NEWLINE_xXOngoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)Xx_NEWLINE_xXFor salvage setting patients, lack of documented treatment or management recommendation on fileXx_NEWLINE_xXPatient is considered a poor risk for surgery due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment optionsXx_NEWLINE_xXFor International Prognostic Staging System (IPSS) high-risk or intermediate-2 MDS, participants must be intolerant of hypomethylating agents or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles of azacitidine, or must have progressed at any point after initiation of a hypomethylating agent.Xx_NEWLINE_xXPatients 18 years of age and older who are being evaluated for and/or treated for cancer at the NIH Clinical Center or at participating sites:\r\n* Who have a newly diagnosed malignancy for which they have not yet received treatment, or\r\n* Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:\r\n** Radiographic evidence of tumor growth and/or new metastases, or\r\n** Documented evidence by the treating physician of signs/symptoms of clinical disease progression, or\r\n* Who are currently undergoing treatment (adjuvant, neoadjuvant, etc.), are within the first two (2) cycles of treatment, and for whom disease response has not yet been assessed\r\n** In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle\r\n* For matched pair collections only (tissue + blood), patients with ongoing partial response (PR) or stable disease (SD) are eligible\r\n** Confirmation of viable malignancy and/or < 90% tumor necrosis must be confirmed to the coordinating site, as indicated in the final pathology report, for patients enrolled with PR or SDXx_NEWLINE_xXPrior treatment with sipuleucel-TXx_NEWLINE_xXHave a diagnosis of any type of NHL and =< 5 years from the last treatmentXx_NEWLINE_xXNo treatment with systemic anti-cancer treatment (chemotherapy or biologics) within 2 weeks of starting interferon gammaXx_NEWLINE_xXCurrent treatment with steroids (must be discontinued 1 week before starting IFN gamma)Xx_NEWLINE_xXPrior treatment with MORAb-009Xx_NEWLINE_xXPrior treatment with SS1(dsFv)PE38 (SS1P)Xx_NEWLINE_xXHave either received prior anthracycline treatment or have a reason not to receive anthracycline in the judgment of their treating physicianXx_NEWLINE_xXPrior treatment with trabectedinXx_NEWLINE_xXPatients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatmentXx_NEWLINE_xXRecipient of vaccines within 1 month of or during study drug treatment.Xx_NEWLINE_xXCurrent use of a prohibited medication or requires any of these medications during treatment with GSK1120212Xx_NEWLINE_xXPrior treatment with MEK or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitorsXx_NEWLINE_xXconcurrent NSAID treatments while undergoing treatmentXx_NEWLINE_xXEligible for treatment with paclitaxel, doxorubicin and cyclophosphamideXx_NEWLINE_xXPATIENT: Undergoing treatment for cancer by one of the consented HCPs as per the HCP and/or EMRXx_NEWLINE_xXOngoing or prior treatment with traditional disease-modifying anti-rheumatic drugs or biologic agents (RCT)Xx_NEWLINE_xXHave not had their initial doctor consultation to discuss treatment optionsXx_NEWLINE_xXSymptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.Xx_NEWLINE_xXPrior treatment with oxaliplatin.Xx_NEWLINE_xXPrior treatment with PM060184.Xx_NEWLINE_xXDISEASE CHARACTERISTICS:\n\n          -  Completely resected histologically confirmed adenocarcinoma of the colon\n\n               -  High-risk stage II disease, including one of the following:\n\n                    -  T4 lesions\n\n                    -  Less than 12 sampled lymph nodes\n\n                    -  Poorly differentiated histology\n\n               -  Stage III disease, defined as having at least one pathologically confirmed\n                  positive lymph node or one pathologically confirmed positive tumour deposit.\n\n               -  Synchronous primary colon cancer allowed\n\n          -  Adjuvant chemotherapy treatment for colon cancer with a 5-fluorouracil- based regimen\n             received with an intent to provide a complete course of treatment. While one current\n             standard is 24 weeks of treatment, patients who are pre-planned to receive a shorter\n             duration of chemotherapy, including as part of a research study will also be\n             permitted. The actual treatment received may be less than 24 weeks; participants must\n             have received a minimum of one treatment cycle.\n\n          -  Chemotherapy must have been completed (i.e. last dose received) a minimum of 60 days\n             and a maximum of 180 days prior to registration.\n\n          -  Carcinoembryonic antigen (CEA) ? 5 ?g/L\n\n          -  Current physical activity levels do not meet the recommended guidelines (? 150 minutes\n             of moderate-to-vigorous or ? 75 minutes of vigorous physical activity/week) as\n             calculated using the Leisure Time Exercise Questionnaire (LTEQ)\n\n          -  Completion of chest x-ray or CT, and CT, MRI or ultrasound of abdomen within 60 days\n             of registration; these imaging tests must not show evidence of metastatic or\n             locally-recurrent colon cancer.\n\n          -  No rectal cancer\n\n        PATIENT CHARACTERISTICS:\n\n          -  ECOG performance status 0-1\n\n          -  Absolute granulocyte count ? 1,000/mm³\n\n          -  Platelet count ? 100,000/mm³\n\n          -  Hemoglobin ? 100 g/L\n\n          -  Serum creatinine ? 1.5 times upper limit of normal (ULN)\n\n          -  Total bilirubin ? 1.5 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase < 2.5 times ULN\n\n          -  ALT < 2 times ULN\n\n          -  Not pregnant or planning to become pregnant within the next 3 years\n\n          -  Able (i.e., sufficiently fluent) and willing to effectively communicate with the\n             physical activity consultant affiliated with the originating cancer center\n\n          -  Able (i.e., sufficiently fluent in English or French) and willing to complete the\n             patient-reported outcome questionnaires, social determinants of exercise measurement,\n             health economics, and physical activity questionnaires and logs\n\n          -  Able to complete the baseline exercise test\n\n          -  No significant comorbid conditions precluding participation in a physical activity\n             program as determined by the investigator\n\n          -  Likely to participate in a physical activity program, as assessed by the investigator\n\n          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,\n             curatively treated in situ cancer of the cervix, other solid tumors, Hodgkin lymphoma,\n             or non-Hodgkin lymphoma curatively treated with no evidence of disease for > 5 years\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  See Disease Characteristics\n\n          -  No prior radiotherapy as a component of treatment for primary tumor\n\n          -  No concurrent treatment with additional chemotherapy or radiation\n\n          -  No concurrent treatment with any medications deemed by the investigator as likely to\n             preclude participation in a physical activity program\n\n          -  No concurrent anticancer treatment including chemotherapy, biological, or targeted\n             agentsXx_NEWLINE_xXSubjects with prior treatment with a mechanistic target of rapamycin (mTOR) are eligibleXx_NEWLINE_xXSubjects who have received dasatinib beyond first or second line treatment and meet other enrollment criteria are eligible for the study provided prior Tyrosine-kinase inhibitors (TKI) were discontinued due to intolerance or lack efficacy, although only one instance of lack of efficacy to TKI is allowed.Xx_NEWLINE_xXWOCBP must agree to follow instructions for method(s) of contraception at the restart of treatment with study drug (dasatinib) and for the duration treatment plus 30 days (duration of ovulatory cycle) for a total of 30 days post-treatment completionXx_NEWLINE_xXPatients with a history of non-compliance to CML treatment and monitoring requirementsXx_NEWLINE_xXSexually active subjects or their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec/placebo.Xx_NEWLINE_xXcurrent enrollment in a smoking cessation treatment studyXx_NEWLINE_xXFor inclusion in the study patient should fulfil the following criteria:\n\n        1. Male or female, aged at least 18 years. 2. Histological or cytological confirmation\n        diagnosis of NSCLC. 3. Radiological documentation of disease progression while on a\n        previous continuous treatment with an EGFR TKI, eg gefitinib, erlotinib or afatinib. In\n        addition, other lines of therapy may have been given. All patients must have documented\n        radiological progression on the last treatment administered prior to enrolling in the\n        study.\n\n        4. Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR\n        TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).\n\n        5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration\n        over the previous 2 weeks (Appendix G).\n\n        6. Patients must have a life expectancy of ?12 weeks as estimated at the time of screening.\n\n        7. Females should be using adequate contraceptive measures and must have a negative\n        pregnancy test prior to start of dosing if of child-bearing potential, or must have\n        evidence of non-child-bearing potential by fulfilling one of the following criteria at\n        screening: Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least\n        12 months following cessation of all exogenous hormonal treatments. Women under 50 years\n        old would be considered post-menopausal if they have been amenorrhoeic for 12 months or\n        more following cessation of exogenous hormonal treatments and with LH and FSH levels in the\n        post-menopausal range for the institution. Documentation of irreversible surgical\n        sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not\n        tubal ligation.\n\n        8. Male patients should be willing to use barrier contraception, ie, condoms, until 6\n        months after last study drug is taken.\n\n        9. Contact lens wearers must be prepared to not wear contact lenses and wear glasses for\n        the duration of the rifampicin dosing.\n\n          1. Participation in another clinical study with an IP during the last 14 days (or a\n             longer period depending on the defined characteristics of the agents used).\n\n          2. Treatment with any of the following: Treatment with an EGFR TKI (eg, erlotinib or\n             gefitinib) w/in 8 days or approx. 5 x half-life, whichever is the longer, of the first\n             dose of study treatment; any cytotoxic chemo, investigational agents or other\n             anticancer drugs from a previous treatment regimen w/in 14 days of the first dose of\n             study treatment; major surgery (excluding placement of vascular access) w/in 4 weeks\n             of the first dose of study treatment; radiotherapy with a limited field of radiation\n             for palliation w/in 1 week of the first dose of study treatment, with the exception of\n             patients receiving radiation to more than 30% of bone marrow or with a wide field of\n             radiation which must be completed w/in 4 weeks of the first; patients currently\n             receiving (or unable to stop use prior to receiving the first dose) medications or\n             herbal supplements known to be potent inhibitors of CYP3A4 (at least 1 week prior) and\n             potent inducers of CYP3A4 (at least 3 week prior). All patients must avoid concomitant\n             use of any medications, herbal supplements and/or ingestion of foods with known\n             inducer/inhibitory effects on CYP3A4.\n\n          3. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of\n             starting study treatment with the exception of alopecia and Grade 2, prior\n             platinum-therapy related neuropathy.\n\n          4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges within 7 days of the first\n             administration of the IP until the final PK sample collection on Day 78 of Part A.\n\n          5. Spinal cord compression or brain metastases unless asymptomatic, stable and not\n             requiring steroids for at least 4 weeks prior to start of study treatment.\n\n          6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled\n             hypertension and active bleeding diatheses, which in the Investigator's opinion makes\n             it undesirable for the patient to participate in the study or which would jeopardise\n             compliance with the protocol, or active infection including hepatitis B, hepatitis C\n             and HIV. Screening for chronic conditions is not required.\n\n          7. Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following laboratory values: ANC <1.5 x 10^9/L; Platelet count <100 x 10^9/L;\n             Haemoglobin <90 g/L; ALT >2.5 times the ULN if no demonstrable liver metastases or >5\n             times ULN in the presence of liver metastases; AST >2.5 times ULN if no demonstrable\n             liver metastases or >5 times ULN in the presence of liver metastases; Total bilirubin\n             >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented\n             Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; creatinine\n             >1.5 times ULN concurrent with creatinine clearance <50 ml/min (measured or calculated\n             by Cockcroft and Gault equation); confirmation of creatinine clearance is only\n             required when creatinine is >1.5 times ULN.\n\n          8. Any of the following cardiac criteria: Mean resting corrected QT interval corrected\n             for heart rate using Fridericia's correction factor (QTcF) >470 msec obtained from 3\n             electrocardiograms (ECGs); any clinically important abnormalities in rhythm,\n             conduction or morphology of resting ECG eg, complete left bundle branch block, third\n             degree heart block, second degree heart block, PR interval >250 msec; any factors that\n             increase the risk of QTc prolongation or risk of arrhythmic events such as heart\n             failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome\n             or unexplained sudden death under 40 years of age or any concomitant medication known\n             to prolong the QT interval.\n\n          9. Patients unable to swallow oral medication or patients with GI disorders or\n             significant GI resection likely to interfere with the absorption of AZD9291.\n\n         10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required\n             steroid treatment, or any evidence of clinically active ILD.\n\n         11. Women who are breastfeeding.\n\n         12. Patients with a known hypersensitivity to AZD9291 or rifampicin or any of the\n             excipients of the products.\n\n         13. Concomitant medication contraindicated for use with rifampicin (including, but not\n             limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide,\n             triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methyl-glutaryl coenzyme A\n             (HMG-CoA)-reductase inhibitors metabolised by CYP3A4, such as lovastatin and\n             simvastatin, ergot alkaloids metabolised by CYP3A4, such as dihydroergotamine,\n             ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine).\n\n         14. For optional genetic research: .Previous allogenic bone marrow transplant or\n             Non-leukocyte depleted whole blood transfusion within 120 days of the date of the\n             genetic sample collection.Xx_NEWLINE_xXKey Inclusion Criteria Includes:\n\n        Patients meeting all of the following criteria may be enrolled in the study:\n\n          1. Must be able to understand and voluntarily sign an ICF.\n\n          2. Must be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy\n             (REMS)™ program, and be willing and able to comply with the requirements of the\n             POMALYST REMS™ program (Appendix 9.3).\n\n          3. Must be ? 18 years of age at the time of signing the ICF.\n\n          4. Must be able to adhere to the study visit schedule and other protocol requirements.\n\n          5. Must have a documented diagnosis of MM and have relapsed or relapsed and refractory\n             disease. Patients must have received at least 2 lines of prior therapies. Patients\n             must have relapsed after having achieved at least stable disease for at least 1 cycle\n             of treatment to at least 1 prior regimen and then developed PD. Relapsed and\n             relapsed-and-refractory patients must have documented evidence of PD during or within\n             60 days (measured from the end of the last cycle) of completing treatment with the\n             last antimyeloma drug regimen used just prior to study entry.\n\n          6. Patients must have undergone prior treatment with at least 2 cycles of lenalidomide\n             and at least 2 cycles of a proteasome inhibitor (either in a separate regimen or\n             within the same regimen.\n\n          7. Must not be a candidate for autologous stem cell transplant (ASCT), have declined the\n             option of ASCT, or have relapsed after prior ASCT.\n\n          8. Must have measurable levels of myeloma paraprotein in serum (? 0.5 g/dL) or urine (?\n             0.2 g/24 hours). Patients who do not have myeloma paraprotein must have serum free\n             light chain (SFLC) concentration of ? 10 mg/dL, provided SFLC ratio is abnormal.\n             Nonsecretory myeloma is excluded.\n\n          9. Must have Eastern Cooperative Oncology Group performance status score of 0, 1, or 2.\n\n         10. Females of childbearing potential must have a negative serum or urine pregnancy test\n             as described in Appendix 9.3 for the POMALYST REMS™ program. Females of childbearing\n             potential and males must either commit to continued abstinence from heterosexual\n             intercourse or must abide by birth control requirements as described in Appendix 9.3\n             for the POMALYST REMS™ program.\n\n         11. Must agree to refrain from donating blood while on study drug and for 28 days after\n             discontinuation from this study.\n\n         12. Must agree not to share study medication with another person.\n\n         13. Must be able to take ASA (81 or 325 mg) daily as prophylactic anticoagulation.\n             Patients intolerant to ASA may use low molecular weight heparin. Lovenox is\n             recommended. Coumadin will be allowed provided the patient is fully anticoagulated,\n             with an international normalized ratio of 2 to 3.\n\n        Key Exclusion Criteria Includes:\n\n        Patients meeting any of the following criteria will be excluded from enrollment in the\n        study:\n\n          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that\n             would prevent the patient from signing the ICF or from following the study\n             requirements.\n\n          2. Pregnant or lactating females.\n\n          3. Prior therapy with histone deacetylase inhibitor or pomalidomide.\n\n          4. Any of the following laboratory abnormalities:\n\n               -  ANC < 1,000/µL\n\n               -  Platelet count < 75,000/ µL for patients in whom < 50% of bone marrow nucleated\n                  cells are plasma cells, or a platelet count < 50,000 for patients in whom ? 50%\n                  of bone marrow nucleated cells are plasma cells\n\n               -  Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or\n                  recombinant human erythropoietin use is permitted).\n\n               -  Creatinine clearance < 45 mL/min according to Cockcroft-Gault formula. If\n                  creatinine clearance calculated from the 24 hour urine sample is ? 45 mL/min,\n                  patient will qualify for the trial.\n\n               -  Serum glutamic oxaloacetic transaminase/aspartate aminotransferase, or serum\n                  glutamic pyruvic transaminase/alanine aminotransferase > 3.0 × ULN\n\n               -  Serum total bilirubin > 2.0 mg/dL\n\n          5. Prior history of malignancies, other than MM, unless the patient has been free of the\n             disease for ? 3 years. Exceptions include the following:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Ductal carcinoma in situ; or cervical intraepithelial neoplasia\n\n               -  Carcinoma of the prostate with a current prostate-specific antigen below the\n                  upper limit of normal\n\n          6. Corrected QT interval (QTc) using Fridericia's formula value > 480 msec at Screening;\n             family or personal history of long QTc syndrome or ventricular arrhythmias including\n             ventricular bigeminy at Screening; previous history of drug-induced QTc prolongation\n             or the need for treatment with medications known or suspected of producing prolonged\n             QTc intervals on electrocardiogram.\n\n          7. Known human immunodeficiency virus, hepatitis B virus, and known or suspected active\n             hepatitis C virus infection.\n\n          8. Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone (such as\n             Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically\n             managed is allowable.\n\n          9. Peripheral neuropathy ? Grade 2 despite supportive therapy.\n\n         10. Radiotherapy or systemic therapy (standard or an investigational or biologic\n             anticancer agent) within 14 days of initiation of study drug treatment.\n\n         11. Current enrollment in another clinical trial involving treatment and/or receiving an\n             investigational agent for any reason.\n\n         12. Inability or unwillingness to comply with birth control requirements or any of the\n             POMALYST REMS™ requirements per Appendix 9.3.Xx_NEWLINE_xXFor inclusion in the study, patients should fulfil the following criteria:\n\n          1. Male or female, aged at least 18 years.\n\n          2. Histological or cytological confirmation diagnosis of NSCLC.\n\n          3. Radiological documentation of disease progression while on a previous continuous\n             treatment with an EGFR TKI, eg, gefitinib or erlotinib. In addition, other lines of\n             therapy may have been given. All patients must have documented radiological\n             progression on the last treatment administered prior to enrolling in the study.\n\n          4. Confirmation that the tumour harbours an EGFR mutation known to be associated with\n             EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).\n\n          5. ECOG performance status 0-1 with no deterioration over the previous 2 weeks.\n\n          6. Patients must have a life expectancy of ?12 weeks as estimated at the time of\n             screening.\n\n          7. Evidence of non-childbearing status for women of childbearing potential, or\n             post-menopausal status: negative urine or serum pregnancy test within 28 days of study\n             treatment, confirmed prior to treatment on Day 1 of Part A, or post menopausal status.\n             Females should be using adequate contraceptive measures and must have a negative\n             pregnancy test prior to start of dosing if of child-bearing potential or must have\n             evidence of non-child-bearing potential by fulfilling one of the following criteria at\n             screening: post-menopausal defined as aged more than 50 years and amenorrhoeic for at\n             least 12 months following cessation of all exogenous hormonal treatments; women under\n             50 years old would be consider postmenopausal if they have been amenorrhoeic for 12\n             months or more following cessation of exogenous hormonal treatments and with LH and\n             FSH levels in the post-menopausal range for the institution; documentation of\n             irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or\n             bilateral salpingectomy but not tubal ligation.\n\n          8. Male patients should be willing to use barrier contraception, ie, condoms, until 6\n             months after last study drug is taken.\n\n        Patients should not enter the study if any of the following exclusion criteria are\n        fulfilled:\n\n          1. Participation in another clinical study with an IP during the last 14 days (or a\n             longer period depending on the defined characteristics of the agents used).\n\n          2. Treatment with any of the following: Treatment with an EGFR TKI w/in 8 days or\n             approximately 5x half-life, whichever is the longer, of the first dose of study\n             treatment; Any cytotoxic chemotherapy, investigational agents or other anticancer\n             drugs w/in 14 days of the first dose of study treatment; Major surgery (excluding\n             placement of vascular access) within 4 weeks of the first dose; Radiotherapy with a\n             limited field of radiation for palliation within 1 week of the first dose of study\n             treatment, with the exception of patients receiving radiation to more than 30% of the\n             bone marrow or with a wide field of radiation which must be completed within 4 weeks\n             of the first dose of study treatment; Patients currently receiving (or unable to stop\n             use prior to receiving the first dose of study treatment) medications or herbal\n             supplements known to be potent inhibitors of CYP2C8 and of CYP3A4 (at least 1 week\n             prior) and potent inducers of CYP3A4 (at least 3 week prior). All patients must try to\n             avoid concomitant use of any medications, herbal supplements and/or ingestion of foods\n             with known inducer/inhibitory effects on CYP3A4, CYP2C8, and/ or CYP1A2.\n\n          3. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of\n             starting study treatment with the exception of alopecia and Grade 2, prior\n             platinum-therapy related neuropathy.\n\n          4. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges within 7 days of the first\n             administration of the IP until the end of Part A.\n\n          5. Spinal cord compression or brain metastases unless asymptomatic, stable and not\n             requiring steroids for at least 4 weeks prior to start of study treatment.\n\n          6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled\n             hypertension and active bleeding diatheses, which in the Investigator's opinion makes\n             it undesirable for the patient to participate in the study or which would jeopardise\n             compliance with the protocol, or active infection including hepatitis B, hepatitis C\n             and human immunodeficiency virus (HIV). Screening for chronic conditions is not\n             required.\n\n          7. Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following laboratory values: ANC <1.5 x 10^9/L; Platelet count <100 x 10^9/L;\n             Haemoglobin <90 g/L; ALT >2.5 x the institutional ULN if no demonstrable liver\n             metastases or >5 x institutional ULN in the presence of liver metastases; AST >2.5 x\n             institutional ULN if no demonstrable liver metastases or >5 x institutional ULN in the\n             presence of liver metastases; Total bilirubin >1.5 x institutional ULN if no liver\n             metastases or >3 x institutional ULN in the presence of documented Gilbert's Syndrome\n             or liver metastases; Creatinine >1.5 x institutional ULN concurrent with creatinine\n             clearance <50 mL/min (measured or calculated by Cockcroft-Gault formula); confirmation\n             of creatinine clearance is only required when creatinine is >1.5 x institutional ULN.\n\n          8. Any of the following cardiac criteria: Mean resting corrected QT interval corrected\n             for heart rate using Fridericia's correction factor (QTcF) >450 msec obtained from 3\n             ECGs; Any clinically important abnormalities in rhythm, conduction or morphology of\n             resting ECG eg, complete left bundle branch block, third degree heart block, second\n             degree heart block, PR interval >250 msec; Any factors that increase the risk of QTc\n             prolongation or risk of arrhythmic events such as heart failure, hypokalaemia,\n             congenital long QT syndrome, family history of long QT syndrome or unexplained sudden\n             death under 40 years of age or any concomitant medication known to prolong the QT\n             interval.\n\n          9. Patients unable to swallow oral medication or patients with GI disorders or\n             significant GI resection likely to interfere with the absorption of AZD9291.\n\n         10. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation\n             pneumonitis which required steroid treatment, or any evidence of clinically active\n             ILD.\n\n         11. Women who are breastfeeding.\n\n         12. Patients with a known hypersensitivity to AZD9291 or itranconazole or any of their\n             excipients.\n\n        12. Concomitant medication contraindicated for use with itraconazole (including, but not\n        limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide,\n        triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methyl-glutaryl coenzyme A\n        (HMG-CoA)- reductase inhibitors metabolized by CYP3A4, such as lovastatin and simvastatin,\n        ergot alkaloids metabolized by CYP3A4, such as dihydroergotamine, ergometrine (ergonovine),\n        ergotamine and methylergometrine (methylergonovine).\n\n        13. For optional genetic research: Previous allogenic bone marrow transplant or\n        non-leukocyte depleted whole blood transfusion within 120 days of sample collection.Xx_NEWLINE_xXMinimum of 2 calendar years of nilotinib treatment with at least the last 12 months of nilotinib treatment prior to pre-screening at approved total dialy dose of 600 mg BID or at a reduced dose of 400 mg QD if required from the perspective of tolerance for BCR-ABL positive CML in documented chronic phase at the time of diagnosisXx_NEWLINE_xXPrevious treatment with BCR-ABL inhibitors other than nilotinib for more than a total cumulative duration of 4 weeksXx_NEWLINE_xXPrevious treatment with alpha-interferon of any durationXx_NEWLINE_xXIn the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS subjects (including CMML), and intermediate-2 or high-risk MDS subjects (including CMML) relapsed or refractory to prior HMA treatment are allowed, and treatment-naïve AML subjects who are at least 65 years of age will be allowed if they also have at least one of the following criteriaXx_NEWLINE_xXIn the Dose Expansion Segment, which includes the 10-day regimen, subjects who have received 2 complete full dose cycles or more of a hypomethylating agent (HMA) decitabine or azacitidine (except for intermediate-2 or high-risk MDS subjects (including CMML) relapsed or refractory to prior HMA treatment).Xx_NEWLINE_xXPrior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)Xx_NEWLINE_xXThe patient has either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least 2 tyrosine kinase inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).Xx_NEWLINE_xXTKI treatment failure will be defined as 1 of the following:Xx_NEWLINE_xXPrior treatment with BLZ-100.Xx_NEWLINE_xXFor inclusion in the study as a patient with hepatic impairment, the following criterion\n        must be met:\n\n        1. Patients must have stable chronic hepatic impairment for at least 2 weeks prior to Day\n        1, see Section 4.1.1. Patients with hepatic metastases and/or HCC are eligible for the\n        study, providing the hepatic metastases or HCC are not the sole reason for any changes in\n        liver function satisfying the criteria for mild or moderate hepatic impairment as defined\n        by the Child Pugh criteria. Patients must have globally impaired hepatic function to\n        participate in the study.\n\n        For inclusion in the study as a patient with normal hepatic function, the following\n        criteria must be met:\n\n          1. Negative result for serum hepatitis B surface antigen and hepatitis C antibody\n\n          2. Total bilirubin less than or equal to1.5 x institutional ULN, albumin and prothrombin\n             time within normal limits and must not have ascites (unless related to disease under\n             study) or encephalopathy.\n\n          3. AST and ALT less than or equal to2.5 x institutional ULN unless liver metastases are\n             present in which case it must be less than or equal to5 x ULN.\n\n        All patients must fulfil the following criteria:\n\n          1. Male or female, aged at least 18 years.\n\n          2. Histological or, where appropriate, cytological confirmation of any malignant solid\n             tumour refractory or resistant to standard therapy or for which no suitable effective\n             standard therapy exists. Tumours in which inhibition of the EGFR pathway is considered\n             relevant by the Investigator are not mandated but are encouraged.\n\n          3. ECOG performance status less than or equal to2.\n\n          4. Patients must have a life expectancy of greater than or equal to12 weeks, as estimated\n             at the time of screening.\n\n          5. Females should be using adequate contraceptive measures and must have a negative\n             pregnancy test prior to start of dosing if of child-bearing potential or must have\n             evidence of non-child-bearing potential by fulfilling one of the following criteria at\n             screening: post-menopausal defined as aged more than 50 years and amenorrhoeic for at\n             least 12 months following cessation of all exogenous hormonal treatments; women under\n             50 years old would be consider postmenopausal if they have been amenorrheic for 12\n             months or more following cessation of exogenous hormonal treatments and with LH and\n             FSH levels in the postmenopausal range for the institution; documentation of\n             irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or\n             bilateral salpingectomy but not tubal ligation\n\n          6. Male patients should be willing to use barrier contraception, ie, condoms, until 6\n             months after last study drug is taken.\n\n        Exclusion criteria:\n\n          1. Participation in another clinical study with an IP during the last 14 days (or a\n             longer period depending on the defined characteristics of the agents used).\n\n          2. Treatment in the previous 3 months before dosing in this study with any drug known to\n             have a well-defined potential for fulminant hepatotoxicity (eg, halothane and\n             methotrexate).\n\n          3. Treatment with any of the following: an EGFR TKI w/in 8 days or approximately 5x\n             half-life, whichever is the longer, of the first dose of study treatment; Any\n             cytotoxic chemotherapy, investigational agents or other anticancer drugs w/in 14 days\n             of the first dose of study treatment; Major surgery (excluding placement of vascular\n             access) w/in 4 weeks of the first dose; Radiotherapy with a limited field of radiation\n             for palliation within 1 week of the first dose of study treatment, with the exception\n             of patients receiving radiation to more than 30% of the bone marrow or with a wide\n             field of radiation which must be completed within 4 weeks of the first dose of study\n             treatment; Patients currently receiving (or unable to stop use prior to receiving the\n             first dose of study treatment) medications or herbal supplements known to be potent\n             inhibitors of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3\n             week prior) (Appendix H). All patients in Part B and continued access must try to\n             avoid concomitant use of any medications, herbal supplements and/or ingestion of foods\n             with known potent inducer/inhibitory effects on CYP3A4 (Appendix H).\n\n          4. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of\n             starting study treatment with the exception of alopecia and Grade 2 prior\n             platinum-therapy related neuropathy.\n\n          5. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges within 7 days of the first\n             administration of the IP until final PK sample collection on Day 22.\n\n          6. Spinal cord compression or brain metastases unless asymptomatic, stable and not\n             requiring steroids for at least 4 weeks prior to start of study treatment.\n\n          7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled\n             hypertension and active bleeding diatheses, which in the Investigator's opinion makes\n             it undesirable for the patient to participate in the study or which would jeopardise\n             compliance with the protocol, or active infection including hepatitis B, hepatitis C\n             and human immunodeficiency virus (HIV). Screening for chronic conditions is not\n             required.\n\n          8. Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following laboratory values: ANCless than1.5x10.9/L; platelet count less\n             than100x10.9/L; haemoglobinless than90 g/L; Creatinine greater than1.5 x institutional\n             ULN concurrent with creatinine clearance less than50 mL/min (measured or calculated by\n             Cockcroft-Gault formula); confirmation of creatinine clearance is only required when\n             creatinine is greater than1.5 x institutional ULN.\n\n          9. Any of the following cardiac criteria: Mean resting corrected QT interval corrected\n             for heart rate using Fridericia's correction factor (QTcF) greater than470 msec\n             obtained from 3 ECGs; Any clinically important abnormalities in rhythm, conduction or\n             morphology of resting ECG eg, complete left bundle branch block, third degree heart\n             block, second degree heart block, PR interval greater than250 msec; Any factors that\n             increase the risk of QTc prolongation or risk of arrhythmic events such as heart\n             failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome\n             or unexplained sudden death under 40 years of age or any concomitant medication known\n             to prolong the QT interval.\n\n         10. Patients unable to swallow oral medication or patients with GI disorders or\n             significant GI resection likely to interfere with the absorption of AZD9291.\n\n         11. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation\n             pneumonitis which required steroid treatment, or any evidence of clinically active\n             ILD.\n\n         12. Women who are breastfeeding.\n\n         13. Patients with a known hypersensitivity to AZD9291 or any of its excipients. Patients\n             with normal hepatic function should not have a history or presence of hepatic disease\n             known to interfere with the absorption, distribution, metabolism or excretion of\n             AZD9291.\n\n        Patients with mild or moderate hepatic function should not enter if the following are\n        fulfilled:\n\n          1. Patients with hepatic encephalopathy within the last 4 weeks prior to Day 1.\n\n          2. Fluctuating or rapidly deteriorating hepatic function as indicated by widely varying\n             or worsening of clinical and/or laboratory signs of hepatic impairment within the\n             screening period.\n\n          3. Presence of acute liver disease caused by drug toxicity or by an infection.\n\n          4. Severe portal hypertension or surgical porto-systemic shunts.\n\n          5. Biliary obstruction or other causes of hepatic impairment not related to parenchymal\n             disorder and/or disease of the liver.\n\n          6. Oesophageal variceal bleeding within the past 2 months.\n\n          7. Anticoagulant therapy with warfarin or related coumadine.NOTE: Preferred format\n             includes lists of inclusion and exclusion criteriaXx_NEWLINE_xXInclusion criteria:\n\n        In the dose escalation part: patients with high MET tumor expression, evaluable or\n        measurable solid tumors for which no standard therapy is available.\n\n        In the expansion cohorts: in the first cohort, patients with diagnosed MET gene amplified\n        including NSCLC patients and measurable tumors for which no standard therapy is available\n        will be eligible. In the second cohort, patients with advanced P-MET positive measurable\n        solid tumor without MET- gene amplification for which no standard therapy is available will\n        be eligible.\n\n        Exclusion criteria:\n\n        Patient less than 18 years old. ECOG performance status >2. Any serious active disease or\n        co-morbid condition, which, in the opinion of the Investigator, may interfere with the\n        safety or the compliance with the study.\n\n        Poor bone marrow reserve as defined by absolute neutrophil count <1.5 x 10^9/L or platelets\n        <100 x 10^9/L.\n\n        Poor organ function as defined by one of the following:\n\n          -  Total bilirubin >1.5 x ULN\n\n          -  AST, ALT, alkaline phosphatase >2.5 x ULN or >5 x ULN in case of documented liver\n             metastasis. Alkaline phosphatase up to 5 x ULN in case of osteolytic bone metastasis\n             without liver metastases is allowed\n\n          -  Serum creatinine >1.5 x ULN or\n\n          -  Serum creatinine between 1.0 and 1.5 x ULN associated with calculated creatinine\n             clearance <60 mL/min\n\n          -  Proteinuria >500 mg/24H Pregnant or breast-feeding women. No use of effective birth\n             control methods, when applicable. No measurable or evaluable tumor lesion in the Dose\n             Escalation part, and no measurable lesions in the expansion cohorts.\n\n        Brain metastasis (other than totally resected or previously pre-irradiated and no\n        progressive/relapsing) or lepto-meningeal carcinomatosis.\n\n        No resolution of any specific toxicities (excluding alopecia) related to any prior\n        anti-cancer therapy to grade ?1 according to the NCI CTCAE v.4.03.\n\n        Wash out period of less than 3 weeks from previous antitumor therapy or any investigational\n        treatment (and less than 6 weeks in case of prior nitroso-urea and or mitomycin C\n        treatment).\n\n        Any surgery with major risk of bleeding performed less than 10 days prior to study\n        treatment administration.\n\n        Any other severe underlying medical conditions, which could impair the ability to\n        participate in the study or the interpretation of its results.\n\n        Patients treated with potent CYP3A inhibitor unless it can be discontinued at least 2 weeks\n        prior to study treatment or 5 elimination half-life, whichever is the longest.\n\n        Patients treated with potent and moderate CYP3A inducers unless it can be discontinued at\n        least 2 weeks prior to study treatment or 5 elimination half-life, whichever is the\n        longest. Patients treated with weak CYP3A inducers such as dexamethasone are eligible.\n\n        Known hypersensitivity or any adverse event related to the study drug excipient.\n\n        Prior treatment with any compound in the same class. Mean QTc interval prolongation.\n\n        The above information is not intended to contain all considerations relevant to a patient's\n        potential participation in a clinical trial.Xx_NEWLINE_xXPatients are eligible to be treated with RT and plan to start treatmentXx_NEWLINE_xXPatients who are not candidates for RT treatmentXx_NEWLINE_xXPatients are eligible to be treated with RT or CRT and plan to start treatmentXx_NEWLINE_xXPatients who are not candidates for RT/CRT treatmentXx_NEWLINE_xXSubjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.Xx_NEWLINE_xXFor Concomitant Treatment: No prior treatment with MRZ or any other PIs, including BTZ, carfilzomib (CFZ), or ixazomib (IXZ)Xx_NEWLINE_xXIndication of systemic treatment for the relapsed EOC, FTC or PPC.Xx_NEWLINE_xXPatients with a known history of hepatitis C (HCV) will be eligible if they have an undetectable viral load; if the patient received treatment for HCV, then that treatment must have been completed at least three weeks prior to enrollmentXx_NEWLINE_xXPrior treatment with talimogene laherparepvec or any other oncolytic virus.Xx_NEWLINE_xXSexually active subjects and their partners unwilling to use a male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec.Xx_NEWLINE_xXNo hemorrhage after treatment.Xx_NEWLINE_xXPrior treatment with any therapy targeting mutant IDH1 (including BAY1436032)Xx_NEWLINE_xXPrior treatment with TGR-1202Xx_NEWLINE_xXDuring the expansion phase of the protocol, patients must have disease amenable to biopsy and be willing to undergo pre- and post-treatment biopsiesXx_NEWLINE_xXInclusion Criteria:\n\n        Locally advanced or metastatic NSCLC that has been cytologically or histologically\n        confirmed\n\n        ALK rearrangement based on FDA approved test (e.g. Vysis breakapart FISH or IHC using\n        Ventana)\n\n        ECOG PS ?2\n\n        Age of ? 18 years\n\n        Brain lesions may be used as target lesions if progressing, ?10mm in longest diameter and\n        if they were not previously treated with any of the following:\n\n          -  Whole brain radiation therapy (WBRT) within 3 months\n\n          -  Stereotactic radiosurgery (SRS)\n\n          -  Surgical resection Availability of core biopsy of progressive lesion taken within 60\n             days prior to D1 of treatment under study therapy or willing to undergo tumor biopsy:\n             NOTE:. All subjects must consent to provide tumor blocks or slides.\n\n          -  If archival tissue is not available and biopsies to obtain fresh tumor tissue cannot\n             be performed with minimal risk to the subject, subjects may be permitted to enroll on\n             the study with prior approval of the Study PI.\n\n          -  In the situation the patient undergoes biopsy within 60 days prior to D1. and there is\n             insufficient tumor tissue subjects for the correlative science part of the protocol\n             patient will be permitted to enroll on the study with prior approval of the study PI\n\n          -  In the situation the patient undergoes molecular testing or next-generation sequencing\n             as part of standard care there must be sufficient tumor sample available for\n             participation in the study (i.e. a next generation sequencing report is not sufficient\n             for enrollment)\n\n        Recovered from toxicities related to prior anticancer treatment to ?Grade 2 or baseline\n        with the exception of alopecia\n\n        Have normal QT interval on ECG evaluation QT corrected Fridericia (QTcF) of ? 450 ms in\n        males or ? 470 ms in females\n\n        Adequate organ function defined as:\n\n        Absolute neutrophil count (ANC) ?1500/µL Platelets ?75,000/µL Hemoglobin? 10g/dL AST /ALT ?\n        2.5 x upper limit of normal (ULN); ? 5 x ULN if liver metastasis Total serum bilirubin ?\n        1.5 x ULN Serum creatinine ? 1.5 x UNL Serum amylase ? 1.5 x UNL\n\n        At least 1 measurable lesion per RECIST version 1.1\n\n        Negative serum pregnancy test within 7 days of D1 of treatment in women of child bearing\n        potential (WOCBP)\n\n        If fertile, willing to use highly effective form of contraception (defined as a combination\n        of at least two of the following methods: condom or other barrier methods, oral\n        contraceptives, implantable contraceptives, intrauterine devices) during the dosing period\n        and for at least 4 months after\n\n        Ability to provide signed informed consent and willing and able to comply with all study\n        requirements\n\n        Inclusion criteria for cohort assignment:\n\n        Cohort A: Progressive disease on any next generation ALK inhibitor except first line\n        alectinib or brigatinib (any line)\n\n        Cohort B: Progressive disease on first-line therapy with alectinib, and no other ALK\n        inhibitors\n\n        Cohort C: Previous treatment brigatinib at 180 mg daily for ?4 weeks without > grade 2\n        drug-related toxicities and with radiographic evidence of progressive disease and no\n        intervening systemic therapies such as chemotherapy, immunotherapy or another ALK inhibitor\n        (radiation therapy allowed as intervening therapy). Patients who are treated on cohorts A\n        and B will be allowed to enroll in cohort C if the meet the inclusion and exclusion\n        criteria\n\n        Exclusion Criteria for cohorts A, B, and C:\n\n        Patients meeting any of the following exclusion criteria will not be able to participate in\n        this study:\n\n        History or the presence of pulmonary interstitial disease, drug-related or immune-related\n        pneumonitis, or radiation pneumonitis requiring medical management within 6 months of trial\n        enrollment\n\n        Prior treatment with brigatinib for cohorts A and B\n\n        History of or active significant gastrointestinal (GI) bleeding within 3 months\n\n        Malabsorption syndrome or other GI illness that could affect oral absorption of the study\n        drug\n\n        Received cytotoxic chemotherapy, investigational agents or radiation within 7 days prior to\n        D1 of study treatment\n\n        Received prior ALK TKI therapy within 7 days prior to D1 of treatment under study drug. 7\n        day wash out period is required after prior ALK inhibitor treatment.\n\n        Have significant, uncontrolled, or active cardiovascular disease, specifically including,\n        but not restricted to:\n\n          -  Myocardial infarction (MI) within 6 months of trial enrollment\n\n          -  Unstable angina within 6 months of trial enrollment\n\n          -  Congestive heart failure (CHF) with 6 months prior to trial enrollment\n\n          -  Any history of ventricular arrhythmia\n\n          -  Cerebrovascular accident or transient ischemic attack within 6 months of D1 of study\n             treatment\n\n          -  Clinically significant atrial arrhythmia or severe baseline bradycardia defined as\n             resting heart rate < 60 beat per minute\n\n          -  Uncontrolled hypertension defined as baseline SBP> 160 and DBP > 100 on 3 separate\n             clinic visits or past history of hypertensive urgency, emergency or encephalopathy\n\n        Have been diagnosed with another primary malignancy within the past 3 years (except for\n        adequately treated non-melanoma skin cancer, cervical cancer in situ, or prostate cancer,\n        which are allowed within 3 years)\n\n        Have symptomatic CNS metastases which require an increasing dose of corticosteroids within\n        the last 2 weeks to remain asymptomatic.\n\n        Have active infection requiring intravenous antibiotics\n\n        Pregnant or breastfeeding\n\n        Have any condition or illness that, in the opinion of the investigator, would compromise\n        patient safety or interfere with evaluation of the study drug.Xx_NEWLINE_xXPrior treatment with lenvatinib.Xx_NEWLINE_xXSubjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or subjects who refuse standard treatmentXx_NEWLINE_xXPatients who have an option for other treatment for B-ALL at the current state of disease.Xx_NEWLINE_xXPrior treatment with TRC105Xx_NEWLINE_xXPrevious treatment with poziotinib prior to study participation.Xx_NEWLINE_xXAgreeable and clinically feasible pre-treatment biopsyXx_NEWLINE_xXNo prior treatment by cetuximab except if given for primary treatment (locally advanced disease) with no progressive disease for at least 4 months following the end of prior cetuximab treatment.Xx_NEWLINE_xXArrhythmia requiring treatment which is not stabilized by the treatmentXx_NEWLINE_xXFor pre-secondary hormone patients, no prior or concurrent treatment with a secondary hormone (e.g. enzalutamide, abiraterone)Xx_NEWLINE_xXFor post-secondary hormone patients, no concurrent treatment with a secondary hormone (e.g. enzalutamide, abiraterone), no metastasis to the liver or brainXx_NEWLINE_xX